2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Classes of recommendations

Table 2

Levels of evidence

2. Introduction

Fifty years of myocardial revascularization

In 2014, coronary artery bypass grafting (CABG) celebrates the 50^th anniversary of the first procedures performed in 1964.¹ Thirteen years later, the first percutaneous coronary intervention (PCI) was performed.² Since then both revascularization techniques have undergone continued advances, in particular the systematic use of arterial conduits in the case of CABG, and the advent of stents. In the meantime, PCI has become one of the most frequently performed therapeutic interventions in medicine,³ and progress has resulted in a steady decline of periprocedural adverse events, resulting in excellent outcomes with both revascularization techniques. Notwithstanding, the differences between the two revascularization strategies should be recognized. In CABG, bypass grafts are placed to the mid-coronary vessel beyond the culprit lesion(s), providing extra sources of bloodflow to the myocardium and offering protection against the consequences of further proximal obstructive disease. In contrast, coronary stents aim at restoring normal bloodflow of the native coronary vasculature by local treatment of obstructive lesions without offering protection against new disease proximal to the stent.

Myocardial revascularization has been subject to more randomized clinical trials (RCTs) than almost any other intervention (Figure 1). In order to inform the current Guidelines, this Task Force performed a systematic review of all RCTs performed since 1980, comparing head-to-head the different revascularization strategies—including CABG, balloon angioplasty, and PCI with bare-metal stents (BMS) or with various US Food and Drug Administration-approved drug-eluting stents (DES)—against medical treatment as well as different revascularization strategies, and retrieved 100 RCTs involving 93 553 patients with 262 090 patient-years of follow-up.⁴

Figure 1

Randomized trials in myocardial revascularization therapy over the past five decades.

Formulation of the best possible revascularization approach, also taking into consideration the social and cultural context, will often require interaction between cardiologists and cardiac surgeons, referring physicians, or other specialists as appropriate. Patients need help with taking informed decisions about their treatment and the most valuable advice will probably be provided to them by the ‘Heart Team’.⁵ Recognizing the importance of the interaction between cardiologists and cardiac surgeons, the leadership of both the ESC and the EACTS has given this Joint Task Force, along with their respective Guideline Committees, and the reviewers of this document the mission to draft balanced, patient-centred, evidence-driven practice guidelines on myocardial revascularization. The respective Chairpersons of these two associations and CPG Chairperson were also given the task to adapt to the declaration of interest policy and to ensure that their Task Force members followed it throughout the development process of the Guidelines. In the event that any of the Task Force members had a potential conflict of interest to declare, he/she did not participate in the final decision of the Task Force on the given subject.

3. Scores and risk stratification

Myocardial revascularization in the elective setting is appropriate when the expected benefits, in terms of survival or health outcomes (symptoms, functional status, and/or quality of life), exceed the expected negative consequences of the procedure. Whether medical therapy, PCI, or CABG is preferred should depend on the risk–benefit ratios of these treatment strategies, weighting the risks of periprocedural death, myocardial infarction and stroke against improvements in health-related quality of life, as well as long-term freedom from death, myocardial infarction or repeat revascularization. The Heart Team should take into consideration the coronary anatomy, disease, age and comorbidities, patient preference, and hospital/operator experience.

Numerous models have been developed for risk stratification, focussing on anatomical complexity or clinical risk, and have demonstrated their value during decision-making.⁶ Those models most frequently used in a clinical setting are summarized in the Tables of recommendation [risk models to assess short-term (in-hospital or 30-day) and medium-to-long-term (≥1 year) outcomes]. Comparative analyses of these models are limited because available studies have largely evaluated individual risk models in different patient populations, with different outcome measures being reported at various time points, and most models are restricted to one type of revascularization. In addition, several important variables, such as frailty, physical independence and porcelain aorta, are not incorporated in current risk scores. An ideal risk–benefit model enables comparison of the short-term benefits of PCI to the long-term benefits of CABG; however, even though risk models may provide useful information for predicting mortality and major adverse events, prediction of which patients will receive benefit in terms of quality of life is so far unavailable.

The EuroSCORE predicts surgical mortality.^7,8 It is based on an old data set and has been shown to overestimate the risk of mortality, and should therefore no longer be used.^9,10
The EuroSCORE II is an update of the logistic EuroSCORE model and is derived from a more contemporary data set better reflecting current cardiac surgical practice.¹¹ Its value has been demonstrated in specific cohorts of patients undergoing CABG.¹² Compared with its original version, the EuroSCORE II may have a better ability to predict mortality.^12–14
The Society of Thoracic Surgeons (STS) score is a risk-prediction model, validated in patients undergoing cardiac surgery, with a specific model for CABG surgery and combined CABG and valve surgery.^15,16 It can be used to predict in-hospital or 30-day mortality (whichever occurs last) and in-hospital morbidity.
The SYNTAX score (Table 3) was developed to grade the anatomical complexity of coronary lesions in patients with left main or three-vessel disease, and was found to be an independent predictor of long-term major adverse cardiac and cerebrovascular event (MACCE) in patients treated with PCI but not CABG.^17,18 It facilitates the selection of optimal treatment by identifying patients at highest risk of adverse events following PCI. The interobserver variability of the Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) score is significant,¹⁹ although development of non-invasive assessments may simplify calculation of the SYNTAX score.²⁰
The National Cardiovascular Database Registry (NCDR CathPCI) risk score has been developed to predict risk in PCI patients and should only be used in this context.²¹
The age, creatinine, ejection fraction (ACEF) model is a simple score as it contains only three variables, and was developed using data from a cohort of surgical patients.²² ACEF has also been validated to predict mortality in patients undergoing PCI.²³
The clinical SYNTAX score is a combination of the ACEF and SYNTAX scores. Originally established as an additive model, the subsequent development of a logistic model has provided more tailored risk assessment.²⁴
The SYNTAX II score is a combination of anatomical and clinical factors [age, creatinine clearance, left ventricular (LV) function, gender, chronic obstructive pulmonary disease, and peripheral vascular disease] and predicts long-term mortality in patients with complex three-vessel or left main (LM) coronary artery disease (CAD).²⁵ It was found to be superior to the conventional SYNTAX score in guiding decision-making between CABG and PCI in the SYNTAX trial, and subsequently validated in the drug-eluting stent for left main coronary artery disease DELTA registry.
For the American College of Cardiology Foundation–Society of Thoracic Surgeons Database Collaboration (ASCERT) study,²⁶ two large datasets from the National Cardiovascular Data Registry (NCDR) and STS were used to develop several models to predict mortality at different time points following CABG and PCI.^27,28

These limitations restrict the ability to recommend one specific risk model. It is also important to acknowledge that no risk score can accurately predict events in an individual patient. Moreover, limitations exist in all databases used to build risk models, and differences in definitions and variable content can affect the performance of risk scores when they are applied across differing populations. Ultimately, risk stratification should be used as a guide, while clinical judgement and multidisciplinary dialogue (The Heart Team) remain essential.²⁵

Table 3

Guide to calculate the SYNTAX score

Risk models to assess short-term (in-hospital or 30-day) outcomes

ACEF = age, creatinine, ejection fraction; (i) CABG = (isolated) coronary artery bypass grafting; NCDR = National Cardiovascular Data Registry; PCI = percutaneous coronary intervention; STS = Society of Thoracic Surgeons.

^aReferences.

^bWhichever occurs last.

^cPermanent stroke, renal failure, prolonged ventilation, deep sternal wound infection, re-operation, length of stay <6 or >14 days.

^dIf creatinine is >2 mg/dl.

Risk models to assess medium- to long-term (≥1 year) outcomes

ASCERT = American College of Cardiology Foundation–Society of Thoracic Surgeons Database Collaboration (ACCF–STS) on the comparative effectiveness of revascularization strategies; (i) CABG = (isolated) coronary artery bypass grafting; MACCE = major adverse cardiac and cerebrovascular events; PCI = percutaneous coronary intervention; SYNTAX = synergy between percutaneous coronary intervention with TAXUS and cardiac surgery.

^aReferences.

4. Process for decision-making and patient information

4.1 Patient information and informed consent

The process of medical decision-making and patient information is guided by the ‘four principles’ approach to healthcare ethics: autonomy, beneficence, non-maleficence, and justice.³¹ The informed consent process should not be regarded as a necessary legal requirement but as an opportunity to optimize decision-making. Patient-related factors, institutional factors and referral patterns may impact the decision-making process.

Informed consent requires transparency, especially if there is controversy over various treatment options. Collaborative care requires the pre-conditions of communication, comprehension, and trust. Treatment decisions should not be based solely on research results and the physician’s appraisal of the patient’s circumstances, since active patient participation in the decision-making process may yield better outcomes. Patients are subject to bias by labels when considering coronary revascularization,³² and patient preference may sometimes contradict evidentiary best practice. Patients may have limited understanding of their disease and sometimes unreasonable expectations with regard to the outcomes of a proposed intervention. As many as 68% of patients are not aware of an alternative revascularization strategy.³³ Short-term procedure-related and long-term risks and benefits—such as survival, relief of angina, quality of life, potential need for late re-intervention, and uncertainties associated with different treatment strategies—should be thoroughly discussed. Patients can only weigh this information in the light of their personal values and cultural background and must therefore have the time to reflect on the trade-offs imposed by the outcome estimates.

In order to seek a second opinion or to discuss the findings and consequences with referring physicians, enough time should be allowed—up to several days, as required—between diagnostic catheterization and intervention. Patient information needs to be unbiased, evidence-based, up-to-date, reliable, accessible, relevant, and consistent with legal requirements. Consistent use of terminology, that the patient understands, is essential. A written patient information document is needed. These recommendations pertain to patients in stable condition, for whom various treatment options exist and who can make a decision without the constraints of an urgent or emergency situation (Table 4).

Anonymous treatment should be avoided. The patient has the right to obtain information on the level of expertise of the operator, the workload of the centre and whether all treatment options including surgery are available on site. Patients considered for revascularization should also be clearly informed of the continuing need for medical therapy, as well as lifestyle modification and other secondary prevention strategies (section 20).

4.2 Multidisciplinary decision-making (Heart Team)

The Heart Team, made up of clinical or non-invasive cardiologists, cardiac surgeons and interventional cardiologists, provides a balanced, multidisciplinary decision-making process.⁵ Additional input may be needed from other specialties involved in the care of the patient. The Heart Team should meet on a regular basis to analyse and interpret the available diagnostic evidence, put into context the clinical condition of the patient, determine the need—or otherwise—for an intervention and the likelihood of safe and effective revascularization with either PCI or CABG. Ad hoc meetings of the Heart Team should facilitate and support efficient clinical workflows.

The demand for an interdisciplinary approach is underlined by reports on (i) underuse of revascularization procedures in 18–40% of patients with CAD,³⁴ and (ii) inappropriate use of revascularization strategies and a lack of case discussions.³⁵ The large variability between European countries in PCI-to-CABG ratios (ranging from 2.0 to 8.6 in 2007) has raised concerns regarding the appropriate selection of revascularization in Europe.³⁶ Rates for the inappropriate use of PCI (11–15%) or doubt over the appropriateness of PCI (40–50%)^5,37 and, to a lesser degree for CABG (1–2% and 0–9%, respectively) are reported.^5,38 The increasing underuse of CABG is in part explained by PCI treatment in patients with indications for surgery.^39,40 Multidisciplinary decision-making in a Heart Team can minimize specialty bias and prevent self-referral from interfering with optimal patient care.^32,41

Standard evidence-based, interdisciplinary, institutional protocols may be used for common case scenarios, to avoid the need for the systematic case-by-case review of all diagnostic angiograms, but complex cases should be discussed individually. In these cases, revascularization should not be performed at the time of diagnostic angiography, to allow sufficient time to assess all available information, and clearly explain and discuss the findings with the patient.⁴¹ The rationale for a decision and consensus on the optimal revascularization treatment should be documented on the patient’s chart. In hospitals without a cardiac surgical unit or in an ambulatory setting, protocols should be designed in collaboration with an expert interventional cardiologist and a cardiac surgeon. Decisions made by a Heart Team seem to be reproducible.⁴²

4.3 Timing of revascularization and ad hoc percutaneous coronary intervention

Studies of patients scheduled for revascularization have revealed that considerable morbidity and mortality are associated with extended delay of treatment.^43,44 The waiting period for diagnostic catheterization should therefore be minimal. Once the decision for revascularization has been reached after diagnostic coronary angiography, the Task Force recommends that patients with severe symptoms Canadian Cardiovascular Society (CCS) Class 3 and those with high-risk anatomy [left main disease or equivalent; three-vessel disease or proximal left anterior descending (LAD) or depressed ventricular function] preferably undergo revascularization (PCI or CABG) within 2 weeks. For all other patients with stable coronary artery disease (SCAD) and an indication for revascularization, it is desirable to perform revascularization (PCI or CABG) within 6 weeks (Table 4).⁴⁴

Ad hoc PCI is defined as a therapeutic intervention performed within the same procedure as the diagnostic coronary angiography. Ad hoc PCI is convenient, associated with fewer access site complications, and often cost-effective and safe.⁴⁵ In the USA, however, up to 30% of patients undergoing ad hoc PCI are potential candidates for CABG.⁴⁵ Although this number may be lower in Europe,³⁵ ad hoc PCI should not be applied as a default approach.^45,46Ad hoc PCI in stable patients is only justified after adequate information given to the patient (see section 4.1) and if a full diagnostic work-up, including functional testing (section 5) is available. Institutional protocols developed by the Heart Team in accordance with current guidelines should define specific anatomical criteria and clinical subsets that may be—or should not be—treated ad hoc. Complex pathologies in stable patients, including lesions of the LM or proximal LAD and three-vessel disease, should in general not be treated ad hoc, but discussed by the Heart Team.

Table 4

Multidisciplinary decision pathways, patient informed consent, and timing of intervention

ACS = acute coronary syndromes; CABG = coronary artery bypass grafting; CCS = Canadian Cardiovascular Society; LAD = left anterior descending; NSTE-ACS = non—ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; SCAD = stable coronary artery disease; STEMI = ST-segment elevation myocardial infarction.

^aThis may not apply to countries that legally do not ask for written informed consent. ESC and EACTS advocate documentation of patient consent for all revascularization procedures.

Recommendations for decision-making and patient information in the elective setting

PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

5. Strategies for diagnosis: functional testing and imaging

Exercise testing and cardiac imaging are used to confirm the diagnosis of CAD, to document ischaemia in patients with stable symptoms, to risk-stratify patients, and to help choose treatment options and evaluate their efficacy as explained in detail in the ESC Guidelines on the management of stable coronary artery disease.⁴⁷

Another indication for non-invasive imaging before revascularization is the detection of myocardial viability in patients with poor LV function.

5.1 Non-invasive tests

The documentation of ischaemia using functional testing is recommended in patients with suspected SCAD before elective invasive procedures, preferably using non-invasive testing before invasive angiography. Although several tests can be used, it is important to avoid unnecessary diagnostic steps. The current evidence supporting the use of various tests for the detection of CAD is based on meta-analyses and multicentre studies, and using only anatomical evaluation of invasive coronary angiography as the reference standard.⁴⁷ The risks of exercise, pharmacological stressors, contrast agents, invasive procedures, and cumulative ionizing radiation must be weighed against the risk of disease or delayed diagnosis.⁴⁸

Multi-detector computed tomography (MDCT) can detect coronary atherosclerosis and stenoses and is reliable for ruling out significant CAD in patients with low-to-moderate probability of CAD.⁴⁹ The tests for detection of ischaemia are based on either reduction of perfusion or induction of ischaemic wall motion abnormalities during exercise or pharmacological stress. The best-established stress imaging techniques are echocardiography and perfusion scintigraphy. Both may be used in combination with exercise stress or pharmacological stress. Newer stress imaging techniques also include stress magnetic resonance imaging (MRI), positron emission tomography (PET), and combined approaches. The term ‘hybrid imaging' refers to imaging systems in which two modalities [MDCT and PET; MDCT and single photon emission computed tomography (SPECT)] are combined in the same scanner, allowing both studies to be performed in a single imaging session. Ischaemia imaging has been regarded the most appropriate in patients with intermediate pre-test probability (15–85%) of significant CAD,⁴⁷ while in asymptomatic patients or in those with low or high pre-test probability, the tests are generally not recommended. More detailed information about the imaging tests in the detection of CAD are available in the ESC Guidelines on the management of SCAD⁴⁷ and in the Web addenda.

5.2 Invasive tests

Invasive coronary angiography has been regarded as the reference standard for the detection and the assessment of the severity of CAD but, as an invasive procedure, it is associated with specific procedure-related adverse events. Even experienced interventional cardiologists cannot, without functional information, accurately predict the significance of many intermediate stenoses on the basis of visual assessment or quantitative coronary angiography. When non-invasive stress imaging is contraindicated, non-diagnostic, or unavailable, the measurement of fractional flow reserve (FFR) or coronary flow reserve is helpful during diagnostic coronary angiography.⁵⁰ Deferral of PCI or CABG in patients with FFR >0.80 appears safe.^51–53 Fractional flow reserve measurement is indicated for the assessment of the functional consequences of moderate coronary stenoses. FFR-guided PCI with medical therapy has been shown to decrease the need for urgent revascularization compared with the best available medical therapy alone.⁵⁴

5.3 Detection of myocardial viability

Non-invasive assessment of myocardial viability has been used to guide the management of patients with chronic ischaemic systolic LV dysfunction. Multiple imaging techniques, including PET, SPECT, and dobutamine stress echocardiography, have been evaluated for assessment of viability and prediction of clinical outcome after myocardial revascularization.⁵⁵ In general, nuclear imaging techniques have a high sensitivity, whereas techniques evaluating contractile reserve have a somewhat lower sensitivity but higher specificity. MRI has a high diagnostic accuracy for assessing the transmural extent of myocardial scar tissue and can also assess contractile reserve, but its ability to detect viability and predict recovery of wall motion is no better than other imaging techniques. The differences in performance between the various imaging techniques are small, and experience and availability commonly determine which technique is used. The evidence is mostly based on observational studies or meta-analyses. One RCT, relating to PET imaging, showed that patients with a substantial amount of dysfunctional but viable myocardium are likely to benefit from myocardial revascularization.⁵⁶

Indications for diagnostic testing in patients with suspected CAD and stable symptoms

CAD = coronary artery disease; CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emission tomography.

^aScreening for silent (asymptomatic) myocardial ischaemia may be considered in selected high-risk patients, such as those with diabetes mellitus.⁸⁴

^bPre-test probability of CAD. Low 0—15%; intermediate 15—85%; high >85% as assessed using the criteria based on ESC Guidelines of SCAD.⁴⁷

^cClass of recommendation.

^dLevel of evidence.

^eReferences.

^fThis refers to CT angiography, not calcium scoring.

^gCT is considered to perform best in the lower range of pre-test probability (15—50%).⁴⁷

6. Revascularization for stable coronary artery disease

6.1 Rationale for revascularization

Prior to revascularization, patients with SCAD must receive guideline-recommended medical treatment, due to its established benefits in terms of prognosis and symptom relief.⁴⁷ Revascularization, by either PCI or CABG, may be indicated in flow-limiting coronary stenoses to reduce myocardial ischaemia and its adverse clinical manifestations.^85–87 The indications for revascularization in patients with SCAD are persistence of symptoms despite medical treatment and/or improvement of prognosis.⁴⁷ Consequently, revascularization and medical therapy should be seen as complementary, rather than competitive treatment strategies. Specific evidence and recommendations for diabetic patients are addressed in section 10.

Angina is associated with impaired quality of life, reduced physical endurance, mental depression, and recurrent hospitalizations and outpatient visits.⁸⁸ Revascularization by PCI or CABG more effectively relieves angina, reduces the use of anti-angina drugs, and improves exercise capacity and quality of life, compared with a strategy of medical therapy alone (Table 2 Web addenda).^54,89–96

Ischaemia is of prognostic importance in patients with SCAD, particularly when occurring at low workload.^97,98 Revascularization relieves myocardial ischaemia more effectively than medical treatment alone.^92,97,99,100 The extent, location, and severity of coronary artery obstruction as assessed by coronary angiography or coronary computed tomography (CT) angiography are important prognostic factors in addition to ischaemia and left ventricular function.^101–103

6.2 Evidence basis for revascularization

The evidence basis for revascularization with PCI and/or CABG, compared with medical treatment, is derived from several RCTs that are summarized in Table 5. It is important to consider that the best current revascularization results achieved with PCI are with new-generation drug-eluting stents (DES) and for CABG with maximal use of arterial grafts. Although revascularization procedures are associated with the risk of biomarker-defined periprocedural myocardial infarction, several studies indicate that pre-PCI—but not post-PCI—biomarker elevations impact adversely on prognosis.¹⁰⁴ While spontaneous myocardial infarction has a well established adverse impact on prognosis and notably mortality, recent studies suggest that, compared with medical treatment, PCI is associated with a lower risk of spontaneous myocardial infarction.¹⁰⁵

Although individual RCTs and subsequent meta-analyses constitute the highest hierarchical form of evidence-based medicine,^106–108 extrapolation of their results to routine clinical practice has its limitations. The majority of RCTs included mainly male patients who were relatively young [with the exception of Trial of Invasive Medical therapy in the Elderly (TIME)], had preserved LV function, and had not previously undergone revascularization. Patients were highly selected, as randomization was usually performed following delineation of coronary anatomy by angiography without routine assessment of ischaemia. By design, all the RCTs compared treatment strategies that allowed subsequent revascularization when patients deteriorated on medical therapy. As a result, the proportion of patients who did not undergo revascularization progressively declined during follow-up, camouflaging differences between the two strategies and making analysis according to the intention-to-treat principle more problematic. Finally, limited duration of follow-up (usually <5 years) incompletely depicts the advantages of CABG related to arterial grafts, which accrue with time but which may also eventually be eroded by progressive vein graft failure.

Table 5

Revascularization versus medical therapy

ACS = acute coronary syndromes; BMS = bare-metal stents; CABG = coronary artery bypass grafting; DES = drug-eluting stents; EF = ejection fraction; MI = myocardial infarction;

MT = medical therapy; MV = multivessel; MVD = multivessel disease; NYHA = New York heart Association; Revasc = revascularization; y = years.

^aP<0.05; ^bCardiac death; ^cInclusion criteria; ^dNo statistical analyses performed; ^eRepeat CABG, excluding PCI.

Only trials with at least 100 patients per treatment arm were included. Age and ejection fraction are reported as means.

6.2.1 Revascularization with the use of percutaneous coronary intervention

The efficacy of PCI in addition to medical therapy in patients with SCAD has been addressed in several RCTs,^54,91,94 meta-analyses,^{106,107,117–120} and large-scale registries.¹²¹ The most important recent studies and their data are summarized in Table 5.

The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE)⁹¹ trial included 2287 patients with SCAD, who showed objective evidence of ischaemia and significant CAD, randomizing them to medical therapy alone or medical therapy plus PCI with BMS. At a median follow-up of 4.6 years, there were no significant differences between the PCI and medical therapy groups in the composite of death, myocardial infarction and stroke. Freedom from angina was significantly greater in the PCI group at 1 year and 3 years but the advantage was eroded by 5 years, by which time 21% of the PCI group and 33% of the medical therapy group had received additional revascularization (P <0.001). The severity of CAD in COURAGE was moderate and the majority of patients (70%) had no or mild ischaemia at baseline and most patients had normal LV function.¹²² Patients with LM disease were excluded.

The Medical, Angioplasty or Surgery Study II (MASS II) trial, covering 611 patients with multivessel disease, all recruited at a single institution, is the only RCT comparing medical therapy with PCI (72% with BMS; 28% with balloon angioplasty only) and with CABG. Over 10 years, comparing medical therapy with PCI, the respective rates for all-cause mortality were 31% and 24.1% (P =0.09), for myocardial infarction 20.7% and 13.3% PCI (P =0.01), and for freedom from angina 43% and 59% (P <0.001).⁹⁴

In the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME-2) trial,⁵⁴ patients with SCAD and at least one functionally significant stenosis (invasive FFR ≤0.80) were randomly assigned to medical therapy alone or to medical therapy plus FFR-guided PCI. The trial was planned to include 1632 patients but the data safety monitoring board stopped the study prematurely after enrolment of 888 patients, due to a highly significant difference in the incidence of the primary endpoint (a composite of death, myocardial infarction, and urgent revascularization) in favour of FFR-guided PCI that was unlikely to be neutralized with recruitment of more patients. Final analysis showed an incidence of the primary endpoint of 4.3% in the PCI group and 12.7% in the medical therapy group (P <0.001) but without a difference in rates of death or myocardial infarction between the two groups. Interpretation of FAME-2 is complicated, in that the decision for urgent revascularization may have been influenced by the open nature of the trial. The definition of 'urgent revascularization' met the criteria for the clinical presentation of an acute coronary syndrome (ACS) and 50% of the patients undergoing urgent revascularization displayed objective evidence of continuing ischaemia.

Most meta-analyses comparing a strategy of PCI against initial medical therapy found no evidence in favour of an invasive strategy, in terms of survival or myocardial infarction.^{117,118,123,125} Two reported a small survival benefit for PCI over medical therapy, although this might have been influenced by the inclusion of a subset of patients who had had a recent (<4 weeks) myocardial infarction.^107,119One meta-analysis, updated for more recent RCTs, showed that, compared with an initial strategy of medical therapy, PCI was not associated with significant improvement in all-cause mortality [risk ratio (RR) 0.85; 95% confidence interval (CI) 0.71–1.01], cardiac death (RR 0.71; 95% CI 0.47–1.06), myocardial infarction (RR 0.93; 95% CI 0.70–1.24), or repeat revascularization (RR 0.93; 95% CI 0.76–1.14) during short- or long-term follow-up.⁹⁶ In a meta-analysis of five RCTs covering 5286 patients and site-reported ischaemia at baseline, there were no differences between PCI and medical treatment in terms of death, myocardial infarction, unplanned revascularization or angina during a median follow-up of 5 years.¹⁰⁰

In the New York State’s Cardiac Diagnostic Catheterization Database, 9586 patients were identified between 2003 and 2008, who had either PCI (n = 8486; 89%) or medical therapy (n = 1100; 11%). A comparison of 933 propensity-score matched patients in each group showed, with PCI over 4 years, a lower incidence of the composite of mortality and myocardial infarction (16.5% vs. 21.2%, respectively; P =0.003) as well as the individual components: death (10.2% vs. 14.5%, respectively; P =0.02) and myocardial infarction (8.0% vs. 11.3%, respectively; P =0.007).¹²¹ The authors caution that part of the difference in outcomes might be explained by the differences between the groups in their use of routine medical therapy.

6.2.2 Percutaneous coronary intervention with drug-eluting stents vs. bare-metal stents

The major limitation of most of the previous comparisons is the lack of use of DES. Several meta-analyses of RCTs comparing early-generation DES with bare-metal stents (BMS) reported similar rates of death, cardiac death, and non-fatal myocardial infarction, but a 50−70% relative risk reduction (RRR) in the need for subsequent or repeat target vessel revascularization (TVR) with DES.^124,125

New-generation DES, with thin strut stent platforms, biocompatible durable or biodegradable polymers and limus-based antiproliferative agents, have further advanced efficacy and safety compared with early-generation DES and BMS (see section 17 for more information). Compared with early-generation DES, repeat revascularization was reduced by 10–20%.^126–129 Compared with bare-metal stents and early-generation DES, new-generation DES have also improved safety outcomes including death, myocardial infarction and stent thrombosis. Several studies have reported an approximately 50% lower risk of definite or probable stent thrombosis, than with early-generation DES, particularly during the late phase,^128–131 and some studies reported a lower risk of stent thrombosis than with BMS.^125,131 A mixed-treatment comparison of DES and BMS, embracing 76 RCTs and 117 762 patient-years of follow-up, did not report a lower risk of death but a lower risk (20–35%) of myocardial infarction with DES (except paclitaxel-eluting stents) than with BMS.¹³² The randomized Basel Stent Kosten Effektivitäts Trial–Prospective Validation Examination (BASKET–PROVE) trial, comparing DES with BMS among patients with large vessels (>3 mm) showed no significant differences between sirolimus-eluting, everolimus-eluting, and bare-metal stents in terms of the rate of death or myocardial infarction; however, there was a lower risk of cardiac death or myocardial infarction with DES (pooled DES vs. BMS: RR 0.60; 95% CI 0.39–0.93; P =0.02) at 2 years of follow-up.¹³³ An individual patient-data meta-analysis of three RCTs including 4989 patients, which compared new-generation everolimus-eluting stents with early-generation paclitaxel-eluting stents, reported a lower risk of death (3.2% vs. 5.1%; hazard ratio (HR) 0.65; 95% CI 0.49–0.86; P = 0.003), cardiac death or myocardial infarction (4.4% vs. 6.3%; HR 0.70; 95% CI 0.54–0.90; P = 0.005), and stent thrombosis (0.7% vs. 1.7%; HR 0.45; 95% CI 0.26–0.78; P = 0.003) after 3 years of follow-up.¹²⁶ A patient-level pooled analysis of 26 RCTs in 11 557 women, reported a lower incidence of the composite of death or myocardial infarction in female patients treated with new-generation DES (9.2%) compared with both early-generation DES (10.9%) and BMS (12.8%; P =0.001) at 3 years.¹²⁹ Similarly, the incidence of definite or probable stent thrombosis was lowest with new-generation DES (1.1%) followed by BMS (1.3%), and early-generation DES (2.1%; P =0.01).

6.2.3 Revascularization with the use of coronary artery bypass grafting

The superiority of CABG to a strategy of initial medical therapy for specific subsets of SCAD was established in a meta-analysis of seven RCTs.¹⁰⁸ It demonstrated a survival benefit from CABG in patients with LM or three-vessel SCAD, particularly when the proximal LAD coronary artery was involved. Benefits were greater in those with severe symptoms, early positive exercise tests, and impaired LV function. Notably, in these early studies only 10% of CABG patients received an internal mammary artery (IMA), which is an important prognostic component of CABG. Furthermore, 40% of patients in the medical group crossed over to CABG during follow-up. A more recent meta-analysis has reported a reduction in the risk of death with CABG vs. medical therapy (HR 0.62; 95% CI 0.50–0.77).¹⁰⁷

The MASS II trial randomly compared medical therapy with PCI and CABG. At 10 years, compared with medical therapy, CABG was associated with reduced rates of cardiac mortality, myocardial infarction and angina.⁹⁴ In the Surgical Treatment IsChemic Heart failure (STICH) trial, 1212 patients with CAD and a left ventricular ejection fraction (LVEF) of ≤35% were randomized to medical therapy or CABG. Patients with LM disease were excluded, and 17% of patients on medical therapy underwent CABG and 6% of patients underwent PCI by the end of the follow-up period. In the intention-to-treat analysis, all-cause mortality was not significantly lower with CABG than with medical therapy (36% vs. 41%; HR 0.86; 95% CI 0.72–1.04; P =0.12); however, all-cause mortality or hospitalization for cardiovascular causes occurred less frequently among patients undergoing CABG (58% vs. 68%; HR 0.74; 95% CI 0.64–0.85; P <0.001). The results with respect to all other secondary clinical outcomes also favoured CABG. In addition, CABG was associated with a reduced risk for the primary outcome, death, in the ‘as treated’ analysis (HR 0.70; 95% CI 0.58–0.84; P <0.001).¹¹²

Indications for revascularization in patients with stable angina or silent ischaemia

CAD = coronary artery disease; FFR = fractional flow reserve; LAD = left anterior descending coronary artery; LV = left ventricular.

^aWith documented ischaemia or FFR ≤ 0.80 for diameter stenosis <90%.

^bClass of recommendation.

^cLevel of evidence.

6.3 Percutaneous coronary intervention vs. coronary artery bypass grafting

The multitude of studies comparing these two revascularization strategies has shown that neither PCI nor CABG alone can provide a solution for the entire spectrum of SCAD patients who need revascularization; however, CABG results in more complete revascularization than PCI, and the placement of bypass grafts on the mid-coronary vessel makes the complexity of proximal lesions less relevant for the procedure, especially when there are chronic proximal occlusions. The evidence derived from RCTs comparing CABG with PCI is summarized in Table 6.

Table 6

Percutaneous versus surgical revascularization

BMS = bare-metal stents; CABG = coronary artery bypass grafting; EF = ejection fraction; MI = myocardial infarction; MV = multivessel; MVD = multivessel disease; PES = paclitaxel-eluting stents; Revasc = revascularization; SES = sirolimus-eluting stents; TVR = target-vessel revascularization; y = years.

^aP<0.05.

^bNon-inferiority met.

^cNon-inferiority failed only trials with at least 100 patients per treatment arm were included.

Age and ejection fraction are reported as means.

6.3.1 Proximal left anterior descending coronary artery disease

Two meta-analyses—one including nine RCTs involving 1210 patients with isolated proximal LAD lesions followed for up to 5 years,¹⁶⁰ and the other including six RCTs and two non-randomized studies with a total of 1952 patients with isolated proximal LAD lesions, who were followed for up to 4 years¹⁶¹—reported no significant difference in mortality, myocardial infarction, or stroke, but a three-fold increase in recurrent angina and a five-fold increase in repeat revascularization with PCI compared with CABG. Most of the above-mentioned studies have used BMS in the PCI arm, while DES have markedly reduced the risk of repeat revascularization. Similarly, only few trials in patients with isolated proximal LAD lesions have reported long-term outcomes, although the angiographic patency of the IMA has been documented to be >90% at two decades of follow-up. Furthermore, the survival benefit of a single IMA in patients with multivessel CAD, initially reported after a decade of follow-up, has now been extended into the second and third decades, especially with bilateral IMAs.^162–165

6.3.2 Left main coronary artery disease

For several decades, CABG was regarded as the standard of care for significant LM disease in patients eligible for surgery, largely based on the Coronary Artery Surgery Study (CASS) registry.¹⁰⁸ It has been suggested that two important pathophysiological features mitigate against the success of PCI in LM lesions (i) up to 80% of LM disease involves the bifurcation, which is known to be at higher risk of restenosis and (ii) up to 80% of LM patients also have multivessel SCAD, where CABG offers a survival advantage independent of the presence of LM disease.^159,166,167 More recent evidence suggests, however, that PCI provides at least equivalent results to CABG for lower-severity LM lesions at up to 5 years of follow-up.

The SYNTAX trial included a pre-specified subgroup analysis of limited power in 705 patients with predominant distal LM disease, who were randomly assigned to CABG or PCI. The primary endpoint of 1-year MACCE—the composite of death, myocardial infarction, stroke, and repeat revascularization—was comparable for both revascularization strategies (CABG 13.7% vs. PCI 15.8%; P =0.44).¹⁶⁸ At 5 years' follow-up, rates of death (CABG = 14.6% vs. PCI = 12.8%; P =0.53) and myocardial infarction (CABG = 4.8% vs. PCI = 8.2%; P =0.10) were not significantly different, whereas CABG was associated with a higher rate of stroke (4.3% vs. 1.5%; P =0.03) and a lower risk of repeat revascularization (15.5% vs. 26.7%; P <0.001) with no significant difference in the overall MACCE rates (31.0% vs. 36.9%; P =0.12).^17,169 MACCE outcomes were comparable for PCI and CABG in the lower (0–22: 30.4% vs. 31.5%; P =0.74) and intermediate (23–32: 32.7% vs. 32.3%; P =0.88) SYNTAX score tertiles. In patients with SYNTAX scores >32, CABG was associated with numerically lower mortality (14.1% vs. 20.9%; P =0.11) and a significantly reduced need for repeat revascularization (11.6% vs. 34.1%; P <0.001) albeit at a numerically higher risk of stroke (4.9% vs. 1.6%; P =0.13).

The Premier of Randomized Comparison of Bypass Surgery vs. Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease (PRECOMBAT) trial randomized 600 patients with LM disease to PCI or CABG.¹⁵⁹ The primary endpoint—the 1-year composite rate of death, myocardial infarction, stroke, or repeat revascularization—was 6.7% in the CABG group and 8.7% in the PCI group (P =0.37). The 1-year composite rate of death, myocardial infarction or stroke was 4.0% for CABG and 3.3% for PCI (P =0.66). The lack of significant differences between the two groups was maintained over 2 years from randomization and was also valid for mortality (3.4% in the CABG group and 2.4% in the PCI group; P =0.45) and for the composite rate of death, myocardial infarction, or stroke (4.4% in the CABG group and 4.7% in the PCI group; P =0.83). In contrast to the findings in SYNTAX, the incidence of stroke was similar for PCI (0.4%) and CABG (0.7%).

A meta-analysis¹⁷⁰ pooled the results of three dedicated RCTs on PCI vs. CABG for LM disease^158,159,171 and one pre-specified LM lesion subset from the largest RCT.¹⁶⁸ In total, this meta-analysis assessed the 1-year outcomes of 1611 patients. The composite of death, myocardial infarction, stroke, or TVR was observed in 11.8% of the CABG group and 14.5% of the PCI group (P =0.11); the composite of death, myocardial infarction, or stroke was 6.8% in the CABG group and 5.3% in the PCI group (P =0.26). Whilst there was no significant difference in mortality (4.1% in the CABG group and 3.0% in the PCI group; P =0.29) or myocardial infarction (2.8% in the CABG group and 2.9% in the PCI group; P =0.95), the CABG group showed a higher rate of stroke (1.7% vs. 0.1%; P =0.01) but a lower rate of TVR (5.4% vs. 11.4%; P <0.001).

The ASAN Medical Centre-Left Main Revascularization Registry compared the outcomes of patients with LM disease who were treated by either PCI or CABG within the same period. In two analyses—one of 10-year outcomes among 100 patients treated with BMS and 250 patients with CABG, and the other of 5-year outcomes among 176 patients with DES and 219 patients with CABG—neither mortality nor the composite of death, myocardial infarction, or stroke was significantly different between the two treatment approaches. CABG was associated with a decreased risk of revascularization in both comparisons.¹⁷² In a registry of 810 patients with LM disease treated by CABG (335 patients) or PCI (475 patients), which ran in parallel with the RCT, no significant difference was observed between the two treatment options in terms of the composite of death, myocardial infarction, or stroke over 2 years, whereas the risk of re-intervention was significantly lower with CABG.¹⁵⁹

6.3.3 Three-vessel coronary artery disease

A meta-analysis, based on individual patient data from RCTs that were performed before the introduction of DES, reported no difference in mortality between PCI and CABG, although mortality was reduced by CABG in diabetic patients and those aged 65 years or more.¹⁰⁶ A meta-analysis of six randomized trials involving 6055 patients, which compared CABG with arterial grafts and PCI (balloon angioplasty, BMS and DES), reported a significant reduction in mortality (RR 0.73; 95% CI 0.62–0.86), myocardial infarction (RR 0.58; 95% CI 0.48–0.72) and repeat revascularization (RR 0.29; 95% CI 0.21–0.41) in favour of CABG.¹⁷³ There was a trend toward excess strokes with CABG (RR 1.36; 95% CI 0.99–1.86; P =0.06). Several RCTs and meta-analyses indicate that CABG is associated with a greater risk of stroke than PCI, which diminishes during long-term follow-up.^174,175

SYNTAX randomly assigned 1800 patients with LM and/or three-vessel CAD to either an early-generation paclitaxel-eluting stent or CABG.¹⁵⁷ At 1 year, 12.4% of CABG and 17.8% of PCI patients (P =0.002) reached the primary composite endpoint of MACCE. At 5 years, CABG, as compared with PCI, significantly reduced overall MACCE with respective rates of 26.9% vs. 37.3% (P <0.001), 11.4% vs. 13.9% had died (P =0.10), 3.8% vs. 9.7% (P <0.0001) had a myocardial infarction, 3.7% vs. 2.4% (P =0.09) incurred a cerebrovascular accident, and 13.7% vs. 25.9% (P <0.0001) of the patients required repeat revascularization.¹⁷ In the 1095 patients with three-vessel CAD, in comparison with PCI, CABG resulted in lower total death (9.2% vs.14.6%; P =0.006), cardiac death (5.3% vs. 9.0%; P =0.003), myocardial infarction (3.3% vs. 10.6%; P< 0.001) and repeat revascularization (12.6% vs. 25.4%; P <0.001).¹⁷⁶ In these patients with low SYNTAX score (0–22), rates of MACCE were similar (26.8% vs. 33.3%; P =0.21) for CABG and PCI, respectively. Conversely, when compared with PCI in patients with intermediate and high SYNTAX scores, CABG showed lower rates of MACCE (22.6% vs. 37.9%; P =0.0008 and 24.1% vs. 41.9%; P =0.0005, respectively), including its mortality, myocardial infarction and repeat revascularization components.¹⁷⁶ Notably, patients who were included in the CABG registry of the SYNTAX trial because of ineligibility for PCI had lower MACCE rates than the randomized CABG cohort (23.3% vs. 26.9%, respectively), this being potentially related to more complete revascularization (76% vs. 63%, respectively).¹⁷

An observational study based on the New York State registry assessed patients with CAD who had been treated with either isolated bypass surgery (13 212 patients) or DES (20 161 patients) between 2003 and 2005, with focus on 5-year survival.¹⁷⁷ The difference in absolute survival in the overall population was small (CABG 78.5% vs. PCI 76%). The main analysis was performed after propensity matching of 8121 pairs of patients, with survival at 5 years of 80.4% for CABG and 73.6% for PCI with DES (HR 0.71; 95% CI 0.67–0.77; P <0.001). A lower risk of death was noted in all subgroups, except for those with two-vessel CAD without proximal LAD lesions. Two main findings can be highlighted from this study: (i) the presence of LAD disease conferred a survival benefit to CABG and (ii) the survival benefit with CABG became evident only during the second half of the 5-year follow-up. In the ASCERT registry of elective patients >65 years of age with two- or three-vessel CAD, 86 244 patients underwent CABG and 103 549 patients underwent PCI (78% with early-generation DES). Using propensity scores and inverse probability adjustment, mortality at 4 years—but not at 1 year—was lower for CABG than for PCI (16.4% vs. 20.8%; RR 0.79; 95% CI 0.76–0.82).²⁶ The observational nature of the studies does not permit assessment of how each patient was selected for each kind of treatment and, despite statistical adjustments, residual confounders cannot be excluded. Early-generation DES were used, which are devoid of the advantages of the newer generation.^{125–131,133} There is notable consistency in the findings on the survival advantage of CABG over PCI for more severe three-vessel CAD.

Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD with suitable coronary anatomy for both procedures and low predicted surgical mortality

CABG = coronary artery bypass grafting; LAD = left anterior descending coronary artery; PCI = percutaneous coronary intervention; SCAD = stable coronary artery disease.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

7. Revascularization in non-ST-segment elevation acute coronary syndromes

Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is the most frequent manifestation of ACS, and mortality and morbidity remain high and equivalent to those of patients with ST-segment elevation myocardial infarction (STEMI) during long-term follow-up. The key objectives of coronary angiography and subsequent revascularization are symptom relief and improvement of prognosis. Overall quality of life, length of hospital stay, and potential risks associated with invasive and pharmacological treatments must also be considered when deciding on a treatment strategy.

Early risk stratification is important, in order to identify patients at high immediate- and long-term risk for death and cardiovascular events, in whom an early invasive strategy with adjunctive medical therapy may reduce that risk. Patients in cardiogenic shock, or after resuscitation, should undergo immediate angiography (within 2 hours) because of the high likelihood of critical CAD, but it is equally important to identify patients at low risk, in whom invasive and medical treatments provide little benefit or may even cause harm. Details on risk stratification, particularly with respect to the interpretation of troponins, are found in the ESC Guidelines on NSTE-ACS.¹⁸⁰

7.1 Early invasive vs. conservative strategy

A meta-analysis of seven RCTs that compared routine angiography followed by revascularization against a selective invasive strategy, showed reduced rates of combined death and myocardial infarction [odds ratio (OR) 0.82; 95% CI 0.72–0.93; P =0.001].¹⁸¹ The routine revascularization strategy was associated with a risk of early death and myocardial infarction during the initial hospitalization; however, four of the seven trials included in this meta-analysis were not contemporary, due to marginal use of stents and glycoprotein (GP) IIb/IIIa receptor inhibitors. Another meta-analysis, covering seven trials with more up-to-date adjunctive medication, showed a significant reduction in risk for all-cause mortality (RR = 0.75; 95% CI 0.63–0.90; P <0.001) and myocardial infarction (RR = 0.83; 95% CI 0.72–0.96; P =0.012), for an early invasive vs. conservative approach at 2 years without excess of death and myocardial infarction at 1 month.¹⁸² A further meta-analysis of eight RCTs showed a significant lower incidence of death, myocardial infarction, or rehospitalization for ACS (OR = 0.78; 95% CI 0.61–0.98) for the invasive strategy at 1 year.¹⁸³ The benefit was carried mainly by improved outcomes in biomarker-positive (high-risk) patients. In a gender-specific analysis, a similar benefit was found in biomarker-positive women, compared with biomarker-positive men. Importantly, biomarker-negative women tended to have a higher event rate with an early invasive strategy, suggesting that early invasive procedures should be avoided in low-risk, troponin-negative, female patients. A more recent meta-analysis, based on individual patient data from three studies that compared a routine invasive against a selective invasive strategy, revealed lower rates of death and myocardial infarction at 5-year follow-up (HR = 0.81; 95% CI 0.71–0.93; P =0.002), with the most pronounced difference in high-risk patients.¹⁸⁴ Age, diabetes, previous myocardial infarction, ST-segment depression, hypertension, body mass index (<25 kg/m² or >35 kg/m²), and treatment strategy were found to be independent predictors of death and myocardial infarction during follow-up. All results supported a routine invasive strategy but highlight the importance of risk stratification in the decision-making process management.

7.2 Timing of angiography and intervention

Patients at highest risk (i.e. those with refractory angina, severe heart failure or cardiogenic shock, life-threatening ventricular arrhythmias, or haemodynamic instability) were generally not included in RCTs, in order not to withhold potentially life-saving treatments. It has been generally accepted that such patients should be taken for an immediate (<2 hours) invasive evaluation, regardless of electrocardiogram (ECG) or biomarker findings.¹⁸⁰

An early invasive strategy (0.5–14 hours of diagnosis), as opposed to a delayed invasive strategy (within 21–86 hours), was tested in several RCTs. In a meta-analysis of three recent trials, early catheterization, followed by coronary intervention on the first day of hospitalization, was shown to be safe and superior in terms of lower risk of recurrent ACS (–41%) and shorter hospital stay (–28%).¹⁸⁵ Similar findings were reported in a more recent meta-analysis.¹⁸⁶

There is growing evidence to suggest benefit from an invasive strategy within 24 hours in patients with a high-risk profile. The Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) trial revealed a significant 38% lower incidence of death, myocardial infarction, or stroke at 6 months in high-risk patients (Global Registry of Acute Coronary Events (GRACE) score >140), with an early (≤24 hours), as compared with a delayed (≥36 hours) strategy.¹⁸⁷ No significant difference was observed in patients with a low- to intermediate-risk profile (GRACE score ≤140). Notably, there was no safety issue relating to an early invasive strategy. In the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) data analysis, a delay of more than 24 hours before PCI was an independent predictor of 30-day and 1-year mortality.¹⁸⁸ This increased ischaemic event rate was most evident among moderate- and high-risk patients [according to the Thrombolysis in Myocardial Infarction (TIMI) risk score].

In summary, the timing of angiography and revascularization should be based on patient risk profile. Patients at very high risk (as defined above) should be considered for urgent coronary angiography (in less than 2 hours). In patients at high risk, with at least one primary high-risk criterion, an early invasive strategy within 24 hours appears to be the reasonable timescale. In lower-risk subsets, with a GRACE risk score of <140 but with at least one secondary high-risk criterion (Table 7), the invasive evaluation can be delayed without increased risk but should be performed during the same hospital stay, preferably within 72 hours of admission. In other low-risk patients without recurrent symptoms, a non-invasive assessment of inducible ischaemia should be performed before hospital discharge.

Table 7

Criteria for high risk with indication for invasive management

CABG = coronary artery bypass grafting; eGFR = estimated glomerular filtration rate; GRACE = Global Registry of Acute Coronary Events; LV = left ventricular; PCI = percutaneous coronary intervention.

7.3 Type of revascularization

There are no specific RCTs comparing PCI with CABG in patients with NSTE-ACS. In all trials comparing an early invasive with a late strategy, or an invasive with a medical management strategy, the decision on whether to perform CABG or PCI was left to the investigator’s discretion.

In stabilized patients, the choice of revascularization modality can be made in analogy to patients with SCAD. In approximately one-third of patients, angiography will reveal single-vessel disease, allowing ad hoc PCI in most cases. Multivessel disease will be present in another 50%. Here the decision is more complex and the choice has to be made between culprit-lesion PCI, multivessel PCI, CABG, or a combined (hybrid) revascularization. The distribution of PCI vs. CABG in patients with multivessel disease suitable for revascularization is approximately 80% vs. 20%.¹⁸⁹ The revascularization strategy in patients with multivessel CAD should be determined early by the Heart Team and based on the patient’s clinical status, as well as the severity and distribution of the CAD and the characteristics of the lesion. The SYNTAX score has proved to be strongly predictive of death, myocardial infarction and TVR.¹⁹⁰

Culprit-lesion PCI is usually the first choice in most patients with NSTE-ACS and multivessel disease; however, there are no prospective studies comparing culprit-lesion PCI with early CABG. In stabilized patients with multivessel disease and a high SYNTAX score (>22), particularly when there is no clearly identified culprit lesion, a strategy of urgent CABG should be preferred. The strategy of multivessel PCI for suitable significant stenoses—rather than PCI limited to the culprit lesion—has not been evaluated in an appropriate, randomized fashion. In a large database including 105 866 multivessel CAD patients with NSTE-ACS, multivessel PCI was compared with single-vessel PCI and was associated with lower procedural success but similar in-hospital mortality and morbidity.¹⁹¹ Complete revascularization at the time of the index procedure did not result in lower mortality rates over 3 years, as compared with a staged procedure strategy.¹⁹² However, incomplete revascularization appears to be associated with more 1-year adverse event rates.¹⁹³

CABG was compared with PCI in a propensity-matched analysis among patients with multivessel disease from the ACUITY trial.¹⁸⁹ PCI-treated patients had lower rates of stroke, myocardial infarction, bleeding, and renal injury, similar 1-month and 1-year mortality, but significantly higher rates of unplanned revascularization at both 1 month and 1 year. However, only 43% of CABG patients could be matched and there was a strong trend for a higher rate of major adverse cardiac events (MACE) at 1 year with PCI, compared with CABG (25.0% vs. 19.5%, respectively; P =0.05). These results are consistent with the 1-year and 5-year outcomes of the multivessel SYNTAX trial, which included 28.5% of patients with a recent ACS, in both the PCI and the CABG arms.^17,157 However, a subanalysis of these patients has not been reported.

Culprit-lesion PCI does not necessarily require a case-by-case review by the Heart Team when, on clinical or angiographic grounds, the procedure needs to be performed ad hoc after angiography. This is the case when there is continuing or recurrent ischaemia, haemodynamic instability, pulmonary oedema, recurrent ventricular arrhythmias, or total occlusion of the culprit coronary artery requiring urgent revascularization. For all other scenarios, revascularization should be discussed in a multidisciplinary setting, with protocols based on the SYNTAX score at each institution, defining specific anatomical criteria and clinical subsets that can be treated ad hoc or transferred to CABG. After culprit-lesion PCI, patients with scores in the two higher terciles of the SYNTAX score should be discussed by the Heart Team, in the context of functional evaluation of the remaining lesions. This also includes the assessment of patients' comorbidities and individual characteristics.

7.3.1 Coronary artery bypass surgery

As there is no randomized study comparing an early with a delayed CABG strategy, the general consensus is to wait 48–72 hours in patients who had culprit-lesion PCI and have residual severe CAD. In a large database analysis of unselected patients admitted for ACS, performance of early CABG, even in higher-risk patients, was associated with low in-hospital mortality.¹⁹⁴ In registries, unadjusted and adjusted analyses showed no difference in outcomes between patients undergoing early (≤48 hours) or in-hospital late (>48 hours) surgery, although CABG was delayed more often in higher-risk patients, suggesting that timing might be appropriately determined by multidisciplinary clinical judgement.¹⁹⁵ Therefore, in patients assigned for CABG, timing of the procedure should be decided on an individual basis, according to symptoms, haemodynamic stability, coronary anatomy, and signs of ischaemia. When there is continuing or recurrent ischaemia, ventricular arrhythmias, or haemodynamic instability, CABG should be performed immediately. Patients with LM or three-vessel CAD involving the proximal LAD should undergo surgery during the same hospital stay. In this decision process, it is important to consider the risk of bleeding complications when initially applying aggressive antiplatelet treatment; however, pre-treatment with a dual antiplatelet regimen should be considered only as a relative contraindication to early CABG and does require specific surgical measures to minimize bleeding.

7.3.2 Percutaneous coronary intervention

The safety and efficacy of DES have not been prospectively tested in a specific population of patients with NSTE-ACS, but this subset comprises up to 50% of patients included in most stent trials particularly those with an all-comer design. There is no particular safety concern in NSTE-ACS as new-generation DES have shown superior safety and efficacy in both SCAD and STEMI patients. Accordingly, new-generation DES are preferred over BMS as the default option.¹⁹⁶ Dual antiplatelet therapy (DAPT) should be maintained for 12 months, irrespective of stent type.

Recommendations for invasive evaluation and revascularization in NSTE-ACS

ACS = acute coronary syndromes; CABG = coronary bypass graft surgery; DES = drug-eluting stent; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; SYNTAX = SYNergy between percutaneous coronary intervention with TAXus.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

8. Revascularization in ST-segment elevation myocardial infarction

8.1 Time delays

Delays in the timely implementation of reperfusion therapy are key issues in the management of STEMI, since the greatest benefit gained from reperfusion therapy occurs within the first 2–3 hours of symptom onset.^201,202 The total ischaemic time, between symptom onset and provision of reperfusion therapy (either starting fibrinolysis or mechanical reperfusion by primary PCI), is probably the most important factor. The aim is to provide optimal care while minimizing delays, in order to improve clinical outcomes (Figure 2).²⁰¹ The reduction of first-medical-contact-to-balloon (FMCTB) time—defined as the time from the (first) medical/hospital door to the time of primary PCI—relies on efficient coordination of care between first medical contact or referral hospitals, the emergency medical service (EMS), and the receiving hospitals. It is currently estimated that about 66% of patients achieve a guideline-recommended overall first-hospital-door-to-balloon time of <120 minutes.²⁰³ The door-to-balloon (DTB) time refers to patients presenting in PCI-capable centres and should be less than 60 minutes. Door-in to door-out (DI–DO) time is a performance measure that assesses the timeliness and quality of initial reperfusion care. It is defined as the duration from arrival to discharge at the first or STEMI-referral hospital. A DI–DO time ≤30 minutes is associated with shorter reperfusion delays (i.e. a first-hospital DTB time <120 minutes) and lower in-hospital mortality, and should be implemented in non-PCI-capable hospitals as a quality metric.^204,205

Figure 2

Organization of STEMI patient disposal describing pre- and in-hospital management and reperfusion strategies within 12 hours of first medical contact with ideal time interval for interventions.

8.2 Selection of reperfusion strategy

Primary PCI is defined as percutaneous catheter intervention in the setting of STEMI, without previous fibrinolysis. It has replaced fibrinolysis as the preferred reperfusion strategy in patients with STEMI, provided it can be performed in a timely manner in high-volume PCI centres with experienced operators and 24-hour, 7-day catheterization laboratory activation.^{201,206–209} In settings where primary PCI cannot be performed in a timely fashion, fibrinolysis should be considered, particularly if it can be administered pre-hospital (e.g. in the ambulance)^210–212 and within the first 120 minutes after symptom onset (Figure 2).^213–215 It should be followed by transfer to PCI-capable centres for routine coronary angiography in all patients and for rescue PCI in case of unsuccessful fibrinolysis.

During the past decade, primary PCI has become established as the dominant reperfusion therapy in Europe, irrespective of whether patients present early or the journey to the primary PCI-capable hospital is long.^{202,203,216,217} Four European Union countries have documented full implementation of primary PCI as the preferred reperfusion strategy, including countries in which travelling can be difficult.²¹⁸ In most other European countries, fibrinolysis for STEMI is becoming a rare therapy; for example 6% of cases in the UK, 7% in Poland, and 8% in France.²¹⁸ It is interesting to note that, even in countries with a large catchment area, such as Denmark—with one primary PCI centre per 1.4 million inhabitants and correspondingly long transportion distances—the STEMI case–fatality rate is among the lowest recorded in Europe, with an in-hospital mortality of only 3%. The initial diagnosis of STEMI is operational and based on ECG findings with a predictive value of 85%.²⁰⁵ False activation of the catheterization laboratory may therefore occur in 15–30% of cases,²¹⁶ in which PCI can be deferred but where fibrinolysis is a hazard. In either case, there are costs and some inherent risks associated with the procedure or treatment.

Primary PCI for myocardial reperfusion in STEMI: indications and logistics

ECG = electrocardiogram; EMS = emergency medical service; LBBB = left bundle branch block; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

8.3 Primary percutaneous coronary intervention

Key points for optimizing and guiding primary PCI are summarized below:

The infarct-related artery should be systematically treated during the initial intervention. Evidence supporting immediate (preventive) intervention in non-infarct-related lesions is a matter of debate.²³³ On the one hand, patients with extensive CAD in vessels remote from the infarct-related artery have reduced success in reperfusion and an adverse prognosis following primary PCI.¹⁸⁸ Staged PCI in patients with multivessel disease and no haemodynamic compromise is an independent predictor of survival, and more frequent ischaemic events have been reported in direct vs. staged revascularization of STEMI patients with multivessel disease.^234–236 In the recent, randomized Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial (n = 465), preventive PCI in non-infarct-related coronary arteries with stenosis ≥50%, when compared with PCI limited to the infarct artery, was associated with a reduced risk of the composite of death, myocardial infarction, or refractory angina (HR in the preventive-PCI group 0.35; 95% CI 0.21–0.58; P <0.001). The HR for non-fatal myocardial infarction was 0.32 (95% CI 0.13–0.75). It remains to be determined how clinicians can identify lesions that should be revascularized beyond the culprit lesion and whether complete revascularization should be performed in single- or multi-stage procedures. At present, multivessel PCI during STEMI should be considered in patients with cardiogenic shock in the presence of multiple, critical stenoses or highly unstable lesions (angiographic signs of possible thrombus or lesion disruption), and if there is persistent ischaemia after PCI on the supposed culprit lesion.
The radial approach should be the preferred method of access, as it has been shown to reduce the incidence of acute bleeding events—especially in ACS—and was associated with lower mortality in the subset of STEMI patients that were enrolled in the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial.^237–239 However, the benefit of radial over femoral access depends upon the operators' expertise in the radial technique.²⁴⁰
Stenting should be preferred over balloon angioplasty in the setting of primary PCI,^241,242 as it reduces the risk of abrupt closure, re-infarction, and repeat revascularization. Although early-generation DES have not been associated with an increased risk of death, myocardial infarction, or stent thrombosis during long-term follow-up,²⁴³ there have been concerns over an increased risk of very late stent thrombosis, owing to delayed arterial healing of stents implanted into lesions with a large necrotic core.^244,245 More recent evidence has, however, demonstrated the superiority of new-generation everolimus-eluting stents in reducing major acute vascular events in STEMI patients, as compared with early-generation sirolimus-eluting stents.²⁴⁶ Two dedicated trials directly compared new-generation DES with BMS among STEMI patients undergoing primary PCI. The everolimus-eluting stent vs. BMS in ST-segment elevation myocardial infarction (EXAMINATION) trial in 1504 STEMI patients reported no significant differences for the primary endpoint of all-cause death, re-infarction and any revascularization, in patients assigned to everolimus-eluting stents, compared with those assigned to BMS, (11.9% vs. 14.2%, respectively, difference -2.3%; 95% CI -5.8–1.1%; P =0.19) at 1 year.²⁴⁷ However, everolimus-eluting stents were associated with a lower risk of revascularization of the target lesion (2.1% vs. 5.0%; P =0.003) and definite stent thrombosis (0.5% vs. 1.9%; P =0.02). The Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare-Metal Stents in Acute ST-Elevation Myocardial Infarction (COMFORTABLE AMI) trial, examining patients assigned to either BMS or to biolimus-eluting stents with a biodegradable polymer, reported that the latter showed a lower risk of the composite primary endpoint of cardiac death, target-vessel myocardial infarction, and target-lesion revascularization (4.3% vs. 8.7%; HR 0.49; 95% CI 0.30–0.80; P =0.004) as well as a lower risk of target-vessel myocardial infarction (0.5% vs. 2.7%; HR 0.20; 95% CI 0.06–0.69; P =0.01) and a trend towards a lower risk of definite stent thrombosis (0.9% vs. 2.1%; HR 0.42; 95% CI 0.15–1.19; P =0.10).²⁴⁸ Results were maintained throughout 2 years of follow-up and a pooled analysis of both trials confirmed a lower risk of stent thrombosis and re-infarction with DES than with BMS.²⁴⁹ Overall, these findings suggest that new-generation DES are more effective and potentially safer than BMS during primary PCI in STEMI.
Thrombus aspiration has been proposed as an adjunct during primary PCI, to further improve epicardial and myocardial reperfusion by prevention of distal embolization of thrombotic material and plaque debris. Individual RCTs and meta-analyses have suggested that the use of manual aspiration thrombectomy during primary PCI may be beneficial to improve epicardial and myocardial reperfusion and reduce the rate of MACE including mortality.^250–255 In the largest randomized trial to date, the Thrombus Aspiration during PCI in Acute Myocardial Infarction (TASTE) study (7244 patients), the primary endpoint of all-cause mortality occurred in 2.8% of patients in the thrombus aspiration group and in 3.0% in the PCI-only group (HR 0.94; 95% CI 0.72–1.22; P =0.63) at 30 days.²⁵⁶ However, events were evaluated at short-term follow-up, and there was a trend towards a reduction of non-adjudicated events including stent thrombosis (0.2% vs. 0.5%, respectively; HR 0.47; 95% CI 0.20–1.02; P =0.06) and re-infarction (0.5% vs. 0.9%, respectively; HR 0.61; 95% CI 0.34–1.07; P =0.06) in favour of thrombus aspiration. Taken together, these results suggest that routine use of thrombus aspiration is not necessary but selected use may be useful to improve Thrombolysis in Myocardial Infarction (TIMI) 3 flow or prevent stent thrombosis. No clinical benefit of routine rheolytic thrombectomy has been demonstrated in primary PCI.^{255,257–259}
Pre- and post-conditioning warrant randomized trials before these procedures can be recommended in routine clinical practice. Remote ischaemic pre-conditioning has engendered little enthusiasm.²⁶⁰ Early administration of metoprolol before PCI in STEMI patients presenting with Killip Class II or less has been shown to reduce infarct size, with a trend toward fewer ischaemic events.²⁶¹ Trials evaluating the use of antithrombotic and vasodilator agents have been disappointing.
Incomplete stent deployment and undersizing should be avoided.²⁶² Massive thrombotic burden and low-pressure delivery, to avoid distal embolization, are the two major contributing factors in stent malapposition in STEMI patients. Self-expanding stents and stents covered with ultra-thin micronets have shown favourable preliminary results in terms of surrogate endpoints.²⁶³ However, large-scale clinical outcome studies are required before these devices can be recommended.

Primary PCI for myocardial reperfusion in STEMI: procedural aspects (strategy and technique)

BMS = bare-metal stent; CABG = coronary artery bypass grafting; DES = drug-eluting stent; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

8.4 Fibrinolysis

Despite its frequent contraindications, limited effectiveness in inducing reperfusion, and greater associated risk of bleeding, fibrinolytic therapy—preferably administered as a pre-hospital treatment—remains an adjunct to mechanical revascularization if the latter cannot be performed in time.^207,208 The incremental benefit of primary PCI over timely fibrinolysis is diminished when PCI-related delay exceeds 120 minutes, depending on patient age, duration of symptoms, and infarct location. Fibrinolysis is discussed in detail in the ESC Guidelines on STEMI.²⁰¹

Pre-hospital fibrinolysis has been compared with primary PCI in early-presenting patients in the STrategic Reperfusion Early After Myocardial infarction (STREAM) study.²¹⁵ In patients with early STEMI (onset <3 hours previously) who could not undergo primary PCI within 60 minutes after first medical contact, pre-hospital fibrinolysis (amended to half dose in patients >75 years of age) with timely coronary angiography (6–24 hours in stable patients) and rescue PCI for failed fibrinolysis was as effective as primary PCI in reducing the primary endpoint, a composite of death, shock, congestive heart failure, or re-infarction up to 30 days (12.4% vs. 14.3%, respectively; RR 0.86; 95% CI 0.68–1.09; P =0.21). However, there was a significant increase in intracranial bleeding (1.0% vs. 0.2%; P =0.04) particularly in patients >75 years of age with fibrinolysis. The median times until reperfusion were 100 minutes in the fibrinolysis group and 178 minutes in the primary PCI group, which are an hour shorter on average than the delays in the DANish trial in Acute Myocardial Infarction (DANAMI) trial, which established the superiority of transfer PCI over in-hospital fibrinolysis.²¹⁹ In view of the lack of superior efficacy and increased rate of intracranial haemorrhage, emphasis should remain on timely PCI within STEMI networks as the preferred treatment for STEMI. Facilitated PCI, defined as routine use of reduced or normal dose fibrinolysis combined with GP IIb/IIIa inhibitors or other antiplatelet agents followed by coronary angiography, has shown no significant advantages over primary PCI alone.²⁷¹

8.5 Secondary percutaneous coronary intervention

Several randomized trials and meta-analyses have shown that early, routine, post-thrombolysis angiography with subsequent PCI (if required) reduced the rates of re-infarction and recurrent ischaemia, compared with a strategy of ‘watchful waiting’, in which angiography and revascularization were indicated only in patients with spontaneous or induced severe ischaemia or LV dysfunction.^272–281 The benefits of early, routine PCI after thrombolysis were seen in the absence of an increased risk of adverse events (stroke or major bleeding). Based on data from the four most recent trials, all of which had a median delay between start of thrombolysis and angiography of 2–6 hours, a time-frame of 3–24 hours after successful lysis is recommended.^{215,272–274} In cases of failed fibrinolysis, or if there is evidence of re-occlusion or re-infarction with recurrence of ST-segment elevation, the patient should undergo immediate coronary angiography and rescue PCI.²⁸²

Patients presenting between 12 and 48 hours after onset of symptoms, even if pain-free and with stable haemodynamics, may still benefit from early coronary angiography and possibly PCI.^223,224 In patients presenting days after the acute event with a completed myocardial infarction, only those with recurrent angina or documented residual ischaemia—and proven viability on non-invasive imaging in a large myocardial territory—may be considered for revascularization when the infarct artery is occluded. Systematic late PCI of an occluded infarct-related artery after myocardial infarction in stable patients has no incremental benefit over medical therapy.¹¹⁵

Management and revascularization after fibrinolysis

PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

8.6 Coronary artery bypass surgery

CABG may be indicated in STEMI patients with unsuitable anatomy for PCI, but who have a patent infarct-related artery, since patency of this artery provides time for transfer to the surgical team and a large myocardial area in jeopardy. It should be considered in patients in cardiogenic shock if the coronary anatomy is not amenable to PCI,²²¹ or at the time of repair for patients with mechanical complications.²⁸⁵

CABG is infrequently used and its benefits are uncertain in STEMI patients with failed PCI, coronary occlusion not amenable to PCI, and in the presence of refractory symptoms after PCI since, in most of these cases, time for implementation of surgical reperfusion will be long and the risks associated with surgery are increased in this setting.²⁸⁶

When possible, in the absence of persistent pain or haemodynamic deterioration, a waiting period of 3–7 days appears the best compromise.²⁸⁶ Patients with multivessel disease, who are receiving primary PCI or secondary (post-fibrinolysis) PCI on the culprit artery, will need risk stratification and further, staged revascularization with PCI or surgery following a Heart Team discussion.

9. Revascularization in patients with heart failure and cardiogenic shock

9.1 Chronic heart failure

Coronary artery disease remains the most common cause of chronic heart failure; patients with depressed LV function remain at risk of sudden cardiac death with or without revascularization, and the indication for prophylactic implantable cardioverter defibrillator (ICD) therapy should always be examined.²⁸⁷

9.1.1 Revascularization

Revascularization with CABG or PCI is indicated for symptomatic relief of angina pectoris in patients with heart failure. The prognostic importance of surgical revascularization in patients with chronic heart failure has recently been studied in the STICH trial,¹¹² with the aim of comparing the efficacy of initial medical therapy with that of revascularization by CABG plus medical therapy in a sample of 1212 patients with CAD and LV dysfunction (EF ≤35%). Patients with significant LM disease or CCS Classes III and IV were excluded. Most patients had two-vessel (31%) or three-vessel (60%) CAD, and 68% had a proximal LAD stenosis. Although the primary outcome of all-cause mortality was not significantly reduced by CABG (HR with CABG 0.86; 95% CI 0.72–1.04; P =0.12) in the intention-to-treat analysis, it offered superior pre-specified secondary outcomes, including cardiovascular mortality (HR 0.81; 95% CI 0.66–1.00; P =0.05) and all-cause mortality or hospitalization for heart failure (HR 0.84; 95% CI 0.71–0.98; P =0.03). Among patients allocated to medical therapy, 17% crossed over to CABG and 6% to PCI. The ‘as-treated’ analysis compared the outcomes of 592 patients treated with medical therapy throughout the first year after randomization with those of 620 patients who underwent CABG—either as a consequence of randomization or crossover—and reported significantly lower all-cause mortality in favour of CABG (HR 0.70; 95% CI 0.58–0.84; P <0.001).¹¹² These findings have been confirmed in a recent propensity-matched observational cohort of similar patients during long-term follow-up over 10 years.²⁸⁸ The choice between CABG and PCI should be made by the Heart Team after careful evaluation of the patient’s clinical status and coronary anatomy, including SYNTAX score, comorbidities, and expected completeness of revascularization. A specialist in heart failure should be consulted.

9.1.2 Myocardial viability and revascularization

The risk–benefit balance for revascularization in patients without angina/ischaemia or viable myocardium remains uncertain. In an observational study using cardiac imaging techniques (stress–rest Rb-82/F-18 fluorodeoxyglucose PET) in 648 patients with an LVEF of 31% ± 12%, hibernating myocardium, ischaemic myocardium, and scarred myocardium were associated with all-cause death (P =0.0015; P =0.0038, and P =0.0010, respectively). An interaction between treatment and hibernating myocardium was present, such that early revascularization in the setting of hibernating myocardium, when compared with medical therapy, was associated with improved survival, especially when the extent of viability exceeded 10% of the myocardium.^289,290The viability substudy of the STICH trial found viable myocardium in 487 of 601 patients (81%) and no viable myocardium in 114 (19%).²⁸⁹ Among patients without viability, 60 were allocated to CABG and 54 to medical therapy and, among the 487 patients with myocardial viability, 244 were assigned to CABG and 243 to medical therapy. The differences in baseline characteristics, between patients who underwent myocardial viability testing and those who did not, indicate some selection bias driven by clinical factors. Viability was arbitrarily defined using different cut-off values for the different tests used. By univariate analysis, there was a significant association between myocardial viability and outcome; however, this association was not significant on multivariable analysis that included other prognostic variables. It is likely that other variables, such as LV volumes and ejection fraction, are causally determined by the extent of viable myocardium. The lack of correlation between myocardial viability status and benefit from CABG in this study indicates that assessment of myocardial viability should not be the sole factor in selecting the best therapy for these patients.

9.1.3 Ventricular reconstruction

The aim of surgical ventricular reconstruction (SVR) is to remove scar tissue from the LV wall by an endoventricular patch plasty, thereby restoring physiological volume, and to restore an elliptical rather than spherical shape. The decision to add SVR to CABG should be based on a careful evaluation of symptoms (heart failure symptoms should take priority over angina), measurement of LV volumes, and assessment of the transmural extent of myocardial scar tissue, and should be performed only in centres with a high level of surgical expertise. The STICH trial failed to show a difference in the primary outcome (death from any cause or hospitalization for cardiac causes) between CABG and the combined procedure (CABG and SVR). The reduction in end-systolic volume index in STICH—smaller than in previously reported observational studies treating larger aneurysms—might explain the inconsistent finding and, thus, the value of reasonable SVR might be underestimated.^291,292 Subgroup analyses of the STICH trial suggest that patients with less-dilated LV and better LVEF may benefit from SVR, while those with larger LV and poorer LVEF may do worse.²⁹³ In the STICH trial, a post-operative left ventricular end-systolic volume index (LVESVI) of 70 mL/m² or lower, after CABG plus SVR, resulted in improved survival compared with CABG alone. In another study, in patients treated with CABG and SVR, a post-operative LVESVI of less than 60 mL/m² was associated with improved survival compared with a post-operative LVESVI of 60 mL/m² or more.²⁹⁴ In some patients with large aneurysms, who would have been excluded from STICH (due to acute heart failure, inotropic support or violation of other inclusion criteria), surgical ventricular restoration has shown favourable outcomes although in the absence of a comparator.²⁹⁵

Recommendations on revascularizations in patients with chronic heart failure and systolic LV dysfunction (ejection fraction ≤35%)

CABG = coronary artery bypass grafting; LAD = left anterior descending; LCx = left circumflex; LM = left main; LVESV = left ventricular end-systolic volume; PCI = percutaneous coronary intervention; SVR = surgical ventricular reconstruction.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

9.2 Cardiogenic shock

Acute myocardial infarction accounts for approximately 75% of all patients with cardiogenic shock, and the incidence has remained somewhat constant for many years at 6–8%.^296–298 Cardiogenic shock complicating acute myocardial infarction is caused by LV failure in about 80% of cases. Mechanical complications, such as papillary muscle rupture with severe mitral valve incompetence (6.9%), ventricular septal defect (3.9%), or free wall rupture (1.4%), are other precipitating causes. Because revascularization is the cornerstone of the treatment in patients with cardiogenic shock complicating ACS, emergency coronary angiography is indicated. The general triage and treatment of these complex patients is presented in Figure 3.

Figure 3

Treatment of patients with cardiogenic shock.

9.2.1 Revascularization

The Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial demonstrated that, in patients with cardiogenic shock due to acute myocardial infarction, emergency revascularization with PCI or CABG improved long-term survival when compared with initial intensive medical therapy. All-cause mortality at 6 months was lower in the group assigned to revascularization than in the group assigned to medical therapy (50.3% vs. 63.1%, respectively; RR 0.80; 95% CI 0.65–0.98; P =0.03).²²¹ Subgroup analysis revealed that the only variable that correlated significantly with treatment both at 30 days and at 6 months was age, with little or no effect of invasive treatment on mortality in elderly patients (>75 years); however, these findings were not corroborated in the SHOCK trial registry, in which a covariate-adjusted model also suggested a lower mortality among elderly patients (>75 years) undergoing revascularization, as compared with initial intensive medical therapy (RR 0.46; 95% CI 0.28–0.75; P =0.002).²⁹⁹

9.2.2 Mechanical circulatory support

Intra-aortic balloon pump (IABP) counterpulsation has been widely used as mechanical support in cardiogenic shock.³⁰⁰ The efficacy of IABP in cardiogenic shock has recently been challenged in the large, randomized Intraaortic Balloon Pump in Cardiogenic Shock IABP-SHOCK II trial, which included 600 patients with cardiogenic shock complicating acute myocardial infarction, who were assigned to IABP or no IABP. The primary endpoint of 30-day mortality was not reduced with the use of IABP (39.7% IABP vs. 41.3% control; RR 0.96; 95% CI 0.79–1.17; P =0.69) and there was no long-term benefit.^301,302 As a result, the use of IABP for this indication is not routinely recommended but remains an adjunct for patients with mechanical complications as a bridge to surgery.

Three randomized trials and a large registry have demonstrated superior haemodynamic support with percutaneous mechanical circulatory assist systems than with IABP, without differences in mortality but with an increased risk of adverse events.^303–306 A meta-analysis, comparing the safety and efficacy of percutaneous left ventricular assist devices (LVAD) in IABP in patients with cardiogenic shock, found LVAD-treated patients to have a similar mortality and incidence of lower extremity ischaemia, but more bleeding than those treated with IABP.³⁰⁷

In younger patients with no contraindication for cardiac transplantation, LVAD therapy can be implemented as a bridge to transplantation. In patients not eligible for transplant, LVADs may be inserted as a bridge to recovery or with the goal of destination therapy.^308–310

9.2.3 Right ventricular failure

Almost 50% of patients with inferior acute myocardial infarction show echocardiographic evidence of right ventricular dysfunction, with haemodynamic compromise developing in <25% of cases.^311–315 Isolated right ventricular failure accounts for 2.8% of cases of cardiogenic shock complicating acute myocardial infarction.^316,317 Successful primary PCI leads to a haemodynamic improvement, recovery of right ventricular free wall and global function and, hence, improved survival compared with unsuccessful reperfusion.^317–319

9.2.4 Mechanical complications

Mechanical complications of acute myocardial infarction comprise myocardial rupture, resulting in either mitral regurgitation due to papillary muscle rupture, ventricular septal defect (VSD), or free wall rupture with tamponade.^320–322

Ventricular septal defect, characterized by haemodynamic compromise, is treated by IABP followed by early surgical repair.³²³ Percutaneous closure devices for patients' post-infarct VSDs have been reported in case series and, in centres with appropriate experience, may be considered in selected cases as alternatives to surgery.^324–326

Rupture of the free wall, resulting in tamponade, should be salvaged by prompt pericardial drainage and surgical intervention. Left ventricular free wall rupture accounts for approximately 15% of in-hospital mortality from myocardial infarction.³²⁷ Data from the SHOCK trial registry, on patients with and without LV free wall rupture who underwent surgery, showed similar mortality rates.^327,328

Acute mitral regurgitation due to rupture of the papillary muscle should be treated by immediate surgery and revascularization.^317,329,330

Recommendations for management of patients with acute heart failure in the setting of ACS

ACS = acute coronary syndromes; CABG = coronary artery bypass grafting; IABP = intra-aortic balloon pump; LV = left ventricular; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction; VSD = ventricular septal defect.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

10. Revascularization in patients with diabetes

10.1 Evidence for myocardial revascularization

Data from randomized trials on revascularization in diabetic patients are summarized in Table 8. For additional information on diabetes, we refer to the ESC Guidelines on diabetes.⁸⁴ Diabetic patients undergoing revascularization, either with CABG or PCI, are at greater risk for kidney injury than patients without diabetes.

10.1.1 Stable coronary artery disease

The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI-2D) trial specifically addressed the question of myocardial revascularization in diabetic patients with SCAD.³³⁴ A total of 2368 patients with diabetes and evidence of ischaemia, or symptoms of angina in the presence of angiographically defined SCAD, were randomized to medical therapy or to myocardial revascularization in addition to medical therapy. Before randomization, patients were placed in either the PCI or CABG stratum of revascularization as deemed appropriate by the responsible physician. The enrolment target of 2800 patients was not met and follow-up had to be extended by 1.5 years to 5.3 years. Patients with LM disease, those who were unstable, requiring immediate revascularization, and patients with creatinine values >2.0 mg/dL or moderate-to-severe heart failure were excluded. The primary endpoint was all-cause mortality and the principal secondary endpoint was a composite of death, myocardial infarction, or stroke (MACCE). The use of DES (35%) was low and restricted to early-generation devices. A total of 42% of patients in the medical therapy group underwent clinically indicated revascularization during follow-up.

At 5 years, survival did not differ between the medical therapy and revascularization groups, and there were no differences in MACCE (Table 8). In the PCI group, there was no outcome difference between PCI and medical therapy. In the CABG stratum, where patients had more extensive CAD, freedom from MACCE was significantly higher with revascularization than with medical treatment.³³⁴ Survival, however, was not significantly different, which may reflect a power issue or the fact that patients with more extensive myocardial perfusion abnormalities or LV function impairment were more likely to receive revascularization over time in the medical therapy group.³³⁵ Compared with medical therapy, the revascularization strategy at the 3-year follow-up had a lower rate of worsening angina (8% vs. 13%, respectively; P <0.001), new angina (37% vs. 51%, respectively; P <0.001), and subsequent coronary revascularizations (18% vs. 33%, respectively; P <0.001), and a higher rate of angina-free status (66% vs. 58%, respectively; P <0.003).

The investigators speculated that the benefit of CABG over medical therapy emerged due to a preference for CABG rather than PCI among patients with more advanced CAD. This was further substantiated in a study of the impact of angiographic (BARI-2D score) risk stratification on outcomes. Among the CABG stratum patients with high-risk angiographic scores, the 5-year risk of death, myocardial infarction or stroke was significantly lower and amplified for those assigned to revascularization, when compared with medical therapy (24.8% vs. 36.8%, respectively; P =0.005).³³⁶

10.1.2 Acute coronary syndromes

Approximately 20–30% of patients with NSTE-ACS have known diabetes, and at least as many have undiagnosed diabetes or impaired glucose tolerance.³³⁷ Mortality in patients with ACS is two- to three-time increased in diabetic patients, compared with non-diabetic.³³⁸ Despite the higher risk, revascularization and thienopyridines are less frequently prescribed among diabetics than non-diabetics, with an impact on in-hospital and long-term mortality.^339–341

In NSTE-ACS patients, there is no clear correlation between the treatment effect of myocardial revascularization and diabetic status.^342,343,364 In both the Fragmin during Instability in Coronary Artery Disease-2 (FRISC-2) and Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy–Thrombolysis in Myocardial Infarction 18 (TACTICS-TIMI 18) trials,^342,343,364 an early invasive strategy in ACS patients was associated with better outcomes than with a conservative strategy; in TACTICS-TIMI 18,³⁶⁴ the magnitude of the benefit to diabetic patients was greater than that to non-diabetic patients. In a recent meta-analysis of nine RCTs with 9904 ACS patients, diabetic patients (n= 1789) had a higher rate of death (9.3% vs. 3.2%; P <0.001), non-fatal myocardial infarction (11.3% vs. 7.1%; P <0.001), and rehospitalization with ACS (18.1% vs. 13.0%; P <0.001) than non-diabetic patients at 1 year post-procedure. An early invasive strategy was associated with a similar risk reduction in death, myocardial infarction, or rehospitalization for ACS in diabetic and non-diabetic patients (RR 0.87; 95% CI 0.70–1.03 vs. 0.86; 95% CI 0.70–1.06; P for interaction 0.83).³³⁸ Accordingly, diabetes presents a secondary indication for high risk and for invasive management, and further efforts need to be made to give diabetic patients with ACS better access to revascularization therapy.¹⁸⁰

Compared with non-diabetic patients, diabetics with STEMI present later, are more likely to experience haemodynamic instability and end-organ damage, and have delayed revascularization. In STEMI patients, the Primary Coronary Angioplasty vs. Thrombolysis (PCAT)-2 collaborative analysis of 19 RCTs with individual patient data from 6315 patients (14% with diabetes mellitus) showed a similar benefit of primary PCI over fibrinolytic treatment in diabetic and non-diabetic patients.³⁶³ The OR for mortality in favour of primary PCI was 0.49 for diabetic patients (95% CI 0.31–0.79). Recurrent myocardial infarction and stroke were also significantly lower in favour of primary PCI. Patients with diabetes had significantly delayed initiation of reperfusion treatments and longer ischaemic times, probably related to atypical symptoms causing significant delays in initiating reperfusion therapy. Owing to a higher absolute risk, the number needed to treat to save one life at 30 days was significantly lower for diabetic patients (number needed to treat = 17; 95% CI 11–28) than for non-diabetic patients (number needed to treat = 48; 95% CI 37–60).

10.2 Type of myocardial revascularization

The presence of diabetes mellitus defines the treatment strategy for an important subset of patients with multivessel CAD.

10.2.1. Randomized clinical trials

The Future Revascularization Evaluation in Patients with Diabetes Mellitus (FREEDOM) trial is the only adequately powered, randomized study comparing CABG against PCI with use of early-generation DES (94%) in diabetic patients undergoing elective revascularization for multivessel disease without LM coronary stenosis.¹⁷⁵ Between 2005 and 2010, 33 966 patients were screened, of whom 3309 were considered eligible and 1900 (6%) enrolled. Their mean SYNTAX score was 26 ± 9. The primary outcome of death from any cause, non-fatal myocardial infarction, or stroke was lower in the CABG than the PCI group, with divergence of the curves starting at 2 years. This difference was driven by a borderline reduction of all-cause mortality (P =0.049) and by a markedly lower rate of myocardial infarction favouring the CABG group (P <0.001). Conversely, rates of stroke were doubled in the CABG group (P =0.03). The superiority of CABG over PCI was consistent across all pre-specified subgroups, including SYNTAX score, the only exception being that patients recruited outside the USA (n = 1130) had a less-pronounced relative benefit from CABG than those enrolled in the USA (n = 770) (P =0.05 for interaction).¹⁷⁵ Detailed assessment of quality of life revealed substantial and durable improvements in cardiovascular-specific health status with both PCI and CABG groups. During the first month after treatment, PCI resulted in more rapid improvement in health status and quality of life, this changing between 6 months and 2 years in favour of CABG and differences disappearing beyond 2 years.³⁴⁴

It is unclear, however, whether the SYNTAX score was analysed by a blinded 'core' laboratory, which is essential for reproducibility. It should be noted that the SYNTAX score became operational during the FREEDOM trial and is not mentioned in the FREEDOM trial study protocol.³⁴⁵ Therefore, the validity of the observation that CABG led to better outcomes than PCI, irrespective of the SYNTAX score, remains unclear, and it is not consistent with the findings related to the diabetic subgroup of the SYNTAX trial. The increased risk of stroke raises the question of treatment selection, particularly among elderly patients. In addition, the median follow-up was 3.8 years but only 23% of patients were at risk at 5 years.

In the subset of 452 diabetic patients with multivessel CAD who were enrolled in the SYNTAX trial, there were no significant differences at 5 years in the composite of all-cause death, myocardial infarction, or stroke (CABG 19.1% vs. PCI 23.9%; P =0.26) or in the individual components such as all-cause death (P =0.07), stroke (P =0.34), or myocardial infarction (P =0.20).³⁴⁶ However, repeat revascularization was less frequently required in the CABG group (P < 0.001). Among patients with low SYNTAX score (≤ 22), rates of MACCE were similar for CABG and PCI (33.7% vs. 42.5%, respectively; P =0.38) but repeat revascularization remained more frequent in the PCI group (18.5% vs. 38.5%, respectively; P =0.01). Interestingly, in the SYNTAX trial, diabetes was not an independent predictor of outcomes once the SYNTAX score was entered into the multivariable model.²⁵

In the Coronary Artery Revascularization in Diabetes (CARDia) trial, 510 diabetic patients with multivessel or complex single-vessel CAD, enrolled at 24 sites, were randomly assigned to either CABG or PCI with use of either BMS or DES and routine use of abciximab. There were no differences between CABG and PCI for the primary endpoint, the 1-year composite of death, myocardial infarction, or stroke.³⁴⁷ Comparing the subset of patients treated with DES, the primary outcome rates were 12.4% in the CABG and 11.6% in the PCI group (HR 0.93; 95% CI 0.51–1.71; P =0.82). Repeat revascularization was more common among patients assigned to PCI (P <0.001), whereas stroke tended to be less common among patients assigned to PCI (P =0.07).

Hence, taking currently available evidence into consideration, CABG is the revascularization modality of choice among diabetic patients with multivessel CAD; however, PCI can be considered as a treatment alternative among diabetic patients with multivessel disease and low SYNTAX score (≤ 22).

Table 8

Randomized trials on revascularization in diabetic patients

BMS = bare-metal stent; CABG = coronary artery bypass grafting; CV = cardiovascular; DES = drug-eluting stent; EF = ejection fraction; MI = myocardial infarction; MT = medical therapy; MVD = multivessel disease; PCI = percutaneous coronary intervention; PES = paclitaxel-eluting stent; Revasc = revascularization; SES = sirolimus-eluting stent; Sx-Score = SYNTAX score; y = years.

^aP<0.05.

^bRandomization stratified by revascularization modality.

^cThree-vessel disease.

^dSubgroup analysis.

Age and ejection fraction are reported as means.

10.2.2 Meta-analyses

A meta-analysis of individual data from 10 RCTs of elective myocardial revascularization¹⁰⁶ confirms a survival advantage for CABG over PCI in diabetic patients, whereas no difference was found for non-diabetic patients; the interaction between diabetic status and type of revascularization was significant. In this pooled analysis, PCI patients were treated with either balloon angioplasty or BMS. A more recent meta-analysis—dedicated to diabetic patients treated with either CABG or PCI, with at least 80% of arterial conduit(s) or stents (BMS and early-generation DES)—showed significantly lower mortality with CABG at 5 years or the longest follow-up (RR 0.67; 95% CI 0.52–0.86; P =0.002).³⁴⁹ On the other hand, this pooled analysis showed increased rates of stroke using CABG vs. PCI at 5-year follow-up (RR 1.72; 95% CI 1.18–2.53; P =0.005). Similarly, a meta-analysis—restricted to four RCTs covering 3052 patients, which compared PCI with use of early-generation DES vs. CABG in diabetic patients with multivessel CAD—reported a higher risk of death and myocardial infarction with revascularization by early-generation DES (RR 1.51; 95% CI 1.09–2.10; P =0.01) but a lower risk of stroke (2.3% vs. 3.8%; RR 0.59; 95% CI 0.39–0.90; P =0.01).³⁵⁰ A sensitivity analysis revealed that the superiority of CABG over early-generation DES for the endpoint MACCE was most pronounced among patients with high SYNTAX score, but not significant in those with low SYNTAX score. All RCTs have shown higher rates of repeat revascularization procedures after PCI compared with CABG, in diabetic patients.^106,346

10.3 Revascularization with the use of percutaneous coronary intervention

A collaborative network meta-analysis has compared DES with BMS in 3852 diabetic patients.³⁵¹ The need for target-lesion revascularization was considerably lower with DES than with BMS [OR 0.29 for sirolimus-eluting stent; 0.38 for paclitaxel-eluting stent]. A more recent mixed-treatment comparison of 42 trials with 22 844 patient-years of follow-up assessed the efficacy and safety of several early and new-generation DES and BMS in patients with diabetes. Compared with BMS, all DES showed a rate of TVR that was lower by 37–69%. Compared with BMS, there were no differences in rates of death, myocardial infarction, or stent thrombosis for any DES in diabetic patients.³⁵² There are no robust data to support the use of any one DES over another in patients with diabetes.

10.4 Revascularization with the use of coronary artery bypass grafting

There is no direct, randomized evidence for or against the use of one vs. two IMA conduits in diabetic patients. Whether use of bilateral IMA increases the risk of deep sternal wound complications is still a matter of debate, although diabetic patients are particularly prone to sternal infections in bilateral IMA operations. However, observational evidence, with follow-up periods up to 30 years, suggests that bilateral IMA use improves long-term outcomes.^23,24 Pending the long-term results of the randomized Arterial Revascularisation Trial (ART) trial,³⁵³ it is still not clear whether bilateral IMA grafting produces better outcomes, but the superior survival observed with bilateral IMA grafting has been seen not to depend on diabetic status.³⁵⁴ In a recent analysis, there was no significant correlation with diabetic status over 15-year follow-up when using multiple arterial grafts.³⁵⁵ Indeed, alternative strategies—including use of the radial artery in patients with an excessively high risk for sternal complications (e.g. obese patients)—have been shown to be safe during follow-up, and to prolong survival compared with using vein grafts.³⁵⁶

10.5 Antithrombotic pharmacotherapy

There is no indication that antithrombotic pharmacotherapy should differ between diabetic and non-diabetic patients undergoing revascularization. Although a correlation between diabetic status and efficacy of GP IIb/IIIa inhibitors was noted in earlier trials without concomitant use of thienopyridines, this was not confirmed in the more recent Early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY-ACS) trial.³⁵⁷ In the current context of use of oral P2Y₁₂ inhibitors, diabetic patients do not specifically benefit from the addition of GP IIb/IIIa inhibitors.

10.6 Anti-diabetic medications

Only a few specific trials of anti-diabetic medications have been conducted in patients undergoing myocardial revascularization.

Metformin

Because of the risk of lactic acidosis in patients receiving iodinated contrast media, it is generally stated that administration of metformin should be suspended before angiography or PCI, and resumed 48 hours later, subject to adequate renal function. The plasma half-life of metformin is 6.2 hours; however, there is no convincing evidence for such a recommendation. Checking renal function after angiography in patients on metformin and witholding the drug when renal function deteriorates might be an acceptable alternative to automatic suspension of metformin. In patients with renal failure, metformin should preferably be stopped before the procedure. Accepted indicators for metformin-induced lactic acidosis are arterial pH <7.35, blood lactate >5 mmol/L (45 mg/dL), and detectable plasma metformin concentration. Accurate recognition of metformin-associated lactic acidosis and prompt initiation of haemodialysis are important steps towards rapid recovery.

Other drugs

Observational data have raised concern over the use of sulphonylureas in patients treated with primary PCI for acute myocardial infarction. Such concern has not been backed up by a post hoc analysis of the Diabetes, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI)-2 trial, although the number of patients undergoing primary PCI in this trial was low.³⁵⁸ Arrhythmias and ischaemic complications were also less frequent in patients receiving gliclazide or glimepiride.³⁵⁹ Thiazolidinediones may be associated with lower rates of restenosis after PCI with BMS,³⁶⁰ but carry an increased risk of heart failure resulting from water retention in the kidney.

No trial has demonstrated that the administration of insulin or glucose–insulin–potassium improves PCI outcome after STEMI. Observational data in patients undergoing CABG suggest that use of a continuous intravenous (i.v.) insulin infusion to achieve moderately tight glycaemic control (6.6–9.9 mmol/L or 120–180 mg/dL) is independently associated with lower rates of mortality and major complications than those observed after tighter (6.6 mmol/L or 120 mg/dL) or more lenient (9.9 mmol/L or 180 mg/dL) glycaemic control.³⁶¹ In the BARI-2D trial, outcomes were similar in patients receiving insulin sensitization vs. insulin provision to control blood glucose. In the CABG group, administration of insulin was associated with more cardiovascular events than the insulin-sensitization medications.¹³⁹

In the Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus SAVOR-TIMI 53 trial, dipeptidyl peptidase 4 (DPP-4) inhibition with saxagliptin neither increased nor decreased the incidence of ischaemic events, although the rate of hospitalization for heart failure was increased.³⁶²

Specific recommendations for revascularization in patients with diabetes

BMS = bare-metal stent; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES = drug-eluting stent; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

11. Revascularization in patients with chronic kidney disease

11.1 Evidence-base for revascularization

Myocardial revascularization is underused in patients with chronic kidney disease (CKD).^369–371 In all categories of kidney function (defined in the web addenda), observational studies suggest that CKD patients with multivessel disease who undergo revascularization have better survival than those who receive medical therapy.^372,373 Particularly among patients with ACS, large-scale registries indicate better short- and long-term survival with early revascularization than with medical therapy across all CKD stages.^371,374 When there is an indication for PCI, DES should be preferred over BMS, because of its lower risk of revascularization and the absence of safety concerns.^375,376 Notwithstanding, the use of contrast media during diagnostic and interventional vascular procedures represents the most common cause of acute kidney injury in hospitalized patients. In addition, patients with CKD have frequent comorbidities that increase the risk of periprocedural ischaemic and bleeding events. Notably, there is little evidence from RCTs, as most therapeutic RCTs on revascularization have excluded CKD patients. Current treatment strategies are therefore based on retrospective analyses of RCTs and data from large registries.

11.1.1 Patients with moderate chronic kidney disease

Observational studies suggest an increased risk of perioperative and short-term (∼12 months) fatal events but lower medium-to-long-term mortality after CABG compared with PCI.^377,378 The absolute risk for end-stage renal disease is smaller than that for fatal events in this patient population and the combined incidence of death or end-stage renal disease may remain lower after CABG at long-term follow-up. In the post hoc analysis of patients with CKD (25% of 1205 patients) in the randomized Arterial Revascularization Therapies Study (ARTS) trial, which compared CABG against multivessel PCI with the use of BMS, no difference was observed in the primary endpoint of death, myocardial infarction, or stroke (19% vs. 17%; HR 0.93; 95% CI 0.54–1.61; P =0.80) as well as mortality after 3 years of follow-up; however, the risk of repeat revascularization was reduced in favour of CABG (25% vs. 8%; HR 0.28; 95% CI 0.14–0.54; P =0.01).³⁷⁹ There is some evidence that suggests that the off-pump approach may reduce the risk of perioperative acute renal failure and/or progression to end-stage renal disease in these patients.³⁸⁰ Predictive tools have been proposed, which hold promise as a means of identifying CKD patients who are likely to derive the most benefit from one particular revascularization strategy, but these have not been systematically validated externally.³⁸¹

11.1.2 Patients with severe chronic kidney disease and end-stage renal disease or in haemodialysis

In the absence of data from RCTs, results from a large cohort of 21 981 patients with end-stage renal disease (data from US Renal Data System) with poor 5-year survival (22–25%) suggest that CABG should be preferred over PCI for multivessel coronary revascularization in appropriately selected patients on maintenance dialysis.³⁸² Compared with PCI, CABG was associated with significantly lower risks for both death and the composite of death or myocardial infarction.³⁸² Selection of the most appropriate revascularization strategy must therefore account for the general condition and life expectancy of the patient, the least invasive approach being more appropriate in the most fragile and compromised patients.

Candidates for renal transplantation must be screened for myocardial ischaemia, and those with significant CAD should not be denied the potential benefit of myocardial revascularization. Renal transplant recipients have been reported to have similar long-term survival after CABG and PCI.³⁸³

11.2 Prevention of contrast-induced nephropathy

Especially if glomerular filtration rate (GFR) is <40mL/min/1.73 m², all patients with CKD who undergo diagnostic catheterization should receive preventive hydration with isotonic saline, to be started approximately 12 hours before angiography and continued for at least 24 hours afterwards to reduce the risk of contrast-induced nephropathy (CIN).^384,385 The implementation of high-dose statin before diagnostic catheterization has been shown to reduce the incidence of CIN and should be considered as an additional preventive measure in patients without contraindications.³⁸⁶ The antioxidant ascorbic acid has been explored in oral and intravenous preparations, for protection against CIN. A recent meta-analysis of nine RCTs in 1536 patients suggested a somewhat lower risk of CIN among pre-existing CKD patients who received ascorbic acid, than in patients who received placebo or an alternate treatment (9.6% vs. 16.8%, respectively; RR = 0.67; 95% CI 0.47 to 0.97; P =0.034)³⁸⁷ but more evidence is required to make definite recommendations. Although performing diagnostic and interventional procedures separately reduces the total volume exposure to contrast media, the risk of renal atheroembolic disease increases with multiple catheterizations. Therefore, in CKD patients with diffuse atherosclerosis, a single invasive approach (diagnostic angiography followed by ad hoc PCI) may be considered, but only if the contrast volume can be maintained <4 mL/kg. The risk of CIN increases significantly when the ratio of total contrast volume to GFR exceeds 3.7:1.^388,389 For patients undergoing CABG, the effectiveness of the implementation of pharmacological preventive measures—such as clonidine, fenoldopam, natriuretic peptides, N-acetylcysteine or elective pre-operative haemodialysis—remains unproven.

Specific recommendations for patients with moderate or severe CKD

BMS = bare-metal stent; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CKD = chronic kidney disease; DES = drug-eluting stent; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

Recommendations for prevention of contrast-induced nephropathy

AKI = acute kidney injury; CIN = contrast-induced nephropathy; CKD = chronic kidney disease; GFR = glomerular filtration rate; LV = left ventricular; MDCT = multidetector computer tomography; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

^dEspecially in patients with eGFR <40 mL/min/1.73 m².

12. Revascularization in patients requiring valve interventions

12.1 Primary indication for valve interventions

Overall, 40% of patients with valvular heart disease will have concomitant CAD. Coronary angiography is recommended in all patients with valvular heart disease requiring valve surgery, apart from young patients (men <40 years and pre-menopausal women) without risk factors for CAD or when the risks of angiography outweigh the benefits (e.g. in cases of aortic dissection, a large aortic vegetation in front of the coronary ostia, or occlusive prosthetic thrombosis leading to an unstable haemodynamic condition).⁴¹¹ In patients undergoing aortic valve replacement (AVR) who also have significant CAD, the combination of CABG and aortic valve surgery reduces the rates of perioperative myocardial infarction, perioperative mortality, late mortality, and morbidity, when compared with patients not undergoing simultaneous CABG.^412–415 This combined operation, however, carries an increased risk of mortality over isolated AVR.^11,416–418 In a contemporary analysis of a large cohort, the greater risk of the combined operation than with isolated AVR was associated with effects of pre-existing ischaemic myocardial damage and comorbidities.⁴¹⁹

In patients with severe comorbidities, the Heart Team may opt for transcatheter valve interventions. Although a systematic review of observational studies has shown no significant impact of CAD on mortality in patients undergoing transcatheter aortic valve implantation (TAVI),⁴²⁰ a recent single-centre investigation found an increased risk of cardiovascular adverse events among patients with advanced CAD (SYNTAX score >22).⁴²¹ PCI, among patients with CAD undergoing TAVI, does not appear to increase the short-term risks of death, myocardial infarction, or stroke, compared with patients undergoing isolated TAVI; however, its impact on long-term prognosis is not well established.^422–425 The selection of lesions treated by PCI is usually based on clinical presentation and angiography, as functional methods of detecting ischaemia have not been validated among patients with severe aortic stenosis.^{422,423,426–428} Currently, there is no conclusive evidence as to whether PCI should be performed as a staged intervention or during the same procedure, and the decision may be made on an individual basis according to the leading clinical problem, renal failure, and complexity of the underlying CAD.^{422,424,425,428,429} Published experience with PCI and percutaneous mitral valve repair is currently limited to case reports.

Alternative treatments for high-risk patients also include ‘hybrid’ procedures, which involve a combination of scheduled surgery for valve replacement and planned PCI for myocardial revascularization. At present, however, the data on hybrid valve/PCI procedures are very limited, being confined to case reports and small case series.⁴³⁰ Individual treatment decisions in these complex patients are best formulated by the Heart Team.

12.2 Primary indication for coronary revascularization

Many patients with CAD and reduced LV function have concomitant secondary mitral regurgitation. Observational data from the STICH trial suggest that adding mitral valve repair to CABG in patients with LV dysfunction (LVEF ≤35%) and moderate-to-severe mitral regurgitation offers better survival than CABG alone.⁴³¹ Likewise, in patients undergoing CABG for the clinically leading problem of CAD, aortic valves with moderate stenosis should be replaced.⁴¹¹ Case-by-case decisions by the Heart Team are needed for patients with an indication for PCI and moderate-to-severe valve disease.

Recommendations for combined valvular and coronary interventions

CABG = coronary artery bypass grafting; CAD = coronary artery disease; CT = computed tomography; LV = left ventricular; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; TAVI = transcatheter aortic valve implantation.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

13. Associated carotid/peripheral artery disease

13.1 Associated coronary and carotid artery disease

The prevalence of severe carotid artery stenosis increases with the severity of CAD and is an indicator of impaired prognosis.⁴³³ Although the association between carotid artery stenosis and CAD is evident, the prevalence of significant carotid artery stenosis in the entire cohort remains relatively low. Conversely, up to 40% of patients undergoing carotid endarterectomy (CEA) have significant CAD and may benefit from pre-operative cardiac risk assessment.

13.1.1 Risk factors for stroke associated with myocardial revascularization

The incidence of stroke after CABG varies depending on age, comorbidities and surgical technique. The FREEDOM trial, which compared PCI with CABG in diabetic patients with multivessel CAD, showed a 30-day rate of stroke of 1.8% after CABG and 0.3% after PCI (P =0.002).¹⁷⁵ Similarly, a greater risk of stroke was reported in the SYNTAX trial, which diminished during long-term follow-up and was no longer significant at 5 years (CABG 3.7% vs. PCI 2.4%; P =0.09).¹⁷ In a meta-analysis of 19 randomized trials with 10 944 patients, the risk of stroke was lower among patients assigned to PCI than in those assigned to CABG after 30 days and at 1 year.¹³¹ These findings indicate that CABG carries a greater periprocedural risk of stroke but that the long-term risk of cerebrovascular events persists with both treatments.¹⁷ The most common cause of CABG-related stroke is embolization of atherothrombotic debris from the ascending aorta, particularly during aortic cannulation. The risk of periprocedural stroke after CABG in patients with carotid artery stenosis is associated with the severity of stenosis but even more with a history of stroke or transient ischaemic attack (TIA) (within 6 months).⁴³⁴ There is a lack of strong evidence that CAD is a significant cause of perioperative stroke.⁴³⁵ The extension of atherosclerotic disease to intracerebral and extracerebral territories, radiographic demonstration of previous stroke and aortic atheromatous disease, are the most important factors for predicting an increased risk of perioperative stroke.⁴³⁵

Although symptomatic carotid artery stenosis is associated with a greater risk of stroke, 50% of patients suffering strokes after CABG do not have significant carotid artery disease and 60% of territorial infarctions on CT scan/autopsy cannot be attributed to carotid disease alone. Furthermore, only around 40% of strokes following CABG are identified within the first day after surgery, while 60% of strokes occur after uneventful recovery from anaesthesia. In a recent study including 45 432 patients undergoing CABG, 1.6% experienced a stroke and risk factors for all strokes were age, smaller body surface area, emergency surgery, previous stroke, pre-operative atrial fibrillation (AF), and on-pump CABG with hypothermic circulatory arrest. For intraoperative strokes, additional risk factors were peripheral and carotid artery disease, previous cardiac surgery, worse clinical condition, LV dysfunction, left circumflex (LCx) coronary artery stenosis >70%, and on-pump CABG with arrested heart or hypothermic circulatory arrest.⁴³⁶

Although the risk of stroke is low among patients with carotid artery disease undergoing PCI, ACS, heart failure, and extensive atherosclerosis are independent risk factors for this adverse event. In a large registry of 348 092 PCI patients, the rates of stroke and TIA amounted to only 0.11% and did not differ between transfemoral and radial access.⁴³⁷

13.1.2 Preventive measures to reduce the risk of stroke after coronary artery bypass grafting

Detection of severe carotid artery bifurcation disease may lead to concomitant carotid revascularization in selected cases. Identification of an atherosclerotic aorta is believed to be an important step in reducing the risk of stroke after CABG. Pre-operative CT scan or intraoperative ultrasound epiaortic scanning—better than aortic palpation—can lead to modifications in the operative management that may reduce the risk of stroke associated with CABG.^438,439 There is conflicting evidence regarding the influence of off-pump CABG on the incidence of stroke.⁴⁴⁰ A recent randomized trial showed no difference in the incidence of stroke between off-pump CABG and on-pump CABG at 30 days.⁴⁴¹ However, studies employing a 'minimal touch' technique for the aorta reported a lower risk of stroke and MACCE with off-pump CABG.^442,443

Perioperative medical therapy plays a fundamental role in the prevention of neurological complications following CABG. Statins in combination with beta-blockers have shown a protective effect on the risk of stroke after CABG.⁴⁴⁴

Carotid artery screening before CABG

CABG = coronary artery bypass grafting; CAD = coronary artery disease; CT = computed tomography; MRI = magnetic resonance imaging; PAD = peripheral artery disease; TIA = transient ischaemic attack.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

13.1.3 Carotid revascularization in patients scheduled for myocardial revascularization

In patients with previous TIA or stroke and the presence of carotid artery stenosis (50–99% in men; 70–99% in women), CEA performed by experienced teams may reduce the risk of perioperative stroke or death.⁴³⁴ Conversely, isolated myocardial revascularization should be performed among patients with asymptomatic unilateral carotid artery stenosis because of the small risk reduction in stroke and death achieved by concomitant carotid revascularization (1% per year).⁴³⁴ Carotid revascularization may be considered in asymptomatic men with bilateral severe carotid artery stenosis or contralateral occlusion, provided that the risk of stroke or death within 30 days can be reliably documented to be <3% in the presence of a life expectancy >5 years. In women with asymptomatic carotid disease or patients with a life expectancy of <5 years, the benefit of carotid revascularization remains unclear.⁴³⁴ In the absence of clear proof that staged or synchronous CEA or carotid artery stenting (CAS) is beneficial in patients undergoing CABG, patients should be assessed on an individual basis by a multidisciplinary team including a neurologist. This strategy is also valid for patients scheduled for PCI. The strategy of combining PCI with CAS in the same procedure in elective patients is not routinely recommended, except in the infrequent circumstance of concomitant acute severe carotid and coronary syndromes.

13.1.4 Type of revascularization in patients with associated carotid and coronary artery disease

Few patients scheduled for CABG require synchronous or staged carotid revascularization.^445–448 In the absence of randomized trials comparing management strategies in patients with concomitant CAD and carotid disease, the choice of carotid revascularization modality (CEA vs. CAS) should be based on patient comorbidities, supra-aortic vessel anatomy, degree of urgency for CABG and local expertise.⁴⁴⁹ Operator proficiency impacts on results of both carotid revascularization methods but even more in CAS, with higher mortality rates in patients treated by low-volume operators or early in their experience.⁴⁵⁰ If CAS is performed before elective CABG, the need for dual antiplatelet therapy (DAPT) usually delays cardiac surgery for 4–5 weeks.^451,452

Carotid artery revascularization in patients scheduled for CABG

CABG = coronary artery bypass grafting; CAS = carotid artery stenting; CEA = carotid endarterectomy; TIA = transient ischaemic attack.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

The term carotid artery stenosis refers to a stenosis of the extracranial portion of the internal carotid artery, and the degree of stenosis is according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria.⁴⁵¹

Type of carotid artery revascularization

ASA = acetylsalicylic acid; CABG = coronary artery bypass grafting; CAS = carotid artery stenting; CEA = carotid endarterectomy.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

13.2 Associated coronary and peripheral arterial disease

Peripheral artery disease (PAD) is an important predictor of adverse outcome after myocardial revascularization, and portends a poor long-term outcome.^457,458 Patients with clinical evidence of PAD are at increased risk for procedural complications after either PCI or CABG. When comparing the outcomes of CABG vs. PCI in patients with PAD and multivessel disease, CABG is associated with a trend for better survival. Risk-adjusted registry data have shown that patients with multivessel disease and PAD undergoing CABG have better survival at 3 years than similar patients undergoing PCI, in spite of higher in-hospital mortality. In the case of CABG, surgeons should avoid harvesting veins from legs that are affected by significant clinical symptoms of PAD; however, with no solid data available in this population, the two myocardial revascularization approaches are probably as complementary in patients with PAD as they are in other CAD patients.

Non-cardiac vascular surgery in patients with associated coronary artery disease

Patients scheduled for non-cardiac vascular surgery are at greater risk of cardiovascular morbidity and mortality due to a high incidence of underlying symptomatic or asymptomatic CAD.^451,459 Results of the largest RCT have demonstrated that, among 510 patients randomized to prophylactic myocardial revascularization (by either PCI or CABG) or to medical therapy alone, there is no advantage in terms of incidence of perioperative myocardial infarction, early or long-term mortality before major vascular surgery.⁴⁶⁰ Patients included in this study had preserved LV function and SCAD. A RCT with 208 patients at moderate or high cardiac risk, who were scheduled for major vascular surgery, reported similar results: patients undergoing systematic pre-operative coronary angiography and revascularization had similar in-hospital outcomes but greater freedom from cardiovascular events at 4 years than with a selective strategy.⁴⁶¹ In summary, selected high-risk patients may benefit from staged or concomitant myocardial revascularization, with options varying from a one-stage surgical approach to combined PCI and peripheral endovascular repair or hybrid procedures.

RCTs involving high-risk patients, cohort studies, and meta-analyses provide consistent evidence, in patients undergoing high-risk non-cardiac vascular surgery or endovascular procedures, of lower incidences of cardiac mortality and myocardial infarction related to medical therapy including statins.⁴⁵⁸ In summary, perioperative cardiovascular complications are common in PAD patients with associated CAD and result in significant morbidity following non-cardiac vascular surgery. All patients require pre-operative screening to identify and minimize immediate and future risk, with a careful focus on known CAD, risk factors for CAD, and functional capacity.^451,462

Management of patients with associated CAD and PAD

ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; CAD = coronary artery disease; PAD = peripheral artery disease; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

^dHigh cardiac risk (reported cardiac risk often >5%): 1) aortic and other major vascular surgery; 2) peripheral vascular surgery.⁴⁶²

14. Repeat revascularization and hybrid procedures

14.1 Early graft failure

Early graft failure after CABG is reported in up to 12% of grafts (left IMA 7%; saphenous vein graft 8%) as evaluated by intraoperative angiographic control,⁴⁶³ but only a minority, around 3%, are clinically apparent.⁴⁶⁴ Graft failure can be due to conduit defects, anastomotic technical errors, poor native vessel run-off, or competitive flow with the native vessel. When clinically relevant, acute graft failure may result in myocardial infarction with consequently increased mortality and major cardiac events. The suspicion of graft failure should arise in the presence of ECG signs of ischaemia, ventricular arrhythmias, important biomarker modifications, new wall motion abnormalities, or haemodynamic instability.⁴⁶⁵ Owing to the low specificity of ECG modifications and echocardiographic wall motion abnormalities during the post-operative course and the delay in appearance of biomarker changes, a careful assessment of all variables will influence the decision-making for angiographic evaluation.

Perioperative angiography is recommended in cases of suspected myocardial ischaemia to detect its cause and help decide on appropriate treatment.^463,465,466 In symptomatic patients, early graft failure can be identified as the cause of ischaemia in about 82% of cases.⁴⁶⁷ In early post-operative graft failure, emergency PCI may limit the extent of myocardial infarction compared with re-do surgery.⁴⁶⁷ The target for PCI is the body of the native vessel or the IMA graft, while the acutely occluded saphenous vein graft (SVG) and the anastomosis should be avoided due to concerns over embolization or perforation. Re-do surgery should be favoured if anatomy is unsuitable for PCI, or if several important grafts are occluded. Early mortality in the range of 9–15% has been reported in this group of patients, without any difference between the two revascularization strategies.⁴⁶⁷ In asymptomatic patients, repeat revascularization should be considered if the artery is of appropriate size and supplies a large territory of myocardium. The optimal treatment strategy in patients with acute graft failure should be decided by ad hoc consultation between cardiovascular surgeon and interventional cardiologist, on the basis of the patient’s clinical condition and extent of myocardium at risk.

14.2 Disease progression and late graft failure

Ischaemia after CABG may be due to progression of disease in native vessels or disease of bypass grafts (Table 9). Repeat revascularization in these patients is indicated in the presence of significant symptoms despite medical treatment, and in asymptomatic patients with objective evidence of myocardial ischaemia (>10% LV).^54,143 The survival of patients with patent left IMA to LAD and ischaemia in the territories of the right- and circumflex arteries does not appear to be influenced by mechanical revascularization when compared with medical therapy alone.⁴⁶⁸

Table 9

Graft patency after CABG

CABG = coronary artery bypass grafting; IMA = internal mammary artery.

Re-do coronary artery bypass grafting or percutaneous coronary intervention

Percutaneous coronary intervention in patients with previous CABG has worse acute and long-term outcomes than in patients without prior CABG. Re-do CABG has a two- to four-fold increased mortality compared with first-time CABG.^477,478 There are limited data comparing the efficacy of PCI vs. re-do CABG in patients with previous CABG. In the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME) RCT and registry, overall in-hospital mortality was higher with re-do CABG than with PCI.^151,479 More recent observational data have shown similar long-term results in patients treated by re-do CABG and PCI, with a higher revascularization rate for the PCI group.^479,480 In view of the higher risk of procedural mortality with re-do CABG and the similar long-term outcome, PCI is the preferred revascularization strategy in patients with patent left internal mammary artery (LIMA) and amenable anatomy. CABG is preferred for patients with extensively diseased or occluded bypass grafts, reduced systolic LV function, several total occlusions of native arteries and absence of patent arterial grafts. The IMA is the conduit of choice for revascularization during re-do CABG.⁴⁸¹

Percutaneous coronary intervention via the by-passed native artery should be the preferred approach provided the native vessel is not chronically occluded. Percutaneous coronary intervention for a chronic total occlusion (CTO) may be indicated when ischaemic symptoms are present with evidence of significant ischaemia and viable myocardium in the territory supplied. If PCI in the native vessel fails, PCI in the diseased SVG remains an option.

Percutaneous coronary intervention for saphenous vein graft lesions

Percutaneous coronary intervention for SVGs is associated with an increased risk of distal coronary embolization, resulting in periprocedural myocardial infarction.⁴⁸² Percutaneous coronary intervention of de-novo SVG stenosis is considered a high-risk intervention because SVG atheroma is friable and more prone to distal embolization. A pooled analysis of five RCTs reported that GP IIb/IIIa inhibitors are less effective for interventions in SVGs than in native vessels.⁴⁸³ Several different approaches have been evaluated to prevent distal embolization of particulate debris, including distal occlusion/aspiration, proximal occlusion, suction, filter devices or mesh-covered stents.⁴⁸⁴ Unlike occlusive devices, distal protection using filters offers the inherent advantage of maintaining antegrade perfusion and the opportunity for contrast injections. Combined data, mostly from comparative studies between devices and surrogate endpoints, support the use of distal embolic protection during SVG PCI.^485,486 In an RCT comparing different distal-protection devices in SVG PCI, the only independent predictor of 30-day MACE was plaque volume, and not the type of protection device used.⁴⁸⁷ Experience with other devices used for SVG PCI, such as mesh-based stents, is limited.⁴⁸⁸

Implantation of DES in SVG lesions is associated with a lower risk of repeat revascularization than with BMS.^489–497 In the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) of 3063 procedures with 4576 stents—including BMS and DES in SVG lesions—the incidence of death was lower among patients who received DES.⁴⁸⁹ However, no differences in terms of death, myocardial infarction, or stent thrombosis were observed in the randomized Is Drug-Eluting-Stenting Associated with Improved Results in Coronary Artery Bypass Grafts (ISAR-CABG) trial.⁴⁹⁵

Long-term results (up to 7 years post-procedure) of early-generation DES in SVG lesions are satisfactory, with no excess risk of stent thrombosis and maintained lower rate of restenosis than with BMS.^494,496 Compared with PCI of native coronary vessels, patients undergoing PCI of SVGs have impaired long-term clinical outcomes.⁴⁹⁸

14.3 Acute percutaneous coronary intervention failure

Most PCI-related complications (including dissections, vessel occlusion, intracoronary thrombosis, and coronary perforation) are successfully treated in the catheterization laboratory;^499,500 on-site or stand-by surgery is therefore not required during these procedures. The need for urgent surgery to manage PCI-related complications is uncommon and only required in patients with major complications that cannot be adequately resolved by percutaneous techniques.^499,500 This is mainly confined to patients with a large, evolving myocardial infarction due to iatrogenic vessel occlusion that cannot be salvaged percutaneously, and to those with iatrogenic cardiac tamponade with failed pericardiocentesis or recurrent tamponade.^499,500 When severe haemodynamic instability is present, IABP or mechanical circulatory assistance may be desirable before emergency surgery.

14.4 Repeat percutaneous coronary intervention

Recurrence of symptoms or ischaemia after PCI is the result of restenosis, incomplete initial revascularization, or disease progression. Infrequently, patients may require repeat PCI due to late and very late stent thrombosis.

Restenosis

Restenosis associated with angina or ischaemia should be treated by repeat revascularization and repeat PCI remains the strategy of choice for these patients if technically feasible. Originally, balloon angioplasty was frequently used in this setting, with good initial results but high rates of recurrence.^501,502 Bare-metal stents provided superior early results in patients with in-stent restenosis but produced unfavourable late outcomes and were therefore reserved for patients with suboptimal initial results after balloon angioplasty or for those with large vessels.^501,502 Ablative techniques (including rotational atherectomy and laser) have failed to improve results in such patients. Although brachytherapy was effective for in-stent restenosis, it never achieved widespread use, mainly due to logistical issues. Currently DES implantation is recommended in patients with BMS or DES in-stent restenosis. In this setting, the results from DES are superior to those obtained with balloon angioplasty, BMS implantation or brachytherapy.^501–505 Drug-coated balloons are also effective in these patients and are particularly attractive when more than two stent layers are already present in the vessel. Drug-coated balloons are superior to balloon angioplasty and give results similar to early-generation DES in patients with BMS or DES in-stent restenosis.^506–512 The use of intracoronary imaging may provide insights into the underlying mechanisms of in-stent restenosis. The presence of an underexpanded stent should, if possible, be corrected during the repeat procedure. In patients with recurrent episodes of diffuse in-stent restenosis—and in those with associated multivessel disease, especially in the presence of other complex lesions such as chronic total occlusions—CABG should be considered before a new PCI attempt.

Disease progression

Patients with symptomatic disease progression after PCI account for up to 50% of re-interventions.^513,514 They should be managed using criteria similar to patients without previous revascularization if angiographic and functional results of previous interventions remain satisfactory. Percutaneous coronary intervention is an excellent therapy for these patients but care should be taken to identify the sites of prior patent stents as, occasionally, these may complicate re-interventions in the same vessel. Preventive pharmacological strategies should be maximized in this population.

Stent thrombosis

Although stent thrombosis is very rare it may have devastating clinical consequences. Stent thrombosis usually presents as a large myocardial infarction and patients should undergo emergency primary PCI.⁵¹⁵ Owing to the rarity of this complication, the interventional strategy of choice remains unsettled but the use of thromboaspiration and intracoronary IIb/IIIa platelet inhibitors is frequently advocated. Aggressive, high-pressure balloon dilation should be used to correct underlying, stent-related, predisposing, mechanical problems.⁵¹⁶ In this challenging setting, it has been suggested that intracoronary diagnostic techniques be used to correct mechanical problems and optimize final results.^516,517 While optical coherence tomography (OCT) provides superior near-field resolution to intravascular ultrasound imaging (IVUS) and is able to identify red thrombus, thrombus shadowing may interfere with imaging of the underlying structures.⁵¹⁶ Some patients with very late stent thrombosis actually have neoatherosclerosis as the underlying pathological substrate, and this can be recognized with intracoronary imaging.⁵¹⁶ Although the value of repeat stenting in patients with stent thrombosis is under debate and should be avoided when satisfactory results are obtained with balloon dilation, a new stent may be required to overcome edge-related dissections and adjacent lesions or to optimize final results.⁵¹⁷ Detection and correction of any predisposing thrombogenic milieu remains important during these interventions.⁵¹⁶

Adequate inhibition of platelet aggregation is of great importance in minimizing the risk of stent thrombosis, as well as its recurrence. Hence, in patients presenting with stent thrombosis, particular care should be taken to select the most appropriate P2Y₁₂ inhibitor and ensure the importance of compliance by adequate patient information. There is no evidence to suggest that platelet function testing is effective in guiding the decision-making process with respect to type of P2Y₁₂ inhibitor in this specific setting. Since prasugrel and ticagrelor lower the risk of primary ST,^341,518 these agents should be preferred over clopidogrel, if clinically indicated. Duration of treatment should be at least 12 months after the acute event and potentially longer if well tolerated. In cases where these new agents are not available or contra-indicated, doubling the dose of clopidogrel may be reasonable.⁵¹⁹

14.5 Hybrid procedures

Hybrid myocardial revascularization is a planned intervention combining cardiac surgery with a catheter-based intervention performed within a predefined time.^520–523 Procedures can be performed consecutively in a hybrid operating room, or sequentially on separate occasions in the conventional surgical and PCI environments. The Heart Team discussion and the design of a joint strategy are critical for these patients. Hybrid procedures consisting of IMA to LAD and PCI of other territories appear reasonable when PCI of the LAD is not an option or is unlikely to portend good long-term results or when achieving a complete revascularization during CABG might be associated with an increased surgical risk.^520,521 Although in most centres the number of hybrid procedures is relatively small, it remains important to consider when they may be clinically indicated. Options include: In addition, some patients with complex multivessel disease presenting with STEMI initially require primary PCI of the culprit vessel, but subsequently may require complete surgical revascularization. A similar situation occurs when patients with combined valvular and CAD require urgent revascularization with PCI. Finally, when a heavily calcified aorta is found in the operating room the surgeon may elect not to attempt complete revascularization and to offer delayed PCI.

Selected patients with single-vessel disease of the LAD, or in multivessel disease but with poor surgical targets except for the LAD territory, in whom minimally invasive direct coronary artery bypass grafting (MIDCAB) can be performed to graft the LAD using the LIMA. The remaining lesions in other vessels are subsequently treated by PCI.
Patients who had previous CABG and now require valve surgery, and who have at least one important patent graft (e.g. IMA to LAD) and one or two occluded grafts with a native vessel suitable for PCI.
Combination of revascularization with non-sternotomy valve intervention (e.g. PCI and minimally invasive mitral valve repair, or PCI and transapical aortic valve implantation).

Repeat revascularization

BMS = bare-metal stent; CABG = coronary artery bypass grafting; CTO = chronic total occlusions; DAPT = dual antiplatelet therapy; DES = drug-eluting stent; ECG = electrocardiogram; IMA = internal mammary artery; LAD = left anterior descending artery; IVUS = intravascular ultrasound; LV = left ventricular; OCT = optical coherence tomography; PCI = percutaneous coronary intervention; SVG = saphenous vein graft.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

15. Arrhythmias

15.1 Ventricular arrhythmias

15.1.1 Revascularization for prevention of sudden cardiac death in patients with stable coronary artery disease and reduced left ventricular function

Revascularization plays an important role in reducing the frequency of ventricular arrhythmias in normal and mildly reduced LV function (CASS study,⁵²⁵ European Coronary Surgery Study).¹⁰⁹ Thus, revascularization significantly decreased the risk for sudden cardiac death in patients with CAD and LVEF <35% [Studies of Left Ventricular Dysfunction (SOLVD)].⁵²⁶ Likewise, simultaneous ICD implantation during CABG did not improve survival in patients with reduced LV function (CABG Patch).⁵²⁷ Conversely, an adjusted increased risk of ventricular tachycardia (VT) or ventricular fibrillation (VF) of 5% or 8%, respectively, was observed with every 1-year increment of time elapsed from revascularization, irrespective of the mode of revascularization, potentially related to a gradual progression of CAD (Multicenter Automatic Defibrillator Implantation Trial – Cardiac Resynchronization Therapy (MADIT-CRT).⁵²⁸ Indirect evidence for a protective effect of coronary revascularization in terms of sudden cardiac death is provided by retrospective analysis of data from the Multicentre Automatic Defibrillator Implantation Trial II (MADIT II) and Sudden Cardiac Death in Heart Failure Trial (SCD-HEFT) studies, in which ICD implantation was performed for primary prophylaxis of sudden cardiac death in patients with CAD and an ejection fraction <30–35%, respectively. In these studies, ICD implantation did not reduce sudden death if revascularization had been performed within 6 months (MADIT II)⁶⁰⁸ or 2 years (SCD-HEFT)⁵²⁹ prior to ICD implantation. Finally, the STICH trial, which investigated the effect of revascularization (CABG) in patients with reduced LV function (<35%) revealed a non-significant trend towards lower overall mortality in the CABG group but a significant benefit in cardiovascular endpoints (e.g. death from cardiac causes including sudden death).¹¹² Because of the protective effect of revascularization of ventricular arrhythmias, patients with ischaemic LV dysfunction (LVEF <35%) who are considered for primary preventive ICD implantation should be evaluated for residual ischaemia and for potential revascularization targets.

Since revascularization by CABG led to a 46% risk reduction of sudden cardiac death in the SOLVD study, and in view of the low risk for sudden cardiac death within 2 years after revascularization in MADIT-II, reassessment of LV function up to 6 months after revascularization may be considered before primary preventive ICD implantation in patients with CAD and LVEF <35%. This is based on the observation that reverse LV remodelling and improvement of LV function may occur up to 6 months after revascularization procedures.^530,531

15.1.2 Revascularization for treatment of electrical storm

Electrical storm is a life-threatening syndrome related to incessant ventricular arrhythmias, which is most frequently observed in patients with ischaemic heart disease, advanced systolic heart failure, valve disease, corrected congenital heart disease, and genetic disorders such as Brugada syndrome, early repolarisation and long-QT syndromes. In the MADIT-II study, the occurrence of interim post-enrolment ischaemic events (angina or myocardial infarction) was independently predictive of the electrical storm, although there was no close correlation between the timing of the two.⁵³² Urgent coronary angiography and revascularization should be part of the management of patients with electrical storm, as well as antiarrhythmic drug therapy and/or ablation of ventricular tachycardia.

15.1.3 Revascularization after out-of-hospital cardiac arrest

Approximately 70% of survivors of out-of-hospital cardiac arrest have CAD, with acute vessel occlusion observed in 50%.⁵³³ Multiple non-randomized studies suggest that emergency coronary angiography and PCI after out-of-hospital cardiac arrest yields a favourable survival rate of up to 60% at 1 year, which is considerably higher than the 25% overall survival rate in patients with aborted cardiac arrest.^534,535 More recent data suggest that almost one-quarter of patients, resuscitated from cardiac arrest but without ST-segment elevation, show a culprit lesion (either vessel occlusion or irregular lesion).^536,537 Notably, in the prospective Parisian Region Out of Hospital Cardiac Arrest (PROCAT) registry, 96% of patients with STEMI and 58% without STEMI after out-of-hospital cardiac arrest revealed at least one significant coronary artery lesion, and hospital survival rates were significantly higher if immediate PCI was performed successfully.^538,539 Thus, in survivors of out-of-hospital cardiac arrest, early coronary angiography and PCI—if appropriate—should be performed irrespective of the ECG pattern if no obvious non-cardiac cause of the arrhythmia is present.⁵⁴⁰

15.2 Atrial arrhythmias

15.2.1 Atrial fibrillation complicating percutaneous coronary intervention

New-onset AF in patients undergoing PCI occurs in 2–6% of procedures and increases with age, pre-existing heart failure, acute myocardial infarction and arterial hypertension.^541–544 Notably, new-onset AF (defined as change from sinus rhythm at admission to AF during/after PCI) typically occurs during the first 4 days after acute myocardial infarction and is associated with impaired prognosis, more than doubling the risk of death, congestive heart failure and stroke.

The use of oral anticoagulation in addition to antiplatelet therapy appears to decrease the risk of stroke after PCI as found in observational studies.^543,545,546 Information on the duration of new-onset AF after PCI is scarce but most of these episodes are probably of paroxysmal nature or are terminated by cardioversion during the hospital stay. It is not clear whether AF represents an independent risk factor for cardiovascular events after PCI, or merely mirrors the severity of underlying heart disease. Antithrombotic treatment for stroke prevention, in patients with AF occurring during or after PCI, should follow the guidelines for antithrombotic treatment of AF that occurs outside the setting of PCI, although prospective studies are scarce (see section 18). A potentially higher bleeding risk in this patient population should be assessed as outlined in the ESC Guidelines for AF.⁵⁴⁷

15.2.2 Atrial fibrillation complicating coronary artery bypass grafting

Continuous telemetry during the entire hospital stay revealed that new-onset post-operative AF may occur in one-third of patients undergoing isolated CABG.⁵⁴⁸ The presence of post-operative AF after CABG is independently associated with increased cardiac morbidity and mortality, prolonged hospitalization, increased healthcare expenditure, and poor long-term prognosis.^549,550 Several attempts to prevent and manage post-operative AF have been evaluated, including magnesium, statins, steroids and antioxidative drugs.⁵⁴⁷

Pre-operative anti-arrhythmic drug treatment may be initiated but will have to be weighed against side-effects. Beta-blockers significantly decrease the risk of AF after CABG.^551–557 Because beta-blockers are effective for prevention of post-operative AF and can be applied with low risk, they are recommended for decreasing the incidence of AF after CABG; however, beta blockers may be discontinued after CABG if AF was not present and other reasons for beta-blockade do not apply (e.g. reduced LV systolic function). The optimum treatment period before discontinuing beta blockade is unknown but a 3-month period seems reasonable, given the fact that the occurrence of post-operative AF declines rapidly after CABG.⁶³¹

Amiodarone is effective in preventing post-operative AF,^552,558,559but may cause bradycardia.

15.2.3 Post-operative atrial fibrillation and stroke risk

Post-operative AF carries a two- to fourfold increased risk for embolic events. A recent analysis of >16 000 patients undergoing CABG revealed that oral anticoagulation, initiated at discharge in 20% of patients with post-operative AF, led to a 22% relative risk reduction for death.⁵⁶⁰ In patients with post-operative AF, the cumulative risk for embolic death increases during the first year after CABG and continues to increase until 2 years after surgery before plateauing, thus indicating that stroke risk in CABG patients with post-operative AF is not just a perioperative issue. Antithrombotic treatment for stroke prevention in patients with post-operative AF should follow the Guidelines for antithrombotic treatment of AF occurring outside the setting of CABG.⁵⁴⁷ Anticoagulation with heparin or non-vitamin K antagonist oral anticoagulants (NOAC) should be initiated if post-operative AF persists for more than 48 hours and should be maintained for at least 4 weeks after restoration of sinus rhythm; longer in the case of stroke risk factors.⁵⁴⁷ The absence of documented AF during follow-up—even on subsequent intensified monitoring for AF and stroke risk—should not necessarily result in withholding anticoagulation therapy in light of the high incidence of asymptomatic ‘silent’ AF episodes.⁵⁶¹ There are no data on whether prophylactic intraoperative ablation of AF has an impact on the occurrence of post-operative AF.

15.3 Concomitant surgical procedures for atrial fibrillation or stroke treatment

The original cut-and-sew 'maze' procedure for AF, described by Cox et al.,⁵⁶² included removal or ligation of the left atrial appendage (LAA). In addition, a retrospective analysis demonstrated that surgical LAA occlusion independent of intraoperative AF surgery reduces the risk of stroke.⁵⁶³ Likewise, transcatheter LAA occlusion in the Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (PROTECT AF) trial was non-inferior to oral anticoagulation with vitamin K antagonists in patients with AF.⁵⁶⁴ Whether surgical LAA obliteration (which does not employ a prosthesis in direct contact with the blood, thus potentially obviating the need for prolonged antiplatelet/anticoagulation therapy) reduces stroke risk has not yet been investigated in randomized, prospective studies. Currently, concomitant surgical LAA obliteration may be considered to reduce stroke risk in CABG patients with a history of AF, but randomized studies are needed to further clarify this issue. Removal or closure of the LAA should be considered as an adjunct to anticoagulation and not as an alternative for anticoagulant therapy until more and longer-term data are available.

Recommendations for treatment of arrhythmias after revascularization

Recommendations for prevention of ventricular arrhythmias by revascularization

AF = atrial fibrillation; CABG = coronary artery bypass grafting; CAD = coronary artery disease; ECG = electrocardiogram; ICD = implantable cardioverter defibrillator; LV = left ventricular; LVEF = left ventricular ejection fraction; LAA = left atrial appendage; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

16. Procedural aspects of coronary artery bypass grafting

16.1 Pre-operative management

Most patients admitted for surgical revascularization are already medically treated with angiotensin-converting enzyme (ACE) inhibitors, statins, antiplatelet drugs, beta-blockers, and/or other antianginal drugs. Beta-blockers should not be stopped to avoid acute ischaemia and statins should be continued until surgery—or initiated if not previously introduced. Angiotensin-converting enzyme inhibitors might be discontinued 1–2 days before CABG, to avoid the potential deleterious consequences of perioperative hypotension.

The section on antithrombotic and antiplatelet therapy (section 18) will cover perioperative care around CABG relating to this particular aspect.

16.2 Blood management

16.2.1 Blood salvage interventions

There is strong evidence that use of cell-savers reduces allogenic blood product exposure (OR 0.63; 95% CI 0.43–0.94; P <0.02) but also reduces red blood cells and the mean volume of total allogenic blood products transfused per patient (P <0.002).⁵⁶⁹

16.2.2 Pharmacological strategies

Antifibrinolytic drugs are effective in reducing blood loss, the need for allogenic red blood cell transfusion, and the need for re-operation due to continued post-operative bleeding in cardiac surgery.⁵⁷⁰ Lysine analogues (e.g. tranexamic acid) are effective and relatively free from serious adverse events.

16.2.3 Blood transfusion

There is ample evidence that the number of transfused red blood cell units is an independent risk factor for worse outcomes after cardiac surgery.^571,572 Transfusion trigger to a target haematocrit of around 24% is as safe as a liberal strategy of 30% with respect to 30-day mortality and complications.⁵⁷³ Platelet transfusion should be considered in patients recently exposed to P2Y₁₂ inhibitors if there are clinical signs of poor haemostasis.

16.3 Surgical procedures

16.3.1 Conduit harvest

Saphenous vein harvest

Saphenous vein harvest can be accomplished using open and endoscopic techniques. Endoscopic vein graft harvesting, as well as radial artery harvesting, have been introduced into clinical practice in the past decade. While a reduced rate of leg wound infection and impaired wound healing are well documented in almost all studies, short- and long-term patency of endoscopically harvested vein grafts, compared with openly harvested grafts, has been challenged.^574,575 Although there is no unequivocal evidence concerning patency rates, most recent data from meta-analyses and randomized and non-randomized trials do not demonstrate inferior clinical outcomes with endoscopic vein harvest.^576–579 Endoscopic vein graft harvest should be undertaken by experienced surgeons or physician assistants with appropriate training and reasonable caseload.^580–582 Endoscopic radial harvesting is likewise possible but robust clinical-scientific evidence concerning its safety and efficacy is scarce.⁵⁸³ If performed ‘open’, the ‘no-touch’ SVG harvesting technique may reduce graft injury and improve patency.^584,585

Mammary artery harvesting

Internal mammary arteries are dissected from the chest wall, either as a pedicle or as an isolated (skeletonized) vessel. While the skeletonized technique has a higher theoretical potential for injury during harvest, the benefits include a longer conduit, more versatility (sequential anastomosis), higher blood flow and, most importantly, fewer wound healing problems.^586–590

16.3.2 Coronary vessel

Coronary artery bypass grafting aims at revascularizing coronary arteries with a flow-reducing luminal stenosis, supplying a viable and sizable area that is otherwise at risk.

The patency of a bypass graft is influenced by the characteristics of the anastomosed vessel, the run-off area, the graft material, its manipulation, and its construction.¹ Important coronary characteristics are the internal lumen size, the severity of proximal stenosis, the quality of the wall at the site of anastomosis, and the distal vascular bed.

16.3.3 Completeness of revascularization

Ideally, a generally accepted definition of completeness of myocardial revascularization would comprise (i) the size of the vessel, (ii) the severity of the lesion, (iii) the ischaemic burden caused by the lesion and (iv) the viability of the depending myocardial territory.^591–593 Current surgical practice is based on an anatomical definition of complete revascularization, defined as bypass grafting to all epicardial vessels ≥1.5 mm with a diameter reduction ≥50% in at least one angiographic view.⁵⁹⁴ However, in other clinical trials, several different definitions of completeness of revascularization have been used. Coronary artery bypass graft patients with incomplete revascularization had an outcome that was either similar^595–599 or inferior^{594,598,600,601} to that of patients with complete revascularization. A pivotal interventional study has shown superior results from FFR-guided functionally complete revascularization than those obtained by anatomically complete revascularization by PCI.⁵⁰ Currently, however, these results cannot be extrapolated to this group of CABG patients.⁵³

16.3.4 Construction of central anastomosis

Use of in situ grafts, still connected to their native take-off (LIMA, right IMA, right gastroepiploic artery) avoids the need for a proximal anastomosis. If free conduits (vein grafts, radial artery) are used, additional central anastomosis for arterial inflow into the bypass vessels is utilized in the majority of cases. Partial or total aortic cross-clamping allows the construction of central anastomoses to the ascending aorta. With a higher atherosclerotic risk profile, the likelihood of atherosclerotic changes in the ascending aorta increases and requires strategies that reduce or avoid manipulation. A single cross-clamp technique may be preferred to multiple manipulations, with the aim of reducing atheroembolic events, but a strict no-touch technique most effectively reduces embolization of atherosclerotic material.⁴⁴² In this situation, grafts are anastomosed end-to-side in a Y- or T-shaped configuration to the IMAs, to facilitate arterial inflow. Devices for clampless aortic anastomoses are also available.

16.3.5 Bypass grafts

The long-term benefit of CABG is maximized with the use of arterial grafts, specifically the IMA.^602,603 Available grafts include the IMA, radial, and gastroepiploic arteries, although the latter is seldomly used in current practice.^17,18 Except in rare circumstances, almost all patients should receive at least one arterial graft—the LIMA—preferentially to the LAD.^602,604

Data from non-randomized studies reveal unequivocally that the use of bilateral IMA is associated with improved long-term survival, as well as fewer non-fatal events such as myocardial infarction, recurrent angina, and need for re-operation.^{165,368,605–610} These advantages have also been demonstrated for diabetic patients. Conversely, BIMA grafting is associated with a small increase in sternal dehiscence and increased rate of mediastinitis; obese and diabetic patients being at particular risk.^{368,586,605,611–614} Thus BIMA grafting is recommended if life expectancy exceeds 5 years and to avoid aortic manipulation.

The radial artery constitutes a reasonable alternative as the second arterial graft, in patients in whom BIMA grafting is contraindicated (e.g. obese, diabetic, old women). Available evidence indicates its superiority (in terms of survival and non-fatal events) over the saphenous vein,^615–617 but inferiority to use of the IMA.⁶⁰⁶ This patency is strongly related to target vessel size and severity of stenosis. Numerous studies have demonstrated a strong, adverse influence on radial artery patency when the native coronary artery stenosis is <70%.⁶¹⁸ Furthermore, using radial artery grafts increases the number of arterial anastomoses beyond the use of both IMA and helps to achieve total arterial revascularization.

Graft flow measurement may be useful in confirming or excluding a technical graft problem indicated by haemodynamic instability or inability to wean the patient from cardiopulmonary bypass, new regional wall motion abnormalities on transoesophageal echocardiography, or ventricular arrhythmias.⁶¹⁹ It has also been shown to reduce the rate of adverse events and graft failure, although interpretation can be challenging in sequential grafts and T-grafts.^619,620

16.3.6 On-pump and off-pump procedures

Despite improved techniques and experience, part of the morbidity related to CABG is caused by the extracorporeal circulation (cardiopulmonary bypass) and access for cardiopulmonary bypass, prompting the off-pump approach. Two recent large, international, randomized trials have shown no difference in 30-day or 1-year clinical outcomes between on- and off-pump surgery, when performed by experienced surgeons.^441,621,622 There is also enough evidence to conclude that, for most patients and surgeons, on-pump CABG provides the best—or equal—short- and long-term outcomes.^621–625 For some surgeons, off-pump CABG is associated with inferior early and late graft patency rates and possibly compromised long-term survival; however, complete off-pump procedures in the hands of highly trained teams appear to be associated with a reduced risk of early morbidity, such as stroke, wound and respiratory infections, as well as fewer transfusions and shorter hospital stay.^626–629 In the subgroup of patients with end-stage CKD, there is some evidence that off-pump CABG is associated with lower in-hospital mortality and need for new renal replacement therapy.³⁸⁰

In the subgroup of patients with atherosclerotic changes of the ascending aorta, a no-touch technique—avoiding any manipulations of the ascending aorta either on- or off-pump—is essential to reduce the risk of stroke.⁴⁴³ The consistent cross-over rate of around 5% from on-pump CABG to off-pump CABG in high-quality RCTs suggests the necessity of routine ECG-gated CT scans of the thoracic aorta before bypass surgery in patients over 70 years of age or those with other risk factors for extensive atherosclerosis.

16.3.7 Minimally invasive procedures

Minimally invasive direct coronary artery bypass may represent an attractive alternative to a sternotomy.⁶³⁰ It has a similar safety and efficacy profile to conventional on- and off-pump CABG, with markedly reduced post-operative length of stay and an early quality-of-life benefit, although spreading of the ribs is associated with increased post-operative pain.^631–633

16.4 Reporting perioperative outcome

Perioperative reporting of outcome after CABG procedures should be done on a risk-adjusted basis. Early clinical outcome at 3 months after CABG is characterized by a 1–2% mortality rate and a 1–2% morbidity rate for each of the following events: stroke, renal, pulmonary and cardiac failure, bleeding, and wound infections. The early risk period after CABG extends up to 3 months, is multifactorial, and depends on the interface between technical variability and patient comorbidity.⁶³⁴

Procedural aspects of CABG

CABG = coronary artery bypass grafting; CT = computed tomography; IMA = internal mammary artery; LAD = left anterior descending.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

17. Procedural aspects of percutaneous coronary intervention

17.1 Percutaneous coronary intervention devices

17.1.1 Balloon angioplasty

Plain balloon angioplasty has been displaced in the treatment of de novo coronary lesions after demonstration of the superiority of BMS and, more recently, DES in terms of repeat revascularization.⁶⁴⁵ Its contribution to the treatment of in-stent restenosis has also diminished after recent studies demonstrated the advantages of DES and drug-coated balloons for this indication.^505,511 However, balloon angioplasty might be a valuable PCI option in all patients in whom implantation of stents is technically not achievable, or in a vessel that is too small to be stented (<2.0 mm), and in patients with critical stenoses who require urgent surgery.

17.1.2 Coronary stents

Bare-metal stents

Coronary stents are very effective in repairing dissections and have eliminated the need for urgent CABG due to abrupt vessel closure. Fully covered stents can be life-saving in the rare event of coronary perforation. The contribution of BMS is its approximately 30% lower rate of restenosis than with plain balloon angioplasty.⁶⁴⁵ Although many efforts have been made to further reduce restenosis by modification of stent design and materials, thinning of stent struts has been the only proven modification capable of reducing restenosis of BMS.^646,647 Bare-metal stents have been associated with favourable outcomes in terms of mortality, myocardial infarction, and stent thrombosis.¹²⁴ However, owing to a 20–30% rate of recurrence of angiographic stenosis within 6–9 months after implantation, restenosis with BMS has often been referred to as the 'Achilles’ heel' of PCI.⁶⁴⁵ There is no indication for BMS over new-generation DES, irrespective of patient and lesion subset. Similarly, there is no clear evidence of a difference between DES and BMS in the risk of stent thrombosis following unplanned disruption of DAPT.⁶⁴⁸

Early-generation drug-eluting stents

The risk of restenosis with BMS led to the development of DES, which consist of a metallic stent platform with controlled release of antiproliferative drugs, mostly controlled by surface polymers. Early-generation DES released sirolimus (e.g. Cypher^®)⁶⁴⁹ or paclitaxel (e.g. Taxus^®).⁶⁵⁰ Both in native vessels and saphenous vein bypass grafts, DES potently reduced angiographic and ischaemia-driven TVR.^124,495 Thus, the risk of clinical restenosis with the use of early-generation DES was 50–70% lower than with BMS, corresponding to a number-needed-to-treat of approximately 7–8.¹²⁴ In RCTs, no significant differences were observed in the long-term rates of death or myocardial infarction after use of DES or BMS.^124,199 Despite the superior anti-restenotic efficacy of early-generation DES over BMS, concerns have been generated by studies showing an increased propensity for very late stent thrombosis.^244,651,652 Although early-generation DES represented an important advance in the field of PCI,⁶⁵³ they currently play an irrelevant role in the treatment of CAD and are largely supplanted by new-generation DES.³

New-generation drug-eluting stents

New-generation DES are characterized by thin-strut, metallic platforms that release limus-based antiproliferative drugs from durable polymers with improved biocompatibility and lower polymer mass,^654,655 biodegradable polymers,^{654,656–658} or polymer-free surfaces.^659,660 Recent studies have shown the superiority of several new-generation DES over early-generation DES, not only with respect to efficacy but also safety.^{128,129,661,662} New-generation DES have addressed previous concerns of very late stent thrombosis and are at least as safe as bare-metal stents during long-term follow-up. Table 10 displays a list of Conformité Européenne (CE)-approved new-generation DES, supported by RCT evidence with clinical endpoints. Table 11 shows a list of CE-approved new-generation DES, the proven efficacy of which was based on angiographic findings from studies with or without a control group. These tables only provide a temporary ’snapshot' of available products, as new devices will be introduced or new evidence of established devices will become available.

Indications for new-generation DES

Increased efficacy and safety of new-generation DES have enabled their unrestricted use in patients with CAD and an indication for PCI, including patients with diabetes, multivessel and LM disease, acute myocardial infarction, SVG and restenotic lesions, and chronic total occlusions.³ New-generation DES should therefore be considered by default in all clinical conditions and lesion subsets. Among patients who require anticoagulation with NOACs, undergo non-cardiac surgery, experience bleeding complications, or are non-compliant with medication intake, previous concerns relating to differences in the duration of DAPT and risks associated with DAPT cessation are not substantiated in recent data sets.^648,663

Table 10

CE-approved new-generation DES recommended for clinical use based on randomized trials with a primary clinical endpoint (in alphabetical order)

CE = Conformité Européenne; DES = drug-eluting stent; PBMA = poly n-butyl methacrylate; PDLLA = poly(d,l)-lactic acid; PHMA = polyhexyl methacrylate; PLLA = poly-L-lactic acid; PVA = polyvinyl acetate; PVDF-HFP = poly(vinylidene fluoride-cohexafluoropropylene).

Table 11

CE-approved DES with angiographic efficacy data from randomized or non-randomized studies (in alphabetical order)

CE = Conformité Européenne; DES = drug-eluting stent; PBMA = poly n-butyl methacrylate; PCL = poly(L-lactide co-ε-caprolactone); PDLLA = poly(d,l)-lactic acid; PLGA = poly(lactide-co-glycolide); PLLA = poly-L-lactic acid; PSU = polysulfone; PVP = polyvinylpyrrolidone.

17.1.3 Bioresorbable stents

Completely bioresorbable stents, which dissolve after fulfilling their support function in the lesion site of the coronary vessel, have been a perennial aim since the introduction of the metallic stents. The combination of resorbable stent platforms with drug-eluting properties has enhanced the efficacy of these devices. Current stent platforms are based on two technologies: the manufacturing of drug-eluting, bioresorbable, polymer-based stents and drug-eluting, resorbable, metallic (magnesium) stents.⁶⁸⁴ The resorption process of the stent platforms takes from several months to 2 years, depending on polymer composition. To date, bioresorbable stents have been shown to dissolve completely over time, to restore the vasomotion of treated segments, and to result in positive remodelling with late lumen enlargement. In small series of patients with relatively simple lesions, early results are promising and appear to be similar to new-generation DES.^685–687 However, confirmation in large-scale RCTs is required to establish the indications for these devices. Table 12 includes the list of devices approved for use in Europe.

Table 12

Bioresorbable stents providing drug-elution with angiographic efficacy data from non-randomized studies (in alphabetical order)

PDLLA = poly(d,l)-lactic acid; PLGA = poly(lactide-co-glycolide); PLLA = poly-L-lactic acid.

17.1.4 Drug-coated balloons

The rationale of using drug-coated balloons is based on the concept that, with highly lipophilic drugs, even short contact times between the balloon surface and the vessel wall are sufficient for effective drug delivery. Using a paclitaxel-coated balloon, three RCTs, Paclitaxel-Coated Balloon Catheter I (PACCOCATH-I) and PACCOCATH–II,^507,508 and Paclitaxel-Eluting PTCA–Catheter In Coronary Disease (PEPCAD)-II,⁶⁸⁹ have targeted in-stent restenosis following BMS implantation, while three others have targeted in-stent restenosis in patients predominantly treated with DES eluting limus-analogues.^509–511 By virtue of the positive results achieved without additional stent implantation, drug-coated balloons may represent an attractive option for patients with restenosis after implantation of DES, although it is not known whether they are as safe and effective for this indication as new-generation DES that elute limus analogues.

In the randomized PEPCAD III study, the combination of a drug-coated balloon with cobalt chromium stent implantation was inferior to a sirolimus-eluting stent for de novo indications.⁶⁹⁰ Also, the Drug Eluting Balloon in Acute Myocardial Infarction (DEB-AMI) trial showed that drug-coated balloons followed by BMS implantation were inferior to paclitaxel-eluting stents in patients with STEMI.⁶⁹¹ A recent angiographic study suggested that drug-coated balloons may serve as an alternative to paclitaxel-eluting stents for the treatment of lesions in small coronary vessels;⁶⁹² however, the role of drug-coated balloons in this setting has not been evaluated against more effective, new-generation DES with limus analogues. There are various types of drug-coated balloons approved for use in Europe and their main characteristics are listed in Table 13. Most of the differences are related to the drug carrier, whereas paclitaxel is currently the sole active drug used. Although specifically designed comparative studies are lacking, one cannot assume a class effect for all drug-coated balloons.⁶⁹³

Table 13

CE-approved drug-coated balloons (in alphabetical order)

BTHC = butyryl-tri-hexyl citrate; CE = Conformité Européenne.

17.1.5 Other devices

Although routine use of rotational atherectomy did not improve outcomes after DES,⁶⁹⁸ such a device might technically be required in cases of tight and calcified lesions, to allow subsequent passage of balloons and stents. There is a resurgence in the use of rotational atherectomy for the purpose of optimal lesion preparation among patients undergoing implantation of bioresorbable stents.

17.2 Adjunctive invasive diagnostic tools

17.2.1 Intravascular ultrasound

Coronary angiography is unable to visualize the atherosclerotic involvement of the arterial wall. Intravascular ultrasound imaging allows a real-time, tomographic assessment of lumen area and plaque composition, size, and distribution. As a result of diffuse disease and remodelling, coronary angiography underestimates the extent and severity of the disease compared with IVUS.⁶⁹⁹ Although invasive by nature, IVUS is the established standard for accurate measurement of plaque burden, and the technique has been systematically used to determine the influence of different drugs on coronary plaque progression or regression.^700,701

Several RCTs addressed the potential of IVUS in reducing restenosis and adverse events after BMS implantation—with conflicting results. Most of these RCTs focussed on optimizing stent expansion using IVUS. Findings from meta-analyses subsequently suggested that better clinical and angiographic results may be obtained under IVUS guidance.^702–704 In the DES era, a threshold of stent expansion (5.0–5.5 mm²) was proposed to predict the occurrence of late events. In the subset of patients with LM disease, observational studies suggest that IVUS-guided stent implantation is associated with improved survival during long-term clinical follow-up.⁷⁰⁵ The use of intracoronary imaging has also been advocated in patients with stent failure, including restenosis and stent thrombosis, in order to explicate and correct underlying mechanical factors. In a multicentre all-comers study to establish the frequency, predictors, and timing of stent thrombosis, a pre-specified substudy compared outcomes of IVUS against angiographic guidance of DES implantation.⁷⁰⁶ IVUS-guided DES implantation (pre- and post-PCI in 63% of included cases) was performed in 3349 of 8583 patients (39%). In propensity-adjusted multivariable analysis, IVUS guidance was associated with reduced rates of definite or probable stent thrombosis (adjusted HR 0.40; 95% CI 0.21–0.73; P =0.003), myocardial infarction (adjusted HR 0.66; 95% CI 0.49–0.88; P =0.004), and MACE (adjusted HR 0.70; 95% CI 0.55–0.88; P =0.003) at 1 year. Notable limitations of this study were the lack of randomization and lack of pre-specified guidelines for performing and acting on IVUS findings.

In addition to conventional grey-scale IVUS, other ultrasound-based techniques have been used to provide additional diagnostic insights. Assessment of plaque composition may be further improved by analysis of the complete radiofrequency signal using different diagnostic algorithms, including those used in ‘virtual histology’.

17.2.2 Optical coherence tomography

Optical coherence tomography is a light-based modality of intravascular imaging with higher spatial resolution than IVUS (15 vs. 150 µm) and is ideally suited to accurate detection of intraluminal structures. Plaque composition, including the presence of lipid pools and intraluminal thrombi, can also be determined.⁷⁰⁷ Notably, this is the only technique capable of providing accurate measurements of the thickness of the fibrous cap and to detect even minor cap disruptions.^707,708 Early stages of cardiac allograft vasculopathy are frequently angiographically silent, yet can be visualized with OCT or IVUS and are associated with important prognostic implications.⁷⁰⁸ Optical coherence tomography requires complete blood clearance from the lumen for imaging, has a limited penetration on the vessel wall and is therefore unable to assess the complete plaque burden. After stent implantation, OCT is more accurate than IVUS in detecting subtle morphological details including malapposition, residual thrombus, plaque prolapse, and residual dissections, although the clinical significance of these findings remains to be determined.^709,710 During longitudinal follow-up investigations, OCT is more accurate than IVUS for assessing even neointimal thickness, strut apposition, and coverage. These findings are important surrogate markers of the efficacy and safety of DES and are frequently used to compare new DES. A recent retrospective and observational study suggested that OCT-guided stenting might improve clinical outcomes.⁷¹¹ Owing to its very high resolution, OCT is used to reveal the underlying mechanisms in patients with stent failure, including in-stent restenosis and stent thrombosis.⁵¹⁶ Likewise, intrastent neointimal tissue may be characterized, including the detection of neoatherosclerosis, which represents a potential link between in-stent restenosis and stent thrombosis.^516,712 Further studies are needed to define the clinical value of OCT.

17.2.3 Pressure-derived fractional flow reserve

Fractional flow reserve is the current standard of care for the functional assessment of lesion severity.⁷¹³ Imaging techniques provide useful information (i.e. minimal lumen area) but FFR is able to provide a physiological assessment. Initial studies suggested that the cut-off figure of 0.75 was reliable for identifying ischaemia-producing lesions, but subsequently the 0.80 criterion has gained widespread acceptance and its clinical role has been validated in outcome studies. Fractional flow reserve evaluation is valuable in patients undergoing diagnostic coronary angiography without prior non-invasive functional testing in the presence of borderline lesions and in patients with multivessel disease. The concept of avoiding unnecessary treatment of lesions that are not haemodynamically relevant was demonstrated in the DEFER and Fractional Flow Reserve Vs. Angiography for Multivessel Evaluation (FAME) trials.^50,51 More recently, the FAME II trial demonstrated that, in patients with SCAD, FFR-guided PCI using DES resulted in less need for urgent revascularization than with medical treatment.⁵⁴ While FFR requires maximal and stable hyperaemia—usually obtained by intravenous adenosine—new methods and indices [including instantaneous wave-free ratio (iFR)] that do not rely on the concept of maximal hyperaemia have been proposed, in order to simplify studies and facilitate a wider adoption of physiological assessment. Further studies will need to confirm the value of these new indices in clinical decision-making.⁷¹⁴ Fractional flow reserve can also be ascertained along the entire coronary tree using the anatomical information obtained by multislice CT.^715,716 Although appealing, owing to its non-invasive nature, CT-derived FFR requires further clinical validation before its clinical use may be justified.

Recommendations for the clinical value of intracoronary diagnostic techniques

FFR = fractional flow reserve; IVUS = intravascular ultrasound; OCT = optical coherence tomography. PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

17.3 Specific lesion subsets

17.3.1 Bifurcation stenosis

Bifurcation lesions are common and represent 10–15% of all coronary interventions.⁷¹⁷ Coronary bifurcation lesions are defined as stenosis of a main branch at the origin of a side branch, with or without lesions extending into the ostium of the side branch. They are best described according to the Medina classification, which uses the three components of a bifurcation: the main branch proximal, the main branch distal, and the side branch, giving a binary value (1 or 0) according to whether or not each of the segments previously defined is compromised.²⁹

PCI of bifurcation lesions is technically challenging, owing to multiple factors that include anatomical variability related to bifurcation site, plaque burden and morphology, bifurcation angle, and branch diameter.^718–724 Also, bifurcation anatomy may have dynamic variability during PCI, with plaque shift or dissection causing side-branch occlusion and requiring adjustments in the interventional approach.⁷²⁰

Despite many attempts with a variety of different stenting techniques (T-stenting, V-stenting, crush and its modifications, culotte, etc.), the optimal strategy for every anatomical subset has not yet been established. Variables to be considered are plaque distribution, size, and downstream territory of each vessel (main and side branch), and the bifurcation angle. Stent implantation in the main vessel only, followed by provisional balloon angioplasty with or without stenting of the side branch, seems preferable to routine stenting of both vessels,^725,726 although some studies have reported similar or improved results with specific strategies of complex stenting.^727–732 Fractional flow reserve data from side branches suggest that angiography overestimates the functional severity of side-branch stenosis. Final ‘kissing' balloon dilation is recommended when two stents are eventually required, with no advantage from final kissing with the one-stent technique.^733,734 Several stents, designed specifically for treatment of bifurcation lesions, have undergone extensive evaluation with good angiographic and clinical results, especially with side branch size >2.5 mm.

Percutaneous coronary intervention for left main bifurcations

Significant unprotected LM disease is observed in 5–7% of patients undergoing coronary angiography. For bifurcation and LM lesions, DES are preferred, with special attention to adequate sizing and deployment. Unprotected distal LM bifurcation PCI is a challenging percutaneous procedure and has worse long-term clinical outcome than the favourable results obtained with ostial- or shaft-LM lesions.^735,736 There are few systematic data supporting a specific stenting technique for LM bifurcation lesions.⁷³⁷

17.3.2 Chronic total coronary occlusion

Chronic total occlusion is defined as complete vessel occlusion with TIMI 0 flow within the occluded segment and an estimated occlusion duration of ≥3 months.⁷³⁸ In a consecutive series of patients without previous CABG surgery or recent myocardial infarction, who underwent angiography, totally occluded vessels were observed in 25% of cases.⁷³⁹ Patients with CTO underwent PCI less frequently than those without CTO (11% vs. 36%, respectively; P <0.0001) but were more frequently assigned to CABG or medical therapy.⁷³⁹

Treatment of CTOs should be considered in the presence of symptoms or objective evidence of viability/ischaemia in the territory of the occluded artery. Given the usually high procedural contrast volume, the potential long-term risk of radiation exposure and contrast-induced nephropathy should be considered. Ad hoc PCI is not recommended for CTOs. Observational studies suggest that successfully revascularized CTOs confer a long-term survival advantage over failed revascularization.^{740–742,743,744} In addition, better relief of angina and functional status was observed after successful CTO recanalization.⁷⁴⁵ In the post hoc analysis of 4-year results of the SYNTAX trial, the presence of CTO was the strongest independent predictor of incomplete revascularization (46.6% in the PCI arm), and had an adverse effect on clinical outcomes, including mortality.⁵⁹⁴

The procedural success rate is lower for PCI of CTO than for non-CTO lesions, with a similar rate of complications.^746,747 In a meta-analysis of 13 studies encompassing 7288 patients, recanalization was successful in 69% of cases (ranging from 51–74%).⁷⁴³ Success rates are strongly dependent on operator skills, experience with specific procedural techniques, and the availability of dedicated equipment (specialized guide wires and catheters or very low profile CTO balloons). Bilateral angiography and IVUS can be very helpful, as can special techniques such as guide-anchoring, various retrograde approaches, and specific wiring manipulation techniques, including parallel or anchoring wire.⁷⁴⁸ A retrograde approach via collateral pathways offers an additional possibility of success after failure of antegrade crossing, especially for right coronary artery and LAD occlusions.⁷⁴⁹ In general, this technique is not regarded as a first-line approach and is generally reserved for previous failed attempts. The overall success rate with the retrograde approach in a multicentre registry of 175 patients was 83.4%.⁷⁵⁰

In recently published systematic reviews and one RCT with long-term follow-up, DES provided superior clinical outcome to BMS, mainly due to a lower risk of revascularization.^751–754

17.3.3 Ostial lesions

Ostial disease is defined as a lesion arising within 3 mm of the vessel origin. It may be classified by location as aorto-ostial, non-aorto-ostial, or branch-ostial.⁷⁵⁵ Coronary ostial lesions are frequently not a manifestation of coronary atherosclerosis, but rather related to aortitis or radiation exposure.^756–758

Ostial lesions are usually recognized as fibrotic, calcified, and relatively rigid.^759,760 Aorto-ostial disease is resistant to dilation and prone to recoil, due to the greater thickness of muscular and elastic tissue in the aortic wall.⁷⁵⁵ Coronary stents—particularly DES—have improved procedural efficacy and safety.

In ostial coronary lesions, additional judgement and caution is essential before proceeding to PCI:⁷⁵⁵

(1) In aorto-ostial lesions coronary spasm has to be absent;

(2) In ostial LAD or LCx stenoses, a decision must be made on whether to attempt precise positioning of the stent at the ostium of the artery or whether stenting across the LCx/LAD ostium into the LM artery is preferable.

Lesion assessment with IVUS may be helpful, particularly in LM ostial stenosis, including assessment of the degree of calcification, need for adjunctive devices and assessment of stent expansion. Fractional flow reserve measurement may also be valuable in the assessment of angiographically borderline aorto-ostial and side-branch ostial lesions,⁷⁶¹ taking special care to avoid a wedge position of the guiding catheter and using intravenous, rather than intracoronary, adenosine.

Proper selection of the guiding catheter is important in aorto-ostial lesions, to avoid deep intubation and compromise of coronary flow.

Preparation and debulking of the lesion with rotational atherectomy and special balloons, cutting or scoring, may be useful in highly calcified, rigid ostial lesions.^762–765

Drug eluting stents are the default devices for ostial lesions.

The accurate positioning of the stent, precisely in the coronary ostium, may be technically challenging and some specialized techniques have been described that achieve the optimal stent placement.^766–768

Treatment of restenotic and saphenous vein graft lesions are discussed in section 14.

Recommendations for the treatment of specific lesion subsets

CTO = chronic total occlusion; DES = drug-eluting stent; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

18. Antithrombotic treatments

The choice, initiation, combination, and duration of antithrombotic strategies for myocardial revascularization depend on the clinical setting [SCAD, NSTE-ACS, STEMI], and the urgency and mode (PCI vs. CABG) of the intervention. To maximize the effectiveness of therapy and reduce the hazard of bleeding, ischaemic and bleeding risks should be evaluated on an individual basis.

18.1 Percutaneous coronary intervention in stable coronary artery disease

18.1.1 Oral antiplatelet therapy

Dual antiplatelet therapy includes a 150–300 mg oral loading dose of acetylsalicylic acid (ASA) (or 80–150 mg i.v.) followed by 75–100 mg per os (p.o.) daily plus a clopidogrel 300–600 mg loading dose followed by 75 mg daily.^773–775 Acetylsalicylic acid acts via irreversible inhibition of platelet cyclo-oxygenase-1 (COX-1), which is normally complete with chronic dosing ≥75 mg/day. Contrary to the antiplatelet effects, the gastrointestinal side-effects of ASA increase at higher doses. The optimal risk–benefit ratio appears to be achieved with an ASA dosage of 75–150 mg/day.^774,776

There is no evidence of benefit for systematic clopidogrel pre-loading before diagnostic coronary angiography in SCAD.⁷⁷⁷ A loading dose of 600 mg or more is recommended in patients scheduled for elective PCI if coronary anatomy is known. The use of a higher maintenance dose (150 mg) has been proposed in patients with high thrombotic risk (e.g. in diabetes, after recurrent myocardial infarction, after early and late stent thrombosis, for complex lesions, or in life-threatening situations should occlusion occur); however, no studies have established a short- or long-term benefit of a 150 mg daily maintenance dose. Specifically, the Gauging Responsiveness with A VerifyNow assay: Impact on Thrombosis And Safety (GRAVITAS) trial failed to show a benefit of doubling the clopidogrel maintenance dose in subjects deemed to be non-responders.⁷⁷⁸

Lifelong single antiplatelet therapy is recommended. Patients should be instructed not to prematurely discontinue oral antiplatelet therapy after stenting, due to the risks of stent thrombosis and myocardial infarction.^774,779 Data from the Patterns of Non-Adherence to Anti-Platelet Regimens In Stented Patients (PARIS) registry indicate that cardiac events after cessation of DAPT depend on the clinical circumstances and reason for cessation and that they attenuate over time.⁶⁴⁸ Half of the cases in which treatment was discontinued within 2 years of stent implantation were due to a physician’s guidance, and did not result in any adverse effect. Disruptions due to bleeding or non-compliance represented 14% of the cessations and were associated with a substantially increased risk of MACE, although this association largely attenuated after 30 days. Although the overall contribution of DAPT cessation to cardiac risk was small—thereby challenging existing paradigms for extension of antiplatelet treatment in otherwise stable patients after PCI—these findings highlights the need for patient education.

18.1.2 Intravenous antiplatelet therapy

Recent trials did not demonstrate additional benefit from GP IIb/IIIa inhibitors after a clopidogrel loading dose of 600 mg.^780–782 Anecdotal experience, however, suggests that GP IIb/IIIa inhibitors may be beneficial in ‘bail-out’ situations (intraprocedure thrombus formation, slow flow, threatened vessel closure).⁸⁶ The use of cangrelor is reviewed in section 18.4.2.

18.1.3 Anticoagulation

The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial demonstrated that outcome with bivalirudin and provisional GP IIb/IIIa blockade is similar to that of unfractionated heparin (UFH) plus planned GP IIb/IIIa inhibition during PCI for SCAD.⁷⁸³ Subsequently, Intracoronary Stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatment (ISAR-REACT) 3, performed in patients pre-treated with clopidogrel, showed similar net clinical outcomes to bivalirudin and UFH,⁷⁸⁴ but UFH dosage was higher (140 U/kg) than recommended, leading to an excess in major bleeding in patients preferentially undergoing procedures via femoral access. In view of the primary endpoint results and a trend towards a lower risk of myocardial infarction, anticoagulation with UFH with an i.v. bolus of 70–100 U/kg remains the standard anticoagulant treatment for elective PCI. Among PCI patients with negative biomarkers, bivalirudin reduced bleeding without affecting mortality and might therefore be considered for use in patients at high risk for bleeding.⁷⁸⁵

The Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention Randomized Evaluation (STEEPLE) trial has demonstrated lower bleeding with intravenous enoxaparin (0.5 mg/kg; P =0.01; 0.75 mg/kg; P =0.05) and 57% less major bleeding with both doses (P <0.01 for both), when compared with UFH with similar efficacy.⁷⁸⁶ Yet a significant benefit with respect to the primary endpoint was found only in the low-dose arm, which was stopped prematurely because of a non-significant trend towards excess mortality not related to ischaemic events and not confirmed at 1 year of follow-up.⁷⁸⁷ A recent meta-analysis confirmed the favourable safety profile.⁷⁸⁸

Recommendations for antithrombotic treatment in SCAD patients undergoing PCI

ASA = acetylsalicylic acid; BMS = bare-metal stent; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; DES = drug-eluting stent; GP =glycoprotein; i.v. = intravenous; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; SCAD = stable coronary artery disease.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

18.2 Non-ST-segment elevation acute coronary syndrome

High ischaemic risk is associated with dynamic ST-segment and troponin changes (primary indications), diabetes status, a GRACE score >140, LV function <40%, creatinine clearance <60 mL/min, recent PCI, and post-myocardial infarction angina (secondary indicators).¹⁸⁰ Bleeding risk can be assessed using risk scores, which may remain valid despite the increased use of the radial route to perform PCI.^808,809

18.2.1 Oral antiplatelet therapy

Dual antiplatelet therapy includes ASA with an oral loading dose of 150–300 mg (or 80–150 mg i.v.), followed by 75–100 mg p.o. daily, and a P2Y₁₂-receptor antagonist, as discussed below.⁷⁷⁴

Prasugrel and ticagrelor

Prasugrel (60 mg loading and 10 mg daily maintenance dose), a prodrug that irreversibly blocks the P2Y₁₂ platelet receptor with a faster onset and a more potent antiplatelet inhibition, has been tested in the TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel–Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI-38) trial against the 300 mg loading dose of clopidogrel—both started in the catheterization laboratory after diagnostic angiography in thienopyridine-naïve patients—and proved beneficial with respect to a composite ischaemic outcome.⁵¹⁸ Patients with NSTE-ACS treated conservatively were not included in this study. Recurrent cardiovascular events were fewer in prasugrel-treated patients (from 11.2% to 9.3%; RRR 0.82; 95% CI 0.73–0.93; P =0.002), mostly driven by a significantly lower risk for myocardial infarction (from 9.2% to 7.1%; RRR 23.9%; 95% CI 12.7–33.7; P <0.001). Severe bleeding complications were more common with prasugrel than with clopidogrel (TIMI non-CABG major bleeding 2.4% vs. 1.8%, respectively; HR 1.32; 95% CI 1.03–1.68; P =0.03), driven mostly by an increase in spontaneous bleeds (1.6% vs. 1.1%, respectively; HR 1.51; 95% CI 1.09–2.08; P =0.01), but also in fatal bleeding (0.4% vs. 0.1%, respectively; HR 4.19; 95% CI 1.58–11.11; P =0.002). Bleeding was also increased in prasugrel-treated patients referred for early CABG. Excluding patients with a higher bleeding risk, prasugrel offers significant benefit over clopidogrel with respect to cardiovascular events (HR 0.74; 95% CI 0.66–0.84; P <0.001) without significantly increasing major bleeding (HR 1.24; 95% CI 0.91–1.69; P =0.17).⁵¹⁸ In diabetic patients presenting with ACS, prasugrel confers a particularly greater treatment effect than clopidogrel, without significantly increased bleeding.³³⁷ Prasugrel should be considered in patients who present with stent thrombosis despite adherence to clopidogrel therapy.⁸¹⁰ Prasugrel is contraindicated in patients with prior stroke or TIA. Treatment with prasugrel is generally not recommended for patients of ≥75 years of age. If, after a careful individual risk–benefit evaluation by the prescribing physician, treatment is deemed necessary in the ≥75 years age or low body weight (<60 kg) groups then, following a loading dose of 60 mg, a reduced maintenance dose of 5 mg should be prescribed.

Alternatively, ticagrelor can be administered.⁸¹¹ Ticagrelor [180 mg loading dose; 90 mg b.i.d. (twice daily) daily maintenance dose] a cyclopentyltriazolopyrimidine, is an oral, reversibly binding P2Y₁₂ inhibitor with a plasma half-life of approximately 6–12 hours. The Study of Platelet Inhibition and Patient Outcomes (PLATO) study randomly assigned ACS patients—with or without prior loading with clopidogrel and irrespective of strategy (invasive vs. non-invasive)—to treatment with ticagrelor or clopidogrel and showed significantly superior results in favour of ticagrelor in the composite ischaemic endpoint (11.7% in the clopidogrel group and 9.8% in the ticagrelor group; HR 0.84; 95% CI 0.77–0.92; P <0.001) and mortality (from 5.1% to 4.0%, respectively; HR 0.79; 95% CI 0.69–0.91; P =0.001).³⁴¹ Patients undergoing PCI, with moderate- to high-risk NSTE-ACS, were allowed to receive an additional blinded 300 mg loading dose of clopidogrel (total loading dose 600 mg) or its placebo after the initial loading dose. Those patients with a final diagnosis of non-ST-segment elevation myocardial infarction (NSTEMI) had a significantly lower primary endpoint result with ticagrelor than with clopidogrel (11.4% vs. 13.9%, respectively; HR 0.83, CI 0.73–0.94) in contrast to patients with a final diagnosis of unstable angina (8.6% vs. 9.1%, respectively; HR 0.96, CI 0.75–1.22). The rate of TIMI major non-CABG-related bleeding was similar to that with prasugrel in the TRITON-TIMI 38 trial and was higher, at 2.8%, in the ticagrelor group, than the 2.2% of the clopidogrel group (HR 1.25; 95% CI 1.03–1.53; P =0.03). TIMI major CABG-related bleeding occurred in 5.3% of the patients in the ticagrelor group and in 5.8% in the clopidogrel group. There was no difference in the overall rates of fatal haemorrhage (0.3% in both groups) despite a higher rate of fatal intracranial haemorrhage in the ticagrelor group (0.1% vs. 0.001%; P =0.02). Ticagrelor was associated with an increased rate of adverse effects including dyspnoea, increased frequency of ventricular pauses, and asymptomatic increases in uric acid.¹⁸⁰

Clopidogrel

Clopidogrel is a prodrug that is converted in active metabolites through a two-step reaction involving cytochrome P450 (CYP450) enzymes, leading to an irreversible blockade of the P2Y₁₂ receptor. Compared with prasugrel and ticagrelor, this conversion results in a slower onset of action and a larger variability in oral bioavailability. The Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events − Seventh Organization to Assess Strategies in Ischemic Syndromes 7 (CURRENT-OASIS) 7 trial tested whether a double-dose regimen of clopidogrel (600 mg loading dose followed by 150 mg maintenance dose from day 2 to day 7, then 75 mg maintenance dose) was superior to a standard-dose regimen of clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) in ACS patients (treated conservatively and invasively). Overall, the higher dose regimen was no more effective than the conventional dosage, with a similar 30-day rate of the composite endpoint of cardiovascular death, myocardial infarction, or stroke (4.2% vs. 4.4%, respectively; HR 0.94; 95% CI 0.83–1.06; P =0.30), but was associated with increased 30-day rates of TIMI major bleeding (1.7% vs. 1.3%; HR 1.26; 95% CI 1.03–1.54; P =0.03) and the need for blood transfusion (2.2% vs. 1.7%; HR 1.28, 1.07–1.54; P =0.01).⁵¹⁹ The primary efficacy endpoint did not differ according to ASA dose (high vs. low) nor did the safety endpoint, major bleeding. When analysing the results from the pre-specified subgroup of 17 263 patients with ACS who underwent PCI, the double-dose regimen of clopidogrel led to 14% fewer cardiovascular events (3.9% vs. 4.5%; HR 0.86; 95% CI 0.74–0.99; P =0.039); however, the P-value for interaction was 0.03 and did not meet the pre-specified criterion (P <0.01) that rendered these results statistically significant. Therefore, the benefit was formally restricted to the 31% lower risk of stent thrombosis (1.6% vs. 2.3%; HR 0.69; 95% CI 0.56–0.87; P =0.001).⁸¹² Major bleeding was more common with double-dose than with standard-dose clopidogrel (1.6% vs. 1.1%; HR 1.41; 95% CI, 1.09–1.83; P =0.009). It is difficult to disentangle the impact of the chosen strategy of a short (1 week) treatment period with 150 mg. High-dose and low-dose ASA did not differ for the primary efficacy outcome (4.1% vs. 4.2%, respectively; HR 0.98; 95% CI 0.84–1.13; P =0.76) and the safety outcome major bleeding (1.5% vs. 1.3%; HR 1.18; 95% CI, 0.92–1.53; P =0.20). Based on these findings, the high-dose clopidogrel regimen of 600 mg loading dose and 150 mg maintenance dose in the first week may be considered only when prasugrel and ticagrelor are not available or if they are contraindicated.

18.2.2 Intravenous antiplatelet therapy

In the era before DAPT, trials of adequately dosed GP IIb/IIIa inhibitors in patients undergoing balloon angioplasty and coronary stent implantation demonstrated a lower incidence of composite ischaemic events in favour of GP IIb/IIIa treatment in combination with UFH, than with UFH alone, primarily through a reduction in myocardial infarction.⁸¹³ In the ISAR-REACT 2 trial, this benefit—according to the primary endpoint of death, myocardial infarction, or urgent TVR within 30 days—was maintained despite clopidogrel pre-treatment with a loading dose of 600 mg in patients with NSTEMI (13.1% vs. 18.3%; RR 0.71; 95% CI 0.54–0.95; P =0.02), but not in unstable angina without biomarker protein elevation (4.6% vs. 4.6%; RR 0.99; 95% CI 0.56–1.76; P =0.98).⁸¹⁴

The ACUITY trial—which compared a regimen of bivalirudin alone (with bail-out GP IIb/IIIa inhibitors in 7.4%) against UFH plus GP IIb/IIIa inhibitors—found a significant benefit of bivalirudin alone with respect to the primary 30-day composite endpoint of ischaemic and bleeding complications (10.1% vs. 11.7%, respectively; RR 0.86; 95% CI 0.77–0.97; P =0.02), driven by a reduction in major bleeding complications (3.0% vs. 5.7%, respectively; RR 0.53; 95% CI 0.43–0.65; P <0.001) without a significant increase in ischaemic complications (7.8% vs. 7.3%, respectively; RR 1.08; 95% CI 0.93–1.24; P =0.32).⁸¹⁵ This benefit of bivalirudin was found regardless of whether GP IIb/IIIa inhibitors were administered downstream or upstream and was maintained during 1-year follow-up.⁸¹⁶ The more recent ISAR-REACT 4 trial in PCI patients with NSTEMI did not find a significant benefit of UFH with abciximab, compared with bivalirudin alone. The primary endpoint of death, recurrent myocardial infarction, urgent TVR, or major bleeding within 30 days occurred in 10.9% of patients in the heparin-plus-abciximab group, as opposed to 11.0% in the bivalirudin group (RR 0.99; 95% CI 0.74–1.32; P =0.94).⁸¹⁷ However, heparin plus abciximab was associated with significantly more major bleeding than bivalirudin (4.6% vs. 2.6%, respectively; RR 1.84; 95% CI 1.10–3.07; P =0.02).

Consistent with ACUITY and ISAR-REACT 4, the EARLY-ACS trial did not confirm a benefit from upstream eptifibatide, with or without clopidogrel pre-treatment (9.3% vs. 10.0%, respectively; OR 0.92; 95% CI 0.80–1.06; P =0.23), but was associated with a higher bleeding risk with eptifibatide (TIMI major haemorrhage 2.6% vs. 1.8%, respectively; OR 1.42; 95% CI 1.07–1.89; P =0.02).³⁵⁷

In TRITON-TIMI 38, 7414 patients (54.5% of the total study population) received a GP IIb/IIIa inhibitor and, in terms of reducing the risk of cardiovascular death, myocardial infarction or stroke, a consistent advantage was observed from prasugrel when compared with clopidogrel, irrespective of the use of GP IIb/IIIa inhibitors (with GP IIb/IIIa inhibitors: HR 0.76; 95% CI 0.64–0.90; without GP IIb/IIIa inhibitors: HR 0.78; 95% CI 0.63–0.97; P-value for interaction 0.83). The risk of TIMI major or minor bleeding was not significantly different with either prasugrel or clopidogrel, regardless of whether or not patients were treated with GP IIb/IIIa inhibitors (P-value for interaction 0.19).⁸¹⁸

Overall, there is no evidence for an additional benefit of routine upstream use of GP IIb/IIIa inhibitors in NSTE-ACS patients scheduled for coronary angiography.

18.2.3 Anticoagulation

A general rule is to avoid crossover between antithrombins (with the exception of adding UFH to fondaparinux)—especially between UFH and low-molecular-weight heparin (LMWH)^819,820—and to discontinue antithrombins after PCI except in specific situations (e.g. LV aneurysm and/or thrombus, AF, prolonged bed rest, deferred sheath removal).

Among patients with high-risk ACS—as evidenced by positive biomarkers, ST-segment changes, or a GRACE risk score >140 with an intended urgent or early invasive strategy—bivalirudin plus provisional GP IIb/IIIa receptor inhibitors is recommended as an alternative to UFH plus GP IIb/IIIa receptor inhibitors, particularly in patients with a high risk of bleeding. ACUITY demonstrated the superiority of bivalirudin over UFH or low molecular weight heparin (LMWH) plus GP IIb/IIIa inhibitor, a regimen previously shown to be superior to heparin alone.⁸¹⁵ For patients with NSTEMI undergoing PCI, ISAR-REACT 4 presented additional evidence in favour of bivalirudin, with a better safety profile than the combination of UFH and abciximab. The use of bivalirudin preserves the option for bail-out GP IIb/IIIa inhibition.⁸¹⁷ However, in lower-risk patients pre-treated with clopidogrel, bivalirudin does not appear to offer an advantage over heparin.⁸²¹ We acknowledge that most of the evidence in support of bivalirudin is derived from trials in which the comparator was UFH plus GP IIb/IIIa inhibitor, a combination that is no longer routinely applied.

A substantial number of patients will undergo catheterization after a conservative treatment phase. Many of these patients will be on fondaparinux, an indirect factor Xa inhibitor, as recommended by current guidelines based on the Optimal Antiplatelet Strategy for Interventions (OASIS)-5 trial.^180,822 In this trial, the combined ischaemic event rate was similar, but severe bleeding complications were significantly lower with fondaparinux than with enoxaparin. This favourable net clinical outcome included reduced long-term mortality and stroke rates. Because of a higher rate of catheter thrombosis in patients undergoing PCI treated with fondaparinux alone, full-dose intravenous UFH (85 U/kg) must be added to prevent formation of catheter thrombi.⁸²³

Earlier studies on ACS patients receiving predominantly conservative treatment demonstrated the superiority of enoxaparin over UFH.⁸²⁴ The more recent studies in the setting of PCI did not find an advantage of enoxaparin over UFH when pre-randomization anticoagulation was not consistent with the study treatment or when there was a post-randomization cross-over.^819,820 A benefit of enoxaparin over UFH in reducing mortality and bleeding complications was recently reported in a meta-analysis covering NSTE-ACS patients.⁷⁸⁸

Recommendations for antithrombotic treatment in patients with NSTE-ACS undergoing PCI

ASA = acetylsalicylic acid; GP =glycoprotein; i.v. = intravenous; LMWH = low-molecular-weight heparin; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; UFH = unfractionated heparin.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

18.3 ST-segment elevation myocardial infarction

Patients undergoing primary PCI should receive a combination of DAPT with ASA and a P2Y₁₂ receptor blocker as early as possible before angiography, and a parenteral anticoagulant.

18.3.1 Oral antiplatelet therapy

An oral loading dose of ASA 150–300 mg (or i.v. 80–150 mg) followed by 75–100 mg p.o. daily should be given to ensure inhibition of TXA2-dependent platelet aggregation.⁸⁸⁷

The preferred P2Y₁₂inhibitors are prasugrel (60 mg p.o. loading dose; 10 mg maintenance dose) and ticagrelor (180 mg p.o. loading dose; 90 mg maintenance dose b.i.d.).^341,518 In the pre-specified subgroups of patients with STEMI undergoing PCI in the TRITON–TIMI 38 trial, the benefit of prasugrel was consistent for the primary endpoint at 15 months (prasugrel 10.0% vs. clopidogrel 12.4%; HR 0.79; 95% CI 0.65–0.97; P =0.02), without a significant increase in non-CABG-related bleeding risk (2.4% vs. 2.1%, respectively; HR 1.11; 95% CI 0.70–1.77; P =0.65). There was a lower risk of stent thrombosis (1.6% vs. 2.8%, respectively; HR 0.58; 95% CI 0.36–0.93; P =0.02), as well as of cardiovascular mortality (1.4% vs. 2.4%, respectively; HR 0.61; 95% CI 0.37–1.00; P =0.047)⁸²⁸ in favour of prasugrel at 30-day and 15-month follow-up (2.4% vs. 3.4%, respectively; HR 0.74; 95% CI 0.50–1.09; P =0.129). Notably, two-thirds of STEMI patients underwent PCI as the primary revascularization strategy and one-third underwent late or secondary PCI after fibrinolysis or lack of early revascularization. Prasugrel is contraindicated in patients with prior stroke or TIA. Treatment with prasugrel is generally not recommended for patients aged 75 years or more. In the ≥75 years age group—if treatment is deemed necessary after a careful, individual risk–benefit evaluation by the prescribing physician—then, following a loading dose of 60 mg, a reduced maintenance dose of 5 mg should be prescribed.⁸¹¹ In patients with body weight less than 60 kg, a maintenance dose of 5 mg is also recommended; this was shown to result in lower platelet reactivity—to a similar extent to prasugrel 10 mg/day in high body weight patients—and in greater platelet inhibition and lower HPR than with clopidogrel 75 mg/day, with similar bleeding rates.⁸²⁹

In the subset of patients with STEMI randomized in the PLATO trial, the benefit of ticagrelor over clopidogrel for the primary endpoint (9.4% vs. 10.8%, respectively; HR 0.87; 95% CI 0.75–1.01; P =0.07; Pfor interaction 0.29),⁸²³ was consistent with the overall results, without higher risk of bleeding (TIMI non-CABG major 2.5% vs. 2.2%, respectively; HR 1.09; 95% CI 0.80–1.48; P =0.60) but with a trend towards a lower risk of cardiovascular mortality at 1 year (4.7% vs. 5.4%, respectively; HR 0.84; 95% CI 0.69–1.03; P =0.07). In a pooled analysis of 48 599 patients, of whom 94% presented with acute coronary syndrome and 84% had PCI, novel P2Y₁₂inhibitors—including prasugrel and ticagrelor—have been associated with a mortality benefit and no significant excess of major bleeding among STEMI patients.⁸³⁰

Importantly, the more potent agents (prasugrel and ticagrelor) should not be used in patients with prior haemorrhagic stroke or with moderate-to-severe liver disease. When neither of these agents is available (or if they are contraindicated), clopidogrel 600 mg p.o. should be given instead, according to the pre-specified PCI analysis of CURRENT-OASIS 7.⁸¹²

18.3.2 Intravenous antiplatelet therapy

Several trials—performed before the use of pre-loading with thienopyridines and mostly using abciximab (i.v. bolus followed by infusion of 0.125 µg/kg/min up to a maximum of 10 µg/min for 12 hours)—documented clinical benefits from GP IIb/IIIa inhibitors as adjunct to primary PCI performed with UFH,^{242,831–833} including a significant 1-year survival benefit that was revealed in a meta-analysis of GP IIb/IIIa inhibitors with abciximab.⁸³¹

The large Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) study tested whether or not upstream administration at the time of first medical contact might improve the clinical efficacy of GP IIb/IIIa inhibitors, compared with administration at the time of primary PCI. In this trial, patients were randomly assigned to upstream abciximab vs. abciximab in the catheterization laboratory.²⁷¹ Upstream vs. in-cath-lab administration of abciximab had no significant effect on the primary endpoint of death, recurrent myocardial infarction, and heart failure, but significantly increased the risk of bleeding. In subgroup analyses, a benefit was observed with early use of abciximab in patients recruited by the ambulance system or in high-risk patients presenting rapidly at ‘spoke’ centres and requiring transfer for primary PCI.⁸³⁴ The randomized, double-blind Continuing TIrofiban in Myocardial infarction Evaluation (On-TIME-2) trial, using high-dose tirofiban, demonstrated a significant benefit of upstream compared with downstream provisional administration on the primary surrogate endpoint of ST-segment resolution and on the primary composite clinical endpoint of death, recurrent myocardial infarction, urgent target vessel re-intervention or thrombotic bail-out.⁸³⁵ However, the clinical benefit was related predominantly to a reduction in the perceived need for bail-out tirofiban. After pooling the On-TIME-2 data with the 414 patients of an open-label run-in phase, using the same inclusion and exclusion criteria and concomitant treatment, the rate of MACE was significantly reduced by systematic high-dose tirofiban versus no tirofiban or placebo (5.8% vs. 8.6%; P =0.043), with reduced mortality (2.2% vs. 4.1%, respectively; P =0.051) and no increased risk of major bleeding (3.4% vs. 2.9%, respectively; P =0.58).⁸³⁶ It remains unclear whether the effects observed in On-TIME-2 are due to upstream vs. downstream administration or due to systematic vs. provisional administration. However, time from symptom onset to study drug in FINESSE was twice as long as in On-TIME 2;⁸³⁷ only about 40% of patients needed to be transferred from a hospital without a catheterization facility to a hospital with such a facility, and a handful were recruited by the ambulance system. This may account for the differences between the two trials.

Intracoronary—as compared with intravenous—administration of GP IIb/IIIa inhibitors has been tested in several small studies and was associated with some benefits, which have not been confirmed in larger trials.^838,839

In the event of angiographic evidence of large thrombus, slow- or no-reflow, and other thrombotic complications, use of GP IIb/IIIa inhibitors as bail-out therapy appears reasonable, although this has not been tested in a randomized trial.

18.3.3 Anticoagulation

In the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, an RCT involving 3602 patients with STEMI, bivalirudin with bail-out GP IIb/IIIa inhibitors (in 7.2% of patients) was found superior to systematic GP IIb/IIIa inhibitors (mostly abciximab) plus UFH in respect of the two primary endpoints of net adverse clinical events (9.2% vs. 12.1%, respectively; RR 0.76; 95% CI 0.63–0.92; P =0.005) and major bleeding (4.9% vs. 8.3%, respectively; RR 0.60; 95% CI 0.46–0.77; P <0.001).⁸⁴⁰ The clinical benefit comprised a significant survival benefit from bivalirudin as compared with the GP IIb/IIIa inhibitor arm, both at 30 days and at 3 years (2.1% vs. 3.1%, respectively; P =0.049 and 5.9% vs. 7.7%; P =0.03; respectively). However, there was a higher incidence of stent thrombosis during the first 24 hours in the bivalirudin group (1.3% vs. 0.3%; P <0.001), which diminished during follow-up, while pre-randomization UFH and 600 mg clopidogrel loading dose were independent predictors of lower risk of acute and subacute stent thrombosis. The more recent, open-label European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) trial compared a strategy of pre-hospital bivalirudin with UFH or LMWH with optional use of glycoprotein IIb/IIIa inhibitors (69%) in 2218 STEMI patients, with frequent use of radial access (47%) and pre-treatment with P2Y₁₂ inhibitors (98%).⁸⁴¹ The primary endpoint of death or non-CABG major bleeding at 30 days was significantly lower with pre-hospital administration of bivalirudin than with UFH plus optional GP IIb/IIIa inhibitors (5.1% vs. 8.5%, respectively; RR 0.60; 95% CI 0.43–0.82; P <0.001). There were no differences in death (2.9% vs. 3.1%, respectively; RR 0.96; 95% CI 0.60–1.54; P =0.86), but there was a lower risk of major bleeding (2.6% vs. 6.0%, respectively; RR 0.43; 95% CI 0.28–0.66; P <0.001) mainly driven by differences in blood transfusion, whereas rates of TIMI major bleeding were not significantly reduced (1.3% vs. 2.1%, respectively; RR 0.62; 95% CI 0.32–1.20; P =0.15). Sensitivity analyses showed results to be consistent without significant interactions with arterial access site; however, stent thrombosis was more frequent in the bivalirudin group (1.6% vs. 0.5%, respectively; RR 2.89; 95% CI 1.14–7.29; P =0.02) at 30 days, solely driven by a difference during the first 24 hours, which was paralleled by a trend towards a higher rate of re-infarction (1.7% vs. 0.9%, respectively; RR 1.93; 95% CI 0.90–4.14; P =0.08) despite use of novel P2Y₁₂ inhibitors in more than half of the patients. The mortality benefit observed in the HORIZONS-AMI trial was not confirmed by EUROMAX, and the excess of stent thrombosis remained despite prolonged infusion of bivalirudin. The How Effective are Antithrombotic Therapies in PPCI (HEAT-PCI) study is a single-centre randomised trial comparing bivalirudin and unfractionated heparin in 1829 STEMI patients planned to undergo primary PCI.⁸⁴² The study represents contemporary practice with restriction of GP IIb/IIIa inhibitors to bail-out situations (in 15% of the randomised patients population), the frequent use of novel P2Y₁₂ inhibitors (89% of the patients), radial approach and predominant DES implantation. Among the 1812 patients included in the final analysis, 1491 actually underwent primary PCI. The primary efficacy outcome measure, a composite of all-cause mortality, stroke, recurrent infarction and unplanned target lesion revascularization, was higher in the bivalirudin than in the UFH group (8.7% vs. 5.7%, respectively; HR 1.52; 95% CI 1.09–2.13; P =0.01) including an increase in stent thrombosis (3.4% vs. 0.9%, respectively, RR 3.91; 95% CI 1.61–9.52; P =0.001) but no significant difference in mortality (5.1% vs. 4.3%, respectively). The primary safety outcome—defined as major BARC 3-5 bleeding—was 3.5% in the bilvalirudin group vs. 3.1% in the UFH group (P =0.59). The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial examined the question of whether a strategy of prasugrel plus bivalirudin (n = 269) was superior to a strategy with clopidogrel plus UFH (n = 275) in primary PCI STEMI patients and was interrupted due to slow patient recruitment.⁸⁴³ The primary endpoint—a composite of death, myocardial infarction, unplanned revascularization of the infarct-related artery, stent thrombosis, stroke or major bleeding evaluated at 30 days—occurred in 15.6% vs. 14.5%, respectively (RR 1.09; 95% CI 0–1.79; P =0.68), the secondary composite ischaemic endpoint (death, myocardial infarction, revascularization of the infarct-related artery, stent thrombosis or stroke) was seen in 4.8% vs. 5.5%, respectively (RR 0.89; 95% CI 0.40–1.96; P =0.89) and the secondary bleeding endpoint (non-CABG related bleeding according to the HORIZONS-AMI definition) in 14.1% vs. 12.0%, respectively (RR 1.18; 95% CI 0.74–1.88 P =0.54). In summary, recent trials comparing bivalirudin with UFH without systematic use of GP IIb/IIIa antagonists uphold concerns over an excess risk for acute stent thrombosis with bivalirudin, while differences in major bleeding are small.

Enoxaparin [0.5 mg/kg i.v. followed by subcutaneous (s.c.) treatment] was compared with UFH in one randomized, open-label trial, known as Acute STEMI Treated with primary PCI and intravenous enoxaparin Or UFH to Lower ischaemic and bleeding events at short- and Long-term follow-up (ATOLL) trial. The primary composite endpoint of 30-day death, complication of myocardial infarction, procedural failure, and major bleeding was not significantly lower for the enoxaparin arm (−17%; P =0.063), but there were reductions in the composite main secondary endpoint of death, recurrent myocardial infarction or ACS, or urgent revascularization, and in other secondary composite endpoints—such as death, or resuscitated cardiac arrest and death, or complication of myocardial infarction. There was no indication of higher incidence of bleeding from use of enoxaparin over UFH. In the per-protocol analysis of the ATOLL trial—pertinent to more than 87% of the study population—i.v. enoxaparin was superior to UFH in reducing the primary endpoint (RR 0.76; 95% CI 0.62–0.94; P =0.012) but also ischaemic endpoints, mortality (RR 0.36; 95% CI 0.18–0.74; P =0.003) and major bleedings (RR 0.46; 95% CI 0.21—1.01; P = 0.050), contributing to the improvement of the net clinical benefit (RR 0.46; 95% CI 0.3—0.74; P = 0.0002) in patients undergoing primary PCI. Based on these considerations, enoxaparin may be considered as an alternative to UFH as anticoagulant to primary PCI.⁸⁴⁴

Use of fondaparinux in the context of primary PCI was associated with potential harm in the OASIS-6 trial and is therefore not recommended.⁸⁴⁵ In particular, when used alone during primary PCI, fondaparinux is associated with the risk of catheter thrombosis. Thus, an additional anticoagulant with anti-IIa activity (unfractionated heparin or enoxaparin) should be administered.

Recommendations for antithrombotic treatment in patients with STEMI undergoing primary PCI

ASA = acetylsalicylic acid; GP = glycoprotein; i.v. = intravenous; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

18.4 Points of interest and special conditions

18.4.1 Pre-treatment with P2Y₁₂ inhibitors

Clopidogrel

The concept of pre-treatment with P2Y₁₂-receptor blockers is based on the observation that the risk of PCI depends on the intraprocedural level of platelet inhibition. The three largest clinical studies supporting this concept are (i) Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), with the PCI-CURE subset, (ii) Clopidogrel for the Reduction of Events During Observation (CREDO) with the subset of patients with sufficient delay between intake of clopidogrel 300 mg and PCI, and (iii) Do Tirofiban and Reo- Pro Give Similar Efficacy Outcome Trial (TARGET), with its non-randomized pre-treatment towards a background of GP IIb/IIIa inhibition.^791,825,851 Additional circumstantial evidence for pre-treatment with P2Y₁₂-receptor blockers comes from the notion that benefit of GP IIb/IIIa inhibition over placebo in historic studies is mitigated in more recent studies with systematic upstream P2Y₁₂-receptor inhibition.^269,817,821

A recent meta-analysis evaluated the relationships of clopidogrel pre-treatment vs. no treatment with mortality and major bleeding among patients undergoing PCI. Pre-treatment with clopidogrel had no effect on death (OR 0.80; 95% CI 0.57–1.11) or the risk of major bleeding (OR 1.18; 95% CI 0.93–1.50) but the risk of major cardiac events was significantly reduced (OR 0.77; 95% CI 0.66–0.89; P <0.001).⁷⁷⁷ There was substantial heterogeneity according to the type of clinical presentation of SCAD, NSTE-ACS, and STEMI, suggesting the lack of a consistent treatment effect—especially with respect to mortality—across the entire clinical spectrum. The benefit of pre-treatment was greater with increasing severity of clinical presentation.

In particular, clopidogrel pre-loading did not improve ischaemic outcomes in PCI for SCAD, with a trend towards more bleedings.⁷⁷⁷ In NSTE-ACS, there was a significant reduction in major cardiovascular events (OR 0.78; 95% CI 0.66–0.91; P =0.002) driven mainly by myocardial infarction, with a trend towards more TIMI major bleeds (OR 1.28; 95% CI 0.98–1.67; P =0.07). In primary PCI for STEMI, a single trial has evaluated the administration of DAPT before hospital admission, rather than in hospital, and has been terminated prematurely due to slow recruitment, with a trend towards a higher proportion of TIMI 2 or 3 flow and fewer ischaemic events in the pre-treatment group.⁸⁴⁶ However, this common practice in Europe is supported by a lower mortality (OR 0.50; 95% CI 0.26–0.96) without significant excess in major bleedings (OR 0.78; 95% CI 0.42–1.45).⁷⁷⁷

Prasugrel and ticagrelor

A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pre-treatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI) (the ACCOAST study) is the largest and the only pre-treatment study that has investigated the use of prasugrel (30 mg) vs. placebo before PCI in 4033 NSTE-ACS patients. Overall, 69% of patients underwent PCI and 5% CABG. When PCI was performed, an additional dose of 30 mg prasugrel was given after diagnostic coronary angiography in the pre-treatment group and 60 mg prasugrel was given in the placebo group. The primary endpoint—a composite of cardiovascular death, myocardial infarction, stroke, urgent revascularization, and bail-out GP IIb/IIIa inhibitor use at 7 days—was similar for both groups (HR with pre-treatment, 1.02; 95% CI 0.84–1.25; P =0.81). The rate of the safety endpoint of TIMI major bleeding, through day 7, was higher with pre-treatment (HR 1.90; 95% CI 1.19–3.02; P =0.006). The study was stopped 1 month before the end of enrolment due to an excess of major bleeding, and further highlights the lack of benefit of pre-treatment in NSTE-ACS patients.⁸²⁶ Pre-treatment with 30 mg prasugrel, with an average time delay of 6 hours before angiography, led to a much faster and more profound inhibition of platelet aggregation than a 600 mg clopidogrel loading dose as given in Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty (ARMYDA)-5.⁷⁸⁹ Within one hour after PCI, there was a catch-up phenomenon of the pharmacodynamic profile of pre-treatment and in-lab treatment group with 60 mg prasugrel. These very different pharmacodynamic profiles may account for the excess of periprocedural major bleedings reported in the pre-treatment group, namely access site-related bleeds and pericardium drainage. No such dramatic differences were observed with 600 mg clopidogrel, with which safety profiles of in-lab vs. pre-treatment were similar.⁷⁸⁹

A pre-treatment strategy, compared with a delayed administration of ticagrelor, has not so far been tested. In PLATO, all patients had received pre-treatment with clopidogrel or ticagrelor, irrespective of treatment strategy (invasive vs. non-invasive) and patients undergoing PCI had received P2Y₁₂ receptor inhibitors at a median of 4 hours prior to the intervention. Therefore, the risk–benefit ratio of pre-treatment using ticagrelor prior to diagnostic coronary angiography is not known.

18.4.2 Intravenous P2Y₁₂inhibitors

Cangrelor is a direct reversible, short-acting (half-life 3 min) P2Y₁₂ inhibitor that does not require metabolic conversion, although it is not available for oral administration. It has been used during PCI with mixed results. In Cangrelor vs. Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION)-PHOENIX, a double-blind, placebo-controlled trial, 11 145 patients who were undergoing either urgent or elective PCI and received guideline-recommended therapy, were randomized to receive a bolus and infusion of cangrelor (30 µg/kg; 4 µg/kg/min) or a loading dose of 300 mg or 600 mg of clopidogrel. The rate of the primary efficacy endpoint—defined as a composite of death, myocardial infarction, ischaemia-driven revascularization, or stent thrombosis at 48 hours after randomization—was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (adjusted OR 0.78; 95% CI 0.66–0.93; P =0.005).⁸⁵² Stent thrombosis developed in 0.8% of the patients in the cangrelor group and in 1.4% in the clopidogrel group (OR 0.62; 95% CI 0.43–0.90; P =0.01). Severe bleeding at 48 hours did not differ significantly. Although the universal definition of myocardial infarction was used, the incidence of Q-wave myocardial infarction did not differ between the study groups.⁸⁵² The pre-specified pooled analysis of patient-level data from the three cangrelor trials (CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-PHOENIX) confirmed the lower rates of PCI periprocedural thrombotic complications (3.8% for cangrelor vs. 4.7% for control; OR 0.81; 95% CI 0.71–0.91; P =0.0007) and of stent thrombosis (0.5% vs. 0.8%, respectively; OR 0.59; 95% CI 0.43–0.80; P =0.0008) with no difference in Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) major bleeding.⁸⁵³ These early benefits were maintained at 30 days and found to be consistent across all the pre-specified subgroups. There was no correlation between treatment effect and clinical presentation and there was a significant lower incidence of Q-wave myocardial infarction in favour of cangrelor. Altogether, cangrelor seems to be a good therapeutic option in P2Y₁₂ inhibitor-naïve patients undergoing coronary stent implantation. It should be pointed out that there was no effect on mortality and that the benefit of cangrelor was mainly derived from preventing intraprocedural stent thrombosis.⁸⁵³

In addition, the use of cangrelor allows platelet inhibition to be maintained up to surgery in patients discontinuing oral antiplatelet therapy, without any excess of perioperative bleeding, in contrast to interruption of oral P2Y₁₂ several days before CABG surgery.⁸⁵⁴

Cangrelor has not yet been approved by the European Medical Agency or the Federal Drug Administration and therefore no specific recommendation about its use can be given.

18.4.3 Anticoagulation after percutaneous coronary intervention in acute coronary syndrome patients

The recent trial known as Anti-Xa Therapy to Lower cardiovascular events in Addition to Standard therapy in subjects with Acute Coronary Syndrome–Thrombolysis In Myocardial Infarction 51 (ATLAS ACS 2–TIMI 51) demonstrated that the addition of rivaroxaban—either 2.5 mg or 5.0 mg, twice daily—to ASA and clopidogrel among ACS patients lowered the composite primary efficacy endpoint of cardiovascular death, myocardial infarction, and stroke (9.1% vs. 10.7%, respectively; HR 0.84; 95% CI 0.74–0.96; P =0.008) but was associated with a near four-fold increased risk of non-CABG-associated major bleeding (2.1% vs. 0.6%, respectively; HR 3.96; 95% CI 2.46–6.38; P <0.001) and an increased risk of intracranial haemorrhage.⁸⁵⁵ The twice-daily 2.5 mg dose of rivaroxaban resulted in significantly lower rates of all-cause and cardiovascular mortality, which was not observed with the twice-daily 5.0 mg dose. The composite of definite and probable stent thrombosis was lower in the pooled (1.9% vs. 1.5%, respectively; HR 0.65; P =0.017) and 2.5 mg twice-daily groups (1.9% vs. 1.5%, respectively; HR 0.61; P = 0.023) with a trend towards lower incidences in the 5 mg twice-daily treatment group (1.9% vs. 1.5%, respectively; HR 0.70; P =0.089).⁸⁵⁶ The ATLAS ACS 2-TIMI 51 trial did not test the combination of rivaroxaban with prasugrel or ticagrelor, which might be associated with an even higher bleeding risk. This trial suggests that low-dose rivaroxaban (2.5 mg twice daily) may be considered in patients who receive ASA and clopidogrel after ACS, particularly after STEMI.⁸⁵⁷ However, a phase III trial of apixaban, another factor Xa antagonist, the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE-2),⁸⁵⁸ which compared full-dose apixaban (5 mg b.i.d.) in combination with DAPT against DAPT alone, was stopped early due to safety concerns related to an excess bleeding risk in the absence of a benefit in ischaemic outcomes in high-risk ACS patients. Notably, the study population carried higher comorbidities and the apixaban dose regimen was the full dose used to prevent cardioembolic stroke in non-valvular atrial fibrillation. Finally, darexaban and dabigatran were both tested in phase II dose-ranging trials in post-ACS patients.^859,860 In both cases, dose-dependent increases in major bleeding were observed, but there was no sign of added efficacy when adding anticoagulant therapy to antiplatelet therapy in this setting. Conversely, the phase II dose-ranging trials with rivaroxaban and apixaban demonstrated a dose-dependent higher incidence in major bleeding but a significantly lower rate of death, myocardial infarction or stroke than with placebo for rivaroxaban and a trend for apixaban.^861,862 Pharmacological features of direct oral anticoagulants are summarized in Table 14.

In conclusion, the role of direct oral anticoagulants in combination with DAPT in secondary prevention of ACS is promising, but interpretation of the totality of evidence for the class of oral anticoagulants is inconclusive and requires further study.

Table 14

Pharmacological features of novel oral anticoagulants

ACS = acute coronary syndrome; AF = atrial fibrillation; b.i.d. = bis in diem (twice daily); BRCP = breast cancer resistance protein; q.d. = quaque die; T_max = time to reach peak plasma concentration.

18.4.4 Anticoagulation during percutaneous coronary intervention in patients on oral anticoagulation

A sizeable proportion of patients (6–8%) undergoing PCI have an indication for long-term oral anticoagulation with a vitamin K antagonist (VKA) or NOAC, due to various conditions such as moderate-to-high embolic risk AF, mechanical heart valves, or venous thromboembolism. Interruption of VKA therapy may expose the patient to an increased risk of thromboembolic episodes.⁸⁶³ Percutaneous coronary intervention may be a delicate process under full VKA anticoagulation or NOAC.

In elective PCI, no additional anticoagulation is needed if the international normalized ratio (INR) is >2.5. Radial access should be the preferred choice, to reduce the risk of periprocedural bleeding. PCI without interruption of VKAs, to avoid bridging therapy that may lead to more bleeding or ischaemic complications, should be the preferred strategy. The use of GP IIb/IIIa inhibitors, unless for bail-out, should be also avoided.

Primary PCI in patients on therapeutic oral anticoagulation should be performed via a radial approach with use of additional parenteral anticoagulation, regardless of the timing of the last dose of oral anticoagulant. Given its short-term action of 25 minutes and lower bleeding risk bivalirudin—used during the procedure and discontinued immediately after primary PCI—may be preferred over UFH or enoxaparin, especially when patients are exposed to dabigatran. Enoxaparin should be the preferred parenteral anticoagulant in cases of prior exposure to direct anti-Xa inhibitors (rivaroxaban or apixaban) to avoid cross-over. Unless for bail-out situations, glycoprotein IIb/IIIa inhibitors should generally be avoided.

18.4.5 Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulation

Long-term exposure of patients to triple therapy is associated with a high risk of bleeding.⁸⁶⁴ Fatal bleeds represent 1 in 10 of all bleeds, of which half are of intracranial origin and half from the gastrointestinal tract.⁸⁶⁵ Evidence is too weak to provide clear guidance.^866,867 Triple therapy, consisting of ASA, clopidogrel, and (N)OAC after PCI, should only be given if a compelling indication exists (i.e. paroxysmal, persistent, or permanent AF with Cardiac failure, Hypertension, Age ≥75 [Doubled], Diabetes, Stroke [Doubled]–Vascular disease, Age 65–74 and Sex category [Female] (CHA₂DS₂-VASc) score ≥2; mechanical valves; recent or recurrent history of deep venous thrombosis or pulmonary embolism).

Triple therapy should be limited in duration, depending on the clinical setting, thromboembolic (CHA₂DS₂-VASc score) and bleeding risks Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol (HAS-BLED) score. The use of prasugrel or ticagrelor as part of triple therapy should be avoided, given the lack of established benefit and the greater risk of major bleeding compared with clopidogrel (HR 4.6; 95% CI 1.9–11.4; P <0.001) in an observational study.⁸⁶⁸ Gastric protection should be implemented with a proton pump inhibitor. The dose intensity of oral anticoagulation should be carefully monitored with a target INR of 2.0–2.5 in the case of vitamin K antagonists and use of lower tested dose for stroke prevention in the case of NOACs (dabigatran 110 mg b.i.d.; rivaroxaban 15 mg once daily, etc.). Recommendations on stent type (DES vs. BMS) are difficult in the absence of conclusive data. Although DAPT is routinely recommended for a duration of at least 1 month after BMS and for 6 months after DES, the risk of stent thrombosis (and other ischaemic endpoints) between 1 and 12 months after stenting appears similar with both stent platforms.^124,352,869 In addition, recent data on the risk of adverse events among patients who have ceased DAPT medication⁶⁴⁸ and patients undergoing non-cardiac surgery suggest no differences between BMS and DES.⁶⁶³ Until data from randomized trials become available, this task force recommends the use of new-generation DES over BMS in patients requiring oral anticoagulation who are at low bleeding risk (HAS-BLED score ≤2). Among patients undergoing PCI who require oral anticoagulation and have a high bleeding risk (HAS-BLED score ≥3) the choice between BMS and new-generation DES needs to be decided on an individual basis.

Omission of ASA while maintaining clopidogrel has been evaluated in the What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) trial, which randomized 573 patients either to dual therapy with oral anticoagulation and clopidogrel (75 mg daily) or to triple therapy with oral anticoagulation, clopidogrel, and ASA 80 mg daily. Treatment was continued for 1 month after BMS placement in 35% of the patients and for 1 year after DES placement in the remaining 65%; follow-up was for 1 year.⁸⁷⁰ Percutaneous coronary intervention was performed on VKA in half of the patients and one-third presented with NSTE-ACS. The primary endpoint of any TIMI bleeding was significantly lower in the dual therapy arm (19.5% vs. 44.9%; HR 0.36; 95% CI 0.26–0.50; P <0.001). The rates of myocardial infarction, stroke, TVR, or stent thrombosis did not differ significantly, but all-cause mortality was lower in the dual therapy group (dual 2.5% vs. triple 6.4%; P =0.027) at 1 year. However, differences were driven by minor bleeding as major bleeding was not significantly lower, femoral access was used in the majority of patients (74%), and triple therapy was extended to 1 year. Although the trial was too small to assess ischaemic outcomes, dual therapy with clopidogrel and oral anticoagulants may be considered as an alternative to triple therapy in patients with high bleeding risk.

Recommendations for antithrombotic treatment in patients undergoing PCI who require oral anticoagulation

ACS = acute coronary syndrome; ASA = acetylsalicylic acid; BMS = bare-metal stent; CHA₂DS₂-VASc = Cardiac failure, Hypertension, Age ≥75 [Doubled], Diabetes, Stroke [Doubled]–Vascular disease, Age 65–74 and Sex category [Female]); DAPT = dual antiplatelet therapy; DES = drug-eluting stent; (N)OAC = (non-vitamin K antagonist) oral anticoagulant; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol; INR = international normalized ratio; LV = left ventricular; PCI = percutaneous coronary intervention; SCAD = stable coronary artery disease; UFH = unfractionated heparin.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

18.4.6 Duration of dual antiplatelet therapy after percutaneous coronary intervention

In the pivotal studies establishing the value of early-generation DES, the duration of DAPT was 2–3 months for the sirolimus-eluting stent and 6 months for the paclitaxel-eluting stent. Following concerns of a greater risk of stent thrombosis and ischaemic adverse events,⁶⁵¹ several guideline documents recommended DAPT for 1 year or longer after DES implantation.⁷⁷⁹ Detailed analyses comparing early-generation DES with BMS confirmed no safety issue, with similar rates of death, and myocardial infarction, during long-term follow-up throughout 5 years with heterogeneous duration of DAPT, ranging from 2 months up to 1 year.^124,649,650 Although very late stent thrombosis was more frequent, this infrequent event was offset by a somewhat lower rate of early stent thrombosis and a lower risk of myocardial infarction related to repeat revascularization. More recently, new-generation DES have been shown to have a safety profile similar to or even better than BMS, including the risk of very late stent thrombosis.^{125,129–132}

Currently available data do not support prolonging DAPT following DES beyond 1 year. A randomized trial called The Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events/REAL-world Patients Treated with Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events (ZEST-LATE/REAL-LATE) assigned stable patients, 1 year after DES implantation, to continuation with clopidogrel plus ASA or to ASA alone.⁸⁷¹ After a median follow-up of 19 months, there was a non-significantly higher rate of myocardial infarction, stroke, and death in the patients who had continued clopidogrel treatment than in those who stopped clopidogrel at random assignment 1 year after implantation.

Several randomized trials including Efficacy of Xience/Promus vs. Cypher in reducing Late Loss After stenting (EXCELLENT),⁸⁰³ Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation (RESET),⁸⁰⁵ Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE)⁸⁰⁴ and PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY (PRODIGY),⁷⁹⁹ compared short duration (3–6 months) of DAPT against extended duration (12–24 months) and consistently showed a lack of benefit in terms of ischaemic outcome but a higher risk of bleeding. A recent meta-analysis of data comparing brief vs. prolonged DAPT (beyond 12 months) duration concluded that extension of DAPT beyond 6 months increased the risk of bleeding without reducing ischaemic events.⁸⁰² It should be pointed out that none of these trials were powered for ischaemic endpoints; all were open-label and the time from stenting to randomization varied. Therefore, weighing the quality of available evidence is difficult and these inferences need be confirmed by continuing large-scale trials including Intracoronary Stenting and Antithrombotic Regimen: Safety And eFficacy of a 6-month DAT after drug-Eluting stenting (ISAR-SAFE; NCT00661206) and DAPT (NCT00977938).

In view of the well-established risks of bleeding associated with DAPT beyond 12 months, and the lack of evidence of a benefit in the prevention of ischaemic complications, routine extension of DAPT beyond 6 months after new-generation DES implantation in SCAD cannot be recommended based on currently available data. Observational data from new-generation zotarolimus-eluting and everolimus-eluting stents suggest that even shorter durations of DAPT may be sufficient.^872,873 In the OPTIMIZE trial, clinical non-inferiority of 3 months vs. 12 months of DAPT was assessed in patients undergoing PCI with zotarolimus-eluting stents.⁸⁰⁴ The rate of net adverse clinical events did not differ between short-term DAPT and extended-duration DAPT (6.0% vs. 5.8%, respectively; risk difference, 0.17; 95% CI −1.52 to 1.86). Rates of bleeding, major or otherwise, were not statistically different. Owing to the paucity of high-quality data for a 3-month (or shorter) duration of DAPT with new-generation DES, this regimen should be reserved for patients at high risk of bleeding or requiring oral anticoagulation.

In patients undergoing myocardial revascularization for high-risk ACS, DAPT is recommended for 1 year, irrespective of stent type. This recommendation is based on the early CURE study—which demonstrated a continuously increasing benefit of DAPT over ASA during the entire study follow-up period—as well as the more recent results of TRITON-TIMI 38 and PLATO, which showed a continuously increasing benefit of DAPT with the new more potent P2Y₁₂-receptor blockers. After stenting for ACS, particularly STEMI, extended DAPT reduces the risk of stent thrombosis, re-infarction, and cardiovascular mortality,⁸²⁵ and more potent DAPTs are associated with the greatest post-ACS clinical benefits of any type.⁸³⁰ It is important to inform patients and their physicians about the need to avoid premature discontinuation of DAPT.

In summary, it is recommended that DAPT be administered for at least 1 month after BMS implantation in SCAD,⁸⁶ for 6 months after new-generation DES implantation in SCAD,⁸⁶ and for up to 1 year in patients after ACS, irrespective of revascularization strategy.¹⁸⁰

18.4.7 Drug interactions: a clopidogrel-related topic

Those statins which are substrates of the CYP3A4 isoform (i.e, simvastatin, atorvastatin and lovastatin) may interact with clopidogrel metabolism, a drug interaction that has little, if any, clinical relevance.

European and USA regulatory agencies have issued warnings about diminished clopidogrel action when combined with proton pump inhibitors (especially omeprazole and esomeprazole). Treatment with proton pump inhibitors should be carefully considered in patients with previous gastrointestinal complications or risk factors for gastro-intestinal bleedings (e.g. the elderly, concomitant use of warfarin, glucocorticoids, non-steroidal anti-inflammatory drugs, or Helicobacter pylori infection) who require DAPT. Several studies have shown a proton pump inhibitor-related impact on the pharmacodynamics of antithrombotic drugs, whereas few studies support significant effects on clinical outcomes. There is insufficient data to discourage the use of proton pump inhibitors in patients treated with ASA, prasugrel, ticagrelor, dabigatran, or one of the oral factor Xa inhibitors (rivaroxaban and apixaban). By far the most extensively investigated proton pump inhibitor interaction is with clopidogrel. Notwithstanding, potential interactions between the antiplatelet effect of clopidogrel and proton pump inhibitors are controversial, without firm conclusions on clinical implications. Clopidogrel is most often prescribed with ASA, and patients on DAPT have an increased risk of gastrointestinal bleeding; however, proton pump inhibitors should not be used automatically in these patients but should be prescribed to patients with previous gastrointestinal complications or who are at an increased risk of bleeding. Pharmacodynamic studies—but not clinical outcome studies—support the use of newer proton pump inhibitors such as pantoprazole instead of omeprazole.⁸⁷⁴

18.4.8 Renal dysfunction

Renal dysfunction is present in 30–40% of patients with CAD and the extent of CKD is strongly related to the risk of in-hospital adverse outcomes. Impaired clinical outcomes of patients with CKD are possibly explained by more frequent pre-existing cardiovascular disease, more extended atherothrombosis, a more serious presentation of ACS, lower revascularization rates, and under-utilization of evidence-based therapies, with potential overdosing of medication in patients whose metabolism and excretion depend on renal function. Creatinine clearance should be calculated with the Cockroft–Gault formula, to comply with drug labelling and avoid overdosing with antithrombotics—a frequent situation in patients with CKD—leading to increased bleeding risk.^875,876 In patients referred for acute PCI, the first dose of an antithrombotic drug does not usually add to the risk of bleeding in the case of CKD. Repeated infusion or intake might lead to drug accumulation and increased bleeding risk. Accordingly, in the absence of contraindications, patients with CKD should receive the same first-line treatment as any other patient. Thereafter, dose adaptation with respect to kidney function is essential and specific antithrombotic agents may be preferred (Table 15). It is important, in minimizing the risk of CIN, to ensure proper hydration during and after primary PCI and to limit the dose of contrast agents (see section 11.4).

Renal dysfunction was one of several risk criteria that had to be considered in the PLATO study and only patients with end-stage renal failure requiring dialysis were excluded. Patients with CKD (21%) did particularly benefit from ticagrelor, with a 23% RRR for the primary ischaemic endpoint (compared with a non-significant 10% lower figure in patients without CKD), and an even more pronounced 4.0% absolute and 28% RRR in all-cause mortality.⁸⁷⁷

18.4.9 Surgery in patients on dual antiplatelet therapy

Management of patients on DAPT who are referred for surgical procedures depends on the level of emergency and the thrombotic and bleeding risk of the individual patient (Figure 4).⁸⁷⁸ Most surgical procedures can be performed on DAPT or at least on ASA alone with acceptable rates of bleeding. A multidisciplinary approach is required (cardiologist, anaesthesiologist, haematologist, and surgeon) to determine the patient’s risk (bleeding and thrombosis) and to choose the best strategy. Indeed, surgery-related bleeding increases 30-day and long-term mortality.⁵⁷³

Figure 4

Pre-operative management of patients considered for/undergoing surgery under DAPT. ASA = acetylsalicylic acid; DAPT = dual antiplatelet therapy.

Observational data from a large cohort study (124 844 BMS or DES implantations) indicate that the strongest risk factors for MACE following non-cardiac surgery are the need for non-elective surgery, a history of myocardial infarction within 6 months of surgery and advanced cardiac disease. While timing of surgery was associated with MACE during the first 6 months after PCI, this was no longer apparent beyond 6 months.⁶⁶³ Notably, stent type (BMS vs. DES) was not associated with MACE after surgery. In order to reduce the risk of bleeding and thrombosis, it is recommended that elective non-cardiac surgery be delayed until completion of the full course of recommended DAPT (ideally 6 months in SCAD and 1 year in ACS patients) and that surgery be performed without discontinuation of aspirin, if possible. Shorter duration of DAPT may be justifiable if surgery cannot be delayed.

In preparation for surgical procedures with high-to-very-high bleeding risk, it is recommended that clopidogrel be discontinued 5 days before surgery to reduce bleeding and the need for transfusion, while maintaining ASA throughout the perioperative period.⁸⁷⁹ Prasugrel should be stopped 7 days before surgery, based on its prolonged and more effective platelet inhibition than clopidogrel. Interestingly, despite higher levels of observed TIMI major bleeding (OR 4.73; 95% CI 1.9–11.8), platelet transfusion, and surgical re-exploration for bleeding, prasugrel was associated with a lower rate of death after CABG than with clopidogrel in the small subgroup of patients in the TRITON-TIMI 38 trial (2.3% vs. 8.7%, respectively; adjusted OR 0.26; P =0.025).⁸⁸⁰ Most cases of CABG were planned and undertaken after discharge from the qualifying event, and the study drug was usually resumed after CABG. In the PLATO trial, in the subgroup of patients undergoing CABG within 7 days after the last study drug intake (3–5 days), ticagrelor, compared with clopidogrel, was also associated with lower all-cause mortality (4.6% vs. 9.2%, respectively; P =0.002) without excess risk of CABG-related bleeding.⁸⁸¹ More than half of the cases of CABG were undertaken during the qualifying event. This was accounted for by fewer deaths associated with bleeding and infection as well as fewer ischaemic events. A total of 37% did not restart study medication within 7 days of discharge.

Accordingly, withdrawal of P2Y₁₂ inhibitors is not recommended in high-risk cohorts, such as those with continuing ischaemia and high-risk anatomy (e.g. LM or severe proximal multivessel disease). These patients should undergo CABG while maintaining P2Y₁₂ inhibition, while paying particular attention to reducing bleeding. It may be reasonable—though only in patients whose risk of bleeding is very high—to withhold P2Y₁₂ inhibitors before surgery, even among those with active ischaemia, and to consider bridging strategies (see below). Dual antiplatelet therapy should be resumed as soon as possible, including a loading dose for clopidogrel, ticagrelor, or prasugrel (if possible within 24 hours of surgery), although the optimal timing for resumption of medication following CABG surgery remains uncertain.

Treatment monitoring, using bedside tests, has been suggested as an option for guiding interruption of treatment, rather than use of an arbitrary, specified period. Platelet inhibitory response to clopidogrel determines CABG-related bleeding,⁸⁸² and a strategy based on pre-operative platelet function testing, to determine the timing of CABG in clopidogrel-treated patients, led to ∼50% shorter waiting time than recommended in the current Guidelines.⁸⁸³ For these reasons, the 2012 update of the Society of Thoracic Surgeons guidelines suggested that a delay of even a day or two is reasonable, to decrease bleeding and thrombotic risk in ACS patients.⁸⁷⁹

In very high-risk situations, such as in the first weeks after stent implantation, it has been suggested that, 5 days before surgery, a patient may be switched from clopidogrel to a reversible antiplatelet agent with a short half-life (e.g. the i.v. GP IIb/IIIa inhibitors tirofiban or eptifibatide), stopping the infusion 4 hours before surgery,⁸⁸⁴ but there is no clinical evidence, based solely on pharmacokinetic or pharmacodynamic studies, to support this approach. In the Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) study, the use of cangrelor, an intravenous, reversible P2Y₁₂ platelet inhibitor for bridging thienopyridine-treated patients to CABG surgery, was evaluated against placebo.⁸⁵⁴ Oral P2Y₁₂ inhibitors were stopped 48 hours before CABG. Cangrelor resulted in a higher rate of maintenance of platelet inhibition (primary endpoint, P2Y₁₂ reaction units <240; 98.8% (83/84) vs. 19.0% (16/84), respectively; RR 5.2; 95% CI 3.3–8.1; P <0.001). Bridging with a prolonged infusion of cangrelor did not increase major bleeding before surgery.

The substitution of DAPT with LMWH or UFH is ineffective.⁸⁸⁵ In surgical procedures with low-to-moderate bleeding risk, surgeons should be encouraged to operate while maintaining DAPT.

Resuming clopidogrel after CABG appears to be safe and effective according to a recent meta-analysis of five randomized trials and six observational studies that included 25 728 patients who, when clopidogrel was added to ASA, as opposed to ASA alone, showed a better early vein graft patency (RR 0.59; 95% CI 0.43–0.82; P =0.02) and lower in-hospital or 30-day mortality (0.8% vs. 1.9%; P <0.0001).⁸⁸⁶ The mortality benefit after CABG in PLATO and in TRITON-TIMI 38 suggests that ticagrelor and prasugrel may be restarted after CABG; however, the evidence is limited, with only one-third of patients restarting ticagrelor in PLATO and no randomized evaluation.⁸⁸¹

18.4.10 Antiplatelet therapy monitoring and genetic testing

Platelet function testing has provided a measure of certainty to the understanding of cardiovascular diseases: agents that provide powerful and consistent inhibition of P2Y₁₂-mediated reactivity reduce post-procedural myocardial infarction and stent thrombosis, confirming the mechanistic hypothesis that P2Y₁₂-receptor signalling is a major component of pathophysiological thrombus formation in patients with ACS treated with PCI.⁷⁷⁴ In the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) trial—the largest observational platelet function study conducted to date—close to 50% of 30-day post-PCI stent thrombosis was attributable to high platelet reactivity, defined as a P2Y₁₂ reaction unit value of >208 when using the VerifyNow^®bedside test.⁸⁸⁷ However, even if on-treatment platelet reactivity appears as a reliable and independent measure of the risk of future events,^888,889 the concept of selective, intensive antiplatelet therapy based on a measured drug effect has never been successfully proven.⁸⁹⁰ Randomized trials examining the platelet function test hypothesis, namely GRAVITAS and Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI), have been limited by low event rates, insufficient pharmacodynamic intervention, potential selection bias for low-risk patients, and an intervention in patients deemed to be non-responders after stent placement.^778,891 The recent Assessment by a double Randomization of a Conventional antiplatelet strategy vs. a monitoring-guided strategy for drug-eluting stent implantation and, of Treatment Interruption vs. Continuation 1 year after stenting (ARCTIC) trial, which randomized the use of a bedside platelet function test, with repeated measures of ASA and clopidogrel response before and after platelet function test, with numerous pharmacodynamic interventions in poor responders (including the use of GP IIb/IIIa inhibitors, reloading, and switching to more potent P2Y₁₂ inhibitors) was neutral.⁸⁹² This study was appropriately powered, with a significantly more aggressive pharmacological intervention in non-responders leading to a two-fold reduction in the rate of non-responders. In summary, measuring treatment response by platelet function assays should be limited to clinical research but should not be routinely used in clinical practice.

Genetic variability in metabolism and absorption of clopidogrel is a key factor, responsible for the inefficient generation of the active drug metabolite. The two-step hepatic cytochrome P450 (CYP)-dependent oxidative metabolism of the prodrug appears to be of particular importance. Pharmacogenomic analyses have identified loss-of-function variant alleles of CYP 2C19—and specifically the 2C19*2 allele—as the predominant genetic mediators of the antiplatelet effect of clopidogrel. Carriers have been shown to have lower active metabolite levels of clopidogrel, higher platelet reactivity and associated poorer outcomes.^893–896 Rapid and accurate point-of-care genetic tests are available to identify these alleles. There are pending questions about the role of such testing, such as patient selection and whether personalized treatment based on genotype has a positive impact on clinical outcome and economy.⁸⁹⁷ At present, genetic testing cannot be recommended in routine clinical practice, due to insufficient prospective data.

In conclusion, platelet function testing or genetic testing may be considered in specific high-risk situations (e.g. history of stent thrombosis; compliance issue; suspicion of resistance; high bleeding risk).

18.4.11 Patients with hypersensitivity to acetylsalicylic acid

In patients with ASA hypersensitivity, and in whom ASA therapy is necessary, a rapid desensitization procedure may be performed.⁸⁹⁸ Clopidogrel 75 mg daily is an appropriate alternative in patients who are intolerant of, or allergic to, ASA as long-term treatment.⁸⁹⁹ Alternatively, in cases of aspirin intolerance, a more potent, novel P2Y₁₂ inhibitor (prasugrel or ticagrelor) may be preferred over clopidogrel as single antiplatelet therapy for a limited duration (1 to 6 months) after PCI.

18.4.12 Heparin-induced thrombocytopaenia

In patients with a history of heparin-induced thrombocytopaenia, neither UFH nor LMWH should be used, owing to concerns over cross-reactivity. In this case, bivalirudin is the best option for anticoagulation; other possible options are argatroban, hirudin, lepirudin, and danaparoid.

Table 15

Antithrombotic drugs dose adjustment in patients with CKD

ASA = acetylsalicylic acid; CKD = chronic kidney disease; GFR = glomerular filtration rate; i.v. = intravenous; o.d. = omni diem (every day); q.d. = quaque die; s.c. = subcutaneous; PCI = percutaneous coronary intervention.

General recommendations on antiplatelet therapy

ASA = acetylsalicylic acid; CABG = coronary artery bypass grafting; DAPT = dual antiplatelet therapy; NSAID = non-steroidal anti-inflammatory drug; SCAD = stable coronary artery disease.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

19. Volume–outcome relationship for revascularization procedures

Operator experience influences outcomes, in particular in critical, complex situations. The greater total experience of an entire hospital team—consisting of supporting members in the operating room or catheterization laboratory and those responsible for post-operative care—results in favourable outcomes. Therefore, the Leapfrog initiative has promoted PCI and CABG in high-volume centres.⁹⁰²

19.1 Coronary artery bypass grafting

A meta-analysis, evaluating the impact of hospital volume on in-hospital mortality, showed that among seven studies comprising 1 470 990 patients in 2040 hospitals, high-volume hospitals had lower mortality rates (OR 0.85; 95% confidence interval 0.83–0.91) even after adjustment for differences in case-mix.⁹⁰³ The volume of cases handled by a particular hospital may be high, but the number of procedures per surgeon may vary, making the surgeon–volume relationship a better marker. Although a recent study reported no significant difference in rates of in-hospital complications and 5-year mortality between surgical trainees and consultant surgeons after multivariable adjustment for differences in baseline characteristics (HR 1.02; 95% CI 0.87–1.20),⁹⁰⁴ the data substantiating a relationship is quite strong. Birkmeyer and co-authors found that surgeons' case volume, as a continuous variable, was inversely related to operative mortality (adjusted OR 1.36; 95% CI 1.28–1.45).⁹⁰⁵ Moreover, when hospital case volume was taken into account, the impact of the surgeon’s case volume changed only marginally and remained a strong predictor (adjusted OR 1.33; 95% CI 1.25–1.42). Hospital volume itself had an OR of 1.13 (95% CI 1.03–1.24) if corrected for surgeon volume. It has been suggested, especially for the technically more challenging procedure of off-pump CABG, that surgical experience is of importance.⁹⁰⁶

Although the evidence accumulated over the years indicates that both surgeon and hospital case volumes matter,⁹⁰⁷ several studies suggest that quality measures are more important than volume per se and high volume does not necessarily result in better quality.^908,909 Statistics on the rate of use of an IMA and on perioperative use of medication, and allowing data collection and monitoring by national registries, are several examples of these quality measures, all of which have been shown to be vital for improvement of outcomes. An observational cohort study of 81 289 CABG procedures performed by 1451 surgeons at 164 hospitals in North Carolina, USA, reported that missing quality indicators strongly predicted hospital mortality, irrespective of surgeon- or hospital case volume.⁹¹⁰

Taking into consideration these data, the current American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines on CABG surgery provide a IIb recommendation that cardiac surgery programmes with less than 125 CABG procedures annually be affiliated with high-volume tertiary centres [level of evidence (LoE) C].²⁸⁵

19.2 Percutaneous coronary intervention

Numerous studies have investigated the relationship between volume of procedures and outcomes of PCI, suggesting a volume–outcome relationship at operator level, as well as institutional level.^{903,911–915} In a meta-analysis of 10 studies including over 1.3 million patients undergoing PCI at 1746 institutions between 1984 and 2005, treatment at high-volume centres was associated with a 13% RRR for in-hospital mortality (OR 0.87; 95% CI 0.83–0.91) compared with treatment at low-volume centres.⁹⁰³ Using a meta-regression analysis of mean study year, the effect size did not attenuate appreciably over time. These findings are consistent with a population-based study from the PCI reporting system of New York, indicating that hospital case volumes of <400 PCIs per year and operator case volumes of <75 PCIs per year were associated with impaired outcomes.⁹¹¹ Some have suggested that procedural outcomes were levelled by technological improvements in PCI material, with progressive narrowing of outcome disparities and complication rates between high-volume and low-volume centres in the case of elective procedures.⁹¹⁶ However, findings from studies carried out in the coronary stent era indicate that both operator- and hospital-volume experience continue to correlate with outcomes, with a relationship suggesting that the best outcomes are obtained with high-volume operators practising in high-volume institutions.^912,917

Among patients with ACS, particularly STEMI, operator and hospital volume play an important role. A large study in the USA reported that, in a cohort of 36 535 patients undergoing primary PCI, shorter door-to-balloon times and lower in-hospital mortality resulted in institutions with higher primary PCI volumes.⁹¹⁸ Similar results were observed in three more recent European observational studies.^914,919,920 In another analysis of 29 513 patients with acute myocardial infarction who underwent primary PCI, treatment in high-volume centres was associated with a significantly lower door-to-balloon time than at medium- and low-volume centres (88 vs. 90 vs. 98 minutes, respectively; P-value for trend <0.001), although in-hospital mortality did not differ significantly (OR 1.22; 95% CI 0.78–1.91 for low-volume centres, and OR 1.14; 95% CI 0.78–1.66 for high-volume centres).⁹²¹ Nallamothu and colleagues showed a direct relationship between degree of an institution’s specialization (operator and hospital experience, 24-hour/7-day availability, early activation of catheterization laboratory, written processes for emergency care) and outcomes in terms of in-hospital mortality among patients with acute myocardial infarction undergoing primary PCI.⁹¹³

Current ACCF/AHA guidelines recommend that elective PCI should be performed by operators with annual case volumes of at least 75 procedures, at high-volume centres handling at least 400 procedures per year (Class I C) or, alternatively, by operators with annual volume of at least 75 procedures at centres handling at least 200 procedures per year (Class IIa C). In the case of primary PCI, it is recommended that, annually, operators should perform at least 75 elective procedures and ideally 11 primary PCI procedures in institutions that perform more than 400 elective PCIs per year and more than 36 primary procedures for STEMI.⁹²² The ESC Guidelines on STEMI recommend that primary PCI should be performed only in centres providing 24-hour/7-day coverage.²⁰¹ Owing to the continuing expansion of knowledge pertinent to PCI, increasing demands on technical skills needed to independently and expertly perform PCI, and the importance of Heart Teams in the management of patients with CAD, the ESC/EACTS Task Force on myocardial revascularization has issued recommendations on operator training and competence.

Training in interventional cardiology

A European training programme in interventional cardiology has been proposed by the European Association for Percutaneous Cardiovascular Interventions (EAPCI) in order to ensure high quality of patient care and clinical excellence.⁹²³ The programme should last 1–2 years at high-volume institutions that handle at least 800 PCIs per year and that have established 24-hour/7-day service for the treatment of patients with ACS.

During the programme, trainees should perform at least 200 PCI procedures as first- or only operator, acting under supervision for one-third (>66) of these procedures in emergency or ACS patients before becoming independent. Additionally, trainees are required to attend at least 30 days (240 hours) of formal learning, including attendance at accredited national and international courses in interventional cardiology.⁹²³

Recommendations for training, proficiency, and operator/institutional competence in CABG and PCI

ACS = acute coronary syndromes; CABG = coronary artery bypass grafting; EACTS = European Association for Cardio-Thoracic Surgery; EAPCI = European Association for Percutaneous Cardiovascular Interventions; ESC = European Society of Cardiology; LM = left main; PCI = percutaneous coronary intervention; SCAD = stable coronary artery disease.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

20. Medical therapy, secondary prevention, and strategies for follow-up

Myocardial revascularization must be accompanied by medical therapy and other secondary prevention strategies for risk factor modification and permanent lifestyle changes.⁹²⁵ Secondary prevention and cardiac rehabilitation are an integral part of the management strategy after revascularization, because such measures reduce future morbidity and mortality in a cost-effective way and can further ameliorate symptoms.

Long-term medical therapy after myocardial revascularization to improve prognosis and recommendations for lifestyle changes and participation in cardiac rehabilitation programmes

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ASA = acetylsalicylic acid; b.p.m. = beats per minute; CAD = coronary artery disease; DBP = diastolic blood pressure; EF = ejection fraction; HbA_1c = glycated haemoglobin A1c; LDL-C = low-density lipoprotein cholesterol; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

^dFor antithrombotic therapy in addition to ASA after PCI see section 18.

Although the need to detect restenosis has diminished in the DES era, the recurrence of symptoms due to disease progression or restenosis deserves attention. Likewise, the durability of CABG results has increased with the use of arterial grafts, and ischaemia stems mainly from SVG attrition and/or progression of CAD in native vessels.

Strategies for follow-up and management in patients after myocardial revascularization

CABG = coronary artery bypass grafting; LM = left main; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

^cReferences.

^dSpecific patient subsets indicated for early stress testing with imaging:

– patients with safety-critical professions (e.g. pilots, drivers, divers) and competitive athletes;

– patients engaging in recreational activities for which high oxygen consumption is required;

– patients resuscitated from sudden death;

– patients with incomplete or suboptimal revascularization, even if asymptomatic;

– patients with a complicated course during revascularization (perioperative myocardial infarction, extensive dissection during PCI, endarterectomy during CABG, etc.);

– patients with diabetes (especially those requiring insulin);

– patients with multivessel disease and residual intermediate lesions, or with silent ischaemia.

^eIntermediate- and high-risk findings at stress imaging are ischaemia at low workload, early onset ischaemia, multiple zones of high-grade wall motion abnormality, or reversible perfusion defect.

21. Addenda

ESC National Cardiac Societies actively involved in the review process of the 2014 ESC/EACTS Guidelines on myocardial revascularization:

Austria, Austrian Society of Cardiology, Franz Weidinger; Azerbaijan, Azerbaijan Society of Cardiology, Firdovsi Ibrahimov; Belgium, Belgian Society of Cardiology, Victor Legrand; Bosnia and Herzegovina, Association of Cardiologists of Bosnia and Herzegovina, Ibrahim Terzić; Bulgaria,Bulgarian Society of Cardiology, Arman Postadzhiyan; Croatia, Croatian Cardiac Society, Bosko Skoric; Cyprus, Cyprus Society of Cardiology, Georgios M. Georgiou; Czech Republic, Czech Society of Cardiology, Michael Zelizko; Denmark, Danish Society of Cardiology, Anders Junker; Estonia, Estonian Society of Cardiology, Jaan Eha; Finland, Finnish Cardiac Society, Hannu Romppanen; France, French Society of Cardiology, Jean-Louis Bonnet; Georgia, Georgian Society of Cardiology, Alexander Aladashvili; Germany, German Cardiac Society, Rainer Hambrecht; Hungary, Hungarian Society of Cardiology, Dávid Becker; Iceland, Icelandic Society of Cardiology, Thorarinn Gudnason; Israel, Israel Heart Society, Amit Segev; Italy, Italian Federation of Cardiology, Raffaele Bugiardini; Kazakhstan, Association of Cardiologists of Kazakhstan, Orazbek Sakhov; Kyrgyzstan, Kyrgyz Society of Cardiology, Aibek Mirrakhimov; Luxembourg, Luxembourg Society of Cardiology, Bruno Pereira; Malta, Maltese Cardiac Society, Herbert Felice; Norway, Norwegian Society of Cardiology, Thor Trovik; Poland, Polish Cardiac Society, Dariusz Dudek; Portugal, Portuguese Society of Cardiology, Hélder Pereira; Serbia, Cardiology Society of Serbia, Milan A. Nedeljkovic; Slovakia, Slovak Society of Cardiology, Martin Hudec; Spain, Spanish Society of Cardiology, Angel Cequier; Sweden, Swedish Society of Cardiology, David Erlinge; Switzerland, Swiss Society of Cardiology, Marco Roffi; The Former Yugoslav Republic of Macedonia, Macedonian FYR Society of Cardiology, Sasko Kedev; Tunisia, Tunisian Society of Cardiology and Cardio-Vascular Surgery, Faouzi Addad; Turkey,Turkish Society of Cardiology, Aylin Yildirir; United Kingdom, British Cardiovascular Society, John Davies.

References

1

Head

SJ

Kieser

TM

Falk

V

Huysmans

HA

Kappetein

AP

,

Coronary artery bypass grafting: Part 1:the evolution over the first 50 years

,

Eur Heart J

,

2013

, vol.

34

37

(pg.

2862

-

2872

)

2

Gruntzig

A

,

Transluminal dilatation of coronary-artery stenosis

,

Lancet

,

1978

, vol.

1

(8058):263

3

Stefanini

GG

Holmes

DR

Jr.

,

Drug-eluting coronary-artery stents

,

N Engl J Med

,

2013

, vol.

368

3

(pg.

254

-

265

)

4

Windecker

S

Stortecky

S

Stefanini

GG

da Costa

B

Rutjes

AW

di Nisio

M

Siletta

MG

Maione

A

Alfonso

F

Clemmensen

P

Collet

JP

Cremer

J

Falk

F

Filippatos

G

Hamm

C

Head

SJ

Kappetein

AP

Kastrati

A

Knuuti

J

Landmesser

U

Laufer

G

Neumann

FJ

Richter

D

Schauerte

P

Sousa-Uva

M

Taggart

D

Torracca

L

Valgimigli

M

Wijns

W

Witkowski

A

Kolh

P

Juni

P

,

Revascularisation vs. Medical Treatment in Patients With Stable Coronary Artery Disease: A Network Meta-Analysis.

,

BMJ

,

2014

Jun 23;348:g3859

5

Head

SJ

Kaul

S

Mack

MJ

Serruys

PW

Taggart

DP

Holmes

DR

Jr.

Leon

MB

Marco

J

Bogers

AJ

Kappetein

AP

,

The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease

,

Eur Heart J

,

2013

, vol.

34

32

(pg.

2510

-

2518

)

6

Head

SJ

Holmes

DR

Jr.

Mack

MJ

Serruys

PW

Mohr

FW

Morice

MC

Colombo

A

Kappetein

AP

Investigators

S

,

Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries

,

JACC Cardiovasc Interv

,

2012

, vol.

5

6

(pg.

618

-

625

)

7

Nashef

SA

Roques

F

Michel

P

Gauducheau

E

Lemeshow

S

Salamon

R

,

European system for cardiac operative risk evaluation (EuroSCORE)

,

Eur J Cardiothorac Surg

,

1999

, vol.

16

1

(pg.

9

-

13

)

8

Roques

F

Michel

P

Goldstone

AR

Nashef

SA

,

The logistic EuroSCORE

,

Eur Heart J

,

2003

, vol.

24

9

(pg.

881

-

882

)

9

Siregar

S

Groenwold

RH

de Heer

F

Bots

ML

van der Graaf

Y

van Herwerden

LA

,

Performance of the original EuroSCORE

,

Eur J Cardiothorac Surg

,

2012

, vol.

41

4

(pg.

746

-

754

)

10

Hickey

GL

Grant

SW

Murphy

GJ

Bhabra

M

Pagano

D

McAllister

K

Buchan

I

Bridgewater

B

,

Dynamic trends in cardiac surgery: why the logistic EuroSCORE is no longer suitable for contemporary cardiac surgery and implications for future risk models

,

Eur J Cardiothorac Surg

,

2013

, vol.

43

6

(pg.

1146

-

1152

)

11

Nashef

SA

Roques

F

Sharples

LD

Nilsson

J

Smith

C

Goldstone

AR

Lockowandt

U

,

EuroSCORE II

,

Eur J Cardiothorac Surg

,

2012

, vol.

41

(4):734–744; discussion

(pg.

744

-

745

)

12

Biancari

F

Vasques

F

Mikkola

R

Martin

M

Lahtinen

J

Heikkinen

J

,

Validation of EuroSCORE II in patients undergoing coronary artery bypass surgery

,

Ann Thorac Surg

,

2012

, vol.

93

6

(pg.

1930

-

1935

)

13

Chalmers

J

Pullan

M

Fabri

B

McShane

J

Shaw

M

Mediratta

N

Poullis

M

,

Validation of EuroSCORE II in a modern cohort of patients undergoing cardiac surgery

,

Eur J Cardiothorac Surg

,

2013

, vol.

43

4

(pg.

688

-

694

)

14

Grant

SW

Hickey

GL

Dimarakis

I

Trivedi

U

Bryan

A

Treasure

T

Cooper

G

Pagano

D

Buchan

I

Bridgewater

B

,

How does EuroSCORE II perform in UK cardiac surgery; an analysis of 23 740 patients from the Society for Cardiothoracic Surgery in Great Britain and Ireland National Database. Heart

,

2012

, vol.

98

21

(pg.

1568

-

1572

)

15

Shahian

DM

O'Brien

SM

Filardo

G

Ferraris

VA

Haan

CK

Rich

JB

Normand

SL

DeLong

ER

Shewan

CM

Dokholyan

RS

Peterson

ED

Edwards

FH

Anderson

RP

Society of Thoracic Surgeons Quality Measurement Task F

,

The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3: valve plus coronary artery bypass grafting surgery

,

Ann Thorac Surg

,

2009

, vol.

88

1 Suppl)

S43–62

16

Shahian

DM

O'Brien

SM

Filardo

G

Ferraris

VA

Haan

CK

Rich

JB

Normand

SL

DeLong

ER

Shewan

CM

Dokholyan

RS

Peterson

ED

Edwards

FH

Anderson

RP

Society of Thoracic Surgeons Quality Measurement Task F

,

The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1: coronary artery bypass grafting surgery

,

Ann Thorac Surg

,

2009

, vol.

88

1 Suppl)

(pg.

S2

-

22

)

17

Mohr

FW

Morice

MC

Kappetein

AP

Feldman

TE

Stahle

E

Colombo

A

Mack

MJ

Holmes

DR

Jr.

,

Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial

,

Lancet

,

2013

, vol.

381

9867

(pg.

629

-

638

)

18

Mohr

FW

Rastan

AJ

Serruys

PW

Kappetein

AP

Holmes

DR

Pomar

JL

Westaby

S

Leadley

K

Dawkins

KD

Mack

MJ

,

Complex coronary anatomy in coronary artery bypass graft surgery: impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years

,

J Thorac Cardiovasc Surg

,

2011

, vol.

141

1

(pg.

130

-

140

)

19

Genereux

P

Palmerini

T

Caixeta

A

Cristea

E

Mehran

R

Sanchez

R

Lazar

D

Jankovic

I

Corral

MD

Dressler

O

Fahy

MP

Parise

H

Lansky

AJ

Stone

GW

,

SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements

,

Circ Cardiovasc Interv

,

2011

, vol.

4

6

(pg.

553

-

561

)

20

Papadopoulou

SL

Girasis

C

Dharampal

A

Farooq

V

Onuma

Y

Rossi

A

Morel

MA

Krestin

GP

Serruys

PW

de Feyter

PJ

Garcia Garcia

HM

,

CT-SYNTAX score: a feasibility and reproducibility Study

,

JACC Cardiovasc Imaging

,

2013

, vol.

6

3

(pg.

413

-

415

)

21

Peterson

ED

Dai

D

DeLong

ER

Brennan

JM

Singh

M

Rao

SV

Shaw

RE

Roe

MT

Ho

KK

Klein

LW

Krone

RJ

Weintraub

WS

Brindis

RG

Rumsfeld

JS

Spertus

JA

Participants

NR

,

Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry

,

J Am Coll Cardiol

,

2010

, vol.

55

18

(pg.

1923

-

1932

)

22

Ranucci

M

Castelvecchio

S

Menicanti

L

Frigiola

A

Pelissero

G

,

Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony

,

Circulation

,

2009

, vol.

119

24

(pg.

3053

-

3061

)

23

Wykrzykowska

JJ

Garg

S

Onuma

Y

de Vries

T

Goedhart

D

Morel

MA

van Es

GA

Buszman

P

Linke

A

Ischinger

T

Klauss

V

Corti

R

Eberli

F

Wijns

W

Morice

MC

di Mario

C

van Geuns

RJ

Juni

P

Windecker

S

Serruys

PW

,

Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial

,

Circ Cardiovasc Interv

,

2011

, vol.

4

1

(pg.

47

-

56

)

24

Farooq

V

Vergouwe

Y

Raber

L

Vranckx

P

Garcia-Garcia

H

Diletti

R

Kappetein

AP

Morel

MA

de Vries

T

Swart

M

Valgimigli

M

Dawkins

KD

Windecker

S

Steyerberg

EW

Serruys

PW

,

Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score

,

Eur Heart J

,

2012

, vol.

33

24

(pg.

3098

-

3104

)

25

Farooq

V

van Klaveren

D

Steyerberg

EW

Meliga

E

Vergouwe

Y

Chieffo

A

Kappetein

AP

Colombo

A

Holmes

DR

Jr.

Mack

M

Feldman

T

Morice

MC

Stahle

E

Onuma

Y

Morel

MA

Garcia-Garcia

HM

van Es

GA

Dawkins

KD

Mohr

FW

Serruys

PW

,

Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II

,

Lancet

,

2013

, vol.

381

9867

(pg.

639

-

650

)

26

Weintraub

WS

Grau-Sepulveda

MV

Weiss

JM

O'Brien

SM

Peterson

ED

Kolm

P

Zhang

Z

Klein

LW

Shaw

RE

McKay

C

Ritzenthaler

LL

Popma

JJ

Messenger

JC

Shahian

DM

Grover

FL

Mayer

JE

Shewan

CM

Garratt

KN

Moussa

ID

Dangas

GD

Edwards

FH

,

Comparative effectiveness of revascularization strategies

,

N Engl J Med

,

2012

, vol.

366

16

(pg.

1467

-

1476

)

27

Shahian

DM

O'Brien

SM

Sheng

S

Grover

FL

Mayer

JE

Jacobs

JP

Weiss

JM

Delong

ER

Peterson

ED

Weintraub

WS

Grau-Sepulveda

MV

Klein

LW

Shaw

RE

Garratt

KN

Moussa

ID

Shewan

CM

Dangas

GD

Edwards

FH

,

Predictors of long-term survival after coronary artery bypass grafting surgery: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT study)

,

Circulation

,

2012

, vol.

125

12

(pg.

1491

-

1500

)

28

Weintraub

WS

Grau-Sepulveda

MV

Weiss

JM

Delong

ER

Peterson

ED

O'Brien

SM

Kolm

P

Klein

LW

Shaw

RE

McKay

C

Ritzenthaler

LL

Popma

JJ

Messenger

JC

Shahian

DM

Grover

FL

Mayer

JE

Garratt

KN

Moussa

ID

Edwards

FH

Dangas

GD

,

Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry

,

Circulation

,

2012

, vol.

125

12

(pg.

1501

-

1510

)

29

Medina

A

Suarez de Lezo

J

Pan

M

,

[A new classification of coronary bifurcation lesions]

,

Rev Esp Cardiol

,

2006

, vol.

59

(2):183

30

Sianos

G

Morel

MA

Kappetein

AP

Morice

MC

Colombo

A

Dawkins

K

van den Brand

M

Van Dyck

N

Russell

ME

Mohr

FW

Serruys

PW

,

The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease

,

EuroIntervention

,

2005

, vol.

1

2

(pg.

219

-

227

)

31

Beauchamp

T

Childress

J

,

Principles of Biomedical Ethics

,

1994

4th

New York

Oxford University Press

Google Preview

32

Tong

BC

Huber

JC

Ascheim

DD

Puskas

JD

Ferguson

TB

Jr.

Blackstone

EH

Smith

PK

,

Weighting composite endpoints in clinical trials: essential evidence for the Heart Team

,

Ann Thorac Surg

,

2012

, vol.

94

6

(pg.

1908

-

1913

)

33

Chandrasekharan

DP

Taggart

DP

,

Informed consent for interventions in stable coronary artery disease: problems, etiologies, and solutions

,

Eur J Cardiothorac Surg

,

2011

, vol.

39

6

(pg.

912

-

917

)

34

Filardo

G

Maggioni

AP

Mura

G

Valagussa

F

Valagussa

L

Schweiger

C

Ballard

DJ

Liberati

A

,

The consequences of under-use of coronary revascularization; results of a cohort study in Northern Italy

,

Eur Heart J

,

2001

, vol.

22

8

(pg.

654

-

662

)

35

Yates

MT

Soppa

GK

Valencia

O

Jones

S

Firoozi

S

Jahangiri

M

,

Impact of European Society of Cardiology and European Association for Cardiothoracic Surgery Guidelines on Myocardial Revascularization on the activity of percutaneous coronary intervention and coronary artery bypass graft surgery for stable coronary artery disease

,

J Thorac Cardiovasc Surg

,

2014

, vol.

147

2

(pg.

606

-

610

)

36

OECD

,

Health at a glance

,

2009

OECD Publishing

37

Hannan

EL

Cozzens

K

Samadashvili

Z

Walford

G

Jacobs

AK

Holmes

DR

Jr.

Stamato

NJ

Sharma

S

Venditti

FJ

Fergus

I

King

SB

3rd

,

Appropriateness of coronary revascularization for patients without acute coronary syndromes

,

J Am Coll Cardiol

,

2012

, vol.

59

21

(pg.

1870

-

1876

)

38

Frutkin

AD

Lindsey

JB

Mehta

SK

House

JA

Spertus

JA

Cohen

DJ

Rumsfeld

JS

Marso

SP

Ncdr

,

Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry)

,

JACC Cardiovasc Interv

,

2009

, vol.

2

7

(pg.

614

-

621

)

39

Epstein

AJ

Polsky

D

Yang

F

Yang

L

Groeneveld

PW

,

Coronary revascularization trends in the United States

,

JAMA 2011

,

2001–2008

, vol.

305

17

(pg.

1769

-

1776

)

40

Hannan

EL

Racz

MJ

Gold

J

Cozzens

K

Stamato

NJ

Powell

T

Hibberd

M

Walford

G

American College of

C

American Heart

A

,

Adherence of catheterization laboratory cardiologists to American College of Cardiology/American Heart Association guidelines for percutaneous coronary interventions and coronary artery bypass graft surgery: what happens in actual practice?

,

Circulation

,

2010

, vol.

121

2

(pg.

267

-

275

)

41

Denvir

MA

Pell

JP

Lee

AJ

Rysdale

J

Prescott

RJ

Eteiba

H

Walker

A

Mankad

P

Starkey

IR

,

Variations in clinical decision-making between cardiologists and cardiac surgeons; a case for management by multidisciplinary teams?

,

J Cardiothorac Surg

,

2006

, vol.

1

pg.

2

42

Long

J

Luckraz

H

Thekkudan

J

Maher

A

Norell

M

,

Heart Team discussion in managing patients with coronary artery disease: outcome and reproducibility

,

Interact CardioVasc Thorac Surg

,

2012

, vol.

14

5

(pg.

594

-

598

)

43

Sobolev

BG

Fradet

G

Kuramoto

L

Rogula

B

,

The occurrence of adverse events in relation to time after registration for coronary artery bypass surgery: a population-based observational study

,

J Cardiothorac Surg

,

2013

, vol.

8

pg.

74

44

Graham

MM

Knudtson

ML

O'Neill

BJ

Ross

DB

,

Treating the right patient at the right time: Access to cardiac catheterization, percutaneous coronary intervention and cardiac surgery

,

Can J Cardiol

,

2006

, vol.

22

8

(pg.

679

-

683

)

45

Hannan

EL

Samadashvili

Z

Walford

G

Holmes

DR

Jacobs

A

Sharma

S

Katz

S

King

SB

3rd

,

Predictors and outcomes of ad hoc vs. non-ad hoc percutaneous coronary interventions

,

JACC Cardiovasc Interv

,

2009

, vol.

2

4

(pg.

350

-

356

)

46

Nallamothu

BK

Krumholz

HM

,

Putting ad hoc PCI on pause

,

JAMA

,

2010

, vol.

304

18

(pg.

2059

-

2060

)

47

Montalescot

G

Sechtem

U

Achenbach

S

Andreotti

F

Arden

C

Budaj

A

Bugiardini

R

Crea

F

Cuisset

T

Di Mario

C

Ferreira

JR

Gersh

BJ

Gitt

AK

Hulot

JS

Marx

N

Opie

LH

Pfisterer

M

Prescott

E

Ruschitzka

F

Sabate

M

Senior

R

Taggart

DP

van der Wall

EE

Vrints

CJ

Zamorano

JL

Baumgartner

H

Bax

JJ

Bueno

H

Dean

V

Deaton

C

Erol

C

Fagard

R

Ferrari

R

Hasdai

D

Hoes

AW

Kirchhof

P

Knuuti

J

Kolh

P

Lancellotti

P

Linhart

A

Nihoyannopoulos

P

Piepoli

MF

Ponikowski

P

Sirnes

PA

Tamargo

JL

Tendera

M

Torbicki

A

Wijns

W

Windecker

S

Valgimigli

M

Claeys

MJ

Donner-Banzhoff

N

Frank

H

Funck-Brentano

C

Gaemperli

O

Gonzalez-Juanatey

JR

Hamilos

M

Husted

S

James

SK

Kervinen

K

Kristensen

SD

Maggioni

AP

Pries

AR

Romeo

F

Ryden

L

Simoons

ML

Steg

PG

Timmis

A

Yildirir

A

,

2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology

,

Eur Heart J

,

2013

, vol.

34

38

(pg.

2949

-

3003

)

48

Knuuti

J

Bengel

F

Bax

JJ

Kaufmann

PA

Le Guludec

D

Perrone Filardi

P

Marcassa

C

Ajmone Marsan

N

Achenbach

S

Kitsiou

A

Flotats

A

Eeckhout

E

Minn

H

Hesse

B

,

Risks and benefits of cardiac imaging: an analysis of risks related to imaging for coronary artery disease

,

Eur Heart J

,

2014

, vol.

35

10

(pg.

633

-

638

)

49

Hulten

E

Villines

TC

Cheezum

MK

Berman

DS

Dunning

A

Achenbach

S

Al-Mallah

M

Budoff

MJ

Cademartiri

F

Callister

TQ

Chang

HJ

Cheng

VY

Chinnaiyan

K

Chow

BJ

Cury

RC

Delago

A

Feuchtner

G

Hadamitzky

M

Hausleiter

J

Kaufmann

PA

Karlsberg

RP

Kim

YJ

Leipsic

J

Lin

FY

Maffei

E

Plank

F

Raff

GL

Labounty

TM

Shaw

LJ

Min

JK

Investigators

C

,

Usefulness of coronary computed tomography angiography to predict mortality and myocardial infarction among Caucasian, African and East Asian ethnicities (from the CONFIRM [Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter] Registry)

,

Am J Cardiol

,

2013

, vol.

111

4

(pg.

479

-

485

)

50

Tonino

PA

De Bruyne

B

Pijls

NH

Siebert

U

Ikeno

F

van't Veer

M

Klauss

V

Manoharan

G

Engstrom

T

Oldroyd

KG

Ver Lee

PN

MacCarthy

PA

Fearon

WF

Investigators

FS

,

Fractional flow reserve vs. angiography for guiding percutaneous coronary intervention

,

N Engl J Med

,

2009

, vol.

360

3

(pg.

213

-

224

)

51

Pijls

NH

van Schaardenburgh

P

Manoharan

G

Boersma

E

Bech

JW

van't Veer

M

Bar

F

Hoorntje

J

Koolen

J

Wijns

W

de Bruyne

B

,

Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study

,

J Am Coll Cardiol

,

2007

, vol.

49

21

(pg.

2105

-

2111

)

52

Botman

KJ

Pijls

NH

Bech

JW

Aarnoudse

W

Peels

K

van Straten

B

Penn

O

Michels

HR

Bonnier

H

Koolen

JJ

,

Percutaneous coronary intervention or bypass surgery in multivessel disease? A tailored approach based on coronary pressure measurement

,

Catheter Cardiovasc Interv

,

2004

, vol.

63

2

(pg.

184

-

191

)

53

Toth

G

De Bruyne

B

Casselman

F

De Vroey

F

Pyxaras

S

Di Serafino

L

Van Praet

F

Van Mieghem

C

Stockman

B

Wijns

W

Degrieck

I

Barbato

E

,

Fractional flow reserve-guided vs. angiography-guided coronary artery bypass graft surgery

,

Circulation

,

2013

, vol.

128

13

(pg.

1405

-

1411

)

54

De Bruyne

B

Pijls

NH

Kalesan

B

Barbato

E

Tonino

PA

Piroth

Z

Jagic

N

Mobius-Winkler

S

Rioufol

G

Witt

N

Kala

P

MacCarthy

P

Engstrom

T

Oldroyd

KG

Mavromatis

K

Manoharan

G

Verlee

P

Frobert

O

Curzen

N

Johnson

JB

Juni

P

Fearon

WF

Investigators FT

,

Fractional flow reserve-guided PCI vs. medical therapy in stable coronary disease

,

N Engl J Med

,

2012

, vol.

367

11

(pg.

991

-

1001

)

55

Allman

KC

Shaw

LJ

Hachamovitch

R

Udelson

JE

,

Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis

,

J Am Coll Cardiol

,

2002

, vol.

39

7

(pg.

1151

-

1158

)

56

Beanlands

RS

Nichol

G

Huszti

E

Humen

D

Racine

N

Freeman

M

Gulenchyn

KY

Garrard

L

deKemp

R

Guo

A

Ruddy

TD

Benard

F

Lamy

A

Iwanochko

RM

Investigators P-

,

F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2)

,

J Am Coll Cardiol

,

2007

, vol.

50

20

(pg.

2002

-

2012

)

57

Meijboom

WB

Meijs

MF

Schuijf

JD

Cramer

MJ

Mollet

NR

van Mieghem

CA

Nieman

K

van Werkhoven

JM

Pundziute

G

Weustink

AC

de Vos

AM

Pugliese

F

Rensing

B

Jukema

JW

Bax

JJ

Prokop

M

Doevendans

PA

Hunink

MG

Krestin

GP

de Feyter

PJ

,

Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study

,

J Am Coll Cardiol

,

2008

, vol.

52

25

(pg.

2135

-

2144

)

58

Miller

JM

Rochitte

CE

Dewey

M

Arbab-Zadeh

A

Niinuma

H

Gottlieb

I

Paul

N

Clouse

ME

Shapiro

EP

Hoe

J

Lardo

AC

Bush

DE

de Roos

A

Cox

C

Brinker

J

Lima

JA

,

Diagnostic performance of coronary angiography by 64-row CT

,

N Engl J Med

,

2008

, vol.

359

22

(pg.

2324

-

2336

)

59

Sarno

G

Decraemer

I

Vanhoenacker

PK

De Bruyne

B

Hamilos

M

Cuisset

T

Wyffels

E

Bartunek

J

Heyndrickx

GR

Wijns

W

,

On the inappropriateness of noninvasive multidetector computed tomography coronary angiography to trigger coronary revascularization: a comparison with invasive angiography

,

JACC Cardiovasc Interv

,

2009

, vol.

2

6

(pg.

550

-

557

)

60

Schuijf

JD

Wijns

W

Jukema

JW

Decramer

I

Atsma

DE

de Roos

A

Stokkel

MP

Dibbets-Schneider

P

van der Wall

EE

Bax

JJ

,

A comparative regional analysis of coronary atherosclerosis and calcium score on multislice CT vs. myocardial perfusion on SPECT

,

J Nucl Med

,

2006

, vol.

47

11

(pg.

1749

-

55

)

61

Budoff

MJ

Dowe

D

Jollis

JG

Gitter

M

Sutherland

J

Halamert

E

Scherer

M

Bellinger

R

Martin

A

Benton

R

Delago

A

Min

JK

,

Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial

,

J Am Coll Cardiol

,

2008

, vol.

52

21

(pg.

1724

-

1732

)

62

Neglia

D

Rovai

D

Caselli

C

Kaufmann

P

Lombardi

M

Lorenzoni

V

Marinelli

M

Nekolla

D

Pietila

M

Scholte

A

Sicari

R

Teresinska

A

Zamorano

J

Underwood

R

Knuuti

J

For the EVINCI Investigators

,

Detection of obstructive coronary artery disease by non invasive anatomical and functional imaging. Results of the multicenter European EVINCI study

,

Circulation

,

2013

63

Elhendy

A

Shub

C

McCully

RB

Mahoney

DW

Burger

KN

Pellikka

PA

,

Exercise echocardiography for the prognostic stratification of patients with low pretest probability of coronary artery disease

,

Am J Med

,

2001

, vol.

111

1

(pg.

18

-

23

)

64

Elhendy

A

Mahoney

DW

Burger

KN

McCully

RB

Pellikka

PA

,

Prognostic value of exercise echocardiography in patients with classic angina pectoris

,

Am J Cardiol

,

2004

, vol.

94

5

(pg.

559

-

563

)

65

Sicari

R

Pasanisi

E

Venneri

L

Landi

P

Cortigiani

L

Picano

E

Echo Persantine International Cooperative Study

G

Echo Dobutamine International Cooperative Study

G

,

Stress echo results predict mortality: a large-scale multicenter prospective international study

,

J Am Coll Cardiol

,

2003

, vol.

41

4

(pg.

589

-

595

)

66

Giri

S

Shaw

LJ

Murthy

DR

Travin

MI

Miller

DD

Hachamovitch

R

Borges-Neto

S

Berman

DS

Waters

DD

Heller

GV

,

Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease

,

Circulation

,

2002

, vol.

105

1

(pg.

32

-

40

)

67

Mc Ardle

BA

Dowsley

TF

deKemp

RA

Wells

GA

Beanlands

RS

,

Does rubidium-82 PET have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease?: A systematic review and meta-analysis

,

J Am Coll Cardiol

,

2012

, vol.

60

18

(pg.

1828

-

1837

)

68

Shaw

LJ

Hendel

R

Borges-Neto

S

Lauer

MS

Alazraki

N

Burnette

J

Krawczynska

E

Cerqueira

M

Maddahi

J

Myoview Multicenter

R

,

Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients

,

J Nucl Med

,

2003

, vol.

44

2

(pg.

134

-

139

)

69

Bateman

TM

Heller

GV

McGhie

AI

Friedman

JD

Case

JA

Bryngelson

JR

Hertenstein

GK

Moutray

KL

Reid

K

Cullom

SJ

,

Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT

,

J Nucl Cardiol

,

2006

, vol.

13

1

(pg.

24

-

33

)

70

Parker

MW

Iskandar

A

Limone

B

Perugini

A

Kim

H

Jones

C

Calamari

B

Coleman

CI

Heller

GV

,

Diagnostic accuracy of cardiac positron emission tomography vs. single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis

,

Circ Cardiovasc Imaging

,

2012

, vol.

5

6

(pg.

700

-

707

)

71

Nandalur

KR

Dwamena

BA

Choudhri

AF

Nandalur

MR

Carlos

RC

,

Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis

,

J Am Coll Cardiol

,

2007

, vol.

50

14

(pg.

1343

-

1353

)

72

Schwitter

J

Wacker

CM

van Rossum

AC

Lombardi

M

Al-Saadi

N

Ahlstrom

H

Dill

T

Larsson

HB

Flamm

SD

Marquardt

M

Johansson

L

,

MR-IMPACT: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial

,

Eur Heart J

,

2008

, vol.

29

4

(pg.

480

-

489

)

73

Schwitter

J

Wacker

CM

Wilke

N

Al-Saadi

N

Sauer

E

Huettle

K

Schonberg

SO

Luchner

A

Strohm

O

Ahlstrom

H

Dill

T

Hoebel

N

Simor

T

Investigators M-I

,

MR-IMPACT II: Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary artery disease Trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative multicentre, multivendor trial

,

Eur Heart J

,

2013

, vol.

34

10

(pg.

775

-

781

)

74

Jahnke

C

Nagel

E

Gebker

R

Kokocinski

T

Kelle

S

Manka

R

Fleck

E

Paetsch

I

,

Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging

,

Circulation

,

2007

, vol.

115

13

(pg.

1769

-

1776

)

75

Korosoglou

G

Elhmidi

Y

Steen

H

Schellberg

D

Riedle

N

Ahrens

J

Lehrke

S

Merten

C

Lossnitzer

D

Radeleff

J

Zugck

C

Giannitsis

E

Katus

HA

,

Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1,493 consecutive patients: assessment of myocardial wall motion and perfusion

,

J Am Coll Cardiol

,

2010

, vol.

56

15

(pg.

1225

-

1234

)

76

Dorbala

S

Di Carli

MF

Beanlands

RS

Merhige

ME

Williams

BA

Veledar

E

Chow

BJ

Min

JK

Pencina

MJ

Berman

DS

Shaw

LJ

,

Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry

,

J Am Coll Cardiol

,

2013

, vol.

61

2

(pg.

176

-

184

)

77

Murthy

VL

Naya

M

Foster

CR

Gaber

M

Hainer

J

Klein

J

Dorbala

S

Blankstein

R

Di Carli

MF

,

Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus

,

Circulation

,

2012

, vol.

126

15

(pg.

1858

-

1868

)

78

Kajander

S

Joutsiniemi

E

Saraste

M

Pietila

M

Ukkonen

H

Saraste

A

Sipila

HT

Teras

M

Maki

M

Airaksinen

J

Hartiala

J

Knuuti

J

,

Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease

,

Circulation

,

2010

, vol.

122

6

(pg.

603

-

613

)

79

Pazhenkottil

AP

Nkoulou

RN

Ghadri

JR

Herzog

BA

Kuest

SM

Husmann

L

Wolfrum

M

Goetti

R

Buechel

RR

Gaemperli

O

Luscher

TF

Kaufmann

PA

,

Impact of cardiac hybrid single-photon emission computed tomography/computed tomography imaging on choice of treatment strategy in coronary artery disease

,

Eur Heart J

,

2011

, vol.

32

22

(pg.

2824

-

2829

)

80

Danad

I

Raijmakers

PG

Appelman

YE

Harms

HJ

de Haan

S

van den Oever

ML

Heymans

MW

Tulevski

II

van Kuijk

C

Hoekstra

OS

Lammertsma

AA

Lubberink

M

van Rossum

AC

Knaapen

P

,

Hybrid imaging using quantitative H215O PET and CT-based coronary angiography for the detection of coronary artery disease

,

J Nucl Med

,

2013

, vol.

54

1

(pg.

55

-

63

)

81

Schaap

J

de Groot

JA

Nieman

K

Meijboom

WB

Boekholdt

SM

Post

MC

Van der Heyden

JA

de Kroon

TL

Rensing

BJ

Moons

KG

Verzijlbergen

JF

,

Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions

,

Heart

,

2013

, vol.

99

3

(pg.

188

-

194

)

82

Fiechter

M

Ghadri

JR

Wolfrum

M

Kuest

SM

Pazhenkottil

AP

Nkoulou

RN

Herzog

BA

Gebhard

C

Fuchs

TA

Gaemperli

O

Kaufmann

PA

,

Downstream resource utilization following hybrid cardiac imaging with an integrated cadmium-zinc-telluride/64-slice CT device

,

Eur J Nucl MedMol Imaging

,

2012

, vol.

39

3

(pg.

430

-

436

)

83

van Werkhoven

JM

Heijenbrok

MW

Schuijf

JD

Jukema

JW

van der Wall

EE

Schreur

JH

Bax

JJ

,

Combined non-invasive anatomical and functional assessment with MSCT and MRI for the detection of significant coronary artery disease in patients with an intermediate pre-test likelihood

,

Heart

,

2010

, vol.

96

6

(pg.

425

-

431

)

84

Ryden

L

Grant

PJ

Anker

SD

Berne

C

Cosentino

F

Danchin

N

Deaton

C

Escaned

J

Hammes

HP

Huikuri

H

Marre

M

Marx

N

Mellbin

L

Ostergren

J

Patrono

C

Seferovic

P

Uva

MS

Taskinen

MR

Tendera

M

Tuomilehto

J

Valensi

P

Zamorano

JL

Achenbach

S

Baumgartner

H

Bax

JJ

Bueno

H

Dean

V

Erol

C

Fagard

R

Ferrari

R

Hasdai

D

Hoes

AW

Kirchhof

P

Knuuti

J

Kolh

P

Lancellotti

P

Linhart

A

Nihoyannopoulos

P

Piepoli

MF

Ponikowski

P

Sirnes

PA

Tamargo

JL

Torbicki

A

Wijns

W

Windecker

S

De Backer

G

Ezquerra

EA

Avogaro

A

Badimon

L

Baranova

E

Betteridge

J

Ceriello

A

Funck-Brentano

C

Gulba

DC

Kjekshus

JK

Lev

E

Mueller

C

Neyses

L

Nilsson

PM

Perk

J

Reiner

Z

Sattar

N

Schachinger

V

Scheen

A

Schirmer

H

Stromberg

A

Sudzhaeva

S

Viigimaa

M

Vlachopoulos

C

Xuereb

RG

,

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)

,

Eur Heart J

,

2013

, vol.

34

39

(pg.

3035

-

3087

)

85

Kolh

P

Wijns

W

Danchin

N

Di Mario

C

Falk

V

Folliguet

T

Garg

S

Huber

K

James

S

Knuuti

J

Lopez-Sendon

J

Marco

J

Menicanti

L

Ostojic

M

Piepoli

MF

Pirlet

C

Pomar

JL

Reifart

N

Ribichini

FL

Schalij

MJ

Sergeant

P

Serruys

PW

Silber

S

Sousa Uva

M

Taggart

D

,

Guidelines on myocardial revascularization

,

Eur J Cardiothorac Surg

,

2010;

, vol.

38 Suppl

(pg.

S1

-

S52

)

86

Wijns

W

Kolh

P

Danchin

N

Di Mario

C

Falk

V

Folliguet

T

Garg

S

Huber

K

James

S

Knuuti

J

Lopez-Sendon

J

Marco

J

Menicanti

L

Ostojic

M

Piepoli

MF

Pirlet

C

Pomar

JL

Reifart

N

Ribichini

FL

Schalij

MJ

Sergeant

P

Serruys

PW

Silber

S

Sousa Uva

M

Taggart

D

Vahanian

A

Auricchio

A

Bax

J

Ceconi

C

Dean

V

Filippatos

G

Funck-Brentano

C

Hobbs

R

Kearney

P

McDonagh

T

Popescu

BA

Reiner

Z

Sechtem

U

Sirnes

PA

Tendera

M

Vardas

PE

Widimsky

P

Alfieri

O

Dunning

J

Elia

S

Kappetein

P

Lockowandt

U

Sarris

G

Vouhe

P

von Segesser

L

Agewall

S

Aladashvili

A

Alexopoulos

D

Antunes

MJ

Atalar

E

Brutel de la Riviere

A

Doganov

A

Eha

J

Fajadet

J

Ferreira

R

Garot

J

Halcox

J

Hasin

Y

Janssens

S

Kervinen

K

Laufer

G

Legrand

V

Nashef

SA

Neumann

FJ

Niemela

K

Nihoyannopoulos

P

Noc

M

Piek

JJ

Pirk

J

Rozenman

Y

Sabate

M

Starc

R

Thielmann

M

Wheatley

DJ

Windecker

S

Zembala

M

,

Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)

,

Eur Heart J

,

2010

, vol.

31

20

(pg.

2501

-

2555

)

87

Deb

S

Wijeysundera

HC

Ko

DT

Tsubota

H

Hill

S

Fremes

SE

,

Coronary artery bypass graft surgery vs.percutaneous interventions in coronary revascularization: a systematic review

,

JAMA

,

2013

, vol.

310

19

(pg.

2086

-

2095

)

88

Spertus

JA

Salisbury

AC

Jones

PG

Conaway

DG

Thompson

RC

,

Predictors of quality-of-life benefit after percutaneous coronary intervention

,

Circulation

,

2004

, vol.

110

25

(pg.

3789

-

3794

)

89

Coronary angioplasty vs. medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants

,

Lancet

,

1997

, vol.

350

9076

(pg.

461

-

468

)

90

TIME Investigators. Trial of invasive vs. medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial

,

Lancet

,

2001

, vol.

358

9286

(pg.

951

-

957

)

91

Boden

WE

O'Rourke

RA

Teo

KK

Hartigan

PM

Maron

DJ

Kostuk

WJ

Knudtson

M

Dada

M

Casperson

P

Harris

CL

Chaitman

BR

Shaw

L

Gosselin

G

Nawaz

S

Title

LM

Gau

G

Blaustein

AS

Booth

DC

Bates

ER

Spertus

JA

Berman

DS

Mancini

GB

Weintraub

WS

Group

CTR

,

Optimal medical therapy with or without PCI for stable coronary disease

,

N Engl J Med

,

2007

, vol.

356

15

(pg.

1503

-

1516

)

92

Erne

P

Schoenenberger

AW

Burckhardt

D

Zuber

M

Kiowski

W

Buser

PT

Dubach

P

Resink

TJ

Pfisterer

M

,

Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial

,

JAMA

,

2007

, vol.

297

18

(pg.

1985

-

1991

)

93

Frye

RL

August

P

Brooks

MM

Hardison

RM

Kelsey

SF

MacGregor

JM

Orchard

TJ

Chaitman

BR

Genuth

SM

Goldberg

SH

Hlatky

MA

Jones

TL

Molitch

ME

Nesto

RW

Sako

EY

Sobel

BE

,

A randomized trial of therapies for type 2 diabetes and coronary artery disease

,

N Engl J Med

,

2009

, vol.

360

24

(pg.

2503

-

2515

)

94

Hueb

W

Lopes

N

Gersh

BJ

Soares

PR

Ribeiro

EE

Pereira

AC

Favarato

D

Rocha

AS

Hueb

AC

Ramires

JA

,

Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease

,

Circulation

,

2010

, vol.

122

10

(pg.

949

-

957

)

95

Wijeysundera

HC

Nallamothu

BK

Krumholz

HM

Tu

JV

Ko

DT

,

Meta-analysis: effects of percutaneous coronary intervention vs. medical therapy on angina relief

,

Ann Intern Med

,

2010

, vol.

152

6

(pg.

370

-

379

)

96

Pursnani

S

Korley

F

Gopaul

R

Kanade

P

Chandra

N

Shaw

RE

Bangalore

S

,

Percutaneous coronary intervention vs. optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials

,

Circ Cardiovasc Interv

,

2012

, vol.

5

4

(pg.

476

-

490

)

97

Hachamovitch

R

Rozanski

A

Shaw

LJ

Stone

GW

Thomson

LE

Friedman

JD

Hayes

SW

Cohen

I

Germano

G

Berman

DS

,

Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy

,

Eur Heart J

,

2011

, vol.

32

8

(pg.

1012

-

1024

)

98

Sajadieh

A

Nielsen

OW

Rasmussen

V

Hein

HO

Hansen

JF

,

Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease

,

Eur Heart J

,

2005

, vol.

26

14

(pg.

1402

-

1409

)

99

Shaw

LJ

Berman

DS

Maron

DJ

Mancini

GB

Hayes

SW

Hartigan

PM

Weintraub

WS

O'Rourke

RA

Dada

M

Spertus

JA

Chaitman

BR

Friedman

J

Slomka

P

Heller

GV

Germano

G

Gosselin

G

Berger

P

Kostuk

WJ

Schwartz

RG

Knudtson

M

Veledar

E

Bates

ER

McCallister

B

Teo

KK

Boden

WE

Investigators C

,

Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy

,

Circulation

,

2008

, vol.

117

10

(pg.

1283

-

1291

)

100

Stergiopoulos

K

Boden

WE

Hartigan

P

Mobius-Winkler

S

Hambrecht

R

Hueb

W

Hardison

RM

Abbott

JD

Brown

DL

,

Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia: A Collaborative Meta-analysis of Contemporary Randomized Clinical Trials

,

JAMA Intern Med

,

2014

, vol.

174

2

(pg.

232

-

240

)

101

Min

JK

Dunning

A

Lin

FY

Achenbach

S

Al-Mallah

M

Budoff

MJ

Cademartiri

F

Callister

TQ

Chang

HJ

Cheng

V

Chinnaiyan

K

Chow

BJ

Delago

A

Hadamitzky

M

Hausleiter

J

Kaufmann

P

Maffei

E

Raff

G

Shaw

LJ

Villines

T

Berman

DS

,

Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease

,

J Am Coll Cardiol

,

2011

, vol.

58

8

(pg.

849

-

860

)

102

Min

JK

Shaw

LJ

Devereux

RB

Okin

PM

Weinsaft

JW

Russo

DJ

Lippolis

NJ

Berman

DS

Callister

TQ

,

Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality

,

J Am Coll Cardiol

,

2007

, vol.

50

12

(pg.

1161

-

1170

)

103

Califf

RM

Armstrong

PW

Carver

JR

D'Agostino

RB

Strauss

WE

,

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management

,

J Am Coll Cardiol

,

1996

, vol.

27

5

(pg.

1007

-

1019

)

104

Prasad

A

Rihal

CS

Lennon

RJ

Singh

M

Jaffe

AS

Holmes

DR

Jr.

,

Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients

,

Circ Cardiovasc Interv

,

2008

, vol.

1

(pg.

10

-

19

)

105

Bangalore

S

Pursnani

S

Kumar

S

Bagos

PG

,

Percutaneous coronary intervention vs. optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease

,

Circulation

,

2013

, vol.

127

7

(pg.

769

-

781

)

106

Hlatky

MA

Boothroyd

DB

Bravata

DM

Boersma

E

Booth

J

Brooks

MM

Carrie

D

Clayton

TC

Danchin

N

Flather

M

Hamm

CW

Hueb

WA

Kahler

J

Kelsey

SF

King

SB

Kosinski

AS

Lopes

N

McDonald

KM

Rodriguez

A

Serruys

P

Sigwart

U

Stables

RH

Owens

DK

Pocock

SJ

,

Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials

,

Lancet

,

2009

, vol.

373

9670

(pg.

1190

-

1197

)

107

Jeremias

A

Kaul

S

Rosengart

TK

Gruberg

L

Brown

DL

,

The impact of revascularization on mortality in patients with nonacute coronary artery disease

,

Am J Med

,

2009

, vol.

122

2

(pg.

152

-

161

)

108

Yusuf

S

Zucker

D

Peduzzi

P

Fisher

LD

Takaro

T

Kennedy

JW

Davis

K

Killip

T

Passamani

E

Norris

R

et al. ,

Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration

,

Lancet

,

1994

, vol.

344

8922

(pg.

563

-

570

)

109

Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris

,

European Coronary Surgery Study Group

,

Lancet

,

1982

, vol.

2

8309

(pg.

1173

-

1180

)

110

Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina

,

The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group

,

N Engl J Med

,

1984

, vol.

311

21

(pg.

1333

-

1339

)

111

Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial

,

N Engl J Med

,

1984

, vol.

310

12

(pg.

750

-

758

)

112

Velazquez

EJ

Lee

KL

Deja

MA

Jain

A

Sopko

G

Marchenko

A

Ali

IS

Pohost

G

Gradinac

S

Abraham

WT

Yii

M

Prabhakaran

D

Szwed

H

Ferrazzi

P

Petrie

MC

O'Connor

CM

Panchavinnin

P

She

L

Bonow

RO

Rankin

GR

Jones

RH

Rouleau

JL

,

Coronary-artery bypass surgery in patients with left ventricular dysfunction

,

N Engl J Med

,

2011

, vol.

364

17

(pg.

1607

-

1616

)

113

Pitt

B

Waters

D

Brown

WV

van Boven

AJ

Schwartz

L

Title

LM

Eisenberg

D

Shurzinske

L

McCormick

LS

,

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin vs. Revascularization Treatment Investigators

,

N Engl J Med

,

1999

, vol.

341

2

(pg.

70

-

76

)

114

Zeymer

U

Uebis

R

Vogt

A

Glunz

HG

Vohringer

HF

Harmjanz

D

Neuhaus

KL

,

Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte

,

Circulation

,

2003

, vol.

108

11

(pg.

1324

-

1328

)

115

Hochman

JS

Lamas

GA

Buller

CE

Dzavik

V

Reynolds

HR

Abramsky

SJ

Forman

S

Ruzyllo

W

Maggioni

AP

White

H

Sadowski

Z

Carvalho

AC

Rankin

JM

Renkin

JP

Steg

PG

Mascette

AM

Sopko

G

Pfisterer

ME

Leor

J

Fridrich

V

Mark

DB

Knatterud

GL

,

Coronary intervention for persistent occlusion after myocardial infarction

,

N Engl J Med

,

2006

, vol.

355

23

(pg.

2395

-

2407

)

116

Nishigaki

K

Yamazaki

T

Kitabatake

A

Yamaguchi

T

Kanmatsuse

K

Kodama

I

Takekoshi

N

Tomoike

H

Hori

M

Matsuzaki

M

Takeshita

A

Shimbo

T

Fujiwara

H

,

Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study

,

JACC Cardiovasc Interv

,

2008

, vol.

1

5

(pg.

469

-

479

)

117

Bucher

HC

Hengstler

P

Schindler

C

Guyatt

GH

,

Percutaneous transluminal coronary angioplasty vs. medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials

,

BMJ

,

2000

, vol.

321

7253

(pg.

73

-

77

)

118

Katritsis

DG

Ioannidis

JP

,

Percutaneous coronary intervention vs. conservative therapy in nonacute coronary artery disease: a meta-analysis

,

Circulation

,

2005

, vol.

111

22

(pg.

2906

-

2912

)

119

Schomig

A

Mehilli

J

de Waha

A

Seyfarth

M

Pache

J

Kastrati

A

,

A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease

,

J Am Coll Cardiol

,

2008

, vol.

52

11

(pg.

894

-

904

)

120

Trikalinos

TA

Alsheikh-Ali

AA

Tatsioni

A

Nallamothu

BK

Kent

DM

,

Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis

,

Lancet

,

2009

, vol.

373

9667

(pg.

911

-

918

)

121

Hannan

EL

Samadashvili

Z

Cozzens

K

Walford

G

Jacobs

AK

Holmes

DR

Jr.

Stamato

NJ

Gold

JP

Sharma

S

Venditti

FJ

Powell

T

King

SB

3rd

,

Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York

,

Circulation

,

2012

, vol.

125

15

(pg.

1870

-

1879

)

122

Shaw

LJ

Weintraub

WS

Maron

DJ

Hartigan

PM

Hachamovitch

R

Min

JK

Dada

M

Mancini

GB

Hayes

SW

O'Rourke

RA

Spertus

JA

Kostuk

W

Gosselin

G

Chaitman

BR

Knudtson

M

Friedman

J

Slomka

P

Germano

G

Bates

ER

Teo

KK

Boden

WE

Berman

DS

,

Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention

,

Am Heart J

,

2012

, vol.

164

2

(pg.

243

-

250

)

123

Stergiopoulos

K

Brown

DL

,

Initial coronary stent implantation with medical therapy vs.medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials

,

Arch Intern Med

,

2012

, vol.

172

4

(pg.

312

-

319

)

124

Stettler

C

Wandel

S

Allemann

S

Kastrati

A

Morice

MC

Schomig

A

Pfisterer

ME

Stone

GW

Leon

MB

de Lezo

JS

Goy

JJ

Park

SJ

Sabate

M

Suttorp

MJ

Kelbaek

H

Spaulding

C

Menichelli

M

Vermeersch

P

Dirksen

MT

Cervinka

P

Petronio

AS

Nordmann

AJ

Diem

P

Meier

B

Zwahlen

M

Reichenbach

S

Trelle

S

Windecker

S

Juni

P

,

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis

,

Lancet

,

2007

, vol.

370

9591

(pg.

937

-

948

)

125

Bangalore

S

Kumar

S

Fusaro

M

Amoroso

N

Attubato

MJ

Feit

F

Bhatt

DL

Slater

J

,

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials

,

Circulation

,

2012

, vol.

125

23

(pg.

2873

-

2891

)

126

Dangas

GD

Serruys

PW

Kereiakes

DJ

Hermiller

J

Rizvi

A

Newman

W

Sudhir

K

Smith

RS

Jr.

Cao

S

Theodoropoulos

K

Cutlip

DE

Lansky

AJ

Stone

GW

,

Meta-analysis of everolimus-eluting vs. paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)

,

JACC Cardiovasc Interv

,

2013

, vol.

6

9

(pg.

914

-

922

)

127

Baber

U

Mehran

R

Sharma

SK

Brar

S

Yu

J

Suh

JW

Kim

HS

Park

SJ

Kastrati

A

de Waha

A

Krishnan

P

Moreno

P

Sweeny

J

Kim

MC

Suleman

J

Pyo

R

Wiley

J

Kovacic

J

Kini

AS

Dangas

GD

,

Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials

,

J Am Coll Cardiol

,

2011

, vol.

58

15

(pg.

1569

-

1577

)

128

Stefanini

GG

Byrne

RA

Serruys

PW

de Waha

A

Meier

B

Massberg

S

Juni

P

Schomig

A

Windecker

S

Kastrati

A

,

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials

,

Eur Heart J

,

2012

, vol.

33

10

(pg.

1214

-

1222

)

129

Stefanini

GG

Baber

U

Windecker

S

Morice

MC

Sartori

S

Leon

MB

Stone

GW

Serruys

PW

Wijns

W

Weisz

G

Camenzind

E

Steg

PG

Smits

PC

Kandzari

D

Von Birgelen

C

Galatius

S

Jeger

RV

Kimura

T

Mikhail

G

Itchhaporia

D

Mehta

L

Ortega

R

Kim

HS

Valgimigli

M

Kastrati

A

Chieffo

A

Mehran

R

,

Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials

,

Lancet

,

2013

, vol.

382

9908

(pg.

1879

-

1888

)

130

Stefanini

GG

Kalesan

B

Serruys

PW

Heg

D

Buszman

P

Linke

A

Ischinger

T

Klauss

V

Eberli

F

Wijns

W

Morice

MC

Di Mario

C

Corti

R

Antoni

D

Sohn

HY

Eerdmans

P

van Es

GA

Meier

B

Windecker

S

Juni

P

,

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents vs. durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial

,

Lancet

,

2011

, vol.

378

9807

(pg.

1940

-

1948

)

131

Palmerini

T

Biondi-Zoccai

G

Della Riva

D

Stettler

C

Sangiorgi

D

D'Ascenzo

F

Kimura

T

Briguori

C

Sabate

M

Kim

HS

De Waha

A

Kedhi

E

Smits

PC

Kaiser

C

Sardella

G

Marullo

A

Kirtane

AJ

Leon

MB

Stone

GW

,

Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis

,

Lancet

,

2012

, vol.

379

9824

(pg.

1393

-

1402

)

132

Bangalore

S

Toklu

B

Amoroso

N

Fusaro

M

Kumar

S

Hannan

EL

Faxon

DP

Feit

F

,

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis

,

BMJ

,

2013

, vol.

347

pg.

f6625

133

Kaiser

C

Galatius

S

Erne

P

Eberli

F

Alber

H

Rickli

H

Pedrazzini

G

Hornig

B

Bertel

O

Bonetti

P

De Servi

S

Brunner-La Rocca

HP

Ricard

I

Pfisterer

M

,

Drug-eluting vs. bare-metal stents in large coronary arteries

,

N Engl J Med

,

2010

, vol.

363

24

(pg.

2310

-

2319

)

134

Bittl

JA

He

Y

Jacobs

AK

Yancy

CW

Normand

SL

,

Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease

,

Circulation

,

2013

, vol.

127

22

(pg.

2177

-

2185

)

135

Dzavik

V

Ghali

WA

Norris

C

Mitchell

LB

Koshal

A

Saunders

LD

Galbraith

PD

Hui

W

Faris

P

Knudtson

ML

,

Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators

,

Am Heart J

,

2001

, vol.

142

1

(pg.

119

-

126

)

136

Smith

PK

Califf

RM

Tuttle

RH

Shaw

LK

Lee

KL

Delong

ER

Lilly

RE

Sketch

MH

Jr.

Peterson

ED

Jones

RH

,

Selection of surgical or percutaneous coronary intervention provides differential longevity benefit

,

Ann Thorac Surg

,

2006

, vol.

82

4

(pg.

1420

-

1428

)

discussion 1428–1429

137

Hannan

EL

Wu

C

Walford

G

Culliford

AT

Gold

JP

Smith

CR

Higgins

RS

Carlson

RE

Jones

RH

,

Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease

,

N Engl J Med

,

2008

, vol.

358

4

(pg.

331

-

341

)

138

Caracciolo

EA

Davis

KB

Sopko

G

Kaiser

GC

Corley

SD

Schaff

H

Taylor

HA

Chaitman

BR

,

Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience

,

Circulation

,

1995

, vol.

91

9

(pg.

2335

-

2344

)

139

Chaitman

BR

Hardison

RM

Adler

D

Gebhart

S

Grogan

M

Ocampo

S

Sopko

G

Ramires

JA

Schneider

D

Frye

RL

,

Bypass Angioplasty Revascularization Investigation 2 Diabetes Study G. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction

,

Circulation

,

2009

, vol.

120

25

(pg.

2529

-

2540

)

140

Passamani

E

Davis

KB

Gillespie

MJ

Killip

T

,

A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction

,

N Engl J Med

,

1985

, vol.

312

26

(pg.

1665

-

1671

)

141

Jones

RH

Kesler

K

Phillips

HR

3rd

Mark

DB

Smith

PK

Nelson

CL

Newman

MF

Reves

JG

Anderson

RW

Califf

RM

,

Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease

,

J Thorac Cardiovasc Surg

,

1996

, vol.

111

5

(pg.

1013

-

1025

)

142

Baker

DW

Jones

R

Hodges

J

Massie

BM

Konstam

MA

Rose

EA

,

Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction

,

JAMA

,

1994

, vol.

272

19

(pg.

1528

-

1534

)

143

Hachamovitch

R

Hayes

SW

Friedman

JD

Cohen

I

Berman

DS

,

Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography

,

Circulation

,

2003

, vol.

107

23

(pg.

2900

-

2907

)

144

Davies

RF

Goldberg

AD

Forman

S

Pepine

CJ

Knatterud

GL

Geller

N

Sopko

G

Pratt

C

Deanfield

J

Conti

CR

,

Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy vs. revascularization

,

Circulation

,

1997

, vol.

95

8

(pg.

2037

-

2043

)

145

Thomas

S

Gokhale

R

Boden

WE

Devereaux

PJ

,

A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris

,

Can J Cardiol

,

2013

, vol.

29

4

(pg.

472

-

482

)

146

Coronary angioplasty vs. coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial

,

Lancet

,

1993

, vol.

341

8845

(pg.

573

-

580

)

147

Hamm

CW

Reimers

J

Ischinger

T

Rupprecht

HJ

Berger

J

Bleifeld

W

,

A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI)

,

N Engl J Med

,

1994

, vol.

331

16

(pg.

1037

-

1043

)

148

King

SB

3rd

Lembo

NJ

Weintraub

WS

Kosinski

AS

Barnhart

HX

Kutner

MH

Alazraki

NP

Guyton

RA

Zhao

XQ

,

A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty vs. Surgery Trial (EAST)

,

N Engl J Med

,

1994

, vol.

331

16

(pg.

1044

-

1050

)

149

First-year results of CABRI (Coronary Angioplasty vs. Bypass Revascularisation Investigation). CABRI Trial Participants

,

Lancet

,

1995

, vol.

346

8984

(pg.

1179

-

1184

)

150

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators

,

N Engl J Med

,

1996

, vol.

335

4

(pg.

217

-

225

)

151

Morrison

DA

Sethi

G

Sacks

J

Henderson

W

Grover

F

Sedlis

S

Esposito

R

Ramanathan

K

Weiman

D

Saucedo

J

Antakli

T

Paramesh

V

Pett

S

Vernon

S

Birjiniuk

V

Welt

F

Krucoff

M

Wolfe

W

Lucke

JC

Mediratta

S

Booth

D

Barbiere

C

Lewis

D

Angina With Extremely Serious Operative Mortality

E

,

Percutaneous coronary intervention vs. coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME)

,

J Am Coll Cardiol

,

2001

, vol.

38

1

(pg.

143

-

149

)

152

Rodriguez

A

Bernardi

V

Navia

J

Baldi

J

Grinfeld

L

Martinez

J

Vogel

D

Grinfeld

R

Delacasa

A

Garrido

M

Oliveri

R

Mele

E

Palacios

I

O'Neill

W

,

Argentine Randomized Study: Coronary Angioplasty with Stenting vs. Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators

,

J Am Coll Cardiol

,

2001

, vol.

37

1

(pg.

51

-

58

)

153

Serruys

PW

Unger

F

Sousa

JE

Jatene

A

Bonnier

HJ

Schonberger

JP

Buller

N

Bonser

R

van den Brand

MJ

van Herwerden

LA

Morel

MA

van Hout

BA

,

Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease

,

N Engl J Med

,

2001

, vol.

344

15

(pg.

1117

-

1124

)

154

Coronary artery bypass surgery vs. percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial

,

Lancet

,

2002

, vol.

360

9338

(pg.

965

-

970

)

155

Eefting

F

Nathoe

H

van Dijk

D

Jansen

E

Lahpor

J

Stella

P

Suyker

W

Diephuis

J

Suryapranata

H

Ernst

S

Borst

C

Buskens

E

Grobbee

D

de Jaegere

P

,

Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty

,

Circulation

,

2003

, vol.

108

23

(pg.

2870

-

2876

)

156

Thiele

H

Oettel

S

Jacobs

S

Hambrecht

R

Sick

P

Gummert

JF

Mohr

FW

Schuler

G

Falk

V

,

Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up

,

Circulation

,

2005

, vol.

112

22

(pg.

3445

-

3450

)

157

Serruys

PW

Morice

MC

Kappetein

AP

Colombo

A

Holmes

DR

Mack

MJ

Stahle

E

Feldman

TE

van den Brand

M

Bass

EJ

Van Dyck

N

Leadley

K

Dawkins

KD

Mohr

FW

,

Percutaneous coronary intervention vs. coronary-artery bypass grafting for severe coronary artery disease

,

N Engl J Med

,

2009

, vol.

360

10

(pg.

961

-

972

)

158

Boudriot

E

Thiele

H

Walther

T

Liebetrau

C

Boeckstegers

P

Pohl

T

Reichart

B

Mudra

H

Beier

F

Gansera

B

Neumann

FJ

Gick

M

Zietak

T

Desch

S

Schuler

G

Mohr

FW

,

Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents vs. coronary artery bypass grafting in unprotected left main stem stenosis

,

J Am Coll Cardiol

,

2011

, vol.

57

5

(pg.

538

-

545

)

159

Park

SJ

Kim

YH

Park

DW

Yun

SC

Ahn

JM

Song

HG

Lee

JY

Kim

WJ

Kang

SJ

Lee

SW

Lee

CW

Park

SW

Chung

CH

Lee

JW

Lim

DS

Rha

SW

Lee

SG

Gwon

HC

Kim

HS

Chae

IH

Jang

Y

Jeong

MH

Tahk

SJ

Seung

KB

,

Randomized trial of stents vs. bypass surgery for left main coronary artery disease

,

N Engl J Med

,

2011

, vol.

364

18

(pg.

1718

-

1727

)

160

Kapoor

JR

Gienger

AL

Ardehali

R

Varghese

R

Perez

MV

Sundaram

V

McDonald

KM

Owens

DK

Hlatky

MA

Bravata

DM

,

Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery

,

JACC Cardiovasc Interv

,

2008

, vol.

1

5

(pg.

483

-

491

)

161

Aziz

O

Rao

C

Panesar

SS

Jones

C

Morris

S

Darzi

A

Athanasiou

T

,

Meta-analysis of minimally invasive internal thoracic artery bypass vs. percutaneous revascularisation for isolated lesions of the left anterior descending artery

,

BMJ

,

2007

, vol.

334

(7594):617

162

Loop

FD

Lytle

BW

Cosgrove

DM

Stewart

RW

Goormastic

M

Williams

GW

Golding

LA

Gill

CC

Taylor

PC

Sheldon

WC

et al. ,

Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events

,

N Engl J Med

,

1986

, vol.

314

1

(pg.

1

-

6

)

163

Cameron

A

Davis

KB

Green

GE

Myers

WO

Pettinger

M

,

Clinical implications of internal mammary artery bypass grafts: the Coronary Artery Surgery Study experience

,

Circulation

,

1988

, vol.

77

4

(pg.

815

-

819

)

164

Lytle

BW

Blackstone

EH

Sabik

JF

Houghtaling

P

Loop

FD

Cosgrove

DM

,

The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years

,

Ann Thorac Surg

,

2004

, vol.

78

(6):2005–2012; discussion

(pg.

2012

-

2014

)

165

Kurlansky

PA

Traad

EA

Dorman

MJ

Galbut

DL

Zucker

M

Ebra

G

,

Thirty-year follow-up defines survival benefit for second internal mammary artery in propensity-matched groups

,

Ann Thorac Surg

,

2010

, vol.

90

1

(pg.

101

-

108

)

166

Taggart

DP

Kaul

S

Boden

WE

Ferguson

TB

Jr.

Guyton

RA

Mack

MJ

Sergeant

PT

Shemin

RJ

Smith

PK

Yusuf

S

,

Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery

,

J Am Coll Cardiol

,

2008

, vol.

51

9

(pg.

885

-

892

)

167

Mehilli

J

Kastrati

A

Byrne

RA

Bruskina

O

Iijima

R

Schulz

S

Pache

J

Seyfarth

M

Massberg

S

Laugwitz

KL

Dirschinger

J

Schomig

A

,

Paclitaxel- vs. sirolimus-eluting stents for unprotected left main coronary artery disease

,

J Am Coll Cardiol

,

2009

, vol.

53

19

(pg.

1760

-

1768

)

168

Morice

MC

Serruys

PW

Kappetein

AP

Feldman

TE

Stahle

E

Colombo

A

Mack

MJ

Holmes

DR

Torracca

L

van Es

GA

Leadley

K

Dawkins

KD

Mohr

F

,

Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial

,

Circulation

,

2010

, vol.

121

24

(pg.

2645

-

2653

)

169

Morice

MC

Serruys

PW

Kappetein

AP

Feldman

TE

Stahle

E

Colombo

A

Mack

MJ

Holmes

DR

Choi

JW

Ruzyllo

W

Religa

G

Huang

J

Roy

K

Dawkins

KD

Mohr

F

,

Five-Year Outcomes in Patients with Left Main Disease Treated with Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the SYNTAX Trial

,

Circulation

,

2014

, vol.

129

(pg.

2388

-

2394

)

170

Capodanno

D

Stone

GW

Morice

MC

Bass

TA

Tamburino

C

,

Percutaneous coronary intervention vs. coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data

,

J Am Coll Cardiol

,

2011

, vol.

58

14

(pg.

1426

-

1432

)

171

Buszman

PE

Buszman

PP

Kiesz

RS

Bochenek

A

Trela

B

Konkolewska

M

Wallace-Bradley

D

Wilczynski

M

Banasiewicz-Szkrobka

I

Peszek-Przybyla

E

Krol

M

Kondys

M

Milewski

K

Wiernek

S

Debinski

M

Zurakowski

A

Martin

JL

Tendera

M

,

Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry

,

J Am Coll Cardiol

,

2009

, vol.

54

16

(pg.

1500

-

1511

)

172

Park

DW

Kim

YH

Yun

SC

Lee

JY

Kim

WJ

Kang

SJ

Lee

SW

Lee

CW

Kim

JJ

Choo

SJ

Chung

CH

Lee

JW

Park

SW

Park

SJ

,

Long-term outcomes after stenting vs. coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry

,

J Am Coll Cardiol

,

2010

, vol.

56

17

(pg.

1366

-

1375

)

173

Sipahi

I

Akay

MH

Dagdelen

S

Blitz

A

Alhan

C

,

Coronary Artery Bypass Grafting vs.Percutaneous Coronary Intervention and Long-term Mortality and Morbidity in Multivessel Disease: Meta-analysis of Randomized Clinical Trials of the Arterial Grafting and Stenting Era

,

JAMA Intern Med

,

2014

, vol.

174

2

(pg.

223

-

230

)

174

Bravata

DM

Gienger

AL

McDonald

KM

Sundaram

V

Perez

MV

Varghese

R

Kapoor

JR

Ardehali

R

Owens

DK

Hlatky

MA

,

Systematic review: the comparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery

,

Ann Intern Med

,

2007

, vol.

147

10

(pg.

703

-

716

)

175

Farkouh

ME

Domanski

M

Sleeper

LA

Siami

FS

Dangas

G

Mack

M

Yang

M

Cohen

DJ

Rosenberg

Y

Solomon

SD

Desai

AS

Gersh

BJ

Magnuson

EA

Lansky

A

Boineau

R

Weinberger

J

Ramanathan

K

Sousa

JE

Rankin

J

Bhargava

B

Buse

J

Hueb

W

Smith

CR

Muratov

V

Bansilal

S

King

S

3rd

Bertrand

M

Fuster

V

Investigators FT

,

Strategies for multivessel revascularization in patients with diabetes

,

N Engl J Med

,

2012

, vol.

367

25

(pg.

2375

-

2384

)

176

Head

SJ

Davierwala

PM

Serruys

PW

Redwood

SR

Colombo

A

Mack

MJ

Morice

MC

Holmes

DR

Feldman

TE

Staehle

E

Underwood

P

Dawkins

KD

Kappetein

AP

Mohr

FW

,

Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial

,

Eur Heart J

Published online 21 May 2014;

10.1093/eurheartj/ehu213

177

Wu

C

Camacho

FT

Zhao

S

Wechsler

AS

Culliford

AT

Lahey

SJ

King

SB

3rd

Walford

G

Gold

JP

Smith

CR

Jordan

D

Higgins

RS

Hannan

EL

,

Long-term mortality of coronary artery bypass graft surgery and stenting with drug-eluting stents

,

Ann Thorac Surg

,

2013

, vol.

95

4

(pg.

1297

-

1305

)

178

Blazek

S

Holzhey

D

Jungert

C

Borger

MA

Fuernau

G

Desch

S

Eitel

I

de Waha

S

Lurz

P

Schuler

G

Mohr

FW

Thiele

H

,

Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial

,

JACC Cardiovasc Interv

,

2013

, vol.

6

1

(pg.

20

-

26

)

179

Thiele

H

Neumann-Schniedewind

P

Jacobs

S

Boudriot

E

Walther

T

Mohr

FW

Schuler

G

Falk

V

,

Randomized comparison of minimally invasive direct coronary artery bypass surgery vs. sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis

,

J Am Coll Cardiol

,

2009

, vol.

53

25

(pg.

2324

-

2331

)

180

Hamm

CW

Bassand

JP

Agewall

S

Bax

J

Boersma

E

Bueno

H

Caso

P

Dudek

D

Gielen

S

Huber

K

Ohman

M

Petrie

MC

Sonntag

F

Uva

MS

Storey

RF

Wijns

W

Zahger

D

Guidelines

ESCCfP

,

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

,

Eur Heart J

,

2011

, vol.

32

23

(pg.

2999

-

3054

)

181

Mehta

SR

Cannon

CP

Fox

KA

Wallentin

L

Boden

WE

Spacek

R

Widimsky

P

McCullough

PA

Hunt

D

Braunwald

E

Yusuf

S

,

Routine vs. selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials

,

JAMA

,

2005

, vol.

293

23

(pg.

2908

-

2917

)

182

Bavry

AA

Kumbhani

DJ

Rassi

AN

Bhatt

DL

Askari

AT

,

Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials

,

J Am Coll Cardiol

,

2006

, vol.

48

7

(pg.

1319

-

1325

)

183

O'Donoghue

M

Boden

WE

Braunwald

E

Cannon

CP

Clayton

TC

de Winter

RJ

Fox

KA

Lagerqvist

B

McCullough

PA

Murphy

SA

Spacek

R

Swahn

E

Wallentin

L

Windhausen

F

Sabatine

MS

,

Early invasive vs.conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis

,

JAMA

,

2008

, vol.

300

1

(pg.

71

-

80

)

184

Fox

KA

Clayton

TC

Damman

P

Pocock

SJ

de Winter

RJ

Tijssen

JG

Lagerqvist

B

Wallentin

L

,

Long-term outcome of a routine vs. selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data

,

J Am Coll Cardiol

,

2010

, vol.

55

22

(pg.

2435

-

2445

)

185

Katritsis

DG

Siontis

GC

Kastrati

A

van't Hof

AW

Neumann

FJ

Siontis

KC

Ioannidis

JP

,

Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes

,

Eur Heart J

,

2011

, vol.

32

1

(pg.

32

-

40

)

186

Navarese

EP

Gurbel

PA

Andreotti

F

Tantry

U

Jeong

YH

Kozinski

M

Engstrom

T

Di Pasquale

G

Kochman

W

Ardissino

D

Kedhi

E

Stone

GW

Kubica

J

,

Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis

,

Ann Intern Med

,

2013

, vol.

158

4

(pg.

261

-

270

)

187

Mehta

SR

Granger

CB

Boden

WE

Steg

PG

Bassand

JP

Faxon

DP

Afzal

R

Chrolavicius

S

Jolly

SS

Widimsky

P

Avezum

A

Rupprecht

HJ

Zhu

J

Col

J

Natarajan

MK

Horsman

C

Fox

KA

Yusuf

S

Investigators T

,

Early vs. delayed invasive intervention in acute coronary syndromes

,

N Engl J Med

,

2009

, vol.

360

21

(pg.

2165

-

2175

)

188

Sorajja

P

Gersh

BJ

Cox

DA

McLaughlin

MG

Zimetbaum

P

Costantini

C

Stuckey

T

Tcheng

JE

Mehran

R

Lansky

AJ

Grines

CL

Stone

GW

,

Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction

,

Eur Heart J

,

2007

, vol.

28

14

(pg.

1709

-

1716

)

189

Ben-Gal

Y

Moses

JW

Mehran

R

Lansky

AJ

Weisz

G

Nikolsky

E

Argenziano

M

Williams

MR

Colombo

A

Aylward

PE

Stone

GW

,

Surgical vs. percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial

,

JACC Cardiovasc Interv

,

2010

, vol.

3

10

(pg.

1059

-

1067

)

190

Palmerini

T

Genereux

P

Caixeta

A

Cristea

E

Lansky

A

Mehran

R

Dangas

G

Lazar

D

Sanchez

R

Fahy

M

Xu

K

Stone

GW

,

Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial

,

J Am Coll Cardiol

,

2011

, vol.

57

24

(pg.

2389

-

2397

)

191

Brener

SJ

Milford-Beland

S

Roe

MT

Bhatt

DL

Weintraub

WS

Brindis

RG

,

Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report

,

Am Heart J

,

2008

, vol.

155

1

(pg.

140

-

146

)

192

Hannan

EL

Samadashvili

Z

Walford

G

Jacobs

AK

Stamato

NJ

Venditti

FJ

Holmes

DR

Jr.

Sharma

S

King

SB

3rd

,

Staged vs. one-time complete revascularization with percutaneous coronary intervention for multivessel coronary artery disease patients without ST-elevation myocardial infarction

,

Circ Cardiovasc Interv

,

2013

, vol.

6

1

(pg.

12

-

20

)

193

Rosner

GF

Kirtane

AJ

Genereux

P

Lansky

AJ

Cristea

E

Gersh

BJ

Weisz

G

Parise

H

Fahy

M

Mehran

R

Stone

GW

,

Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial

,

Circulation

,

2012

, vol.

125

21

(pg.

2613

-

2620

)

194

Monteiro

P

,

Impact of early coronary artery bypass graft in an unselected acute coronary syndrome patient population

,

Circulation

,

2006

, vol.

114

1 Suppl)

I467–I472

195

Parikh

SV

de Lemos

JA

Jessen

ME

Brilakis

ES

Ohman

EM

Chen

AY

Wang

TY

Peterson

ED

Roe

MT

Holper

EM

,

Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines)

,

JACC Cardiovasc Interv

,

2010

, vol.

3

4

(pg.

419

-

427

)

196

Greenhalgh

J

Hockenhull

J

Rao

N

Dundar

Y

Dickson

RC

Bagust

A

,

Drug-eluting stents vs. bare metal stents for angina or acute coronary syndromes

,

Cochrane Database Syst Rev

,

2010

, vol.

5

pg.

CD004587

197

Amsterdam

EA

Kirk

JD

Diercks

DB

Lewis

WR

Turnipseed

SD

,

Immediate exercise testing to evaluate low-risk patients presenting to the emergency department with chest pain

,

J Am Coll Cardiol

,

2002

, vol.

40

2

(pg.

251

-

256

)

198

Nyman

I

Wallentin

L

Areskog

M

Areskog

NH

Swahn

E

,

Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group

,

Int J Cardiol

,

1993

, vol.

39

2

(pg.

131

-

142

)

199

Kirtane

AJ

Gupta

A

Iyengar

S

Moses

JW

Leon

MB

Applegate

R

Brodie

B

Hannan

E

Harjai

K

Jensen

LO

Park

SJ

Perry

R

Racz

M

Saia

F

Tu

JV

Waksman

R

Lansky

AJ

Mehran

R

Stone

GW

,

Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies

,

Circulation

,

2009

, vol.

119

25

(pg.

3198

-

3206

)

200

Moses

JW

Mehran

R

Nikolsky

E

Lasala

JM

Corey

W

Albin

G

Hirsch

C

Leon

MB

Russell

ME

Ellis

SG

Stone

GW

,

Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial

,

J Am Coll Cardiol

,

2005

, vol.

45

8

(pg.

1165

-

1171

)

201

Steg

PG

James

SK

Atar

D

Badano

LP

Blomstrom-Lundqvist

C

Borger

MA

Di Mario

C

Dickstein

K

Ducrocq

G

Fernandez-Aviles

F

Gershlick

AH

Giannuzzi

P

Halvorsen

S

Huber

K

Juni

P

Kastrati

A

Knuuti

J

Lenzen

MJ

Mahaffey

KW

Valgimigli

M

van 't Hof

A

Widimsky

P

Zahger

D

,

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

,

Eur Heart J

,

2012

, vol.

33

20

(pg.

2569

-

2619

)

202

Gershlick

AH

Banning

AP

Myat

A

Verheugt

FW

Gersh

BJ

,

Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?

,

Lancet

,

2013

, vol.

382

9892

(pg.

624

-

632

)

203

Miedema

MD

Newell

MC

Duval

S

Garberich

RF

Handran

CB

Larson

DM

Mulder

S

Wang

YL

Lips

DL

Henry

TD

,

Causes of delay and associated mortality in patients transferred with ST-segment-elevation myocardial infarction

,

Circulation

,

2011

, vol.

124

15

(pg.

1636

-

1644

)

204

Herrin

J

Miller

LE

Turkmani

DF

Nsa

W

Drye

EE

Bernheim

SM

Ling

SM

Rapp

MT

Han

LF

Bratzler

DW

Bradley

EH

Nallamothu

BK

Ting

HH

Krumholz

HM

,

National performance on door-in to door-out time among patients transferred for primary percutaneous coronary intervention

,

Arch Intern Med

,

2011

, vol.

171

21

(pg.

1879

-

1886

)

205

Wang

TY

Nallamothu

BK

Krumholz

HM

Li

S

Roe

MT

Jollis

JG

Jacobs

AK

Holmes

DR

Peterson

ED

Ting

HH

,

Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention

,

JAMA

,

2011

, vol.

305

24

(pg.

2540

-

2547

)

206

O'Gara

PT

Kushner

FG

Ascheim

DD

Casey

DE

Jr.

Chung

MK

de Lemos

JA

Ettinger

SM

Fang

JC

Fesmire

FM

Franklin

BA

Granger

CB

Krumholz

HM

Linderbaum

JA

Morrow

DA

Newby

LK

Ornato

JP

Ou

N

Radford

MJ

Tamis-Holland

JE

Tommaso

CL

Tracy

CM

Woo

YJ

Zhao

DX

Anderson

JL

Jacobs

AK

Halperin

JL

Albert

NM

Brindis

RG

Creager

MA

DeMets

D

Guyton

RA

Hochman

JS

Kovacs

RJ

Ohman

EM

Stevenson

WG

Yancy

CW

,

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

,

Circulation

,

2013

, vol.

127

4

(pg.

e362

-

e425

)

207

Boersma

E

Maas

AC

Deckers

JW

Simoons

ML

,

Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour

,

Lancet

,

1996

, vol.

348

9030

(pg.

771

-

775

)

208

Boersma

E

,

Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients

,

Eur Heart J

,

2006

, vol.

27

7

(pg.

779

-

788

)

209

Keeley

EC

Boura

JA

Grines

CL

,

Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials

,

Lancet

,

2006

, vol.

367

9510

(pg.

579

-

588

)

210

Bonnefoy

E

Lapostolle

F

Leizorovicz

A

Steg

G

McFadden

EP

Dubien

PY

Cattan

S

Boullenger

E

Machecourt

J

Lacroute

JM

Cassagnes

J

Dissait

F

Touboul

P

,

Primary angioplasty vs. prehospital fibrinolysis in acute myocardial infarction: a randomised study

,

Lancet

,

2002

, vol.

360

9336

(pg.

825

-

829

)

211

Bonnefoy

E

Steg

PG

Boutitie

F

Dubien

PY

Lapostolle

F

Roncalli

J

Dissait

F

Vanzetto

G

Leizorowicz

A

Kirkorian

G

Mercier

C

McFadden

EP

Touboul

P

,

Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up

,

Eur Heart J

,

2009

, vol.

30

13

(pg.

1598

-

1606

)

212

Morrison

LJ

Verbeek

PR

McDonald

AC

Sawadsky

BV

Cook

DJ

,

Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis

,

JAMA

,

2000

, vol.

283

20

(pg.

2686

-

2692

)

213

Steg

PG

Bonnefoy

E

Chabaud

S

Lapostolle

F

Dubien

PY

Cristofini

P

Leizorovicz

A

Touboul

P

,

Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial

,

Circulation

,

2003

, vol.

108

23

(pg.

2851

-

2856

)

214

Pinto

DS

Frederick

PD

Chakrabarti

AK

Kirtane

AJ

Ullman

E

Dejam

A

Miller

DP

Henry

TD

Gibson

CM

,

Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase

,

Circulation

,

2011

, vol.

124

23

(pg.

2512

-

2521

)

215

Armstrong

PW

Gershlick

AH

Goldstein

P

Wilcox

R

Danays

T

Lambert

Y

Sulimov

V

Rosell Ortiz

F

Ostojic

M

Welsh

RC

Carvalho

AC

Nanas

J

Arntz

HR

Halvorsen

S

Huber

K

Grajek

S

Fresco

C

Bluhmki

E

Regelin

A

Vandenberghe

K

Bogaerts

K

Van de Werf

F

,

Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction

,

N Engl J Med

,

2013

, vol.

368

15

(pg.

1379

-

1387

)

216

Bates

ER

Jacobs

AK

,

Time to treatment in patients with STEMI

,

N Engl J Med

,

2013

, vol.

369

10

(pg.

889

-

892

)

217

Luepker

RV

Raczynski

JM

Osganian

S

Goldberg

RJ

Finnegan

JR

Jr.

Hedges

JR

Goff

DC

Jr.

Eisenberg

MS

Zapka

JG

Feldman

HA

Labarthe

DR

McGovern

PG

Cornell

CE

Proschan

MA

Simons-Morton

DG

,

Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial

,

JAMA

,

2000

, vol.

284

1

(pg.

60

-

67

)

218

Kristensen

SD

Laut

KG

Fajadet

J

Kaifoszova

Z

Kala

P

Di Mario

C

Wijns

W

Clemmensen

P

Agladze

V

Antoniades

L

Alhabib

KF

De Boer

MJ

Claeys

MJ

Deleanu

D

Dudek

D

Erglis

A

Gilard

M

Goktekin

O

Guagliumi

G

Gudnason

T

Hansen

KW

Huber

K

James

S

Janota

T

Jennings

S

Kajander

O

Kanakakis

J

Karamfiloff

KK

Kedev

S

Kornowski

R

Ludman

PF

Merkely

B

Milicic

D

Najafov

R

Nicolini

FA

Noc

M

Ostojic

M

Pereira

H

Radovanovic

D

Sabate

M

Sobhy

M

Sokolov

M

Studencan

M

Terzic

I

Wahler

S

Widimsky

P

,

Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries

,

Eur Heart J

,

2014

, vol.

35

(pg.

1957

-

1970

)

219

Andersen

HR

Nielsen

TT

Rasmussen

K

Thuesen

L

Kelbaek

H

Thayssen

P

Abildgaard

U

Pedersen

F

Madsen

JK

Grande

P

Villadsen

AB

Krusell

LR

Haghfelt

T

Lomholt

P

Husted

SE

Vigholt

E

Kjaergard

HK

Mortensen

LS

,

A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction

,

N Engl J Med

,

2003

, vol.

349

8

(pg.

733

-

742

)

220

Dalby

M

Bouzamondo

A

Lechat

P

Montalescot

G

,

Transfer for primary angioplasty vs. immediate thrombolysis in acute myocardial infarction: a meta-analysis

,

Circulation

,

2003

, vol.

108

15

(pg.

1809

-

1814

)

221

Hochman

JS

Sleeper

LA

Webb

JG

Sanborn

TA

White

HD

Talley

JD

Buller

CE

Jacobs

AK

Slater

JN

Col

J

McKinlay

SM

LeJemtel

TH

,

Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock

,

N Engl J Med

,

1999

, vol.

341

9

(pg.

625

-

634

)

222

Mehilli

J

Kastrati

A

Schulz

S

Frungel

S

Nekolla

SG

Moshage

W

Dotzer

F

Huber

K

Pache

J

Dirschinger

J

Seyfarth

M

Martinoff

S

Schwaiger

M

Schomig

A

,

Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial

,

Circulation

,

2009

, vol.

119

14

(pg.

1933

-

1940

)

223

Busk

M

Kaltoft

A

Nielsen

SS

Bottcher

M

Rehling

M

Thuesen

L

Botker

HE

Lassen

JF

Christiansen

EH

Krusell

LR

Andersen

HR

Nielsen

TT

Kristensen

SD

,

Infarct size and myocardial salvage after primary angioplasty in patients presenting with symptoms for <12 h vs. 12–72 h

,

Eur Heart J

,

2009

, vol.

30

11

(pg.

1322

-

1330

)

224

Schomig

A

Mehilli

J

Antoniucci

D

Ndrepepa

G

Markwardt

C

Di Pede

F

Nekolla

SG

Schlotterbeck

K

Schuhlen

H

Pache

J

Seyfarth

M

Martinoff

S

Benzer

W

Schmitt

C

Dirschinger

J

Schwaiger

M

Kastrati

A

,

Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial

,

JAMA

,

2005

, vol.

293

23

(pg.

2865

-

2872

)

225

Kalla

K

Christ

G

Karnik

R

Malzer

R

Norman

G

Prachar

H

Schreiber

W

Unger

G

Glogar

HD

Kaff

A

Laggner

AN

Maurer

G

Mlczoch

J

Slany

J

Weber

HS

Huber

K

,

Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry)

,

Circulation

,

2006

, vol.

113

20

(pg.

2398

-

2405

)

226

Henry

TD

Sharkey

SW

Burke

MN

Chavez

IJ

Graham

KJ

Henry

CR

Lips

DL

Madison

JD

Menssen

KM

Mooney

MR

Newell

MC

Pedersen

WR

Poulose

AK

Traverse

JH

Unger

BT

Wang

YL

Larson

DM

,

A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction

,

Circulation

,

2007

, vol.

116

7

(pg.

721

-

728

)

227

Nallamothu

BK

Krumholz

HM

Ko

DT

LaBresh

KA

Rathore

S

Roe

MT

Schwamm

L

,

Development of systems of care for ST-elevation myocardial infarction patients: gaps, barriers, and implications

,

Circulation

,

2007

, vol.

116

2

e68–e72

228

Widimsky

P

Wijns

W

Fajadet

J

de Belder

M

Knot

J

Aaberge

L

Andrikopoulos

G

Baz

JA

Betriu

A

Claeys

M

Danchin

N

Djambazov

S

Erne

P

Hartikainen

J

Huber

K

Kala

P

Klinceva

M

Kristensen

SD

Ludman

P

Ferre

JM

Merkely

B

Milicic

D

Morais

J

Noc

M

Opolski

G

Ostojic

M

Radovanovic

D

De Servi

S

Stenestrand

U

Studencan

M

Tubaro

M

Vasiljevic

Z

Weidinger

F

Witkowski

A

Zeymer

U

,

Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries

,

Eur Heart J

,

2010

, vol.

31

8

(pg.

943

-

957

)

229

Knot

J

Widimsky

P

Wijns

W

Stenestrand

U

Kristensen

SD

Van'T

Hof A

Weidinger

F

Janzon

M

Norgaard

BL

Soerensen

JT

van de Wetering

H

Thygesen

K

Bergsten

PA

Digerfeldt

C

Potgieter

A

Tomer

N

Fajadet

J

,

How to set up an effective national primary angioplasty network: lessons learned from five European countries

,

EuroIntervention

,

2009

, vol.

5

(3):299

(pg.

301

-

309

)

230

Bradley

EH

Herrin

J

Wang

Y

Barton

BA

Webster

TR

Mattera

JA

Roumanis

SA

Curtis

JP

Nallamothu

BK

Magid

DJ

McNamara

RL

Parkosewich

J

Loeb

JM

Krumholz

HM

,

Strategies for reducing the door-to-balloon time in acute myocardial infarction

,

N Engl J Med

,

2006

, vol.

355

22

(pg.

2308

-

2320

)

231

Pinto

DS

Kirtane

AJ

Nallamothu

BK

Murphy

SA

Cohen

DJ

Laham

RJ

Cutlip

DE

Bates

ER

Frederick

PD

Miller

DP

Carrozza

JP

Jr.

Antman

EM

Cannon

CP

Gibson

CM

,

Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy

,

Circulation

,

2006

, vol.

114

19

(pg.

2019

-

2025

)

232

Steg

PG

Cambou

JP

Goldstein

P

Durand

E

Sauval

P

Kadri

Z

Blanchard

D

Lablanche

JM

Gueret

P

Cottin

Y

Juliard

JM

Hanania

G

Vaur

L

Danchin

N

,

Bypassing the emergency room reduces delays and mortality in ST elevation myocardial infarction: the USIC 2000 registry

,

Heart

,

2006

, vol.

92

10

(pg.

1378

-

1383

)

233

Cavender

MA

Milford-Beland

S

Roe

MT

Peterson

ED

Weintraub

WS

Rao

SV

,

Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry)

,

Am J Cardiol

,

2009

, vol.

104

4

(pg.

507

-

513

)

234

Kornowski

R

Mehran

R

Dangas

G

Nikolsky

E

Assali

A

Claessen

BE

Gersh

BJ

Wong

SC

Witzenbichler

B

Guagliumi

G

Dudek

D

Fahy

M

Lansky

AJ

Stone

GW

,

Prognostic impact of staged vs. "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial

,

J Am Coll Cardiol

,

2011

, vol.

58

7

(pg.

704

-

711

)

235

Politi

L

Sgura

F

Rossi

R

Monopoli

D

Guerri

E

Leuzzi

C

Bursi

F

Sangiorgi

GM

Modena

MG

,

A randomised trial of target-vessel vs. multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up

,

Heart

,

2010

, vol.

96

9

(pg.

662

-

667

)

236

Di Mario

C

Mara

S

Flavio

A

Imad

S

Antonio

M

Anna

P

Emanuela

P

Stefano

DS

Angelo

R

Stefania

C

Anna

F

Carmelo

C

Antonio

C

Monzini

N

Bonardi

MA

,

Single vs.multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study

,

Int J Cardiovasc Intervent

,

2004

, vol.

6

3–4

(pg.

128

-

133

)

237

Jolly

SS

Yusuf

S

Cairns

J

Niemela

K

Xavier

D

Widimsky

P

Budaj

A

Niemela

M

Valentin

V

Lewis

BS

Avezum

A

Steg

PG

Rao

SV

Gao

P

Afzal

R

Joyner

CD

Chrolavicius

S

Mehta

SR

,

Radial vs. femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial

,

Lancet

,

2011

, vol.

377

9775

(pg.

1409

-

1420

)

238

Romagnoli

E

Biondi-Zoccai

G

Sciahbasi

A

Politi

L

Rigattieri

S

Pendenza

G

Summaria

F

Patrizi

R

Borghi

A

Di Russo

C

Moretti

C

Agostoni

P

Loschiavo

P

Lioy

E

Sheiban

I

Sangiorgi

G

,

Radial vs. femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Vs. Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study

,

J Am Coll Cardiol

,

2012

, vol.

60

24

(pg.

2481

-

2489

)

239

Baklanov

DV

Kaltenbach

LA

Marso

SP

Subherwal

SS

Feldman

DN

Garratt

KN

Curtis

JP

Messenger

JC

Rao

SV

,

The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011)

,

J Am Coll Cardiol

,

2013

, vol.

61

4

(pg.

420

-

426

)

240

Hamon

M

Pristipino

C

Di Mario

C

Nolan

J

Ludwig

J

Tubaro

M

Sabate

M

Mauri-Ferre

J

Huber

K

Niemela

K

Haude

M

Wijns

W

Dudek

D

Fajadet

J

Kiemeneij

F

,

Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology

,

EuroIntervention

,

2013

, vol.

8

11

(pg.

1242

-

1251

)

241

Nordmann

AJ

Hengstler

P

Harr

T

Young

J

Bucher

HC

,

Clinical outcomes of primary stenting vs. balloon angioplasty in patients with myocardial infarction: a meta-analysis of randomized controlled trials

,

Am J Med

,

2004

, vol.

116

4

(pg.

253

-

262

)

242

Stone

GW

Grines

CL

Cox

DA

Garcia

E

Tcheng

JE

Griffin

JJ

Guagliumi

G

Stuckey

T

Turco

M

Carroll

JD

Rutherford

BD

Lansky

AJ

,

Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction

,

N Engl J Med

,

2002

, vol.

346

13

(pg.

957

-

966

)

243

Stone

GW

Witzenbichler

B

Guagliumi

G

Peruga

JZ

Brodie

BR

Dudek

D

Kornowski

R

Hartmann

F

Gersh

BJ

Pocock

SJ

Dangas

G

Wong

SC

Fahy

M

Parise

H

Mehran

R

,

Heparin plus a glycoprotein IIb/IIIa inhibitor vs. bivalirudin monotherapy and paclitaxel-eluting stents vs. bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial

,

Lancet

,

2011

, vol.

377

9784

(pg.

2193

-

2204

)

244

Kalesan

B

Pilgrim

T

Heinimann

K

Raber

L

Stefanini

GG

Valgimigli

M

da Costa

BR

Mach

F

Luscher

TF

Meier

B

Windecker

S

Juni

P

,

Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction

,

Eur Heart J

,

2012

, vol.

33

8

(pg.

977

-

987

)

245

Nakazawa

G

Finn

AV

Vorpahl

M

Ladich

ER

Kolodgie

FD

Virmani

R

,

Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents

,

J Am Coll Cardiol

,

2011

, vol.

57

4

(pg.

390

-

398

)

246

Hofma

SH

Brouwer

J

Velders

MA

van't Hof

AW

Smits

PC

Queré

M

de Vries

CJ

van Boven

AJ

,

Second-generation everolimus-eluting stents vs. first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial

,

J Am Coll Cardiol

,

2012

, vol.

60

5

(pg.

381

-

387

)

247

Sabate

M

Cequier

A

Iniguez

A

Serra

A

Hernandez-Antolin

R

Mainar

V

Valgimigli

M

Tespili

M

den Heijer

P

Bethencourt

A

Vazquez

N

Gomez-Hospital

JA

Baz

JA

Martin-Yuste

V

van Geuns

RJ

Alfonso

F

Bordes

P

Tebaldi

M

Masotti

M

Silvestro

A

Backx

B

Brugaletta

S

van Es

GA

Serruys

PW

,

Everolimus-eluting stent vs. bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial

,

Lancet

,

2012

, vol.

380

9852

(pg.

1482

-

1490

)

248

Raber

L

Kelbaek

H

Ostojic

M

Baumbach

A

Heg

D

Tuller

D

von Birgelen

C

Roffi

M

Moschovitis

A

Khattab

AA

Wenaweser

P

Bonvini

R

Pedrazzini

G

Kornowski

R

Weber

K

Trelle

S

Luscher

TF

Taniwaki

M

Matter

CM

Meier

B

Juni

P

Windecker

S

,

Effect of biolimus-eluting stents with biodegradable polymer vs.bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial

,

JAMA

,

2012

, vol.

308

8

(pg.

777

-

787

)

249

Sabate

M

Raber

L

Heg

D

Brugaletta

S

Kelbaek

H

Cequier

A

Ostojic

M

Iniguez

A

Tuller

D

Serra

A

Baumbach

A

von Birgelen

C

Hernandez-Antolin

R

Roffi

M

Mainar

V

Valgimigli

M

Serruys

PW

Juni

P

Windecker

S

,

Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction: A Pooled Analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) Trials

,

JACC Cardiovasc Interv

,

2014

, vol.

7

1

(pg.

55

-

63

)

250

Vlaar

PJ

Svilaas

T

van der Horst

IC

Diercks

GF

Fokkema

ML

de Smet

BJ

van den Heuvel

AF

Anthonio

RL

Jessurun

GA

Tan

ES

Suurmeijer

AJ

Zijlstra

F

,

Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study

,

Lancet

,

2008

, vol.

371

9628

(pg.

1915

-

1920

)

251

Sardella

G

Mancone

M

Bucciarelli-Ducci

C

Agati

L

Scardala

R

Carbone

I

Francone

M

Di Roma

A

Benedetti

G

Conti

G

Fedele

F

,

Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial

,

J Am Coll Cardiol

,

2009

, vol.

53

4

(pg.

309

-

315

)

252

De Luca

G

Dudek

D

Sardella

G

Marino

P

Chevalier

B

Zijlstra

F

,

Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

,

Eur Heart J

,

2008

, vol.

29

24

(pg.

3002

-

3010

)

253

Costopoulos

C

Gorog

DA

Di Mario

C

Kukreja

N

,

Use of thrombectomy devices in primary percutaneous coronary intervention: a systematic review and meta-analysis

,

Int J Cardiol

,

2013

, vol.

163

3

(pg.

229

-

241

)

254

De Luca

G

Navarese

EP

Suryapranata

H

,

A meta-analytic overview of thrombectomy during primary angioplasty

,

Int J Cardiol

,

2013

, vol.

166

3

(pg.

606

-

612

)

255

Bavry

AA

Kumbhani

DJ

Bhatt

DL

,

Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials

,

Eur Heart J

,

2008

, vol.

29

24

(pg.

2989

-

3001

)

256

Frobert

O

Lagerqvist

B

Olivecrona

GK

Omerovic

E

Gudnason

T

Maeng

M

Aasa

M

Angeras

O

Calais

F

Danielewicz

M

Erlinge

D

Hellsten

L

Jensen

U

Johansson

AC

Karegren

A

Nilsson

J

Robertson

L

Sandhall

L

Sjogren

I

Ostlund

O

Harnek

J

James

SK

,

Thrombus aspiration during ST-segment elevation myocardial infarction

,

N Engl J Med

,

2013

, vol.

369

17

(pg.

1587

-

1597

)

257

Ali

A

Cox

D

Dib

N

Brodie

B

Berman

D

Gupta

N

Browne

K

Iwaoka

R

Azrin

M

Stapleton

D

Setum

C

Popma

J

,

Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study

,

J Am Coll Cardiol

,

2006

, vol.

48

2

(pg.

244

-

252

)

258

Migliorini

A

Stabile

A

Rodriguez

AE

Gandolfo

C

Rodriguez Granillo

AM

Valenti

R

Parodi

G

Neumann

FJ

Colombo

A

Antoniucci

D

,

Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial

,

J Am Coll Cardiol

,

2010

, vol.

56

16

(pg.

1298

-

1306

)

259

Stone

GW

Webb

J

Cox

DA

Brodie

BR

Qureshi

M

Kalynych

A

Turco

M

Schultheiss

HP

Dulas

D

Rutherford

BD

Antoniucci

D

Krucoff

MW

Gibbons

RJ

Jones

D

Lansky

AJ

Mehran

R

,

Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial

,

JAMA

,

2005

, vol.

293

9

(pg.

1063

-

1072

)

260

Botker

HE

Kharbanda

R

Schmidt

MR

Bottcher

M

Kaltoft

AK

Terkelsen

CJ

Munk

K

Andersen

NH

Hansen

TM

Trautner

S

Lassen

JF

Christiansen

EH

Krusell

LR

Kristensen

SD

Thuesen

L

Nielsen

SS

Rehling

M

Sorensen

HT

Redington

AN

Nielsen

TT

,

Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial

,

Lancet

,

2010

, vol.

375

9716

(pg.

727

-

734

)

261

Ibanez

B

Macaya

C

Sanchez-Brunete

V

Pizarro

G

Fernandez-Friera

L

Mateos

A

Fernandez-Ortiz

A

Garcia-Ruiz

JM

Garcia-Alvarez

A

Iniguez

A

Jimenez-Borreguero

J

Lopez-Romero

P

Fernandez-Jimenez

R

Goicolea

J

Ruiz-Mateos

B

Bastante

T

Arias

M

Iglesias-Vazquez

JA

Rodriguez

MD

Escalera

N

Acebal

C

Cabrera

JA

Valenciano

J

Perez de Prado

A

Fernandez-Campos

MJ

Casado

I

Garcia-Rubira

JC

Garcia-Prieto

J

Sanz-Rosa

D

Cuellas

C

Hernandez-Antolin

R

Albarran

A

Fernandez-Vazquez

F

de la Torre-Hernandez

JM

Pocock

S

Sanz

G

Fuster

V

,

Effect of Early Metoprolol on Infarct Size in ST-Segment-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial

,

Circulation

,

2013

, vol.

128

14

(pg.

1495

-

1503

)

262

van Werkum

JW

Heestermans

AA

Zomer

AC

Kelder

JC

Suttorp

MJ

Rensing

BJ

Koolen

JJ

Brueren

BR

Dambrink

JH

Hautvast

RW

Verheugt

FW

ten Berg

JM

,

Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry

,

J Am Coll Cardiol

,

2009

, vol.

53

16

(pg.

1399

-

1409

)

263

Stone

GW

Abizaid

A

Silber

S

Dizon

JM

Merkely

B

Costa

RA

Kornowski

R

Wojdyla

R

Maehara

A

Dressler

O

Brener

SJ

Bar

E

Dudek

D

,

Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial

,

J Am Coll Cardiol

,

2012

, vol.

60

(pg.

1975

-

1984

)

264

Hannan

EL

Samadashvili

Z

Walford

G

Holmes

DR

Jr.

Jacobs

AK

Stamato

NJ

Venditti

FJ

Sharma

S

King

SB

3rd

,

Culprit vessel percutaneous coronary intervention vs. multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease

,

JACC Cardiovasc Interv

,

2010

, vol.

3

1

(pg.

22

-

31

)

265

Toma

M

Buller

CE

Westerhout

CM

Fu

Y

O'Neill

WW

Holmes

DR

Jr.

Hamm

CW

Granger

CB

Armstrong

PW

,

Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial

,

Eur Heart J

,

2010

, vol.

31

14

(pg.

1701

-

1707

)

266

Vlaar

PJ

Mahmoud

KD

Holmes

DR

Jr.

van Valkenhoef

G

Hillege

HL

van der Horst

IC

Zijlstra

F

de Smet

BJ

,

Culprit vessel only vs. multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis

,

J Am Coll Cardiol

,

2011

, vol.

58

7

(pg.

692

-

703

)

267

Wald

DS

Morris

JK

Wald

NJ

Chase

AJ

Edwards

RJ

Hughes

LO

Berry

C

Oldroyd

KG

,

Randomized trial of preventive angioplasty in myocardial infarction

,

N Engl J Med

,

2013

, vol.

369

12

(pg.

1115

-

1123

)

268

Palmerini

T

Biondi-Zoccai

G

Della Riva

D

Mariani

A

Sabate

M

Valgimigli

M

Frati

G

Kedhi

E

Smits

PC

Kaiser

C

Genereux

P

Galatius

S

Kirtane

AJ

Stone

GW

,

Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis

,

J Am Coll Cardiol

,

2013

, vol.

62

6

(pg.

496

-

504

)

269

Kastrati

A

Dibra

A

Spaulding

C

Laarman

GJ

Menichelli

M

Valgimigli

M

Di Lorenzo

E

Kaiser

C

Tierala

I

Mehilli

J

Seyfarth

M

Varenne

O

Dirksen

MT

Percoco

G

Varricchio

A

Pittl

U

Syvanne

M

Suttorp

MJ

Violini

R

Schomig

A

,

Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction

,

Eur Heart J

,

2007

, vol.

28

22

(pg.

2706

-

2713

)

270

Karrowni

W

Vyas

A

Giacomino

B

Schweizer

M

Blevins

A

Girotra

S

Horwitz

PA

,

Radial vs. femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials

,

JACC Cardiovasc Interv

,

2013

, vol.

6

8

(pg.

814

-

823

)

271

Ellis

SG

Tendera

M

de Belder

MA

van Boven

AJ

Widimsky

P

Janssens

L

Andersen

HR

Betriu

A

Savonitto

S

Adamus

J

Peruga

JZ

Kosmider

M

Katz

O

Neunteufl

T

Jorgova

J

Dorobantu

M

Grinfeld

L

Armstrong

P

Brodie

BR

Herrmann

HC

Montalescot

G

Neumann

FJ

Effron

MB

Barnathan

ES

Topol

EJ

,

Facilitated PCI in patients with ST-elevation myocardial infarction

,

N Engl J Med

,

2008

, vol.

358

21

(pg.

2205

-

2217

)

272

Cantor

WJ

Fitchett

D

Borgundvaag

B

Ducas

J

Heffernan

M

Cohen

EA

Morrison

LJ

Langer

A

Dzavik

V

Mehta

SR

Lazzam

C

Schwartz

B

Casanova

A

Goodman

SG

,

Routine early angioplasty after fibrinolysis for acute myocardial infarction

,

N Engl J Med

,

2009

, vol.

360

26

(pg.

2705

-

2718

)

273

Di Mario

C

Dudek

D

Piscione

F

Mielecki

W

Savonitto

S

Murena

E

Dimopoulos

K

Manari

A

Gaspardone

A

Ochala

A

Zmudka

K

Bolognese

L

Steg

PG

Flather

M

,

Immediate angioplasty vs. standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial

,

Lancet

,

2008

, vol.

371

9612

(pg.

559

-

568

)

274

Bohmer

E

Hoffmann

P

Abdelnoor

M

Arnesen

H

Halvorsen

S

,

Efficacy and safety of immediate angioplasty vs. ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction)

,

J Am Coll Cardiol

,

2010

, vol.

55

2

(pg.

102

-

110

)

275

Fernandez-Aviles

F

Alonso

JJ

Castro-Beiras

A

Vazquez

N

Blanco

J

Alonso-Briales

J

Lopez-Mesa

J

Fernandez-Vazquez

F

Calvo

I

Martinez-Elbal

L

San Roman

JA

Ramos

B

,

Routine invasive strategy within 24 hours of thrombolysis vs. ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial

,

Lancet

,

2004

, vol.

364

9439

(pg.

1045

-

1053

)

276

Le May

MR

Wells

GA

Labinaz

M

Davies

RF

Turek

M

Leddy

D

Maloney

J

McKibbin

T

Quinn

B

Beanlands

RS

Glover

C

Marquis

JF

O'Brien

ER

Williams

WL

Higginson

LA

,

Combined angioplasty and pharmacological intervention vs. thrombolysis alone in acute myocardial infarction (CAPITAL AMI study)

,

J Am Coll Cardiol

,

2005

, vol.

46

3

(pg.

417

-

424

)

277

Scheller

B

Hennen

B

Hammer

B

Walle

J

Hofer

C

Hilpert

V

Winter

H

Nickenig

G

Bohm

M

,

Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction

,

J Am Coll Cardiol

,

2003

, vol.

42

4

(pg.

634

-

641

)

278

Borgia

F

Goodman

SG

Halvorsen

S

Cantor

WJ

Piscione

F

Le May

MR

Fernandez-Aviles

F

Sanchez

PL

Dimopoulos

K

Scheller

B

Armstrong

PW

Di Mario

C

,

Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis

,

Eur Heart J

,

2010

, vol.

31

17

(pg.

2156

-

2169

)

279

Collet

JP

Montalescot

G

Le May

M

Borentain

M

Gershlick

A

,

Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy

,

J Am Coll Cardiol

,

2006

, vol.

48

7

(pg.

1326

-

1335

)

280

D'Souza

SP

Mamas

MA

Fraser

DG

Fath-Ordoubadi

F

,

Routine early coronary angioplasty vs. ischaemia-guided angioplasty after thrombolysis in acute ST-elevation myocardial infarction: a meta-analysis

,

Eur Heart J

,

2011

, vol.

32

8

(pg.

972

-

982

)

281

Desch

S

Eitel

I

Rahimi

K

de Waha

S

Schuler

G

Thiele

H

,

Timing of invasive treatment after fibrinolysis in ST elevation myocardial infarction—a meta-analysis of immediate or early routine vs. deferred or ischemia-guided randomised controlled trials

,

Heart

,

2010

, vol.

96

21

(pg.

1695

-

1702

)

282

Gershlick

AH

Stephens-Lloyd

A

Hughes

S

Abrams

KR

Stevens

SE

Uren

NG

de Belder

A

Davis

J

Pitt

M

Banning

A

Baumbach

A

Shiu

MF

Schofield

P

Dawkins

KD

Henderson

RA

Oldroyd

KG

Wilcox

R

,

Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction

,

N Engl J Med

,

2005

, vol.

353

26

(pg.

2758

-

2768

)

283

Hochman

JS

Sleeper

LA

White

HD

Dzavik

V

Wong

SC

Menon

V

Webb

JG

Steingart

R

Picard

MH

Menegus

MA

Boland

J

Sanborn

T

Buller

CE

Modur

S

Forman

R

Desvigne-Nickens

P

Jacobs

AK

Slater

JN

LeJemtel

TH

,

One-year survival following early revascularization for cardiogenic shock

,

JAMA

,

2001

, vol.

285

2

(pg.

190

-

192

)

284

Ellis

SG

da Silva

ER

Heyndrickx

G

Talley

JD

Cernigliaro

C

Steg

G

Spaulding

C

Nobuyoshi

M

Erbel

R

Vassanelli

C

et al. ,

Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction

,

Circulation

,

1994

, vol.

90

5

(pg.

2280

-

2284

)

285

Hillis

LD

Smith

PK

Anderson

JL

Bittl

JA

Bridges

CR

Byrne

JG

Cigarroa

JE

Disesa

VJ

Hiratzka

LF

Hutter

AM

Jr.

Jessen

ME

Keeley

EC

Lahey

SJ

Lange

RA

London

MJ

Mack

MJ

Patel

MR

Puskas

JD

Sabik

JF

Selnes

O

Shahian

DM

Trost

JC

Winniford

MD

,

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

,

Circulation

,

2011

, vol.

124

(23):e652–e735

286

Weiss

ES

Chang

DD

Joyce

DL

Nwakanma

LU

Yuh

DD

,

Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data

,

J Thorac Cardiovasc Surg

,

2008

, vol.

135

(3):503–11, 511 e1–e3

287

McMurray

JJ

Adamopoulos

S

Anker

SD

Auricchio

A

Bohm

M

Dickstein

K

Falk

V

Filippatos

G

Fonseca

C

Gomez-Sanchez

MA

Jaarsma

T

Kober

L

Lip

GY

Maggioni

AP

Parkhomenko

A

Pieske

BM

Popescu

BA

Ronnevik

PK

Rutten

FH

Schwitter

J

Seferovic

P

Stepinska

J

Trindade

PT

Voors

AA

Zannad

F

Zeiher

A

,

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

,

Eur Heart J 2012

, vol.

33

14

(pg.

1787

-

1847

)

288

Velazquez

EJ

Williams

JB

Yow

E

Shaw

LK

Lee

KL

Phillips

HR

O'Connor

CM

Smith

PK

Jones

RH

,

Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting vs. medical therapy

,

Ann Thorac Surg

,

2012

, vol.

93

2

(pg.

523

-

530

)

289

Bonow

RO

Maurer

G

Lee

KL

Holly

TA

Binkley

PF

Desvigne-Nickens

P

Drozdz

J

Farsky

PS

Feldman

AM

Doenst

T

Michler

RE

Berman

DS

Nicolau

JC

Pellikka

PA

Wrobel

K

Alotti

N

Asch

FM

Favaloro

LE

She

L

Velazquez

EJ

Jones

RH

Panza

JA

Investigators

ST

,

Myocardial viability and survival in ischemic left ventricular dysfunction

,

N Engl J Med

,

2011

, vol.

364

17

(pg.

1617

-

1625

)

290

Ling

LF

Marwick

TH

Flores

DR

Jaber

WA

Brunken

RC

Cerqueira

MD

Hachamovitch

R

,

Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia vs. hibernating myocardium

,

Circ Cardiovasc Imaging

,

2013

, vol.

6

3

(pg.

363

-

372

)

291

Di Donato

M

Castelvecchio

S

Menicanti

L

,

End-systolic volume following surgical ventricular reconstruction impacts survival in patients with ischaemic dilated cardiomyopathy

,

Eur J Heart Fail

,

2010

, vol.

12

4

(pg.

375

-

381

)

292

Jones

RH

Velazquez

EJ

Michler

RE

Sopko

G

Oh

JK

O'Connor

CM

Hill

JA

Menicanti

L

Sadowski

Z

Desvigne-Nickens

P

Rouleau

JL

Lee

KL

,

Coronary bypass surgery with or without surgical ventricular reconstruction

,

N Engl J Med

,

2009

, vol.

360

17

(pg.

1705

-

1717

)

293

Oh

JK

Velazquez

EJ

Menicanti

L

Pohost

GM

Bonow

RO

Lin

G

Hellkamp

AS

Ferrazzi

P

Wos

S

Rao

V

Berman

D

Bochenek

A

Cherniavsky

A

Rogowski

J

Rouleau

JL

Lee

KL

Investigators S

,

Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy

,

Eur Heart J

,

2013

, vol.

34

1

(pg.

39

-

47

)

294

Michler

RE

Rouleau

JL

Al-Khalidi

HR

Bonow

RO

Pellikka

PA

Pohost

GM

Holly

TA

Oh

JK

Dagenais

F

Milano

C

Wrobel

K

Pirk

J

Ali

IS

Jones

RH

Velazquez

EJ

Lee

KL

Di Donato

M

,

Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction

,

J Thorac Cardiovasc Surg

,

2013

, vol.

146

(5):1139–1145 e6

295

Dor

V

Civaia

F

Alexandrescu

C

Sabatier

M

Montiglio

F

,

Favorable effects of left ventricular reconstruction in patients excluded from the Surgical Treatments for Ischemic Heart Failure (STICH) trial

,

J Thorac Cardiovasc Surg

,

2011

, vol.

141

(4):905–916, 916 e1–e4

296

Lindholm

MG

Køber

L

Boesgaard

S

Torp-Pedersen

C

Aldershvile

J

,

Trandolapril Cardiac Evaluation study group. Cardiogenic shock complicating acute myocardial infarction; prognostic impact of early and late shock development

,

Eur Heart J

,

2003

, vol.

24

3

(pg.

258

-

265

)

297

Katz

JN

Stebbins

AL

Alexander

JH

Reynolds

HR

Pieper

KS

Ruzyllo

W

Werdan

K

Geppert

A

Dzavik

V

Van de Werf

F

Hochman

JS

Investigators

T

,

Predictors of 30-day mortality in patients with refractory cardiogenic shock following acute myocardial infarction despite a patent infarct artery

,

Am Heart J

,

2009

, vol.

158

4

(pg.

680

-

687

)

298

Zeymer

U

Vogt

A

Zahn

R

Weber

MA

Tebbe

U

Gottwik

M

Bonzel

T

Senges

J

Neuhaus

KL

Arbeitsgemeinschaft Leitende Kardiologische

K

,

Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK)

,

Eur Heart J

,

2004

, vol.

25

4

(pg.

322

-

328

)

299

Dzavik

V

Sleeper

LA

Cocke

TP

Moscucci

M

Saucedo

J

Hosat

S

Jiang

X

Slater

J

LeJemtel

T

Hochman

JS

Investigators

S

,

Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry

,

Eur Heart J

,

2003

, vol.

24

9

(pg.

828

-

837

)

300

Kantrowitz

A

Tjonneland

S

Freed

PS

Phillips

SJ

Butner

AN

Sherman

JL

Jr.

,

Initial clinical experience with intraaortic balloon pumping in cardiogenic shock

,

JAMA

,

1968

, vol.

203

2

(pg.

113

-

118

)

301

Thiele

H

Zeymer

U

Neumann

FJ

Ferenc

M

Olbrich

HG

Hausleiter

J

Richardt

G

Hennersdorf

M

Empen

K

Fuernau

G

Desch

S

Eitel

I

Hambrecht

R

Fuhrmann

J

Bohm

M

Ebelt

H

Schneider

S

Schuler

G

Werdan

K

Investigators

I-SIT

,

Intraaortic balloon support for myocardial infarction with cardiogenic shock

,

N Engl J Med

,

2012

, vol.

367

14

(pg.

1287

-

1296

)

302

Thiele

H

Zeymer

U

Neumann

FJ

Ferenc

M

Olbrich

HG

Hausleiter

J

de Waha

A

Richardt

G

Hennersdorf

M

Empen

K

Fuernau

G

Desch

S

Eitel

I

Hambrecht

R

Lauer

B

Bohm

M

Ebelt

H

Schneider

S

Werdan

K

Schuler

G

,

Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial

,

Lancet

,

2013

, vol.

382

9905

(pg.

1638

-

1645

)

303

Burkhoff

D

Cohen

H

Brunckhorst

C

O'Neill

WW

TandemHeart Investigators Group

,

A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device vs. conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock

,

Am Heart J

,

2006

, vol.

152

(3):469 e1–e8

304

Kar

B

Basra

SS

Shah

NR

Loyalka

P

,

Percutaneous circulatory support in cardiogenic shock: interventional bridge to recovery

,

Circulation

,

2012

, vol.

125

14

(pg.

1809

-

1817

)

305

Thiele

H

Sick

P

Boudriot

E

Diederich

KW

Hambrecht

R

Niebauer

J

Schuler

Group

,

Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock

,

Eur Heart J

,

2005

, vol.

26

13

(pg.

1276

-

1283

)

306

Seyfarth

M

Sibbing

D

Bauer

I

Frohlich

G

Bott-Flugel

L

Byrne

R

Dirschinger

J

Kastrati

A

Schomig

A

,

A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device vs. intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction

,

J Am Coll Cardiol

,

2008

, vol.

52

19

(pg.

1584

-

1588

)

307

Cheng

JM

den Uil

CA

Hoeks

SE

van der Ent

M

Jewbali

LS

van Domburg

RT

Serruys

PW

,

Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials

,

Eur Heart J

,

2009

, vol.

30

17

(pg.

2102

-

2108

)

308

Kirklin

JK

Naftel

DC

Kormos

RL

Stevenson

LW

Pagani

FD

Miller

MA

Baldwin

JT

Young

JB

,

The Fourth INTERMACS Annual Report: 4,000 implants and counting

,

J Heart Lung Transplant

,

2012

, vol.

31

2

(pg.

117

-

126

)

309

Kirklin

JK

Naftel

DC

Kormos

RL

Stevenson

LW

Pagani

FD

Miller

MA

Timothy Baldwin

J

Young

JB

,

Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients

,

J Heart Lung Transplant

,

2013

, vol.

32

2

(pg.

141

-

156

)

310

Kirklin

JK

Naftel

DC

Pagani

FD

Kormos

RL

Stevenson

L

Miller

M

Young

JB

,

Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?

,

J Thorac Cardiovasc Surg

,

2012

, vol.

144

(3):584–603; discussion

(pg.

597

-

598

)

311

Cohn

JN

Guiha

NH

Broder

MI

Limas

CJ

,

Right ventricular infarction. Clinical and hemodynamic features

,

Am J Cardiol

,

1974

, vol.

33

2

(pg.

209

-

214

)

312

Dell'Italia

LJ

Starling

MR

Crawford

MH

Boros

BL

Chaudhuri

TK

O'Rourke

RA

,

Right ventricular infarction: identification by hemodynamic measurements before after volume loading correlation with noninvasive techniques

,

J Am Coll Cardiol

,

1984

, vol.

4

5

(pg.

931

-

939

)

313

Goldstein

JA

,

Pathophysiology and management of right heart ischemia

,

J Am Coll Cardiol

,

2002

, vol.

40

5

(pg.

841

-

853

)

314

Goldstein

JA

Barzilai

B

Rosamond

TL

Eisenberg

PR

Jaffe

AS

,

Determinants of hemodynamic compromise with severe right ventricular infarction

,

Circulation

,

1990

, vol.

82

2

(pg.

359

-

368

)

315

Lorell

B

Leinbach

RC

Pohost

GM

Gold

HK

Dinsmore

RE

Hutter

AM

Jr.

Pastore

JO

Desanctis

RW

,

Right ventricular infarction. Clinical diagnosis and differentiation from cardiac tamponade and pericardial constriction

,

Am J Cardiol

,

1979

, vol.

43

3

(pg.

465

-

471

)

316

Jacobs

AK

Leopold

JA

Bates

E

Mendes

LA

Sleeper

LA

White

H

Davidoff

R

Boland

J

Modur

S

Forman

R

Hochman

JS

,

Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry

,

J Am Coll Cardiol

,

2003

, vol.

41

8

(pg.

1273

-

1279

)

317

Hochman

JS

Buller

CE

Sleeper

LA

Boland

J

Dzavik

V

Sanborn

TA

Godfrey

E

White

HD

Lim

J

LeJemtel

T

,

Cardiogenic shock complicating acute myocardial infarction:etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?

,

J Am Coll Cardiol

,

2000

, vol.

36

3 Suppl A

(pg.

1063

-

1070

)

318

Brodie

BR

Stuckey

TD

Hansen

C

Bradshaw

BH

Downey

WE

Pulsipher

MW

,

Comparison of late survival in patients with cardiogenic shock due to right ventricular infarction vs. left ventricular pump failure following primary percutaneous coronary intervention for ST-elevation acute myocardial infarction

,

Am J Cardiol

,

2007

, vol.

99

4

(pg.

431

-

435

)

319

Zeymer

U

Neuhaus

KL

Wegscheider

K

Tebbe

U

Molhoek

P

Schroder

R

,

Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement. HIT-4 Trial Group. Hirudin for Improvement of Thrombolysis

,

J Am Coll Cardiol

,

1998

, vol.

32

4

(pg.

876

-

881

)

320

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

,

The GUSTO Angiographic Investigators

,

N Engl J Med

,

1993

, vol.

329

22

(pg.

1615

-

1622

)

321

Kinn

JW

O'Neill

WW

Benzuly

KH

Jones

DE

Grines

CL

,

Primary angioplasty reduces risk of myocardial rupture compared to thrombolysis for acute myocardial infarction

,

Cathet Cardiovasc Diagn

,

1997

, vol.

42

2

(pg.

151

-

157

)

322

Moreno

R

Lopez-Sendon

J

Garcia

E

Perez de Isla

L

Lopez de Sa

E

Ortega

A

Moreno

M

Rubio

R

Soriano

J

Abeytua

M

Garcia-Fernandez

MA

,

Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction

,

J Am Coll Cardiol

,

2002

, vol.

39

4

(pg.

598

-

603

)

323

Menon

V

Webb

JG

Hillis

LD

Sleeper

LA

Abboud

R

Dzavik

V

Slater

JN

Forman

R

Monrad

ES

Talley

JD

Hochman

JS

,

Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?

,

J Am Coll Cardiol

,

2000

, vol.

36

3 Suppl A)

(pg.

1110

-

1116

)

324

Thiele

H

Kaulfersch

C

Daehnert

I

Schoenauer

M

Eitel

I

Borger

M

Schuler

G

,

Immediate primary transcatheter closure of postinfarction ventricular septal defects

,

Eur Heart J

,

2009

, vol.

30

1

(pg.

81

-

88

)

325

Zhu

XY

Qin

YW

Han

YL

Zhang

DZ

Wang

P

Liu

YF

Xu

YW

Jing

QM

Xu

K

Gersh

BJ

Wang

XZ

,

Long-term efficacy of transcatheter closure of ventricular septal defect in combination with percutaneous coronary intervention in patients with ventricular septal defect complicating acute myocardial infarction: a multicentre study

,

EuroIntervention

,

2013

, vol.

8

11

(pg.

1270

-

1276

)

326

Assenza

GE

McElhinney

DB

Valente

AM

Pearson

DD

Volpe

M

Martucci

G

Landzberg

MJ

Lock

JE

,

Transcatheter closure of post-myocardial infarction ventricular septal rupture

,

Circ Cardiovasc Interv

,

2013

, vol.

6

1

(pg.

59

-

67

)

327

Slater

J

Brown

RJ

Antonelli

TA

Menon

V

Boland

J

Col

J

Dzavik

V

Greenberg

M

Menegus

M

Connery

C

Hochman

JS

,

Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock?

,

J Am Coll Cardiol

,

2000

, vol.

36

3 Suppl A)

(pg.

1117

-

1122

)

328

Lopez-Sendon

J

Gonzalez

A

Lopez de Sa

E

Coma-Canella

I

Roldan

I

Dominguez

F

Maqueda

I

Martin Jadraque

L

,

Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria

,

J Am Coll Cardiol

,

1992

, vol.

19

6

(pg.

1145

-

1153

)

329

Menon

V

Hochman

JS

Stebbins

A

Pfisterer

M

Col

J

Anderson

RD

Hasdai

D

Holmes

DR

Bates

ER

Topol

EJ

Califf

RM

Ohman

EM

,

Lack of progress in cardiogenic shock: lessons from the GUSTO trials

,

Eur Heart J

,

2000

, vol.

21

23

(pg.

1928

-

1936

)

330

Chevalier

P

Burri

H

Fahrat

F

Cucherat

M

Jegaden

O

Obadia

JF

Kirkorian

G

Touboul

P

,

Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation

,

Eur J Cardiothorac Surg

,

2004

, vol.

26

2

(pg.

330

-

335

)

331

Hochman

JS

Sleeper

LA

Webb

JG

Dzavik

V

Buller

CE

Aylward

P

Col

J

White

HD

Investigators S

,

Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction

,

JAMA

,

2006

, vol.

295

21

(pg.

2511

-

2515

)

332

Sjauw

KD

Engstrom

AE

Vis

MM

van der Schaaf

RJ

Baan

J

Jr.

Koch

KT

de Winter

RJ

Piek

JJ

Tijssen

JG

Henriques

JP

,

A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?

,

Eur Heart J

,

2009

, vol.

30

4

(pg.

459

-

468

)

333

Buerke

M

Prondzinsky

R

Lemm

H

Dietz

S

Buerke

U

Ebelt

H

Bushnaq

H

Silber

RE

Werdan

K

,

Intra-aortic balloon counterpulsation in the treatment of infarction-related cardiogenic shock:review of the current evidence

,

Artif Organs

,

2012

, vol.

36

6

(pg.

505

-

511

)

334

Frye

RL

August

P

Brooks

MM

Hardison

RM

Kelsey

SF

MacGregor

JM

Orchard

TJ

Chaitman

BR

Genuth

SM

Goldberg

SH

Hlatky

MA

Jones

TL

Molitch

ME

Nesto

RW

Sako

EY

Sobel

BE

,

A randomized trial of therapies for type 2 diabetes and coronary artery disease

,

N Engl J Med

,

2009

, vol.

360

24

(pg.

2503

-

2515

)

335

Shaw

LJ

Cerqueira

MD

Brooks

MM

Althouse

AD

Sansing

VV

Beller

GA

Pop-Busui

R

Taillefer

R

Chaitman

BR

Gibbons

RJ

Heo

J

Iskandrian

AE

,

Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial

,

Journal of Nuclear Cardiology

,

2012

, vol.

19

4

(pg.

658

-

669

)

336

Brooks

MM

Chaitman

BR

Nesto

RW

Hardison

RM

Feit

F

Gersh

BJ

Krone

RJ

Sako

EY

Rogers

WJ

Garber

AJ

King

SB

3rd

Davidson

CJ

Ikeno

F

Frye

RL

,

Clinical, angiographic risk stratification differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial

,

Circulation

,

2012

, vol.

126

17

(pg.

2115

-

2124

)

337

Wiviott

SD

Braunwald

E

Angiolillo

DJ

Meisel

S

Dalby

AJ

Verheugt

FW

Goodman

SG

Corbalan

R

Purdy

DA

Murphy

SA

McCabe

CH

Antman

EM

Investigators

T-T

,

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38

,

Circulation

,

2008

, vol.

118

16

(pg.

1626

-

1636

)

338

O'Donoghue

ML

Vaidya

A

Afsal

R

Alfredsson

J

Boden

WE

Braunwald

E

Cannon

CP

Clayton

TC

de Winter

RJ

Fox

KA

Lagerqvist

B

McCullough

PA

Murphy

SA

Spacek

R

Swahn

E

Windhausen

F

Sabatine

MS

,

An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials

,

J Am Coll Cardiol

,

2012

, vol.

60

2

(pg.

106

-

111

)

339

Malmberg

K

Yusuf

S

Gerstein

HC

Brown

J

Zhao

F

Hunt

D

Piegas

L

Calvin

J

Keltai

M

Budaj

A

,

Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry

,

Circulation

,

2000

, vol.

102

9

(pg.

1014

-

1019

)

340

Mehta

SR

Granger

CB

Eikelboom

JW

Bassand

JP

Wallentin

L

Faxon

DP

Peters

RJ

Budaj

A

Afzal

R

Chrolavicius

S

Fox

KA

Yusuf

S

,

Efficacy and safety of fondaparinux vs. enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial

,

J Am Coll Cardiol

,

2007

, vol.

50

18

(pg.

1742

-

1751

)

341

Wallentin

L

Becker

RC

Budaj

A

Cannon

CP

Emanuelsson

H

Held

C

Horrow

J

Husted

S

James

S

Katus

H

Mahaffey

KW

Scirica

BM

Skene

A

Steg

PG

Storey

RF

Harrington

RA

Freij

A

Thorsen

M

,

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes

,

N Engl J Med

,

2009

, vol.

361

11

(pg.

1045

-

1057

)

342

Lagerqvist

B

Husted

S

Kontny

F

Stahle

E

Swahn

E

Wallentin

L

,

Fast Revascularisation during InStability in Coronary artery disease (FRISC-II) Investigators. I. 5-year outcomes in the FRISC-II randomised trial of an invasive vs. a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study

,

Lancet

,

2006

, vol.

368

9540

(pg.

998

-

1004

)

343

Damman

P

Hirsch

A

Windhausen

F

Tijssen

JG

de Winter

RJ

,

5-year clinical outcomes in the ICTUS (Invasive vs. Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive vs. selective invasive management in patients with non-ST-segment elevation acute coronary syndrome

,

J Am Coll Cardiol

,

2010

, vol.

55

9

(pg.

858

-

864

)

344

Abdallah

MS

Wang

K

Magnuson

EA

Spertus

JA

Farkouh

ME

Fuster

V

Cohen

DJ

Investigators

FT

,

Quality of life after PCI vs.CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial

,

JAMA

,

2013

, vol.

310

15

(pg.

1581

-

1590

)

345

Serruys

PW

Farooq

V

,

Revascularization strategies in patients with diabetes

,

N Engl J Med

,

2013

, vol.

368

15

(pg.

1454

-

1455

)

346

Kappetein

AP

Head

SJ

Morice

MC

Banning

AP

Serruys

PW

Mohr

FW

Dawkins

KD

Mack

MJ

Investigators

S

,

Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial

,

Eur J Cardiothorac Surg

,

2013

, vol.

43

5

(pg.

1006

-

1013

)

347

Kapur

A

Hall

RJ

Malik

IS

Qureshi

AC

Butts

J

de Belder

M

Baumbach

A

Angelini

G

de Belder

A

Oldroyd

KG

Flather

M

Roughton

M

Nihoyannopoulos

P

Bagger

JP

Morgan

K

Beatt

KJ

,

Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial

,

J Am Coll Cardiol

,

2010

, vol.

55

5

(pg.

432

-

440

)

348

Kamalesh

M

Sharp

TG

Tang

XC

Shunk

K

Ward

HB

Walsh

J

King

S

3rd

Colling

C

Moritz

T

Stroupe

K

Reda

D

,

Percutaneous coronary intervention vs. coronary bypass surgery in United States veterans with diabetes

,

J Am Coll Cardiol

,

2013

, vol.

61

8

(pg.

808

-

816

)

349

Verma

S

Farkouh

ME

Yanagawa

B

Fitchett

DH

Ahsan

MR

Ruel

M

Sud

S

Gupta

M

Singh

S

Gupta

N

Cheema

AN

Leiter

LA

Fedak

PW

Teoh

H

Latter

DA

Fuster

V

Friedrich

JO

,

Comparison of coronary artery bypass surgery and percutaneous coronary interventions in patients with diabetes: a meta-analysis of randomised controlled trials

,

Lancet Diabetes & Endocrinology

,

2013

, vol.

1

4

(pg.

317

-

328

)

350

Hakeem

A

Garg

N

Bhatti

S

Rajpurohit

N

Ahmed

Z

Uretsky

BF

,

Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data

,

J Am Heart Assoc

,

2013

, vol.

2

4

e000354

351

Stettler

C

Allemann

S

Wandel

S

Kastrati

A

Morice

MC

Schomig

A

Pfisterer

ME

Stone

GW

Leon

MB

de Lezo

JS

Goy

JJ

Park

SJ

Sabate

M

Suttorp

MJ

Kelbaek

H

Spaulding

C

Menichelli

M

Vermeersch

P

Dirksen

MT

Cervinka

P

De Carlo

M

Erglis

A

Chechi

T

Ortolani

P

Schalij

MJ

Diem

P

Meier

B

Windecker

S

Juni

P

,

Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis

,

BMJ

,

2008

, vol.

337

a1331

352

Bangalore

S

Kumar

S

Fusaro

M

Amoroso

N

Kirtane

AJ

Byrne

RA

Williams

DO

Slater

J

Cutlip

DE

Feit

F

,

Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials

,

BMJ

,

2012

, vol.

345

e5170

353

Taggart

DP

Altman

DG

Gray

AM

Lees

B

Nugara

F

Yu

LM

Campbell

H

Flather

M

,

Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART)

,

Eur Heart J

,

2010

, vol.

31

20

(pg.

2470

-

2481

)

354

Puskas

JD

Sadiq

A

Vassiliades

TA

Kilgo

PD

Lattouf

OM

,

Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients

,

Annals of Thoracic Surgery

,

2012

, vol.

94

3

(pg.

710

-

715

)

discussion 715–716

355

Locker

C

Schaff

HV

Dearani

JA

Joyce

LD

Park

SJ

Burkhart

HM

Suri

RM

Greason

KL

Stulak

JM

Li

Z

Daly

RC

,

Multiple arterial grafts improve late survival of patients undergoing coronary artery bypass graft surgery: analysis of 8622 patients with multivessel disease

,

Circulation

,

2012

, vol.

126

9

(pg.

1023

-

1030

)

356

Schwann

TA

Al-Shaar

L

Engoren

M

Habib

RH

,

Late effects of radial artery vs.saphenous vein grafting for multivessel coronary bypass surgery in diabetics: a propensity-matched analysis

,

Eur J Cardiothorac Surg

,

2013

, vol.

44

4

(pg.

701

-

710

)

357

Giugliano

RP

White

JA

Bode

C

Armstrong

PW

Montalescot

G

Lewis

BS

van 't Hof

A

Berdan

LG

Lee

KL

Strony

JT

Hildemann

S

Veltri

E

Van de Werf

F

Braunwald

E

Harrington

RA

Califf

RM

Newby

LK

Investigators EA

,

Early vs. delayed, provisional eptifibatide in acute coronary syndromes

,

N Engl J Med

,

2009

, vol.

360

21

(pg.

2176

-

2190

)

358

Mellbin

LG

Malmberg

K

Norhammar

A

Wedel

H

Ryden

L

,

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial

,

Eur Heart J

,

2008

, vol.

29

2

(pg.

166

-

176

)

359

Zeller

M

Danchin

N

Simon

D

Vahanian

A

Lorgis

L

Cottin

Y

Berland

J

Gueret

P

Wyart

P

Deturck

R

Tabone

X

Machecourt

J

Leclercq

F

Drouet

E

Mulak

G

Bataille

V

Cambou

JP

Ferrieres

J

Simon

T

,

Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction

,

The Journal of Clinical Endocrinology and Metabolism

,

2010

, vol.

95

11

(pg.

4993

-

5002

)

360

Takagi

T

Okura

H

Kobayashi

Y

Kataoka

T

Taguchi

H

Toda

I

Tamita

K

Yamamuro

A

Sakanoue

Y

Ito

A

Yanagi

S

Shimeno

K

Waseda

K

Yamasaki

M

Fitzgerald

PJ

Ikeno

F

Honda

Y

Yoshiyama

M

Yoshikawa

J

,

A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)

,

JACC Cardiovascular Interventions

,

2009

, vol.

2

6

(pg.

524

-

531

)

361

Bhamidipati

CM

LaPar

DJ

Stukenborg

GJ

Morrison

CC

Kern

JA

Kron

IL

Ailawadi

G

,

Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting

,

J Thorac Cardiovasc Surg

,

2011

, vol.

141

2

(pg.

543

-

551

)

362

Scirica

BM

Bhatt

DL

Braunwald

E

Steg

PG

Davidson

J

Hirshberg

B

Ohman

P

Frederich

R

Wiviott

SD

Hoffman

EB

Cavender

MA

Udell

JA

Desai

NR

Mosenzon

O

McGuire

DK

Ray

KK

Leiter

LA

Raz

I

,

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

,

N Engl J Med

,

2013

, vol.

369

14

(pg.

1317

-

1326

)

363

Timmer

JR

Ottervanger

JP

de Boer

MJ

Boersma

E

Grines

CL

Westerhout

CM

Simes

RJ

Granger

CB

Zijlstra

F

,

Primary Coronary Angioplasty vs.Thrombolysis-2 Trialists Collaborators G. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs. Thrombolysis-2 trial

,

Arch Intern Med

,

2007

, vol.

167

13

(pg.

1353

-

1359

)

364

Cannon

CP

Weintraub

WS

Demopoulos

LA

Vicari

R

Frey

MJ

Lakkis

N

Neumann

FJ

Robertson

DH

DeLucca

PT

DiBattiste

PM

Gibson

CM

Braunwald

E

Investigators TTiMI

,

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

,

N Engl J Med

,

2001

, vol.

344

25

(pg.

1879

-

1887

)

365

Roffi

M

Topol

EJ

,

Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes

,

Eur Heart J

,

2004

, vol.

25

3

(pg.

190

-

198

)

366

Lindahl

B

Toss

H

Siegbahn

A

Venge

P

Wallentin

L

,

Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease

,

N Engl J Med

,

2000

, vol.

343

16

(pg.

1139

-

1147

)

367

Lima

EG

Hueb

W

Garcia

RM

Pereira

AC

Soares

PR

Favarato

D

Garzillo

CL

D'Oliveira Vieira

R

Rezende

PC

Takiuti

M

Girardi

P

Hueb

AC

Ramires

JA

Kalil Filho

R

,

Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial

,

Am Heart J

,

2013

, vol.

166

2

(pg.

250

-

257

)

368

Dorman

MJ

Kurlansky

PA

Traad

EA

Galbut

DL

Zucker

M

Ebra

G

,

Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts

,

Circulation

,

2012

, vol.

126

25

(pg.

2935

-

2942

)

369

Chertow

GM

Normand

SL

McNeil

BJ

,

"Renalism": inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency

,

J Am Soc Nephrol

,

2004

, vol.

15

9

(pg.

2462

-

2468

)

370

Charytan

D

Mauri

L

Agarwal

A

Servoss

S

Scirica

B

Kuntz

RE

,

The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients

,

Am Heart J

,

2006

, vol.

152

3

(pg.

558

-

564

)

371

Szummer

K

Lundman

P

Jacobson

SH

Schon

S

Lindback

J

Stenestrand

U

Wallentin

L

Jernberg

T

,

Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)

,

Circulation

,

2009

, vol.

120

10

(pg.

851

-

858

)

372

Hemmelgarn

BR

Southern

D

Culleton

BF

Mitchell

LB

Knudtson

ML

Ghali

WA

,

Survival after coronary revascularization among patients with kidney disease

,

Circulation

,

2004

, vol.

110

14

(pg.

1890

-

1895

)

373

Reddan

DN

Szczech

LA

Tuttle

RH

Shaw

LK

Jones

RH

Schwab

SJ

Smith

MS

Califf

RM

Mark

DB

Owen

WF

Jr.

,

Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease

,

J Am Soc Nephrol

,

2003

, vol.

14

9

(pg.

2373

-

2380

)

374

Huang

HD

Alam

M

Hamzeh

I

Virani

S

Deswal

A

Aguilar

D

Rogers

P

Kougias

P

Birnbaum

Y

Paniagua

D

Kar

B

Ballantyne

C

Bozkurt

B

Jneid

H

,

Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome

,

Int J Cardiol

,

2013

, vol.

168

4

(pg.

3741

-

3746

)

375

Tsai

TT

Messenger

JC

Brennan

JM

Patel

UD

Dai

D

Piana

RN

Anstrom

KJ

Eisenstein

EL

Dokholyan

RS

Peterson

ED

Douglas

PS

,

Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database

,

J Am Coll Cardiol

,

2011

, vol.

58

18

(pg.

1859

-

1869

)

376

Shenoy

C

Boura

J

Orshaw

P

Harjai

KJ

,

Drug-eluting stents in patients with chronic kidney disease: a prospective registry study

,

PLoS One

,

2010

, vol.

5

11

e15070

377

Ashrith

G

Lee

VV

Elayda

MA

Reul

RM

Wilson

JM

,

Short- and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease

,

Am J Cardiol

,

2010

, vol.

106

3

(pg.

348

-

353

)

378

Charytan

DM

Li

S

Liu

J

Herzog

CA

,

Risks of death and end-stage renal disease after surgical compared with percutaneous coronary revascularization in elderly patients with chronic kidney disease

,

Circulation

,

2012

, vol.

126

(11 Suppl 1)

S164–9

379

Ix

JH

Mercado

N

Shlipak

MG

Lemos

PA

Boersma

E

Lindeboom

W

O'Neill

WW

Wijns

W

Serruys

PW

,

Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS)

,

Am Heart J

,

2005

, vol.

149

3

(pg.

512

-

519

)

380

Chawla

LS

Zhao

Y

Lough

FC

Schroeder

E

Seneff

MG

Brennan

JM

,

Off-pump vs. on-pump coronary artery bypass grafting outcomes stratified by preoperative renal function

,

J Am Soc Nephrol

,

2012

, vol.

23

8

(pg.

1389

-

1397

)

381

Charytan

DM

Yang

SS

McGurk

S

Rawn

J

,

Long and short-term outcomes following coronary artery bypass grafting in patients with and without chronic kidney disease

,

Nephrol Dial Transplant

,

2010

, vol.

25

11

(pg.

3654

-

3663

)

382

Chang

TI

Shilane

D

Kazi

DS

Montez-Rath

ME

Hlatky

MA

Winkelmayer

WC

,

Multivessel coronary artery bypass grafting vs. percutaneous coronary intervention in ESRD

,

J Am Soc Nephrol

,

2012

, vol.

23

12

(pg.

2042

-

2049

)

383

Herzog

CA

Ma

JZ

Collins

AJ

,

Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures

,

Circulation

,

2004

, vol.

109

23

(pg.

2866

-

2871

)

384

Brar

SS

Shen

AY

Jorgensen

MB

Kotlewski

A

Aharonian

VJ

Desai

N

Ree

M

Shah

AI

Burchette

RJ

,

Sodium bicarbonate vs.sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial

,

JAMA

,

2008

, vol.

300

9

(pg.

1038

-

1046

)

385

Merten

GJ

Burgess

WP

Gray

LV

Holleman

JH

Roush

TS

Kowalchuk

GJ

Bersin

RM

Van Moore

A

Simonton

CA

3rd

Rittase

RA

Norton

HJ

Kennedy

TP

,

Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial

,

JAMA

,

2004

, vol.

291

19

(pg.

2328

-

2334

)

386

Li

Y

Liu

Y

Fu

L

Mei

C

Dai

B

,

Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials

,

PLoS One

,

2012

, vol.

7

(4):e34450

387

Sadat

U

Usman

A

Gillard

JH

Boyle

JR

,

Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: a systematic review with meta-analysis of randomized, controlled trials

,

J Am Coll Cardiol

,

2013

, vol.

62

23

(pg.

2167

-

2175

)

388

Marenzi

G

Assanelli

E

Campodonico

J

Lauri

G

Marana

I

De Metrio

M

Moltrasio

M

Grazi

M

Rubino

M

Veglia

F

Fabbiocchi

F

Bartorelli

AL

,

Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality

,

Ann Intern Med

,

2009

, vol.

150

3

(pg.

170

-

177

)

389

Laskey

WK

Jenkins

C

Selzer

F

Marroquin

OC

Wilensky

RL

Glaser

R

Cohen

HA

Holmes

DR

Jr.

,

Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention

,

J Am Coll Cardiol

,

2007

, vol.

50

7

(pg.

584

-

590

)

390

Fox

CS

Muntner

P

Chen

AY

Alexander

KP

Roe

MT

Cannon

CP

Saucedo

JF

Kontos

MC

Wiviott

SD

,

Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry

,

Circulation

,

2010

, vol.

121

3

(pg.

357

-

365

)

391

Yan

LQ

Guo

LJ

Zhang

FC

Gao

W

,

The relationship between kidney function and angiographically-derived SYNTAX score

,

Can J Cardiol

,

2011

, vol.

27

6

(pg.

768

-

772

)

392

Zheng

H

Xue

S

Lian

F

Huang

RT

Hu

ZL

Wang

YY

,

Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease

,

Eur J Cardiothorac Surg

,

2013

, vol.

43

3

(pg.

459

-

467

)

393

Del Duca

D

Iqbal

S

Rahme

E

Goldberg

P

de Varennes

B

,

Renal failure after cardiac surgery: timing of cardiac catheterization and other perioperative risk factors

,

Ann Thorac Surg

,

2007

, vol.

84

4

(pg.

1264

-

1271

)

394

Ranucci

M

Ballotta

A

Kunkl

A

De Benedetti

D

Kandil

H

Conti

D

Mollichelli

N

Bossone

E

Mehta

RH

,

Influence of the timing of cardiac catheterization and the amount of contrast media on acute renal failure after cardiac surgery

,

Am J Cardiol

,

2008

, vol.

101

8

(pg.

1112

-

1118

)

395

Medalion

B

Cohen

H

Assali

A

Vaknin Assa

H

Farkash

A

Snir

E

Sharoni

E

Biderman

P

Milo

G

Battler

A

Kornowski

R

Porat

E

,

The effect of cardiac angiography timing, contrast media dose, and preoperative renal function on acute renal failure after coronary artery bypass grafting

,

J Thorac Cardiovasc Surg

,

2010

, vol.

139

6

(pg.

1539

-

1544

)

396

Sajja

LR

Mannam

G

Chakravarthi

RM

Sompalli

S

Naidu

SK

Somaraju

B

Penumatsa

RR

,

Coronary artery bypass grafting with or without cardiopulmonary bypass in patients with preoperative non-dialysis dependent renal insufficiency: a randomized study

,

J Thorac Cardiovasc Surg

,

2007

, vol.

133

2

(pg.

378

-

388

)

397

Maioli

M

Toso

A

Leoncini

M

Micheletti

C

Bellandi

F

,

Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: a randomized, controlled trial

,

Circ Cardiovasc Interv

,

2011

, vol.

4

5

(pg.

456

-

462

)

398

Aspelin

P

Aubry

P

Fransson

SG

Strasser

R

Willenbrock

R

Berg

KJ

,

Nephrotoxic effects in high-risk patients undergoing angiography

,

N Engl J Med

,

2003

, vol.

348

6

(pg.

491

-

499

)

399

Jo

SH

Youn

TJ

Koo

BK

Park

JS

Kang

HJ

Cho

YS

Chung

WY

Joo

GW

Chae

IH

Choi

DJ

Oh

BH

Lee

MM

Park

YB

Kim

HS

,

Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial

,

J Am Coll Cardiol

,

2006

, vol.

48

5

(pg.

924

-

930

)

400

Solomon

RJ

Natarajan

MK

Doucet

S

Sharma

SK

Staniloae

CS

Katholi

RE

Gelormini

JL

Labinaz

M

Moreyra

AE

,

Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease

,

Circulation

,

2007

, vol.

115

25

(pg.

3189

-

3196

)

401

Leoncini

M

Toso

A

Maioli

M

Tropeano

F

Villani

S

Bellandi

F

,

Early high-dose rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome. Results from Protective effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome (PRATO-ACS Study)

,

J Am Coll Cardiol

,

2014

, vol.

63

1

(pg.

71

-

79

)

402

McCullough

PA

Bertrand

ME

Brinker

JA

Stacul

F

,

A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media

,

J Am Coll Cardiol

,

2006

, vol.

48

4

(pg.

692

-

699

)

403

Briguori

C

Visconti

G

Focaccio

A

Airoldi

F

Valgimigli

M

Sangiorgi

GM

Golia

B

Ricciardelli

B

Condorelli

G

,

Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury

,

Circulation

,

2011

, vol.

124

11

(pg.

1260

-

1269

)

404

Marenzi

G

Ferrari

C

Marana

I

Assanelli

E

De Metrio

M

Teruzzi

G

Veglia

F

Fabbiocchi

F

Montorsi

P

Bartorelli

AL

,

Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial

,

JACC Cardiovasc Interv

,

2012

, vol.

5

1

(pg.

90

-

97

)

405

ACT-Investigators

,

Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT)

,

Circulation

,

2011

, vol.

124

11

(pg.

1250

-

1259

)

406

Klima

T

Christ

A

Marana

I

Kalbermatter

S

Uthoff

H

Burri

E

Hartwiger

S

Schindler

C

Breidthardt

T

Marenzi

G

Mueller

C

,

Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial

,

Eur Heart J

,

2012

, vol.

33

16

(pg.

2071

-

2079

)

407

Marenzi

G

Marana

I

Lauri

G

Assanelli

E

Grazi

M

Campodonico

J

Trabattoni

D

Fabbiocchi

F

Montorsi

P

Bartorelli

AL

,

The prevention of radiocontrast-agent-induced nephropathy by hemofiltration

,

N Engl J Med

,

2003

, vol.

349

14

(pg.

1333

-

1340

)

408

Marenzi

G

Lauri

G

Campodonico

J

Marana

I

Assanelli

E

De Metrio

M

Grazi

M

Veglia

F

Fabbiocchi

F

Montorsi

P

Bartorelli

AL

,

Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients

,

Am J Med

,

2006

, vol.

119

2

(pg.

155

-

162

)

409

Cruz

DN

Goh

CY

Marenzi

G

Corradi

V

Ronco

C

Perazella

MA

,

Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review

,

Am J Med

,

2012

, vol.

125

1

pg.

66

78, e3

410

Vogt

B

Ferrari

P

Schonholzer

C

Marti

HP

Mohaupt

M

Wiederkehr

M

Cereghetti

C

Serra

A

Huynh-Do

U

Uehlinger

D

Frey

FJ

,

Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful

,

Am J Med

,

2001

, vol.

111

9

(pg.

692

-

698

)

411

Vahanian

A

Alfieri

O

Andreotti

F

Antunes

MJ

Baron-Esquivias

G

Baumgartner

H

Borger

MA

Carrel

TP

De Bonis

M

Evangelista

A

Falk

V

Iung

B

Lancellotti

P

Pierard

L

Price

S

Schafers

HJ

Schuler

G

Stepinska

J

Swedberg

K

Takkenberg

J

Von Oppell

UO

Windecker

S

Zamorano

JL

Zembala

M

,

Guidelines on the management of valvular heart disease (version 2012)

,

Eur Heart J

,

2012

, vol.

33

19

(pg.

2451

-

2496

)

412

Czer

LS

Gray

RJ

Stewart

ME

De Robertis

M

Chaux

A

Matloff

JM

,

Reduction in sudden late death by concomitant revascularization with aortic valve replacement

,

J Thorac Cardiovasc Surg

,

1988

, vol.

95

3

(pg.

390

-

401

)

413

Iung

B

Drissi

MF

Michel

PL

de Pamphilis

O

Tsezana

R

Cormier

B

Vahanian

A

Acar

J

,

Prognosis of valve replacement for aortic stenosis with or without coexisting coronary heart disease: a comparative study

,

J Heart Valve Dis

,

1993

, vol.

2

4

(pg.

430

-

439

)

414

Lund

O

Nielsen

TT

Pilegaard

HK

Magnussen

K

Knudsen

MA

,

The influence of coronary artery disease and bypass grafting on early and late survival after valve replacement for aortic stenosis

,

J Thorac Cardiovasc Surg

,

1990

, vol.

100

3

(pg.

327

-

337

)

415

Mullany

CJ

Elveback

LR

Frye

RL

Pluth

JR

Edwards

WD

Orszulak

TA

Nassef

LA

Jr.

Riner

RE

Danielson

GK

,

Coronary artery disease and its management: influence on survival in patients undergoing aortic valve replacement

,

J Am Coll Cardiol

,

1987

, vol.

10

1

(pg.

66

-

72

)

416

Hannan

EL

Wu

C

Bennett

EV

Carlson

RE

Culliford

AT

Gold

JP

Higgins

RS

Smith

CR

Jones

RH

,

Risk index for predicting in-hospital mortality for cardiac valve surgery

,

Ann Thorac Surg

,

2007

, vol.

83

3

(pg.

921

-

929

)

417

van Gameren

M

Kappetein

AP

Steyerberg

EW

Venema

AC

Berenschot

EA

Hannan

EL

Bogers

AJ

Takkenberg

JJ

,

Do we need separate risk stratification models for hospital mortality after heart valve surgery?

,

Ann Thorac Surg

,

2008

, vol.

85

3

(pg.

921

-

930

)

418

Hamm

CW

Mollmann

H

Holzhey

D

Beckmann

A

Veit

C

Figulla

HR

Cremer

J

Kuck

KH

Lange

R

Zahn

R

Sack

S

Schuler

G

Walther

T

Beyersdorf

F

Bohm

M

Heusch

G

Funkat

AK

Meinertz

T

Neumann

T

Papoutsis

K

Schneider

S

Welz

A

Mohr

FW

,

The German Aortic Valve Registry (GARY): in-hospital outcome

,

Eur Heart J

,

2014

, vol.

35

(pg.

1588

-

1598

)

419

Beach

JM

Mihaljevic

T

Svensson

LG

Rajeswaran

J

Marwick

T

Griffin

B

Johnston

DR

Sabik

JF

3rd

Blackstone

EH

,

Coronary artery disease outcomes of aortic valve replacement for severe aortic stenosis

,

J Am Coll Cardiol

,

2013

, vol.

61

8

(pg.

837

-

848

)

420

D'Ascenzo

F

Conrotto

F

Giordana

F

Moretti

C

D'Amico

M

Salizzoni

S

Omede

P

La Torre

M

Thomas

M

Khawaja

Z

Hildick-Smith

D

Ussia

G

Barbanti

M

Tamburino

C

Webb

J

Schnabel

RB

Seiffert

M

Wilde

S

Treede

H

Gasparetto

V

Napodano

M

Tarantini

G

Presbitero

P

Mennuni

M

Rossi

ML

Gasparini

M

Biondi Zoccai

G

Lupo

M

Rinaldi

M

Gaita

F

Marra

S

,

Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A meta-analysis of adjusted observational results

,

Int J Cardiol

,

2013

, vol.

168

3

(pg.

2528

-

2532

)

421

Stefanini

GG

Stortecky

S

Cao

D

et al. ,

Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX-score in patients undergoing transcatheter aortic valve implantation

,

Eur Heart J

,

2014

Published online 28 March 2014; doi:1093/eurheartj/ehu074

422

Wenaweser

P

Pilgrim

T

Guerios

E

Stortecky

S

Huber

C

Khattab

AA

Kadner

A

Buellesfeld

L

Gloekler

S

Meier

B

Carrel

T

Windecker

S

,

Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation

,

EuroIntervention

,

2011

, vol.

7

5

(pg.

541

-

548

)

423

Abdel-Wahab

M

Mostafa

AE

Geist

V

Stocker

B

Gordian

K

Merten

C

Richardt

D

Toelg

R

Richardt

G

,

Comparison of outcomes in patients having isolated transcatheter aortic valve implantation vs. combined with preprocedural percutaneous coronary intervention

,

Am J Cardiol

,

2012

, vol.

109

4

(pg.

581

-

586

)

424

Conradi

L

Seiffert

M

Franzen

O

Baldus

S

Schirmer

J

Meinertz

T

Reichenspurner

H

Treede

H

,

First experience with transcatheter aortic valve implantation and concomitant percutaneous coronary intervention

,

Clin Res Cardiol

,

2011

, vol.

100

4

(pg.

311

-

316

)

425

Van Mieghem

NM

van der Boon

RM

Faqiri

E

Diletti

R

Schultz

C

van Geuns

RJ

Serruys

PW

Kappetein

AP

van Domburg

RT

de Jaegere

PP

,

Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice

,

JACC Cardiovasc Interv

,

2013

, vol.

6

8

(pg.

867

-

875

)

426

Gautier

M

Pepin

M

Himbert

D

Ducrocq

G

Iung

B

Dilly

MP

Attias

D

Nataf

P

Vahanian

A

,

Impact of coronary artery disease on indications for transcatheter aortic valve implantation and on procedural outcomes

,

EuroIntervention

,

2011

, vol.

7

5

(pg.

549

-

555

)

427

Pasic

M

Unbehaun

A

Drews

T

Hetzer

R

,

Late wound healing problems after use of BioGlue for apical hemostasis during transapical aortic valve implantation

,

Interact CardioVasc Thorac Surg

,

2011

, vol.

13

5

(pg.

532

-

534

)

428

Pasic

M

Dreysse

S

Unbehaun

A

Buz

S

Drews

T

Klein

C

D'Ancona

G

Hetzer

R

,

Combined elective percutaneous coronary intervention and transapical transcatheter aortic valve implantation

,

Interact CardioVasc Thorac Surg

,

2012

, vol.

14

4

(pg.

463

-

468

)

429

Goel

SS

Ige

M

Tuzcu

EM

Ellis

SG

Stewart

WJ

Svensson

LG

Lytle

BW

Kapadia

SR

,

Severe aortic stenosis and coronary artery disease:implications for management in the transcatheter aortic valve replacement era: a comprehensive review

,

J Am Coll Cardiol

,

2013

, vol.

62

1

(pg.

1

-

10

)

430

Byrne

JG

Leacche

M

Vaughan

DE

Zhao

DX

,

Hybrid cardiovascular procedures

,

JACC Cardiovasc Interv

,

2008

, vol.

1

5

(pg.

459

-

468

)

431

Deja

MA

Grayburn

PA

Sun

B

Rao

V

She

L

Krejca

M

Jain

AR

Leng Chua

Y

Daly

R

Senni

M

Mokrzycki

K

Menicanti

L

Oh

JK

Michler

R

Wrobel

K

Lamy

A

Velazquez

EJ

Lee

KL

Jones

RH

,

Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial

,

Circulation

,

2012

, vol.

125

21

(pg.

2639

-

2648

)

432

Chan

KM

Punjabi

PP

Flather

M

Wage

R

Symmonds

K

Roussin

I

Rahman-Haley

S

Pennell

DJ

Kilner

PJ

Dreyfus

GD

Pepper

JR

Investigators

R

,

Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial

,

Circulation

,

2012

, vol.

126

21

(pg.

2502

-

2510

)

433

Aboyans

V

Lacroix

P

,

Indications for carotid screening in patients with coronary artery disease

,

Presse Med

,

2009

, vol.

38

6

(pg.

977

-

986

)

434

Chaturvedi

S

Bruno

A

Feasby

T

Holloway

R

Benavente

O

Cohen

SN

Cote

R

Hess

D

Saver

J

Spence

JD

Stern

B

Wilterdink

J

,

Carotid endarterectomy:an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

,

Neurology

,

2005

, vol.

65

6

(pg.

794

-

801

)

435

Li

Y

Walicki

D

Mathiesen

C

Jenny

D

Li

Q

Isayev

Y

Reed

JF

3rd

Castaldo

JE

,

Strokes after cardiac surgery and relationship to carotid stenosis

,

Arch Neurol

,

2009

, vol.

66

9

(pg.

1091

-

1096

)

436

Tarakji

KG

Sabik

JF

3rd

Bhudia

SK

Batizy

LH

Blackstone

EH

,

Temporal onset, risk factors, and outcomes associated with stroke after coronary artery bypass grafting

,

JAMA

,

2011

, vol.

305

4

(pg.

381

-

390

)

437

Ratib

K

Mamas

MA

Routledge

HC

Ludman

PF

Fraser

D

Nolan

J

,

Influence of access site choice on incidence of neurologic complications after percutaneous coronary intervention

,

Am Heart J

,

2013

, vol.

165

3

(pg.

317

-

324

)

438

Wardlaw

JM

Chappell

FM

Stevenson

M

De Nigris

E

Thomas

S

Gillard

J

Berry

E

Young

G

Rothwell

P

Roditi

G

Gough

M

Brennan

A

Bamford

J

Best

J

,

Accurate, practical and cost-effective assessment of carotid stenosis in the UK

,

Health Technol Assess

,

2006

, vol.

10

(30):iii–iv, ix–x

(pg.

1

-

182

)

439

Zingone

B

Rauber

E

Gatti

G

Pappalardo

A

Benussi

B

Dreas

L

Lattuada

L

,

The impact of epiaortic ultrasonographic scanning on the risk of perioperative stroke

,

Eur J Cardiothorac Surg

,

2006

, vol.

29

5

(pg.

720

-

728

)

440

Marui

A

Okabayashi

H

Komiya

T

Tanaka

S

Furukawa

Y

Kita

T

Kimura

T

Sakata

R

,

Benefits of off-pump coronary artery bypass grafting in high-risk patients

,

Circulation

,

2012

, vol.

126

11 Suppl 1

(pg.

S151

-

157

)

441

Lamy

A

Devereaux

PJ

Prabhakaran

D

Taggart

DP

Hu

S

Paolasso

E

Straka

Z

Piegas

LS

Akar

AR

Jain

AR

Noiseux

N

Padmanabhan

C

Bahamondes

JC

Novick

RJ

Vaijyanath

P

Reddy

S

Tao

L

Olavegogeascoechea

PA

Airan

B

Sulling

TA

Whitlock

RP

Ou

Y

Ng

J

Chrolavicius

S

Yusuf

S

,

Off-pump or on-pump coronary-artery bypass grafting at 30 days

,

N Engl J Med

,

2012

, vol.

366

16

(pg.

1489

-

1497

)

442

Emmert

MY

Seifert

B

Wilhelm

M

Grunenfelder

J

Falk

V

Salzberg

SP

,

Aortic no-touch technique makes the difference in off-pump coronary artery bypass grafting

,

J Thorac Cardiovasc Surg

,

2011

, vol.

142

6

(pg.

1499

-

1506

)

443

Misfeld

M

Brereton

RJ

Sweetman

EA

Doig

GS

,

Neurologic complications after off-pump coronary artery bypass grafting with and without aortic manipulation: meta-analysis of 11,398 cases from 8 studies

,

J Thorac Cardiovasc Surg

,

2011

, vol.

142

(2):e11–e17

444

Bouchard

D

Carrier

M

Demers

P

Cartier

R

Pellerin

M

Perrault

LP

Lambert

J

,

Statin in combination with beta-blocker therapy reduces postoperative stroke after coronary artery bypass graft surgery

,

Ann Thorac Surg

,

2011

, vol.

91

3

(pg.

654

-

659

)

445

Ederle

J

Featherstone

RL

Brown

MM

,

Randomized controlled trials comparing endarterectomy and endovascular treatment for carotid artery stenosis: a Cochrane systematic review. Stroke

,

2009

, vol.

40

4

(pg.

1373

-

1380

)

446

Ederle

J

Dobson

J

Featherstone

RL

Bonati

LH

van der Worp

HB

de Borst

GJ

Lo

TH

Gaines

P

Dorman

PJ

Macdonald

S

Lyrer

PA

Hendriks

JM

McCollum

C

Nederkoorn

PJ

Brown

MM

,

Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial

,

Lancet

,

2010

, vol.

375

9719

(pg.

985

-

997

)

447

Brott

TG

Hobson

RW

2nd

Howard

G

Roubin

GS

Clark

WM

Brooks

W

Mackey

A

Hill

MD

Leimgruber

PP

Sheffet

AJ

Howard

VJ

Moore

WS

Voeks

JH

Hopkins

LN

Cutlip

DE

Cohen

DJ

Popma

JJ

Ferguson

RD

Cohen

SN

Blackshear

JL

Silver

FL

Mohr

JP

Lal

BK

Meschia

JF

,

Stenting vs. endarterectomy for treatment of carotid-artery stenosis

,

N Engl J Med

,

2010

, vol.

363

1

(pg.

11

-

23

)

448

Bonati

LH

Lyrer

P

Ederle

J

Featherstone

R

Brown

MM

,

Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis

,

Cochrane Database Syst Rev

,

2012

, vol.

9

pg.

CD000515

449

Shishehbor

MH

Venkatachalam

S

Sun

Z

Rajeswaran

J

Kapadia

SR

Bajzer

C

Gornik

HL

Gray

BH

Bartholomew

JR

Clair

DG

Sabik

JF

3rd

Blackstone

EH

,

A Direct Comparison of Early and Late Outcomes with Three Approaches to Carotid Revascularization and Open Heart Surgery

,

J Am Coll Cardiol

,

2013

, vol.

62

21

(pg.

1948

-

1956

)

450

Nallamothu

BK

Gurm

HS

Ting

HH

Goodney

PP

Rogers

MA

Curtis

JP

Dimick

JB

Bates

ER

Krumholz

HM

Birkmeyer

JD

,

Operator experience and carotid stenting outcomes in Medicare beneficiaries

,

JAMA

,

2011

, vol.

306

12

(pg.

1338

-

1343

)

451

Tendera

M

Aboyans

V

Bartelink

ML

Baumgartner

I

Clement

D

Collet

JP

Cremonesi

A

De Carlo

M

Erbel

R

Fowkes

FG

Heras

M

Kownator

S

Minar

E

Ostergren

J

Poldermans

D

Riambau

V

Roffi

M

Rother

J

Sievert

H

van Sambeek

M

Zeller

T

,

ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)

,

Eur Heart J

,

2011

, vol.

32

22

(pg.

2851

-

2906

)

452

Ziada

KM

Yadav

JS

Mukherjee

D

Lauer

MS

Bhatt

DL

Kapadia

S

Roffi

M

Vora

N

Tiong

I

Bajzer

C

,

Comparison of results of carotid stenting followed by open heart surgery vs. combined carotid endarterectomy and open heart surgery (coronary bypass with or without another procedure)

,

Am J Cardiol

,

2005

, vol.

96

4

(pg.

519

-

523

)

453

Don

CW

House

J

White

C

Kiernan

T

Weideman

M

Ruggiero

N

McCann

A

Rosenfield

K

,

Carotid revascularization immediately before urgent cardiac surgery practice patterns associated with the choice of carotid artery stenting or endarterectomy: a report from the CARE (Carotid Artery Revascularization and Endarterectomy) registry

,

JACC Cardiovasc Interv

,

2011

, vol.

4

11

(pg.

1200

-

1208

)

454

Antithrombotic Trialists

C

,

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

,

BMJ

,

2002

, vol.

324

7329

(pg.

71

-

86

)

455

Dalainas

I

Nano

G

Bianchi

P

Stegher

S

Malacrida

G

Tealdi

DG

,

Dual antiplatelet regime vs. acetyl-acetic acid for carotid artery stenting

,

Cardiovasc Intervent Radiol

,

2006

, vol.

29

4

(pg.

519

-

521

)

456

McKevitt

FM

Randall

MS

Cleveland

TJ

Gaines

PA

Tan

KT

Venables

GS

,

The benefits of combined anti-platelet treatment in carotid artery stenting

,

Eur J Vasc Endovasc Surg

,

2005

, vol.

29

5

(pg.

522

-

527

)

457

Parikh

SV

Saya

S

Divanji

P

Banerjee

S

Selzer

F

Abbott

JD

Naidu

SS

Wilensky

RL

Faxon

DP

Jacobs

AK

Holper

EM

,

Risk of death and myocardial infarction in patients with peripheral arterial disease undergoing percutaneous coronary intervention (from the National Heart, Lung and Blood Institute Dynamic Registry)

,

Am J Cardiol

,

2011

, vol.

107

7

(pg.

959

-

964

)

458

Brilakis

ES

Hernandez

AF

Dai

D

Peterson

ED

Banerjee

S

Fonarow

GC

Cannon

CP

Bhatt

DL

,

Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program

,

Circulation

,

2009

, vol.

120

7

(pg.

560

-

567

)

459

Diehm

N

Schmidli

J

Setacci

C

Ricco

JB

de Donato

G

Becker

F

Robert-Ebadi

H

Cao

P

Eckstein

HH

De Rango

P

Teraa

M

Moll

FL

Dick

F

Davies

AH

Lepantalo

M

Apelqvist

J

,

Chapter III: Management of cardiovascular risk factors and medical therapy

,

Eur J Vasc Endovasc Surg

,

2011

, vol.

42

Suppl 2

S33–42

460

McFalls

EO

Ward

HB

Moritz

TE

Goldman

S

Krupski

WC

Littooy

F

Pierpont

G

Santilli

S

Rapp

J

Hattler

B

Shunk

K

Jaenicke

C

Thottapurathu

L

Ellis

N

Reda

DJ

Henderson

WG

,

Coronary-artery revascularization before elective major vascular surgery

,

N Engl J Med

,

2004

, vol.

351

27

(pg.

2795

-

2804

)

461

Monaco

M

Stassano

P

Di Tommaso

L

Pepino

P

Giordano

A

Pinna

GB

Iannelli

G

Ambrosio

G

,

Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in medium- to high-risk patients: a prospective, randomized study

,

J Am Coll Cardiol

,

2009

, vol.

54

11

(pg.

989

-

996

)

462

Fleisher

LA

Beckman

JA

Brown

KA

Calkins

H

Chaikof

EL

Fleischmann

KE

Freeman

WK

Froehlich

JB

Kasper

EK

Kersten

JR

Riegel

B

Robb

JF

,

2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines

,

Circulation

,

2009

, vol.

120

21

e169–e276

463

Zhao

DX

Leacche

M

Balaguer

JM

Boudoulas

KD

Damp

JA

Greelish

JP

Byrne

JG

Writing Group of the Cardiac Surgery

CA

Interventional Cardiology Groups at the Vanderbilt

H

Vascular

I

Ahmad

RM

Ball

SK

Cleator

JH

Deegan

RJ

Eagle

SS

Fong

PP

Fredi

JL

Hoff

SJ

Jennings

HS

3rd

McPherson

JA

Piana

RN

Pretorius

M

Robbins

MA

Slosky

DA

Thompson

A

,

Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room

,

J Am Coll Cardiol

,

2009

, vol.

53

3

(pg.

232

-

241

)

464

Thielmann

M

Massoudy

P

Jaeger

BR

Neuhauser

M

Marggraf

G

Sack

S

Erbel

R

Jakob

H

,

Emergency re-revascularization with percutaneous coronary intervention, reoperation, or conservative treatment in patients with acute perioperative graft failure following coronary artery bypass surgery

,

Eur J Cardiothorac Surg

,

2006

, vol.

30

1

(pg.

117

-

125

)

465

Thygesen

K

Alpert

JS

Jaffe

AS

Simoons

ML

Chaitman

BR

White

HD

Thygesen

K

Alpert

JS

White

HD

Jaffe

AS

Katus

HA

Apple

FS

Lindahl

B

Morrow

DA

Chaitman

BA

Clemmensen

PM

Johanson

P

Hod

H

Underwood

R

Bax

JJ

Bonow

RO

Pinto

F

Gibbons

RJ

Fox

KA

Atar

D

Newby

LK

Galvani

M

Hamm

CW

Uretsky

BF

Steg

PG

Wijns

W

Bassand

JP

Menasche

P

Ravkilde

J

Ohman

EM

Antman

EM

Wallentin

LC

Armstrong

PW

Simoons

ML

Januzzi

JL

Nieminen

MS

Gheorghiade

M

Filippatos

G

Luepker

RV

Fortmann

SP

Rosamond

WD

Levy

D

Wood

D

Smith

SC

Hu

D

Lopez-Sendon

JL

Robertson

RM

Weaver

D

Tendera

M

Bove

AA

Parkhomenko

AN

Vasilieva

EJ

Mendis

S

Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial

Infarction

,

Third universal definition of myocardial infarction

,

Eur Heart J

,

2012

, vol.

33

20

(pg.

2551

-

2567

)

466

Davierwala

PM

Verevkin

A

Leontyev

S

Misfeld

M

Borger

MA

Mohr

FW

,

Impact of expeditious management of perioperative myocardial ischemia in patients undergoing isolated coronary artery bypass surgery

,

Circulation

,

2013

, vol.

128

(11 Suppl 1)

S226–234

467

Laflamme

M

DeMey

N

Bouchard

D

Carrier

M

Demers

P

Pellerin

M

Couture

P

Perrault

LP

,

Management of early postoperative coronary artery bypass graft failure

,

Interact CardioVasc Thorac Surg

,

2012

, vol.

14

4

(pg.

452

-

456

)

468

Subramanian

S

Sabik

JF

3rd

Houghtaling

PL

Nowicki

ER

Blackstone

EH

Lytle

BW

,

Decision-making for patients with patent left internal thoracic artery grafts to left anterior descending

,

Ann Thorac Surg

,

2009

, vol.

87

(5):1392–1398; discussion 1400

469

Desai

ND

Cohen

EA

Naylor

CD

Fremes

SE

Radial Artery Patency Study

I

,

A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts

,

N Engl J Med

,

2004

, vol.

351

22

(pg.

2302

-

2309

)

470

Deb

S

Cohen

EA

Singh

SK

Une

D

Laupacis

A

Fremes

SE

Investigators

R

,

Radial artery and saphenous vein patency more than 5 years after coronary artery bypass surgery: results from RAPS (Radial Artery Patency Study)

,

J Am Coll Cardiol

,

2012

, vol.

60

1

(pg.

28

-

35

)

471

Tatoulis

J

Buxton

BF

Fuller

JA

,

Patencies of 2127 arterial to coronary conduits over 15 years

,

Ann Thorac Surg

,

2004

, vol.

77

1

(pg.

93

-

101

)

472

Hattler

B

Messenger

JC

Shroyer

AL

Collins

JF

Haugen

SJ

Garcia

JA

Baltz

JH

Cleveland

JC

Jr.

Novitzky

D

Grover

FL

,

Off-Pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: Results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial

,

Circulation

,

2012

, vol.

125

23

(pg.

2827

-

2835

)

473

Alexander

JH

Hafley

G

Harrington

RA

Peterson

ED

Ferguson

TB

Jr.

Lorenz

TJ

Goyal

A

Gibson

M

Mack

MJ

Gennevois

D

Califf

RM

Kouchoukos

NT

,

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial

,

JAMA

,

2005

, vol.

294

19

(pg.

2446

-

2454

)

474

Tatoulis

J

Buxton

BF

Fuller

JA

,

The right internal thoracic artery: the forgotten conduit:5,766 patients and 991 angiograms

,

Ann Thorac Surg

,

2011

, vol.

92

(1):9–15; discussion

(pg.

15

-

17

)

475

Barner

HB

Bailey

M

Guthrie

TJ

Pasque

MK

Moon

MR

Damiano

RJ

Jr.

Lawton

JS

,

Radial artery free and T graft patency as coronary artery bypass conduit over a 15-year period

,

Circulation

,

2012

, vol.

126

11 Suppl 1

(pg.

S140

-

144

)

476

Achouh

P

Boutekadjirt

R

Toledano

D

Hammoudi

N

Pagny

JY

Goube

P

Isselmou

KO

Lancelin

B

Fouquet

R

Acar

C

,

Long-term (5- to 20-year) patency of the radial artery for coronary bypass grafting

,

J Thorac Cardiovasc Surg

,

2010

, vol.

140

(1):73–79, 79 e1–e2

477

Sabik

JF

3rd

Blackstone

EH

Houghtaling

PL

Walts

PA

Lytle

BW

,

Is reoperation still a risk factor in coronary artery bypass surgery?

,

Ann Thorac Surg

,

2005

, vol.

80

5

(pg.

1719

-

1727

)

478

Yap

CH

Sposato

L

Akowuah

E

Theodore

S

Dinh

DT

Shardey

GC

Skillington

PD

Tatoulis

J

Yii

M

Smith

JA

Mohajeri

M

Pick

A

Seevanayagam

S

Reid

CM

,

Contemporary results show repeat coronary artery bypass grafting remains a risk factor for operative mortality

,

Ann Thorac Surg

,

2009

, vol.

87

5

(pg.

1386

-

1391

)

479

Morrison

DA

Sethi

G

Sacks

J

Henderson

WG

Grover

F

Sedlis

S

Esposito

R

Investigators of the Department of Veterans Affairs Cooperative Study AWESOME

,

Percutaneous coronary intervention vs. repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients

,

J Am Coll Cardiol

,

2002

, vol.

40

11

(pg.

1951

-

1954

)

480

Harskamp

RE

Beijk

MA

Damman

P

Kuijt

WJ

Woudstra

P

Grundeken

MJ

Kloek

JJ

Tijssen

JG

de Mol

BA

de Winter

RJ

,

Clinical outcome after surgical or percutaneous revascularization in coronary bypass graft failure

,

J Cardiovasc Med (Hagerstown)

,

2013

, vol.

14

6

(pg.

438

-

445

)

481

Sabik

JF

3rd

Raza

S

Blackstone

EH

Houghtaling

PL

Lytle

BW

,

Value of internal thoracic artery grafting to the left anterior descending coronary artery at coronary reoperation

,

J Am Coll Cardiol

,

2013

, vol.

61

3

(pg.

302

-

310

)

482

Coolong

A

Baim

DS

Kuntz

RE

O'Malley

AJ

Marulkar

S

Cutlip

DE

Popma

JJ

Mauri

L

,

Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients

,

Circulation

,

2008

, vol.

117

6

(pg.

790

-

797

)

483

Roffi

M

Mukherjee

D

Chew

DP

Bhatt

DL

Cho

L

Robbins

MA

Ziada

KM

Brennan

DM

Ellis

SG

Topol

EJ

,

Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials

,

Circulation

,

2002

, vol.

106

24

(pg.

3063

-

3067

)

484

Baim

DS

Wahr

D

George

B

Leon

MB

Greenberg

J

Cutlip

DE

Kaya

U

Popma

JJ

Ho

KK

Kuntz

RE

Saphenous vein graft Angioplasty Free of Emboli Randomized Trial I

,

Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts

,

Circulation

,

2002

, vol.

105

11

(pg.

1285

-

190

)

485

Stone

GW

Rogers

C

Hermiller

J

Feldman

R

Hall

P

Haber

R

Masud

A

Cambier

P

Caputo

RP

Turco

M

Kovach

R

Brodie

B

Herrmann

HC

Kuntz

RE

Popma

JJ

Ramee

S

Cox

DA

FilterWire

EXREI

,

Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts

,

Circulation

,

2003

, vol.

108

5

(pg.

548

-

553

)

486

Mauri

L

Cox

D

Hermiller

J

Massaro

J

Wahr

J

Tay

SW

Jonas

M

Popma

JJ

Pavliska

J

Wahr

D

Rogers

C

,

The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial

,

J Am Coll Cardiol

,

2007

, vol.

50

15

(pg.

1442

-

1449

)

487

Naidu

SS

Turco

MA

Mauri

L

Coolong

A

Popma

JJ

Kereiakes

DJ

,

Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy)

,

Am J Cardiol

,

2010

, vol.

105

8

(pg.

1060

-

1064

)

488

Giugliano

GR

Falcone

MW

Mego

D

Ebersole

D

Jenkins

S

Das

T

Barker

E

Ruggio

JM

Maini

B

Bailey

SR

,

A prospective multicenter registry of laser therapy for degenerated saphenous vein graft stenosis: the COronary graft Results following Atherectomy with Laser (CORAL) trial

,

Cardiovasc Revasc Med

,

2012

, vol.

13

2

(pg.

84

-

89

)

489

Frobert

O

Schersten

F

James

SK

Carlsson

J

Lagerqvist

B

,

Long-term safety and efficacy of drug-eluting and bare metal stents in saphenous vein grafts

,

Am Heart J

,

2012

, vol.

164

1

(pg.

87

-

93

)

490

Wiisanen

ME

Abdel-Latif

A

Mukherjee

D

Ziada

KM

,

Drug-eluting stents vs. bare-metal stents in saphenous vein graft interventions: a systematic review and meta-analysis

,

JACC Cardiovasc Interv

,

2010

, vol.

3

12

(pg.

1262

-

1273

)

491

Brilakis

ES

Lichtenwalter

C

Abdel-karim

AR

de Lemos

JA

Obel

O

Addo

T

Roesle

M

Haagen

D

Rangan

BV

Saeed

B

Bissett

JK

Sachdeva

R

Voudris

VV

Karyofillis

P

Kar

B

Rossen

J

Fasseas

P

Berger

P

Banerjee

S

,

Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial

,

JACC Cardiovasc Interv

,

2011

, vol.

4

2

(pg.

176

-

182

)

492

Hakeem

A

Helmy

T

Munsif

S

Bhatti

S

Mazraeshahi

R

Cilingiroglu

M

Effat

M

Leesar

M

Arif

I

,

Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients

,

Catheter Cardiovasc Interv

,

2011

, vol.

77

3

(pg.

343

-

355

)

493

Mamas

MA

Foley

J

Nair

S

Wiper

A

Clarke

B

El-Omar

M

Fraser

DG

Khattar

R

Neyses

L

Fath-Ordoubadi

F

,

A comparison of drug-eluting stents vs. bare metal stents in saphenous vein graft PCI outcomes: a meta-analysis

,

J Interv Cardiol

,

2011

, vol.

24

2

(pg.

172

-

180

)

494

Ko

DT

Guo

H

Wijeysundera

HC

Zia

MI

Dzavik

V

Chu

MW

Fremes

SE

Cohen

EA

Tu

JV

,

Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study

,

JACC Cardiovasc Interv

,

2011

, vol.

4

9

(pg.

965

-

973

)

495

Mehilli

J

Pache

J

Abdel-Wahab

M

Schulz

S

Byrne

RA

Tiroch

K

Hausleiter

J

Seyfarth

M

Ott

I

Ibrahim

T

Fusaro

M

Laugwitz

KL

Massberg

S

Neumann

FJ

Richardt

G

Schomig

A

Kastrati

A

,

Drug-eluting vs. bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial

,

Lancet

,

2011

, vol.

378

9796

(pg.

1071

-

1078

)

496

Nauta

ST

Van Mieghem

NM

Magro

M

Deckers

JW

Simsek

C

Van Geuns

RJ

Van Der Giessen

WJ

De Jaegere

P

Regar

E

Van Domburg

RT

Serruys

PW

,

Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts

,

Catheter Cardiovasc Interv

,

2012

, vol.

79

6

(pg.

912

-

918

)

497

Alam

M

Bandeali

SJ

Virani

SS

Jneid

HM

Shahzad

SA

Ramanathan

KB

Kar

B

Kleiman

NS

Lakkis

N

,

Clinical outcomes of percutaneous interventions in saphenous vein grafts using drug-eluting stents compared to bare-metal stents: a comprehensive meta-analysisof all randomized clinical trials

,

Clin Cardiol

,

2012

, vol.

35

5

(pg.

291

-

296

)

498

Brilakis

ES

Lasala

JM

Cox

DA

Berger

PB

Bowman

TS

Starzyk

RM

Dawkins

KD

,

Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program

,

JACC Cardiovasc Interv

,

2010

, vol.

3

7

(pg.

742

-

750

)

499

Seshadri

N

Whitlow

PL

Acharya

N

Houghtaling

P

Blackstone

EH

Ellis

SG

,

Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era

,

Circulation

,

2002

, vol.

106

18

(pg.

2346

-

2350

)

500

Richardson

SG

Morton

P

Murtagh

JG

O'Keeffe

DB

Murphy

P

Scott

ME

,

Management of acute coronary occlusion during percutaneous transluminal coronary angioplasty: experience of complications in a hospital without on site facilities for cardiac surgery

,

BMJ

,

1990

, vol.

300

6721

(pg.

355

-

358

)

501

Kastrati

A

Mehilli

J

von Beckerath

N

Dibra

A

Hausleiter

J

Pache

J

Schuhlen

H

Schmitt

C

Dirschinger

J

Schomig

A

,

Sirolimus-eluting stent or paclitaxel-eluting stent vs.balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial

,

JAMA

,

2005

, vol.

293

2

(pg.

165

-

171

)

502

Mehilli

J

Byrne

RA

Tiroch

K

Pinieck

S

Schulz

S

Kufner

S

Massberg

S

Laugwitz

KL

Schomig

A

Kastrati

A

,

Randomized trial of paclitaxel- vs. sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study

,

J Am Coll Cardiol

,

2010

, vol.

55

24

(pg.

2710

-

2716

)

503

Alfonso

F

Perez-Vizcayno

MJ

Hernandez

R

Bethencourt

A

Marti

V

Lopez-Minguez

JR

Angel

J

Mantilla

R

Moris

C

Cequier

A

Sabate

M

Escaned

J

Moreno

R

Banuelos

C

Suarez

A

Macaya

C

,

A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Vs. Elective Sirolimus-Eluting Stenting (RIBS-II) trial

,

J Am Coll Cardiol

,

2006

, vol.

47

11

(pg.

2152

-

2160

)

504

Alfonso

F

Zueco

J

Cequier

A

Mantilla

R

Bethencourt

A

Lopez-Minguez

JR

Angel

J

Auge

JM

Gomez-Recio

M

Moris

C

Seabra-Gomes

R

Perez-Vizcayno

MJ

Macaya

C

,

A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis

,

J Am Coll Cardiol

,

2003

, vol.

42

5

(pg.

796

-

805

)

505

Dibra

A

Kastrati

A

Alfonso

F

Seyfarth

M

Perez-Vizcayno

MJ

Mehilli

J

Schomig

A

,

Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials

,

J Am Coll Cardiol

,

2007

, vol.

49

5

(pg.

616

-

623

)

506

Scheller

B

Clever

YP

Kelsch

B

Hehrlein

C

Bocksch

W

Rutsch

W

Haghi

D

Dietz

U

Speck

U

Bohm

M

Cremers

B

,

Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter

,

JACC Cardiovasc Interv

,

2012

, vol.

5

3

(pg.

323

-

330

)

507

Scheller

B

Hehrlein

C

Bocksch

W

Rutsch

W

Haghi

D

Dietz

U

Bohm

M

Speck

U

,

Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter

,

N Engl J Med

,

2006

, vol.

355

20

(pg.

2113

-

2124

)

508

Unverdorben

M

Vallbracht

C

Cremers

B

Heuer

H

Hengstenberg

C

Maikowski

C

Werner

GS

Antoni

D

Kleber

FX

Bocksch

W

Leschke

M

Ackermann

H

Boxberger

M

Speck

U

Degenhardt

R

Scheller

B

,

Paclitaxel-coated balloon catheter vs. paclitaxel-coated stent for the treatment of coronary in-stent restenosis

,

Circulation

,

2009

, vol.

119

23

(pg.

2986

-

2994

)

509

Rittger

H

Brachmann

J

Sinha

AM

Waliszewski

M

Ohlow

M

Brugger

A

Thiele

H

Birkemeyer

R

Kurowski

V

Breithardt

OA

Schmidt

M

Zimmermann

S

Lonke

S

von Cranach

M

Nguyen

TV

Daniel

WG

Wohrle

J

,

A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study

,

J Am Coll Cardiol

,

2012

, vol.

59

15

(pg.

1377

-

1382

)

510

Habara

S

Mitsudo

K

Kadota

K

Goto

T

Fujii

S

Yamamoto

H

Katoh

H

Oka

N

Fuku

Y

Hosogi

S

Hirono

A

Maruo

T

Tanaka

H

Shigemoto

Y

Hasegawa

D

Tasaka

H

Kusunose

M

Otsuru

S

Okamoto

Y

Saito

N

Tsujimoto

Y

Eguchi

H

Miyake

K

Yoshino

M

,

Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis

,

JACC Cardiovasc Interv

,

2011

, vol.

4

2

(pg.

149

-

154

)

511

Byrne

RA

Neumann

FJ

Mehilli

J

Pinieck

S

Wolff

B

Tiroch

K

Schulz

S

Fusaro

M

Ott

I

Ibrahim

T

Hausleiter

J

Valina

C

Pache

J

Laugwitz

KL

Massberg

S

Kastrati

A

,

Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial

,

Lancet

,

2013

, vol.

381

9865

(pg.

461

-

467

)

512

Indermuehle

A

Bahl

R

Lansky

AJ

Froehlich

GM

Knapp

G

Timmis

A

Meier

P

,

Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart

,

2013

, vol.

99

5

(pg.

327

-

333

)

513

Tousek

P

Pavei

A

Oreglia

J

Martin

G

Sharif

F

Fajadet

J

Farah

B

,

Impact of atherosclerotic disease progression on mid-term clinical outcome in diabetic patients in the drug-eluting stent era

,

EuroIntervention

,

2009

, vol.

4

5

(pg.

588

-

592

)

514

Zellweger

MJ

Kaiser

C

Jeger

R

Brunner-La Rocca

HP

Buser

P

Bader

F

Mueller-Brand

J

Pfisterer

M

,

Coronary artery disease progression late after successful stent implantation

,

J Am Coll Cardiol

,

2012

, vol.

59

9

(pg.

793

-

799

)

515

Chechi

T

Vecchio

S

Vittori

G

Giuliani

G

Lilli

A

Spaziani

G

Consoli

L

Baldereschi

G

Biondi-Zoccai

GG

Sheiban

I

Margheri

M

,

ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients

,

J Am Coll Cardiol

,

2008

, vol.

51

25

(pg.

2396

-

2402

)

516

Alfonso

F

Dutary

J

Paulo

M

Gonzalo

N

Perez-Vizcayno

MJ

Jimenez-Quevedo

P

Escaned

J

Banuelos

C

Hernandez

R

Macaya

C

,

Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis. Heart

,

2012

, vol.

98

16

(pg.

1213

-

1220

)

517

Armstrong

EJ

Feldman

DN

Wang

TY

Kaltenbach

LA

Yeo

KK

Wong

SC

Spertus

J

Shaw

RE

Minutello

RM

Moussa

I

Ho

KK

Rogers

JH

Shunk

KA

,

Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis

,

JACC Cardiovasc Interv

,

2012

, vol.

5

2

(pg.

131

-

140

)

518

Wiviott

SD

Braunwald

E

McCabe

CH

Montalescot

G

Ruzyllo

W

Gottlieb

S

Neumann

FJ

Ardissino

D

De Servi

S

Murphy

SA

Riesmeyer

J

Weerakkody

G

Gibson

CM

Antman

EM

,

Prasugrel vs. clopidogrel in patients with acute coronary syndromes

,

N Engl J Med

,

2007

, vol.

357

20

(pg.

2001

-

2015

)

519

Mehta

SR

Bassand

JP

Chrolavicius

S

Diaz

R

Eikelboom

JW

Fox

KA

Granger

CB

Jolly

S

Joyner

CD

Rupprecht

HJ

Widimsky

P

Afzal

R

Pogue

J

Yusuf

S

Investigators

C-O

,

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

,

N Engl J Med

,

2010

, vol.

363

10

(pg.

930

-

942

)

520

Bonatti

JO

Zimrin

D

Lehr

EJ

Vesely

M

Kon

ZN

Wehman

B

de Biasi

AR

Hofauer

B

Weidinger

F

Schachner

T

Bonaros

N

Friedrich

G

,

Hybrid coronary revascularization using robotic totally endoscopic surgery: perioperative outcomes and 5-year results

,

Ann Thorac Surg

,

2012

, vol.

94

(6):1920–1926; discussion 1926

521

Shen

L

Hu

S

Wang

H

Xiong

H

Zheng

Z

Li

L

Xu

B

Yan

H

Gao

R

,

One-stop hybrid coronary revascularization vs. coronary artery bypass grafting and percutaneous coronary intervention for the treatment of multivessel coronary artery disease: 3-year follow-up results from a single institution

,

J Am Coll Cardiol

,

2013

, vol.

61

25

(pg.

2525

-

2533

)

522

Harskamp

RE

Bonatti

JO

Zhao

DX

Puskas

JD

de Winter

RJ

Alexander

JH

Halkos

ME

,

Standardizing definitions for hybrid coronary revascularization

,

J Thorac Cardiovasc Surg

,

2014

, vol.

147

2

(pg.

556

-

560

)

523

Zembala

M

Tajstra

M

Filipiak

K

Knapik

P

Hrapkowicz

T

Gierlotka

M

Hawranek

M

Polonski

L

Gasior

M

,

Prospective randomised pilOt study evaLuating the safety and efficacy of hybrid revascularisation in Multi-vessel coronary artery DisEaSe (POLMIDES) - study design

,

Kardiol Pol

,

2011

, vol.

69

5

(pg.

460

-

466

)

524

Alfonso

F

Perez-Vizcayno

MJ

Cardenas

A

Garcia Del Blanco

B

Seidelberger

B

Iniguez

A

Gomez-Recio

M

Masotti

M

Velazquez

MT

Sanchis

J

Garcia-Touchard

A

Zueco

J

Bethencourt

A

Melgares

R

Cequier

A

Dominguez

A

Mainar

V

Lopez-Minguez

JR

Moreu

J

Marti

V

Moreno

R

Jimenez-Quevedo

P

Gonzalo

N

Fernandez

C

Macaya

C

,

A Randomized Comparison of Drug-Eluting Balloon Vs. Everolimus-Eluting Stent in Patients With Bare-Metal Stent In-Stent Restenosis: The RIBS V Clinical Trial

,

J Am Coll Cardiol

,

2014

, vol.

63

14

(pg.

1378

-

1386

)

525

Holmes

DR

Jr.

Davis

KB

Mock

MB

Fisher

LD

Gersh

BJ

Killip

T

3rd

Pettinger

M

,

The effect of medical and surgical treatment on subsequent sudden cardiac death in patients with coronary artery disease: a report from the Coronary Artery Surgery Study

,

Circulation

,

1986

, vol.

73

6

(pg.

1254

-

1263

)

526

Veenhuyzen

GD

Singh

SN

McAreavey

D

Shelton

BJ

Exner

DV

,

Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction

,

Circulation

,

2001

, vol.

104

13

(pg.

1489

-

1493

)

527

Bigger

JT

Jr.

,

Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators

,

N Engl J Med

,

1997

, vol.

337

22

(pg.

1569

-

1575

)

528

Barsheshet

A

Goldenberg

I

Moss

AJ

Huang

DT

Zareba

W

McNitt

S

Klein

HU

Guetta

V

,

Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial

,

J Cardiovasc Electrophysiol

,

2011

, vol.

22

11

(pg.

1237

-

1242

)

529

Al-Khatib

SM

Hellkamp

AS

Lee

KL

Anderson

J

Poole

JE

Mark

DB

Bardy

GH

scd-heft i

,

Implantable cardioverter defibrillator therapy in patients with prior coronary revascularization in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

,

J Cardiovasc Electrophysiol

,

2008

, vol.

19

10

(pg.

1059

-

1065

)

530

Funaro

S

La Torre

G

Madonna

M

Galiuto

L

Scara

A

Labbadia

A

Canali

E

Mattatelli

A

Fedele

F

Alessandrini

F

Crea

F

Agati

L

Investigators A

,

Incidence, determinants, and prognostic value of reverse left ventricular remodelling after primary percutaneous coronary intervention: results of the Acute Myocardial Infarction Contrast Imaging (AMICI) multicenter study

,

Eur Heart J

,

2009

, vol.

30

5

(pg.

566

-

575

)

531

Antoni

ML

Mollema

SA

Delgado

V

Atary

JZ

Borleffs

CJ

Boersma

E

Holman

ER

van der Wall

EE

Schalij

MJ

Bax

JJ

,

Prognostic importance of strain and strain rate after acute myocardial infarction

,

Eur Heart J

,

2010

, vol.

31

13

(pg.

1640

-

1647

)

532

Sesselberg

HW

Moss

AJ

McNitt

S

Zareba

W

Daubert

JP

Andrews

ML

Hall

WJ

McClinitic

B

Huang

DT

Group

M-IR

,

Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy

,

Heart Rhythm

,

2007

, vol.

4

11

(pg.

1395

-

1402

)

533

Spaulding

CM

Joly

LM

Rosenberg

A

Monchi

M

Weber

SN

Dhainaut

JF

Carli

P

,

Immediate coronary angiography in survivors of out-of-hospital cardiac arrest

,

N Engl J Med

,

1997

, vol.

336

23

(pg.

1629

-

1633

)

534

Kern

KB

,

Optimal treatment of patients surviving out-of-hospital cardiac arrest

,

JACC Cardiovasc Interv

,

2012

, vol.

5

6

(pg.

597

-

605

)

535

Garot

P

Lefevre

T

Eltchaninoff

H

Morice

MC

Tamion

F

Abry

B

Lesault

PF

Le Tarnec

JY

Pouges

C

Margenet

A

Monchi

M

Laurent

I

Dumas

P

Garot

J

Louvard

Y

,

Six-month outcome of emergency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction

,

Circulation

,

2007

, vol.

115

11

(pg.

1354

-

1362

)

536

Radsel

P

Knafelj

R

Kocjancic

S

Noc

M

,

Angiographic characteristics of coronary disease and postresuscitation electrocardiograms in patients with aborted cardiac arrest outside a hospital

,

Am J Cardiol

,

2011

, vol.

108

5

(pg.

634

-

638

)

537

Anyfantakis

ZA

Baron

G

Aubry

P

Himbert

D

Feldman

LJ

Juliard

JM

Ricard-Hibon

A

Burnod

A

Cokkinos

DV

Steg

PG

,

Acute coronary angiographic findings in survivors of out-of-hospital cardiac arrest

,

Am Heart J

,

2009

, vol.

157

2

(pg.

312

-

318

)

538

Dumas

F

Cariou

A

Manzo-Silberman

S

Grimaldi

D

Vivien

B

Rosencher

J

Empana

JP

Carli

P

Mira

JP

Jouven

X

Spaulding

C

,

Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry

,

Circ Cardiovasc Interv

,

2010

, vol.

3

(pg.

200

-

207

)

539

Cronier

P

Vignon

P

Bouferrache

K

Aegerter

P

Charron

C

Templier

F

Castro

S

El Mahmoud

R

Lory

C

Pichon

N

Dubourg

O

Vieillard-Baron

A

,

Impact of routine percutaneous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation

,

Crit Care

,

2011

, vol.

15

3

R122

540

Noc

M

Fajadet

J

Lassen

JF

Kala

P

MacCarthy

P

Olivecrona

GK

Windecker

S

Spaulding

C

,

Invasive Coronary Treatment Strategies for Out-Of-Hospital Cardiac Arrest: A Consensus Statement from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)/Stent for Life (SFL) groups

,

EuroIntervention

,

2014

, vol.

10

(pg.

31

-

37

)

541

Mrdovic

I

Savic

L

Krljanac

G

Perunicic

J

Asanin

M

Lasica

R

Antonijevic

N

Kocev

N

Marinkovic

J

Vasiljevic

Z

Ostojic

M

,

Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial

,

Coron Artery Dis

,

2012

, vol.

23

1

(pg.

1

-

8

)

542

Lopes

RD

Elliott

LE

White

HD

Hochman

JS

Van de Werf

F

Ardissino

D

Nielsen

TT

Weaver

WD

Widimsky

P

Armstrong

PW

Granger

CB

,

Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial

,

Eur Heart J

,

2009

, vol.

30

16

(pg.

2019

-

2028

)

543

Chan

W

Ajani

AE

Clark

DJ

Stub

D

Andrianopoulos

N

Brennan

AL

New

G

Sebastian

M

Johnston

R

Walton

A

Reid

CM

Dart

AM

Duffy

SJ

Melbourne Interventional Group I

,

Impact of periprocedural atrial fibrillation on short-term clinical outcomes following percutaneous coronary intervention

,

Am J Cardiol

,

2012

, vol.

109

4

(pg.

471

-

477

)

544

Pilgrim

T

Kalesan

B

Zanchin

T

Pulver

C

Jung

S

Mattle

H

Carrel

T

Moschovitis

A

Stortecky

S

Wenaweser

P

Stefanini

GG

Raber

L

Meier

B

Juni

P

Windecker

S

,

Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents

,

EuroIntervention

,

2013

, vol.

8

9

(pg.

1061

-

1071

)

545

Bernard

A

Fauchier

L

Pellegrin

C

Clementy

N

Saint Etienne

C

Banerjee

A

Naudin

D

Angoulvant

D

,

Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation

,

Thromb Haemost

,

2013

, vol.

110

3

(pg.

560

-

568

)

546

Ruiz-Nodar

JM

Marin

F

Roldan

V

Valencia

J

Manzano-Fernandez

S

Caballero

L

Hurtado

JA

Sogorb

F

Valdes

M

Lip

GY

,

Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?

,

Circ Cardiovasc Interv

,

2012

, vol.

5

4

(pg.

459

-

466

)

547

Camm

AJ

Lip

GY

De Caterina

R

Savelieva

I

Atar

D

Hohnloser

SH

Hindricks

G

Kirchhof

P

Guidelines

ESCCfP

,

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

,

Eur Heart J

,

2012

, vol.

33

21

(pg.

2719

-

2747

)

548

Shen

J

Lall

S

Zheng

V

Buckley

P

Damiano

RJ

Jr.

Schuessler

RB

,

The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades

,

J Thorac Cardiovasc Surg

,

2011

, vol.

141

2

(pg.

559

-

570

)

549

Maesen

B

Nijs

J

Maessen

J

Allessie

M

Schotten

U

,

Postoperative atrial fibrillation: a maze of mechanisms

,

Europace

,

2012

, vol.

14

2

(pg.

159

-

174

)

550

Mariscalco

G

Klersy

C

Zanobini

M

Banach

M

Ferrarese

S

Borsani

P

Cantore

C

Biglioli

P

Sala

A

,

Atrial fibrillation after isolated coronary surgery affects late survival

,

Circulation

,

2008

, vol.

118

16

(pg.

1612

-

1618

)

551

Burgess

DC

Kilborn

MJ

Keech

AC

,

Interventions for prevention of postoperative atrial fibrillation and its complications after cardiac surgery: a meta-analysis

,

Eur Heart J

,

2006

, vol.

27

23

(pg.

2846

-

2857

)

552

Crystal

E

Connolly

SJ

Sleik

K

Ginger

TJ

Yusuf

S

,

Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis

,

Circulation

,

2002

, vol.

106

1

(pg.

75

-

80

)

553

Connolly

SJ

Cybulsky

I

Lamy

A

Roberts

RS

O'Brien

B

Carroll

S

Crystal

E

Thorpe

KE

Gent

M

,

Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study

,

Am Heart J

,

2003

, vol.

145

2

(pg.

226

-

232

)

554

Lucio

EA

Flores

A

Blacher

C

Leyes

PE

Lucchese

FA

Ribeiro

JP

,

Effectiveness of metoprolol in preventing atrial fibrillation and flutter in the postoperative period of coronary artery bypass graft surgery

,

Arq Bras Cardiol

,

2003

, vol.

82

(pg.

42

-

46

)

555

Tsuboi

J

Kawazoe

K

Izumoto

H

Okabayashi

H

,

Postoperative treatment with carvedilol, a-adrenergic blocker, prevents paroxysmal atrial fibrillation after coronary artery bypass grafting

,

Circ J

,

2008

, vol.

72

(pg.

588

-

591

)

556

Koniari

I

Apostolakis

E

Rogkakou

C

Baikoussis

NG

Dougenis

DE

,

Pharmacologic prophylaxis for atrial fibrillation following cardiac surgery: a systematic review

,

J Cardiothorac Surg

,

2010

, vol.

5

pg.

121

557

Dunning

J

Treasure

T

Versteegh

M

Nashef

SA

,

Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery

,

Eur J Cardiothorac Surg

,

2006

, vol.

30

(pg.

852

-

872

)

558

Wurdeman

RL

Mooss

AN

Mohiuddin

SM

Lenz

TL

,

Amiodarone vs. sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis

,

Chest

,

2002

, vol.

121

4

(pg.

1203

-

1210

)

559

Zhu

J

Wang

C

Gao

D

Zhang

C

Zhang

Y

Lu

Y

Gao

Y

,

Meta-analysis of amiodarone vs. beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery

,

Intern Med J

,

2012

, vol.

42

10

(pg.

1078

-

1087

)

560

El-Chami

MF

Kilgo

P

Thourani

V

Lattouf

OM

Delurgio

DB

Guyton

RA

Leon

AR

Puskas

JD

,

New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft

,

J Am Coll Cardiol

,

2010

, vol.

55

13

(pg.

1370

-

1376

)

561

Kirchhof

P

Bax

J

Blomstrom-Lundquist

C

Calkins

H

Camm

AJ

Cappato

R

Cosio

F

Crijns

H

Diener

HC

Goette

A

Israel

CW

Kuck

KH

Lip

GY

Nattel

S

Page

RL

Ravens

U

Schotten

U

Steinbeck

G

Vardas

P

Waldo

A

Wegscheider

K

Willems

S

Breithardt

G

,

Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'

,

Eur Heart J

,

2009

, vol.

30

24

2969–2977c

562

Cox

JL

Ad

N

Palazzo

T

,

Impact of the maze procedure on the stroke rate in patients with atrial fibrillation

,

J Thorac Cardiovasc Surg

,

1999

, vol.

118

5

(pg.

833

-

840

)

563

Garcia-Fernandez

MA

Perez-David

E

Quiles

J

Peralta

J

Garcia-Rojas

I

Bermejo

J

Moreno

M

Silva

J

,

Role of left atrial appendage obliteration in stroke reduction in patients with mitral valve prosthesis: a transesophageal echocardiographic study

,

J Am Coll Cardiol

,

2003

, vol.

42

7

(pg.

1253

-

1258

)

564

Holmes

DR

Reddy

VY

Turi

ZG

Doshi

SK

Sievert

H

Buchbinder

M

Mullin

CM

Sick

P

Investigators PA

,

Percutaneous closure of the left atrial appendage vs. warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial

,

Lancet

,

2009

, vol.

374

9689

(pg.

534

-

542

)

565

Bagshaw

SM

Galbraith

PD

Mitchell

LB

Sauve

R

Exner

DV

Ghali

WA

,

Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis

,

Ann Thorac Surg

,

2006

, vol.

82

(pg.

1927

-

1937

)

566

Reddy

VY

Holmes

D

Doshi

SK

Neuzil

P

Kar

S

,

Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry

,

Circulation

,

2011

, vol.

123

(pg.

417

-

424

)

567

Otterstad

JE

Kirwan

BA

Lubsen

J

De Brouwer

S

Fox

KA

Corell

P

Poole-Wilson

PA

Action

I

,

Incidence and outcome of atrial fibrillation in stable symptomatic coronary disease

,

Scand Cardiovasc J

,

2006

, vol.

40

3

(pg.

152

-

159

)

568

Goldenberg

I

Moss

AJ

McNitt

S

Zareba

W

Hall

WJ

Andrews

ML

Wilber

DJ

Klein

HU

Investigators

M-I

,

Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II

,

J Am Coll Cardiol

,

2006

, vol.

47

9

(pg.

1811

-

1817

)

569

Wang

G

Bainbridge

D

Martin

J

Cheng

D

,

The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg

,

2009

, vol.

109

2

(pg.

320

-

30

)

570

McIlroy

DR

Myles

PS

Phillips

LE

Smith

JA

,

Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis

,

Br J Anaesth

,

2009

, vol.

102

2

(pg.

168

-

178

)

571

Bhaskar

B

Dulhunty

J

Mullany

DV

Fraser

JF

,

Impact of blood product transfusion on short and long-term survival after cardiac surgery: more evidence

,

Ann Thorac Surg

,

2012

, vol.

94

2

(pg.

460

-

467

)

572

Jakobsen

CJ

Ryhammer

PK

Tang

M

Andreasen

JJ

Mortensen

PE

,

Transfusion of blood during cardiac surgery is associated with higher long-term mortality in low-risk patients

,

Eur J Cardiothorac Surg

,

2012

, vol.

42

1

(pg.

114

-

120

)

573

Hajjar

LA

Vincent

JL

Galas

FR

Nakamura

RE

Silva

CM

Santos

MH

Fukushima

J

Kalil Filho

R

Sierra

DB

Lopes

NH

Mauad

T

Roquim

AC

Sundin

MR

Leao

WC

Almeida

JP

Pomerantzeff

PM

Dallan

LO

Jatene

FB

Stolf

NA

Auler

JO

Jr.

,

Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial

,

JAMA

,

2010

, vol.

304

14

(pg.

1559

-

1567

)

574

Zenati

MA

Shroyer

AL

Collins

JF

Hattler

B

Ota

T

Almassi

GH

Amidi

M

Novitzky

D

Grover

FL

Sonel

AF

,

Impact of endoscopic vs. open saphenous vein harvest technique on late coronary artery bypass grafting patient outcomes in the ROOBY (Randomized On/Off Bypass) Trial

,

J Thorac Cardiovasc Surg

,

2011

, vol.

141

2

(pg.

338

-

344

)

575

Lopes

RD

Hafley

GE

Allen

KB

Ferguson

TB

Peterson

ED

Harrington

RA

Mehta

RH

Gibson

CM

Mack

MJ

Kouchoukos

NT

Califf

RM

Alexander

JH

,

Endoscopic vs. Open Vein-Graft Harvesting in Coronary-Artery Bypass Surgery

,

N Eng J Med

,

2009

, vol.

361

3

(pg.

235

-

244

)

576

Deppe

AC

Liakopoulos

OJ

Choi

YH

Slottosch

I

Kuhn

EW

Scherner

M

Stange

S

Wahlers

T

,

Endoscopic vein harvesting for coronary artery bypass grafting: a systematic review with meta-analysis of 27,789 patients

,

J Surg Res

,

2012

, vol.

180

1

(pg.

114

-

124

)

577

Yun

KL

Wu

Y

Aharonian

V

Mansukhani

P

Pfeffer

TA

Sintek

CF

Kochamba

GS

Grunkemeier

G

Khonsari

S

,

Randomized trial of endoscopic vs. open vein harvest for coronary artery bypass grafting: six-month patency rates

,

J Thorac Cardiovasc Surg

,

2005

, vol.

129

3

(pg.

496

-

503

)

578

Ouzounian

M

Hassan

A

Buth

KJ

MacPherson

C

Ali

IM

Hirsch

GM

Ali

IS

,

Impact of endoscopic vs. open saphenous vein harvest techniques on outcomes after coronary artery bypass grafting

,

Ann Thorac Surg

,

2010

, vol.

89

2

(pg.

403

-

408

)

579

Williams

JB

Peterson

ED

Brennan

JM

Sedrakyan

A

Tavris

D

Alexander

JH

Lopes

RD

Dokholyan

RS

Zhao

Y

O'Brien

SM

Michler

RE

Thourani

VH

Edwards

FH

Duggirala

H

Gross

T

Marinac-Dabic

D

Smith

PK

,

Association between endoscopic vs. open vein-graft harvesting and mortality, wound complications and cardiovascular events in patients undergoing CABG surgery

,

JAMA

,

2012

, vol.

308

5

(pg.

475

-

484

)

580

Brown

EN

Kon

ZN

Tran

R

Burris

NS

Gu

J

Laird

P

Brazio

PS

Kallam

S

Schwartz

K

Bechtel

L

Joshi

A

Zhang

S

Poston

RS

,

Strategies to reduce intraluminal clot formation in endoscopically harvested saphenous veins

,

J Thorac Cardiovasc Surg

,

2007

, vol.

134

5

(pg.

1259

-

1265

)

581

Khaleel

MS

Dorheim

TA

Duryee

MJ

Durbin

HE

Jr.

Bussey

WD

Garvin

RP

Klassen

LW

Thiele

GM

Anderson

DR

,

High-pressure distention of the saphenous vein during preparation results in increased markers of inflammation: a potential mechanism for graft failure

,

Ann Thorac Surg

,

2012

, vol.

93

2

(pg.

552

-

558

)

582

Rousou

LJ

Taylor

KB

Lu

XG

Healey

N

Crittenden

MD

Khuri

SF

Thatte

HS

,

Saphenous vein conduits harvested by endoscopic technique exhibit structural and functional damage

,

Ann Thorac Surg

,

2009

, vol.

87

1

(pg.

62

-

70

)

583

Navia

JL

Olivares

G

Ehasz

P

Gillinov

AM

Svensson

LG

Brozzi

N

Lytle

B

,

Endoscopic radial artery harvesting procedure for coronary artery bypass grafting

,

Ann Cardiothorac Surg

,

2013

, vol.

2

4

(pg.

557

-

564

)

584

Souza

DS

Dashwood

MR

Tsui

JC

Filbey

D

Bodin

L

Johansson

B

Borowiec

J

,

Improved patency in vein grafts harvested with surrounding tissue: results of a randomized study using three harvesting techniques

,

Ann Thorac Surg

,

2002

, vol.

73

4

(pg.

1189

-

1195

)

585

Johansson

BL

Souza

DS

Bodin

L

Filbey

D

Loesch

A

Geijer

H

Bojo

L

,

Slower progression of atherosclerosis in vein grafts harvested with 'no touch' technique compared with conventional harvesting technique in coronary artery bypass grafting: an angiographic and intravascular ultrasound study

,

Eur J Cardiothorac Surg

,

2010

, vol.

38

4

(pg.

414

-

419

)

586

Deo

SV

Shah

IK

Dunlay

SM

Erwin

PJ

Locker

C

Altarabsheh

SE

Boilson

BA

Park

SJ

Joyce

LD

,

Bilateral internal thoracic artery harvest and deep sternal wound infection in diabetic patients

,

Ann Thorac Surg

,

2013

, vol.

95

3

(pg.

862

-

869

)

587

Sa

MP

Ferraz

PE

Escobar

RR

Vasconcelos

FP

Ferraz

AA

Braile

DM

Lima

RC

,

Skeletonized vs. pedicled internal thoracic artery and risk of sternal wound infection after coronary bypass surgery: meta-analysis and meta-regression of 4817 patients

,

Interact CardioVasc Thorac Surg

,

2013

, vol.

16

6

(pg.

849

-

857

)

588

Sakic

A

Chevtchik

O

Kilo

J

Schistek

R

Mueller

LC

Ulmer

H

Grimm

M

Ruttmann

E

,

Simple adaptations of surgical technique to critically reduce the risk of postoperative sternal complications in patients receiving bilateral internal thoracic arteries

,

Interact CardioVasc Thorac Surg

,

2013

, vol.

17

2

(pg.

378

-

382

)

589

Lytle

BW

,

Skeletonized internal thoracic artery grafts and wound complications

,

J Thorac Cardiovasc Surg

,

2001

, vol.

121

4

(pg.

625

-

627

)

590

Wendler

O

Hennen

B

Markwirth

T

Konig

J

Tscholl

D

Huang

Q

Shahangi

E

Schafers

HJ

,

T grafts with the right internal thoracic artery to left internal thoracic artery vs. the left internal thoracic artery and radial artery: flow dynamics in the internal thoracic artery main stem

,

J Thorac Cardiovasc Surg

,

1999

, vol.

118

5

(pg.

841

-

848

)

591

Taggart

DP

,

Incomplete revascularization: appropriate and inappropriate

,

Eur J Cardiothorac Surg

,

2012

, vol.

41

3

(pg.

542

-

543

)

592

Zimarino

M

Curzen

N

Cicchitti

V

De Caterina

R

,

The adequacy of myocardial revascularization in patients with multivessel coronary artery disease

,

Int J Cardiol

,

2013

, vol.

168

3

(pg.

1748

-

1757

)

593

Ong

AT

Serruys

PW

,

Complete revascularization: coronary artery bypass graft surgery vs. percutaneous coronary intervention

,

Circulation

,

2006

, vol.

114

3

(pg.

249

-

255

)

594

Farooq

V

Serruys

PW

Garcia–Garcia

HM

Zhang

Y

Bourantas

CV

Holmes

DR

Mack

M

Feldman

T

Morice

MC

Stahle

E

James

S

Colombo

A

Diletti

R

Papafaklis

MI

de Vries

T

Morel

MA

van Es

GA

Mohr

FW

Dawkins

KD

Kappetein

AP

Sianos

G

Boersma

E

,

The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial

,

J Am Coll Cardiol

,

2013

, vol.

61

3

(pg.

282

-

294

)

595

Head

SJ

Mack

MJ

Holmes

DR

Jr.

Mohr

FW

Morice

MC

Serruys

PW

Kappetein

AP

,

Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data

,

Eur J Cardiothorac Surg

,

2012

, vol.

41

3

(pg.

535

-

541

)

596

Kim

YH

Park

DW

Lee

JY

Kim

WJ

Yun

SC

Ahn

JM

Song

HG

Oh

JH

Park

JS

Kang

SJ

Lee

SW

Lee

CW

Park

SW

Park

SJ

,

Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease

,

Circulation

,

2011

, vol.

123

21

(pg.

2373

-

2381

)

597

Mohammadi

S

Kalavrouziotis

D

Dagenais

F

Voisine

P

Charbonneau

E

,

Completeness of revascularization and survival among octogenarians with triple-vessel disease

,

Ann Thorac Surg

,

2012

, vol.

93

5

(pg.

1432

-

1437

)

598

Yi

G

Youn

YN

Joo

HC

Hong

S

Yoo

KJ

,

Association of incomplete revascularization with long-term survival after off-pump coronary artery bypass grafting

,

J Surg Res

,

2013

, vol.

185

1

(pg.

166

-

173

)

599

Rastan

AJ

Walther

T

Falk

V

Kempfert

J

Merk

D

Lehmann

S

Holzhey

D

Mohr

FW

,

Does reasonable incomplete surgical revascularization affect early or long-term survival in patients with multivessel coronary artery disease receiving left internal mammary artery bypass to left anterior descending artery?

,

Circulation

,

2009

, vol.

120

(11 Suppl)

S70–77

600

Garcia

S

Sandoval

Y

Roukoz

H

Adabag

S

Canoniero

M

Yannopoulos

D

Brilakis

ES

,

Outcomes after complete vs. incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies

,

J Am Coll Cardiol

,

2013

, vol.

62

16

(pg.

1421

-

1431

)

601

Scott

R

Blackstone

EH

McCarthy

PM

Lytle

BW

Loop

FD

White

JA

Cosgrove

DM

,

Isolated bypass grafting of the left internal thoracic artery to the left anterior descending coronary artery

,

J Thorac Cardiovasc Surg

,

2000

, vol.

120

1

(pg.

173

-

184

)

602

Boylan

MJ

Lytle

BW

Loop

FD

Taylor

PC

Borsh

JA

Goormastic

M

Cosgrove

DM

,

Surgical treatment of isolated left anterior descending coronary stenosis. Comparison of left internal mammary artery and venous autograft at 18 to 20 years of follow-up

,

J Thorac Cardiovasc Surg

,

1994

, vol.

107

(pg.

657

-

662

)

603

Sabik

JF

3rd

Blackstone

EH

Gillinov

AM

Banbury

MK

Smedira

NG

Lytle

BW

,

Influence of patient characteristics and arterial grafts on freedom from coronary reoperation

,

J Thorac Cardiovasc Surg

,

2006

, vol.

131

1

(pg.

90

-

98

)

604

Schmitto

JD

Rajab

TK

Cohn

LH

,

Prevalence and variability of internal mammary graft use in contemporary multivessel coronary artery bypass graft

,

Curr Opin Cardiol

,

2010

, vol.

25

6

(pg.

609

-

612

)

605

Taggart

DP

D'Amico

R

Altman

DG

,

Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries

,

Lancet

,

2001

, vol.

358

9285

(pg.

870

-

875

)

606

Ruttmann

E

Fischler

N

Sakic

A

Chevtchik

O

Alber

H

Schistek

R

Ulmer

H

Grimm

M

,

Second internal thoracic artery vs. radial artery in coronary artery bypass grafting: a long-term, propensity score-matched follow-up study

,

Circulation

,

2011

, vol.

124

12

(pg.

1321

-

1329

)

607

Galbut

DL

Kurlansky

PA

Traad

EA

Dorman

MJ

Zucker

M

Ebra

G

,

Bilateral internal thoracic artery grafting improves long-term survival in patients with reduced ejection fraction: a propensity-matched study with 30-year follow-up

,

J Thorac Cardiovasc Surg

,

2012

, vol.

143

(4):844–853 e4

608

Grau

JB

Ferrari

G

Mak

AW

Shaw

RE

Brizzio

ME

Mindich

BP

Strobeck

J

Zapolanski

A

,

Propensity matched analysis of bilateral internal mammary artery vs. single left internal mammary artery grafting at 17-year follow-up: validation of a contemporary surgical experience

,

Eur J Cardiothorac Surg

,

2012

, vol.

41

4

(pg.

770

-

775

)

discussion 776

609

Lytle

BW

,

Bilateral internal thoracic artery grafting

,

Ann Cardiothorac Surg

,

2013

, vol.

2

4

(pg.

485

-

492

)

610

Weiss

AJ

Zhao

S

Tian

DH

Taggart

DP

Yan

TD

,

A meta-analysis comparing bilateral internal mammary artery with left internal mammary artery for coronary artery bypass grafting

,

Ann Cardiothorac Surg

,

2013

, vol.

2

4

(pg.

390

-

400

)

611

Hemo

E

Mohr

R

Uretzky

G

Katz

G

Popovits

N

Pevni

D

Medalion

B

,

Long-term outcomes of patients with diabetes receiving bilateral internal thoracic artery grafts

,

J Thorac Cardiovasc Surg

,

2013

, vol.

146

3

(pg.

586

-

592

)

612

Taggart

DP

Lees

B

Gray

A

Altman

DG

Flather

M

Channon

K

Investigators

ART

,

Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral vs. single internal mammary grafting in coronary revascularisation [ISRCTN46552265]

,

. Trials

,

2006

, vol.

7

pg.

7

613

Elmistekawy

EM

Gawad

N

Bourke

M

Mesana

T

Boodhwani

M

Rubens

FD

,

Is bilateral internal thoracic artery use safe in the elderly?

,

J Card Surg

,

2012

, vol.

27

1

(pg.

1

-

5

)

614

Toumpoulis

IK

Theakos

N

Dunning

J

,

Does bilateral internal thoracic artery harvest increase the risk of mediastinitis?

,

Interact CardioVasc Thorac Surg

,

2007

, vol.

6

(pg.

787

-

791

)

615

Tranbaugh

RF

Dimitrova

KR

Friedmann

P

Geller

CM

Harris

LJ

Stelzer

P

Cohen

B

Hoffman

DM

,

Radial artery conduits improve long-term survival after coronary artery bypass grafting

,

Ann Thorac Surg

,

2010

, vol.

90

4

(pg.

1165

-

1172

)

616

Tranbaugh

RF

Dimitrova

KR

Friedmann

P

Geller

CM

Harris

LJ

Stelzer

P

Cohen

BM

Ko

W

DeCastro

H

Lucido

D

Hoffman

DM

,

Coronary artery bypass grafting using the radial artery: clinical outcomes, patency, and need for reintervention

,

Circulation

,

2012

, vol.

126

(11 Suppl 1)

S170–175

617

Schwann

TA

Engoren

M

Bonnell

M

Clancy

C

Habib

RH

,

Comparison of late coronary artery bypass graft survival effects of radial artery vs. saphenous vein grafting in male and female patients

,

Ann Thorac Surg

,

2012

, vol.

94

5

(pg.

1485

-

1491

)

618

Hayward

PA

Gordon

IR

Hare

DL

Matalanis

G

Horrigan

ML

Rosalion

A

Buxton

BF

,

Comparable patencies of the radial artery and right internal thoracic artery or saphenous vein beyond 5 years: results from the Radial Artery Patency and Clinical Outcomes trial

,

J Thorac Cardiovasc Surg

,

2010

, vol.

139

1

(pg.

60

-

65

)

discussion 65–67

619

Kieser

TM

Rose

S

Kowalewski

R

Belenkie

I

,

Transit-time flow predicts outcomes in coronary artery bypass graft patients: a series of 1000 consecutive arterial grafts

,

Eur J Cardiothorac Surg

,

2010

, vol.

38

2

(pg.

155

-

162

)

620

Jokinen

JJ

Werkkala

K

Vainikka

T

Perakyla

T

Simpanen

J

Ihlberg

L

,

Clinical value of intra-operative transit-time flow measurement for coronary artery bypass grafting: a prospective angiography-controlled study

,

Eur J Cardiothorac Surg

,

2011

, vol.

39

6

(pg.

918

-

923

)

621

Lamy

A

Devereaux

PJ

Prabhakaran

D

Taggart

DP

Hu

S

Paolasso

E

Straka

Z

Piegas

LS

Akar

AR

Jain

AR

Noiseux

N

Padmanabhan

C

Bahamondes

JC

Novick

RJ

Vaijyanath

P

Reddy

SK

Tao

L

Olavegogeascoechea

PA

Airan

B

Sulling

TA

Whitlock

RP

Ou

Y

Pogue

J

Chrolavicius

S

Yusuf

S

Investigators C

,

Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year

,

N Engl J Med

,

2013

, vol.

368

13

(pg.

1179

-

1188

)

622

Diegeler

A

Borgermann

J

Kappert

U

Breuer

M

Boning

A

Ursulescu

A

Rastan

A

Holzhey

D

Treede

H

Riess

FC

Veeckmann

P

Asfoor

A

Reents

W

Zacher

M

Hilker

M

,

Off-pump vs. on-pump coronary-artery bypass grafting in elderly patients

,

N Engl J Med

,

2013

, vol.

368

13

(pg.

1189

-

1198

)

623

Shroyer

AL

Grover

FL

Hattler

B

Collins

JF

McDonald

GO

Kozora

E

Lucke

JC

Baltz

JH

Novitzky

D

,

On-pump vs. off-pump coronary-artery bypass surgery

,

N Engl J Med

,

2009

, vol.

361

19

(pg.

1827

-

1837

)

624

Houlind

K

Kjeldsen

BJ

Madsen

SN

Rasmussen

BS

Holme

SJ

Nielsen

PH

Mortensen

PE

Group DS

,

On-pump vs. off-pump coronary artery bypass surgery in elderly patients: results from the Danish on-pump vs. off-pump randomization study

,

Circulation

,

2012

, vol.

125

20

(pg.

2431

-

2439

)

625

Hattler

B

Messenger

JC

Shroyer

AL

Collins

JF

Haugen

SJ

Garcia

JA

Baltz

JH

Cleveland

JC

Jr.

Novitzky

D

Grover

FL

Veterans Affairs Randomized

On

/Off Bypass Study

G

,

Off-Pump coronary artery bypass surgery is associated with worse arterial and saphenous vein graft patency and less effective revascularization: Results from the Veterans Affairs Randomized On/Off Bypass (ROOBY) trial

,

Circulation

,

2012

, vol.

125

23

(pg.

2827

-

2835

)

626

Sedrakyan

A

Wu

AW

Parashar

A

Bass

EB

Treasure

T

,

Off-pump surgery is associated with reduced occurrence of stroke and other morbidity as compared with traditional coronary artery bypass grafting: a meta-analysis of systematically reviewed trials

,

Stroke

,

2006

, vol.

37

11

(pg.

2759

-

2769

)

627

Keeling

WB

Kilgo

PD

Puskas

JD

Halkos

ME

Lattouf

OM

Guyton

RA

Thourani

VH

,

Off-pump coronary artery bypass grafting attenuates morbidity and mortality for patients with low and high body mass index

,

J Thorac Cardiovasc Surg

,

2012

, vol.

146

6

(pg.

1142

-

1148

)

628

Puskas

JD

Williams

WH

O'Donnell

R

Patterson

RE

Sigman

SR

Smith

AS

Baio

KT

Kilgo

PD

Guyton

RA

,

Off-pump and on-pump coronary artery bypass grafting are associated with similar graft patency, myocardial ischemia, and freedom from reintervention: long-term follow-up of a randomized trial

,

Ann Thorac Surg

,

2011

, vol.

91

(6):1836–1842; discussion

(pg.

1842

-

1843

)

629

Puskas

JD

Thourani

VH

Kilgo

P

Cooper

W

Vassiliades

T

Vega

JD

Morris

C

Chen

E

Schmotzer

BJ

Guyton

RA

Lattouf

OM

,

Off-pump coronary artery bypass disproportionately benefits high-risk patients

,

Ann Thorac Surg

,

2009

, vol.

88

4

(pg.

1142

-

1147

)

630

Head

SJ

Borgermann

J

Osnabrugge

RL

Kieser

TM

Falk

V

Taggart

DP

Puskas

JD

Gummert

JF

Kappetein

AP

,

Coronary artery bypass grafting: Part 2:optimizing outcomes and future prospects

,

Eur Heart J

,

2013

, vol.

34

37

(pg.

2873

-

2886

)

631

Diegeler

A

Walther

T

Metz

S

Falk

V

Krakor

R

Autschbach

R

Mohr

FW

,

Comparison of MIDCAP vs. conventional CABG surgery regarding pain and quality of life

,

Heart Surg Forum

,

1999

, vol.

2

(4):290–295; discussion

(pg.

295

-

296

)

632

Groh

MA

Sutherland

SE

Burton

HG

3rd

Johnson

AM

Ely

SW

,

Port-access coronary artery bypass grafting: technique and comparative results

,

Ann Thorac Surg

,

1999

, vol.

68

4

(pg.

1506

-

1508

)

633

Lapierre

H

Chan

V

Sohmer

B

Mesana

TG

Ruel

M

,

Minimally invasive coronary artery bypass grafting via a small thoracotomy vs. off-pump: a case-matched study

,

Eur J Cardiothorac Surg

,

2011

, vol.

40

4

(pg.

804

-

810

)

634

Siregar

S

Groenwold

RH

de Mol

BA

Speekenbrink

RG

Versteegh

MI

Brandon Bravo Bruinsma

GJ

Bots

ML

van der Graaf

Y

van Herwerden

LA

,

Evaluation of cardiac surgery mortality rates: 30-day mortality or longer follow-up?

,

Eur J Cardiothorac Surg

,

2013

, vol.

44

5

(pg.

875

-

883

)

635

Peterson

ED

Coombs

LP

DeLong

ER

Haan

CK

Ferguson

TB

,

Procedural volume as a marker of quality for CABG surgery

,

JAMA

,

2004

, vol.

291

2

(pg.

195

-

201

)

636

Sergeant

P

Blackstone

E

Meyns

B

,

Validation and interdependence with patient-variables of the influence of procedural variables on early and late survival after CABG. K.U. Leuven Coronary Surgery Program

,

Eur J Cardiothorac Surg

,

1997

, vol.

12

1

(pg.

1

-

19

)

637

Williams

JB

Peterson

ED

Brennan

JM

Sedrakyan

A

Tavris

D

Alexander

JH

Lopes

DR

Dokholyan

RS

Zhao

Y

O’Brien

SM

Michler

RE

Thourani

VH

Edwards

FH

Duggirala

H

Gross

T

Marinac-Dabic

D

Smith

PK

,

Association Between Endoscopic vs.Open Vein-Graft Harvesting and Mortality, Wound Complications, and Cardiovascular Events in Patients Undergoing CABG Surgery

,

JAMA

,

2012

, vol.

308

5

(pg.

475

-

484

)

638

Bakaeen

FG

,

Endoscopic vein harvest for coronary artery bypass grafting is safe

,

J Surg Res

,

2013

, vol.

185

2

(pg.

522

-

523

)

639

Schmitto

JD

Rajab

TK

Cohn

LH

,

Prevalence and variability of internal mammary graft use in contemporary multivessel coronary artery bypass graft

,

Curr Opin Cardiol

,

2010

, vol.

25

(pg.

609

-

612

)

640

Dorman

MJ

Kurlansky

PA

Traad

EA

Galbut

DL

Zucker

M

Ebra

G

,

Bilateral Internal Mammary Artery Grafting Enhances Survival in Diabetic Patients : A 30-Year Follow-Up of Propensity Score −Matched Cohorts

,

Circulation

,

2012

, vol.

126

(pg.

2935

-

2942

)

641

Kieser

TM

Lewin

AM

Graham

MM

Martin

BJ

Galbraith

PD

Rabi

DM

Norris

CM

Faris

PD

Knudtson

ML

Ghali

WA

Investigators A

,

Outcomes associated with bilateral internal thoracic artery grafting: the importance of age

,

Ann Thorac Surg

,

2011

, vol.

92

(4):1269–1275; discussion

(pg.

1275

-

1276

)

642

Desai

ND

Cohen

EA

Naylor

CD

Fremes

SE

,

A Randomized Comparison of Radial-Artery and Saphenous-Vein Coronary Bypass Grafts

,

N Engl J Med

,

2004

, vol.

351

(pg.

2302

-

2309

)

643

Tatoulis

J

,

Total arterial coronary revascularization-patient selection, stenoses, conduits, targets

,

Ann Cardiothorac Surg

,

2013

, vol.

2

4

(pg.

499

-

506

)

644

Borgermann

J

Hakim

K

Renner

A

Parsa

A

Aboud

A

Becker

T

Masshoff

M

Zittermann

A

Gummert

JF

Kuss

O

,

Clampless off-pump vs. conventional coronary artery revascularization: a propensity score analysis of 788 patients

,

Circulation

,

2012

, vol.

126

(11 Suppl 1)

S176–182

645

Brophy

JM

Belisle

P

Joseph

L

,

Evidence for use of coronary stents. A hierarchical bayesian meta-analysis

,

Ann Intern Med

,

2003

, vol.

138

10

(pg.

777

-

786

)

646

Kastrati

A

Mehilli

J

Dirschinger

J

Dotzer

F

Schuhlen

H

Neumann

FJ

Fleckenstein

M

Pfafferott

C

Seyfarth

M

Schomig

A

,

Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial

,

Circulation

,

2001

, vol.

103

23

(pg.

2816

-

2821

)

647

Pache

J

Kastrati

A

Mehilli

J

Schuhlen

H

Dotzer

F

Hausleiter

J

Fleckenstein

M

Neumann

FJ

Sattelberger

U

Schmitt

C

Muller

M

Dirschinger

J

Schomig

A

,

Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial

,

J Am Coll Cardiol

,

2003

, vol.

41

8

(pg.

1283

-

1288

)

648

Mehran

R

Baber

U

Steg

PG

Ariti

C

Weisz

G

Witzenbichler

B

Henry

TD

Kini

AS

Stuckey

T

Cohen

DJ

Berger

PB

Iakovou

I

Dangas

G

Waksman

R

Antoniucci

D

Sartori

S

Krucoff

MW

Hermiller

JB

Shawl

F

Gibson

CM

Chieffo

A

Alu

M

Moliterno

DJ

Colombo

A

Pocock

S

,

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study

,

Lancet

,

2013

, vol.

382

9906

(pg.

1714

-

1722

)

649

Kastrati

A

Mehilli

J

Pache

J

Kaiser

C

Valgimigli

M

Kelbaek

H

Menichelli

M

Sabate

M

Suttorp

MJ

Baumgart

D

Seyfarth

M

Pfisterer

ME

Schomig

A

,

Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents

,

N Engl J Med

,

2007

, vol.

356

10

(pg.

1030

-

1039

)

650

Stone

GW

Moses

JW

Ellis

SG

Schofer

J

Dawkins

KD

Morice

MC

Colombo

A

Schampaert

E

Grube

E

Kirtane

AJ

Cutlip

DE

Fahy

M

Pocock

SJ

Mehran

R

Leon

MB

,

Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents

,

N Engl J Med

,

2007

, vol.

356

10

(pg.

998

-

1008

)

651

Daemen

J

Wenaweser

P

Tsuchida

K

Abrecht

L

Vaina

S

Morger

C

Kukreja

N

Juni

P

Sianos

G

Hellige

G

van Domburg

RT

Hess

OM

Boersma

E

Meier

B

Windecker

S

Serruys

PW

,

Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study

,

Lancet

,

2007

, vol.

369

9562

(pg.

667

-

678

)

652

De Luca

G

Dirksen

MT

Spaulding

C

Kelbaek

H

Schalij

M

Thuesen

L

van der Hoeven

B

Vink

MA

Kaiser

C

Musto

C

Chechi

T

Spaziani

G

Diaz de la Llera

LS

Pasceri

V

Di Lorenzo

E

Violini

R

Cortese

G

Suryapranata

H

Stone

GW

,

Drug-eluting vs.bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials

,

Arch Intern Med

,

2012

, vol.

172

8

(pg.

611

-

621

)

discussion 621–622

653

Nabel

EG

Braunwald

E

,

A tale of coronary artery disease and myocardial infarction

,

N Engl J Med

,

2012

, vol.

366

1

(pg.

54

-

63

)

654

Stone

GW

Rizvi

A

Newman

W

Mastali

K

Wang

JC

Caputo

R

Doostzadeh

J

Cao

S

Simonton

CA

Sudhir

K

Lansky

AJ

Cutlip

DE

Kereiakes

DJ

,

Everolimus-eluting vs. paclitaxel-eluting stents in coronary artery disease

,

N Engl J Med

,

2010

, vol.

362

18

(pg.

1663

-

1674

)

655

Serruys

PW

Silber

S

Garg

S

van Geuns

RJ

Richardt

G

Buszman

PE

Kelbaek

H

van Boven

AJ

Hofma

SH

Linke

A

Klauss

V

Wijns

W

Macaya

C

Garot

P

DiMario

C

Manoharan

G

Kornowski

R

Ischinger

T

Bartorelli

A

Ronden

J

Bressers

M

Gobbens

P

Negoita

M

van Leeuwen

F

Windecker

S

,

Comparison of zotarolimus-eluting and everolimus-eluting coronary stents

,

N Engl J Med

,

2010

, vol.

363

2

(pg.

136

-

146

)

656

Christiansen

EH

Jensen

LO

Thayssen

P

Tilsted

HH

Krusell

LR

Hansen

KN

Kaltoft

A

Maeng

M

Kristensen

SD

Botker

HE

Terkelsen

CJ

Villadsen

AB

Ravkilde

J

Aaroe

J

Madsen

M

Thuesen

L

Lassen

JF

,

Biolimus-eluting biodegradable polymer-coated stent vs. durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial

,

Lancet

,

2013

, vol.

381

9867

(pg.

661

-

669

)

657

Byrne

RA

Kastrati

A

Kufner

S

Massberg

S

Birkmeier

KA

Laugwitz

KL

Schulz

S

Pache

J

Fusaro

M

Seyfarth

M

Schomig

A

Mehilli

J

,

Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial

,

Eur Heart J

,

2009

, vol.

30

20

(pg.

2441

-

2449

)

658

Smits

PC

Hofma

S

Togni

M

Vazquez

N

Valdes

M

Voudris

V

Slagboom

T

Goy

JJ

Vuillomenet

A

Serra

A

Nouche

RT

den Heijer

P

van der Ent

M

,

Abluminal biodegradable polymer biolimus-eluting stent vs. durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial

,

Lancet

,

2013

, vol.

381

9867

(pg.

651

-

660

)

659

Massberg

S

Byrne

RA

Kastrati

A

Schulz

S

Pache

J

Hausleiter

J

Ibrahim

T

Fusaro

M

Ott

I

Schomig

A

Laugwitz

KL

Mehilli

J

,

Polymer-free sirolimus- and probucol-eluting vs. new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting vs. Zotarolimus-eluting Stents (ISAR-TEST 5) trial

,

Circulation

,

2011

, vol.

124

5

(pg.

624

-

632

)

660

Tada

N

Virmani

R

Grant

G

Bartlett

L

Black

A

Clavijo

C

Christians

U

Betts

R

Savage

D

Su

SH

Shulze

J

Kar

S

,

Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model

,

Circ Cardiovasc Interv

,

2010

, vol.

3

2

(pg.

174

-

183

)

661

Planer

D

Smits

PC

Kereiakes

DJ

Kedhi

E

Fahy

M

Xu

K

Serruys

PW

Stone

GW

,

Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials

,

JACC Cardiovasc Interv

,

2011

, vol.

4

10

(pg.

1104

-

1115

)

662

Park

KW

Kang

SH

Velders

MA

Shin

DH

Hahn

S

Lim

WH

Yang

HM

Lee

HY

Van Boven

AJ

Hofma

SH

Kang

HJ

Koo

BK

Oh

BH

Park

YB

Kandzari

DE

Kim

HS

,

Safety and efficacy of everolimus- vs. sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials

,

Am Heart J

,

2013

, vol.

165

2

241–250 e4

663

Hawn

MT

Graham

LA

Richman

JS

Itani

KM

Henderson

WG

Maddox

TM

,

Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents

,

JAMA

,

2013

, vol.

310

14

(pg.

1462

-

1472

)

664

Stone

GW

Teirstein

PS

Meredith

IT

Farah

B

Dubois

CL

Feldman

RL

Dens

J

Hagiwara

N

Allocco

DJ

Dawkins

KD

,

A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial

,

J Am Coll Cardiol

,

2011

, vol.

57

16

(pg.

1700

-

1708

)

665

von Birgelen

C

Sen

H

Lam

MK

Danse

PW

Jessurun

GA

Hautvast

RW

van Houwelingen

GK

Schramm

AR

Gin

RM

Louwerenburg

JW

de Man

FH

Stoel

MG

Lowik

MM

Linssen

GC

Said

SA

Nienhuis

MB

Verhorst

PM

Basalus

MW

Doggen

CJ

Tandjung

K

,

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

,

Lancet

,

2013

, vol.

383

9915

(pg.

413

-

423

)

666

von Birgelen

C

Basalus

MW

Tandjung

K

van Houwelingen

KG

Stoel

MG

Louwerenburg

JH

Linssen

GC

Said

SA

Kleijne

MA

Sen

H

Lowik

MM

van der Palen

J

Verhorst

PM

de Man

FH

,

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents vs. everolimus-eluting Xience V stents in real-world patients: the TWENTE trial

,

J Am Coll Cardiol

,

2012

, vol.

59

15

(pg.

1350

-

1361

)

667

Kedhi

E

Joesoef

KS

McFadden

E

Wassing

J

van Mieghem

C

Goedhart

D

Smits

PC

,

Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

,

Lancet

,

2010

, vol.

375

9710

(pg.

201

-

209

)

668

Windecker

S

Serruys

PW

Wandel

S

Buszman

P

Trznadel

S

Linke

A

Lenk

K

Ischinger

T

Klauss

V

Eberli

F

Corti

R

Wijns

W

Morice

MC

di Mario

C

Davies

S

van Geuns

RJ

Eerdmans

P

van Es

GA

Meier

B

Juni

P

,

Biolimus-eluting stent with biodegradable polymer vs. sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

,

Lancet

,

2008

, vol.

372

9644

(pg.

1163

-

1173

)

669

Natsuaki

M

Kozuma

K

Morimoto

T

Kadota

K

Muramatsu

T

Nakagawa

Y

Akasaka

T

Igarashi

K

Tanabe

K

Morino

Y

Ishikawa

T

Nishikawa

H

Awata

M

Abe

M

Okada

H

Takatsu

Y

Ogata

N

Kimura

K

Urasawa

K

Tarutani

Y

Shiode

N

Kimura

T

,

Biodegradable polymer biolimus-eluting stent vs. durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial

,

J Am Coll Cardiol

,

2013

, vol.

62

3

(pg.

181

-

190

)

670

Serruys

PW

Garg

S

Abizaid

A

Ormiston

J

Windecker

S

Verheye

S

Dubois

C

Stewart

J

Hauptmann

KE

Schofer

J

Stangl

K

Witzenbichler

B

Wiemer

M

Barbato

E

de Vries

T

den Drijver

AM

Otake

H

Meredith

L

Toyloy

S

Fitzgerald

P

,

A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study

,

EuroIntervention

,

2010

, vol.

6

2

(pg.

195

-

205

)

671

Verheye

S

Ramcharitar

S

Grube

E

Schofer

JJ

Witzenbichler

B

Kovac

J

Hauptmann

KE

Agostoni

P

Wiemer

M

Lefevre

T

Spaargaren

R

Serruys

PW

Garcia-Garcia

HM

van Geuns

RJ

,

Six-month clinical and angiographic results of the STENTYS(R) self-apposing stent in bifurcation lesions

,

EuroIntervention

,

2011

, vol.

7

5

(pg.

580

-

587

)

672

Verheye

S

Agostoni

P

Dubois

CL

Dens

J

Ormiston

J

Worthley

S

Trauthen

B

Hasegawa

T

Koo

BK

Fitzgerald

PJ

Mehran

R

Lansky

AJ

,

9-month clinical, angiographic, and intravascular ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side Branches Effectively) study

,

J Am Coll Cardiol

,

2009

, vol.

53

12

(pg.

1031

-

1039

)

673

Buysschaert

I

Dubois

CL

Dens

J

Ormiston

J

Worthley

S

McClean

D

Ottervanger

JP

Meredith

I

Uren

N

Wijns

W

Whitbourn

R

Mehran

R

Lansky

AJ

Bichalska

M

Meis

S

Verheye

S

,

Three-year clinical results of the Axxess Biolimus A9 eluting bifurcation stent system: the DIVERGE study

,

EuroIntervention

,

2013

, vol.

9

5

(pg.

573

-

581

)

674

Dani

S

Costa

RA

Joshi

H

Shah

J

Pandya

R

Virmani

R

Sheiban

I

Bhatt

S

Abizaid

A

,

First-in-human evaluation of the novel BioMime sirolimus-eluting coronary stent with bioabsorbable polymer for the treatment of single de novo lesions located in native coronary vessels - results from the meriT-1 trial

,

EuroIntervention

,

2013

, vol.

9

4

(pg.

493

-

500

)

675

Haude

M

Lee

SW

Worthley

SG

Silber

S

Verheye

S

Erbs

S

Rosli

MA

Botelho

R

Meredith

I

Sim

KH

Stella

PR

Tan

HC

Whitbourn

R

Thambar

S

Abizaid

A

Koh

TH

Den Heijer

P

Parise

H

Cristea

E

Maehara

A

Mehran

R

,

The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent

,

JACC Cardiovasc Interv

,

2013

, vol.

6

4

(pg.

334

-

343

)

676

Vranckx

P

Serruys

PW

Gambhir

S

Sousa

E

Abizaid

A

Lemos

P

Ribeiro

E

Dani

SI

Dalal

JJ

Mehan

V

Dhar

A

Dutta

AL

Reddy

KN

Chand

R

Ray

A

Symons

J

,

Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9-Month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study

,

EuroIntervention

,

2006

, vol.

2

3

(pg.

310

-

317

)

677

Ormiston

J

Webster

M

Stewart

J

Vrolix

M

Whitbourn

R

Donohoe

D

Knape

C

Lansky

A

Attizzani

GF

Fitzgerald

P

Kandzari

DE

Wijns

W

,

First-in-Human Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent: Imaging and Clinical Results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries)

,

JACC Cardiovasc Interv

,

2013

, vol.

6

10

(pg.

1026

-

1034

)

678

Dani

S

Kukreja

N

Parikh

P

Joshi

H

Prajapati

J

Jain

S

Thanvi

S

Shah

B

Dutta

JP

,

Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic, 30-month clinical follow-up results from the series I prospective study

,

EuroIntervention

,

2008

, vol.

4

1

(pg.

59

-

63

)

679

Seth

A

Chandra

P

Chouhan

NS

Thakkar

AS

,

A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients

,

Indian Heart J

,

2012

, vol.

64

6

(pg.

547

-

552

)

680

Meredith

IT

Verheye

S

Dubois

CL

Dens

J

Fajadet

J

Carrie

D

Walsh

S

Oldroyd

KG

Varenne

O

El-Jack

S

Moreno

R

Joshi

AA

Allocco

DJ

Dawkins

KD

,

Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent

,

J Am Coll Cardiol

,

2012

, vol.

59

15

(pg.

1362

-

1370

)

681

Carrie

D

Berland

J

Verheye

S

Hauptmann

KE

Vrolix

M

Violini

R

Dibie

A

Berti

S

Maupas

E

Antoniucci

D

Schofer

J

,

A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions

,

J Am Coll Cardiol

,

2012

, vol.

59

15

(pg.

1371

-

1376

)

682

Mehilli

J

Kastrati

A

Wessely

R

Dibra

A

Hausleiter

J

Jaschke

B

Dirschinger

J

Schomig

A

,

Randomized trial of a nonpolymer-based rapamycin-eluting stent vs. a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss

,

Circulation

,

2006

, vol.

113

2

(pg.

273

-

279

)

683

Byrne

RA

Iijima

R

Mehilli

J

Pinieck

S

Bruskina

O

Schomig

A

Kastrati

A

,

Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer

,

JACC Cardiovasc Interv

,

2009

, vol.

2

4

(pg.

291

-

299

)

684

Garg

S

Bourantas

C

Serruys

PW

,

New concepts in the design of drug-eluting coronary stents

,

Nat Rev Cardiol

,

2013

, vol.

10

5

(pg.

248

-

260

)

685

Ormiston

JA

Serruys

PW

Regar

E

Dudek

D

Thuesen

L

Webster

MW

Onuma

Y

Garcia-Garcia

HM

McGreevy

R

Veldhof

S

,

A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial

,

Lancet

,

2008

, vol.

371

9616

(pg.

899

-

907

)

686

Serruys

PW

Ormiston

JA

Onuma

Y

Regar

E

Gonzalo

N

Garcia-Garcia

HM

Nieman

K

Bruining

N

Dorange

C

Miquel-Hebert

K

Veldhof

S

Webster

M

Thuesen

L

Dudek

D

,

A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods

,

Lancet

,

2009

, vol.

373

9667

(pg.

897

-

910

)

687

Haude

M

Erbel

R

Erne

P

Verheye

S

Degen

H

Bose

D

Vermeersch

P

Wijnbergen

I

Weissman

N

Prati

F

Waksman

R

Koolen

J

,

Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial

,

Lancet

,

2013

, vol.

381

9869

(pg.

836

-

844

)

688

Verheye

S

Ormiston

JA

Stewart

J

Webster

M

Sanidas

E

Costa

R

Costa

JR

Jr.

Chamie

D

Abizaid

AS

Pinto

I

Morrison

L

Toyloy

S

Bhat

V

Yan

J

Abizaid

A

,

A Next-Generation Bioresorbable Coronary Scaffold System-From Bench to First Clinical Evaluation: Six- and 12-Month Clinical and Multimodality Imaging Results

,

JACC Cardiovasc Interv

,

2013

, vol.

7

1

(pg.

89

-

99

)

689

Maier

LS

Maack

C

Ritter

O

Bohm

M

,

Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008. (PEPCAD, LokalTax, INH, German ablation registry, German device registry, DES.DE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN)

,

Clin Res Cardiol

,

2008

, vol.

97

6

(pg.

356

-

363

)

690

Fischer

D

Scheller

B

Schafer

A

Klein

G

Bohm

M

Clever

Y

Cremers

B

,

Paclitaxcel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study

,

EuroIntervention

,

2012

, vol.

8

4

(pg.

450

-

455

)

691

Belkacemi

A

Agostoni

P

Nathoe

HM

Voskuil

M

Shao

C

Van Belle

E

Wildbergh

T

Politi

L

Doevendans

PA

Sangiorgi

GM

Stella

PR

,

First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent vs. bare-metal stent vs. drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes

,

J Am Coll Cardiol

,

2012

, vol.

59

25

(pg.

2327

-

2337

)

692

Latib

A

Colombo

A

Castriota

F

Micari

A

Cremonesi

A

De Felice

F

Marchese

A

Tespili

M

Presbitero

P

Sgueglia

GA

Buffoli

F

Tamburino

C

Varbella

F

Menozzi

A

,

A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study

,

J Am Coll Cardiol

,

2012

, vol.

60

24

(pg.

2473

-

2480

)

693

Bondesson

P

Lagerqvist

B

James

SK

Olivecrona

GK

Venetsanos

D

Harnek

J

,

Comparison of two drug-eluting balloons: a report from the SCAAR registry

,

EuroIntervention

,

2012

, vol.

8

4

(pg.

444

-

449

)

694

Stella

PR

Belkacemi

A

Waksman

R

Stahnke

S

Torguson

R

von Strandmann

RP

Agostoni

P

Sangiorgi

G

Silber

S

,

The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment

,

EuroIntervention

,

2011

, vol.

7

6

(pg.

705

-

710

)

695

Waksman

R

Serra

A

Loh

JP

Malik

FT

Torguson

R

Stahnke

S

von Strandmann

RP

Rodriguez

AE

,

Drug-coated balloons for de novo coronary lesions: results from the Valentines II trial

,

EuroIntervention

,

2013

, vol.

9

5

(pg.

613

-

619

)

696

Gutierrez-Chico

JL

van Geuns

RJ

Koch

KT

Koolen

JJ

Duckers

H

Regar

E

Serruys

PW

,

Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first

,

EuroIntervention

,

2011

, vol.

7

6

(pg.

711

-

722

)

697

Hehrlein

C

Dietz

U

Kubica

J

Jorgensen

E

Hoffmann

E

Naber

C

Lesiak

M

Schneider

H

Wiemer

M

Tolg

R

Richardt

G

,

Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial

,

Cardiovasc Revasc Med

,

2012

, vol.

13

5

(pg.

260

-

264

)

698

Abdel-Wahab

M

Richardt

G

Joachim Buttner

H

Toelg

R

Geist

V

Meinertz

T

Schofer

J

King

L

Neumann

FJ

Khattab

AA

,

High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial

,

JACC Cardiovasc Interv

,

2013

, vol.

6

1

(pg.

10

-

19

)

699

Mintz

GS

Nissen

SE

Anderson

WD

Bailey

SR

Erbel

R

Fitzgerald

PJ

Pinto

FJ

Rosenfield

K

Siegel

RJ

Tuzcu

EM

Yock

PG

,

American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement, Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents

,

J Am Coll Cardiol

,

2001

, vol.

37

5

(pg.

1478

-

1492

)

700

Nissen

SE

Tuzcu

EM

Schoenhagen

P

Crowe

T

Sasiela

WJ

Tsai

J

Orazem

J

Magorien

RD

O'Shaughnessy

C

Ganz

P

Reversal of Atherosclerosis with Aggressive Lipid Lowering I

,

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

,

N Engl J Med

,

2005

, vol.

352

1

(pg.

29

-

38

)

701

Mintz

GS

Garcia-Garcia

HM

Nicholls

SJ

Weissman

NJ

Bruining

N

Crowe

T

Tardif

JC

Serruys

PW

,

Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies

,

EuroIntervention

,

2011

, vol.

6

(9):1123–1130, 9

702

Casella

G

Klauss

V

Ottani

F

Siebert

U

Sangiorgio

P

Bracchetti

D

,

Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: a meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting

,

Catheter Cardiovasc Interv

,

2003

, vol.

59

3

(pg.

314

-

321

)

703

Parise

H

Maehara

A

Stone

GW

Leon

MB

Mintz

GS

,

Meta-analysis of randomized studies comparing intravascular ultrasound vs. angiographic guidance of percutaneous coronary intervention in pre-drug-eluting stent era

,

Am J Cardiol

,

2011

, vol.

107

3

(pg.

374

-

382

)

704

Zhang

Y

Farooq

V

Garcia-Garcia

HM

Bourantas

CV

Tian

N

Dong

S

Li

M

Yang

S

Serruys

PW

Chen

SL

,

Comparison of intravascular ultrasound vs. angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients

,

EuroIntervention

,

2012

, vol.

8

7

(pg.

855

-

865

)

705

Park

SJ

Kim

YH

Park

DW

Lee

SW

Kim

WJ

Suh

J

Yun

SC

Lee

CW

Hong

MK

Lee

JH

Park

SW

,

Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis

,

Circ Cardiovasc Interv

,

2009

, vol.

2

3

(pg.

167

-

177

)

706

Witzenbichler

B

Maehara

A

Weisz

G

Neumann

FJ

Rinaldi

MJ

Metzger

DC

Henry

TD

Cox

DA

Duffy

PL

Brodie

BR

Stuckey

TD

Mazzaferri

EL

Jr.

Xu

K

Parise

H

Mehran

R

Mintz

GS

Stone

GW

,

Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents: The Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Study

,

Circulation

,

2014

, vol.

129

4

(pg.

463

-

470

)

707

Tearney

GJ

Regar

E

Akasaka

T

Adriaenssens

T

Barlis

P

Bezerra

HG

Bouma

B

Bruining

N

Cho

JM

Chowdhary

S

Costa

MA

de Silva

R

Dijkstra

J

Di Mario

C

Dudek

D

Falk

E

Feldman

MD

Fitzgerald

P

Garcia-Garcia

HM

Gonzalo

N

Granada

JF

Guagliumi

G

Holm

NR

Honda

Y

Ikeno

F

Kawasaki

M

Kochman

J

Koltowski

L

Kubo

T

Kume

T

Kyono

H

Lam

CC

Lamouche

G

Lee

DP

Leon

MB

Maehara

A

Manfrini

O

Mintz

GS

Mizuno

K

Morel

MA

Nadkarni

S

Okura

H

Otake

H

Pietrasik

A

Prati

F

Raber

L

Radu

MD

Rieber

J

Riga

M

Rollins

A

Rosenberg

M

Sirbu

V

Serruys

PW

Shimada

K

Shinke

T

Shite

J

Siegel

E

Sonoda

S

Suter

M

Takarada

S

Tanaka

A

Terashima

M

Thim

T

Uemura

S

Ughi

GJ

van Beusekom

HM

van der Steen

AF

van Es

GA

van Soest

G

Virmani

R

Waxman

S

Weissman

NJ

Weisz

G

International Working Group for Intravascular Optical Coherence T

,

Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation

,

J Am Coll Cardiol

,

2012

, vol.

59

12

(pg.

1058

-

1072

)

708

Cassar

A

Matsuo

Y

Herrmann

J

Li

J

Lennon

RJ

Gulati

R

Lerman

LO

Kushwaha

SS

Lerman

A

,

Coronary atherosclerosis with vulnerable plaque and complicated lesions in transplant recipients: new insight into cardiac allograft vasculopathy by optical coherence tomography

,

Eur Heart J

,

2013

, vol.

34

33

(pg.

2610

-

2617

)

709

Prati

F

Guagliumi

G

Mintz

GS

Costa

M

Regar

E

Akasaka

T

Barlis

P

Tearney

GJ

Jang

IK

Arbustini

E

Bezerra

HG

Ozaki

Y

Bruining

N

Dudek

D

Radu

M

Erglis

A

Motreff

P

Alfonso

F

Toutouzas

K

Gonzalo

N

Tamburino

C

Adriaenssens

T

Pinto

F

Serruys

PW

Di Mario

C

,

Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures

,

Eur Heart J

,

2012

, vol.

33

20

(pg.

2513

-

2520

)

710

Radu

MD

Raber

L

Heo

J

Gogas

BD

Jorgensen

E

Kelbaek

H

Muramatsu

T

Farooq

V

Helqvist

S

Garcia-Garcia

HM

Windecker

S

Saunamaki

K

Serruys

PW

,

Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation

,

EuroIntervention

,

2014

, vol.

9

(pg.

1085

-

1094

)

711

Prati

F

Di Vito

L

Biondi-Zoccai

G

Occhipinti

M

La Manna

A

Tamburino

C

Burzotta

F

Trani

C

Porto

I

Ramazzotti

V

Imola

F

Manzoli

A

Materia

L

Cremonesi

A

Albertucci

M

,

Angiography alone vs. angiography plus optical coherence tomography to guide decision-making during percutaneous coronary intervention: the Centro per la Lotta contro l'Infarto-Optimisation of Percutaneous Coronary Intervention (CLI-OPCI) study

,

EuroIntervention

,

2012

, vol.

8

7

(pg.

823

-

829

)

712

Kang

SJ

Mintz

GS

Akasaka

T

Park

DW

Lee

JY

Kim

WJ

Lee

SW

Kim

YH

Whan Lee

C

Park

SW

Park

SJ

,

Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation

,

Circulation

,

2011

, vol.

123

25

(pg.

2954

-

2963

)

713

Pijls

NH

De Bruyne

B

Peels

K

Van Der Voort

PH

Bonnier

HJ

Bartunek

JKJJ

Koolen

JJ

,

Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses

,

N Engl J Med

,

1996

, vol.

334

26

(pg.

1703

-

1708

)

714

Sen

S

Escaned

J

Malik

IS

Mikhail

GW

Foale

RA

Mila

R

Tarkin

J

Petraco

R

Broyd

C

Jabbour

R

Sethi

A

Baker

CS

Bellamy

M

Al-Bustami

M

Hackett

D

Khan

M

Lefroy

D

Parker

KH

Hughes

AD

Francis

DP

Di Mario

C

Mayet

J

Davies

JE

,

Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study

,

J Am Coll Cardiol

,

2012

, vol.

59

15

(pg.

1392

-

1402

)

715

Nakazato

R

Park

HB

Berman

DS

Gransar

H

Koo

BK

Erglis

A

Lin

FY

Dunning

AM

Budoff

MJ

Malpeso

J

Leipsic

J

Min

JK

,

Non-invasive Fractional Flow Reserve Derived from CT Angiography (FFRCT) for Coronary Lesions of Intermediate Stenosis Severity: Results from the DeFACTO study

,

Circ Cardiovasc Imaging

,

2013

, vol.

6

(pg.

881

-

889

)

716

Koo

BK

Erglis

A

Doh

JH

Daniels

DV

Jegere

S

Kim

HS

Dunning

A

DeFrance

T

Lansky

A

Leipsic

J

Min

JK

,

Diagnosis of ischemia-causing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms. Results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study

,

J Am Coll Cardiol

,

2011

, vol.

58

19

(pg.

1989

-

1997

)

717

Patel

Y

Depta

JP

Novak

E

Yeung

M

Lavine

K

Banerjee

S

Lin

CH

Zajarias

A

Kurz

HI

Lasala

JM

Bach

RG

Singh

J

,

Long-term outcomes with use of intravascular ultrasound for the treatment of coronary bifurcation lesions

,

Am J Cardiol

,

2012

, vol.

109

7

(pg.

960

-

965

)

718

Myler

RK

Shaw

RE

Stertzer

SH

Hecht

HS

Ryan

C

Rosenblum

J

Cumberland

DC

Murphy

MC

Hansell

HN

Hidalgo

B

,

Lesion morphology and coronary angioplasty: current experience and analysis

,

J Am Coll Cardiol

,

1992

, vol.

19

7

(pg.

1641

-

1652

)

719

Steigen

TK

Maeng

M

Wiseth

R

Erglis

A

Kumsars

I

Narbute

I

Gunnes

P

Mannsverk

J

Meyerdierks

O

Rotevatn

S

Niemela

M

Kervinen

K

Jensen

JS

Galloe

A

Nikus

K

Vikman

S

Ravkilde

J

James

S

Aaroe

J

Ylitalo

A

Helqvist

S

Sjogren

I

Thayssen

P

Virtanen

K

Puhakka

M

Airaksinen

J

Lassen

JF

Thuesen

L

,

Randomized study on simple vs. complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study

,

Circulation

,

2006

, vol.

114

18

(pg.

1955

-

1961

)

720

Latib

A

Colombo

A

,

Bifurcation disease: what do we know, what should we do?

,

JACC Cardiovasc Interv

,

2008

, vol.

1

3

(pg.

218

-

226

)

721

Al Suwaidi

J

Yeh

W

Cohen

HA

Detre

KM

Williams

DO

Holmes

DR

Jr.

,

Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry)

,

Am J Cardiol

,

2001

, vol.

87

10

(pg.

1139

-

1144

)

722

Stinis

CT

Hu

SP

Price

MJ

Teirstein

PS

,

Three-year outcome of drug-eluting stent implantation for coronary artery bifurcation lesions

,

Catheter Cardiovasc Interv

,

2010

, vol.

75

3

(pg.

309

-

314

)

723

Iakovou

I

Schmidt

T

Bonizzoni

E

Ge

L

Sangiorgi

GM

Stankovic

G

Airoldi

F

Chieffo

A

Montorfano

M

Carlino

M

Michev

I

Corvaja

N

Briguori

C

Gerckens

U

Grube

E

Colombo

A

,

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents

,

JAMA

,

2005

, vol.

293

17

(pg.

2126

-

2130

)

724

Colombo

A

Moses

JW

Morice

MC

Ludwig

J

Holmes

DR

Jr.

Spanos

V

Louvard

Y

Desmedt

B

Di Mario

C

Leon

MB

,

Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions

,

Circulation

,

2004

, vol.

109

10

(pg.

1244

-

1249

)

725

Iakovou

I

Ge

L

Colombo

A

,

Contemporary stent treatment of coronary bifurcations

,

J Am Coll Cardiol

,

2005

, vol.

46

8

(pg.

1446

-

1455

)

726

Maeng

M

Holm

NR

Erglis

A

Kumsars

I

Niemela

M

Kervinen

K

Jensen

JS

Galloe

A

Steigen

TK

Wiseth

R

Narbute

I

Gunnes

P

Mannsverk

J

Meyerdierks

O

Rotevatn

S

Nikus

K

Vikman

S

Ravkilde

J

James

S

Aaroe

J

Ylitalo

A

Helqvist

S

Sjogren

I

Thayssen

P

Virtanen

K

Puhakka

M

Airaksinen

J

Christiansen

EH

Lassen

JF

Thuesen

L

,

Long-term results after simple vs. complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results

,

J Am Coll Cardiol

,

2013

, vol.

62

1

(pg.

30

-

34

)

727

Ferenc

M

Gick

M

Kienzle

RP

Bestehorn

HP

Werner

KD

Comberg

T

Zhao

M

Buettner

HJ

Neumann

FJ

,

Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents

,

Am Heart J

,

2010

, vol.

159

3

(pg.

454

-

461

)

728

Hildick-Smith

D

de Belder

AJ

Cooter

N

Curzen

NP

Clayton

TC

Oldroyd

KG

Bennett

L

Holmberg

S

Cotton

JM

Glennon

PE

Thomas

MR

Maccarthy

PA

Baumbach

A

Mulvihill

NT

Henderson

RA

Redwood

SR

Starkey

IR

Stables

RH

,

Randomized trial of simple vs. complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies

,

Circulation

,

2010

, vol.

121

10

(pg.

1235

-

1243

)

729

Behan

MW

Holm

NR

Curzen

NP

Erglis

A

Stables

RH

de Belder

AJ

Niemela

M

Cooter

N

Chew

DP

Steigen

TK

Oldroyd

KG

Jensen

JS

Lassen

JF

Thuesen

L

Hildick-Smith

D

,

Simple or complex stenting for bifurcation coronary lesions: a patient-level pooled-analysis of the Nordic Bifurcation Study and the British Bifurcation Coronary Study

,

Circ Cardiovasc Interv

,

2011

, vol.

4

1

(pg.

57

-

64

)

730

Chen

SL

Santoso

T

Zhang

JJ

Ye

F

Xu

YW

Fu

Q

Kan

J

Paiboon

C

Zhou

Y

Ding

SQ

Kwan

TW

,

A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush vs. Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial

,

J Am Coll Cardiol

,

2011

, vol.

57

8

(pg.

914

-

920

)

731

Assali

AR

Vaknin-Assa

H

Lev

E

Teplitsky

I

Dvir

D

Brosh

D

Bental

T

Battler

A

Kornowski

R

,

Drug eluting stenting in bifurcation coronary lesions long-term results applying a systematic treatment strategy

,

Catheter Cardiovasc Interv

,

2012

, vol.

79

4

(pg.

615

-

622

)

732

Song

YB

Hahn

JY

Song

PS

Yang

JH

Choi

JH

Choi

SH

Lee

SH

Gwon

HC

,

Randomized comparison of conservative vs. aggressive strategy for provisional side branch intervention in coronary bifurcation lesions: results from the SMART-STRATEGY (Smart Angioplasty Research Team-Optimal Strategy for Side Branch Intervention in Coronary Bifurcation Lesions) randomized trial

,

JACC Cardiovasc Interv

,

2012

, vol.

5

11

(pg.

1133

-

1140

)

733

Niemela

M

Kervinen

K

Erglis

A

Holm

NR

Maeng

M

Christiansen

EH

Kumsars

I

Jegere

S

Dombrovskis

A

Gunnes

P

Stavnes

S

Steigen

TK

Trovik

T

Eskola

M

Vikman

S

Romppanen

H

Makikallio

T

Hansen

KN

Thayssen

P

Aberge

L

Jensen

LO

Hervold

A

Airaksinen

J

Pietila

M

Frobert

O

Kellerth

T

Ravkilde

J

Aaroe

J

Jensen

JS

Helqvist

S

Sjogren

I

James

S

Miettinen

H

Lassen

JF

Thuesen

L

,

Randomized comparison of final kissing balloon dilatation vs. no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III

,

Circulation

,

2011

, vol.

123

1

(pg.

79

-

86

)

734

Gwon

HC

Hahn

JY

Koo

BK

Song

YB

Choi

SH

Choi

JH

Lee

SH

Jeong

MH

Kim

HS

Seong

IW

Yang

JY

Rha

SW

Jang

Y

Yoon

JH

Tahk

SJ

Seung

KB

Park

SJ

,

Final kissing ballooning and long-term clinical outcomes in coronary bifurcation lesions treated with 1-stent technique: results from the COBIS registry. Heart

,

2012

, vol.

98

3

(pg.

225

-

231

)

735

Mylotte

D

Meftout

B

Moynagh

A

Vaquerizo

B

Darremont

O

Silvestri

M

Louvard

Y

Leymarie

JL

Morice

MC

Lefevre

T

Garot

P

,

Unprotected left main stenting in the real world: five-year outcomes of the French Left Main Taxus registry

,

EuroIntervention

,

2012

, vol.

8

(pg.

970

-

981

)

736

Teirstein

PS

Price

MJ

,

Left main percutaneous coronary intervention

,

J Am Coll Cardiol

,

2012

, vol.

60

17

(pg.

1605

-

1613

)

737

Chen

SL

Zhang

Y

Xu

B

Ye

F

Zhang

J

Tian

N

Liu

Z

Qian

X

Ding

S

Li

F

Zhang

A

Liu

Y

Lin

S

,

Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent vs. two-stent techniques vs. double-kissing crush technique

,

EuroIntervention

,

2012

, vol.

8

7

(pg.

803

-

14

)

738

Di Mario

C

Werner

GS

Sianos

G

Galassi

AR

Buttner

J

Dudek

D

Chevalier

B

Lefevre

T

Schofer

J

Koolen

J

Sievert

H

Reimers

B

Fajadet

J

Colombo

A

Gershlick

A

Serruys

PW

Reifart

N

,

European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club

,

EuroIntervention

,

2007

, vol.

3

1

(pg.

30

-

43

)

739

Christofferson

RD

Lehmann

KG

Martin

GV

Every

N

Caldwell

JH

Kapadia

SR

,

Effect of chronic total coronary occlusion on treatment strategy

,

Am J Cardiol

,

2005

, vol.

95

9

(pg.

1088

-

1091

)

740

Claessen

BE

Dangas

GD

Godino

C

Lee

SW

Obunai

K

Carlino

M

Suh

JW

Leon

MB

Di Mario

C

Park

SJ

Stone

GW

Moses

JW

Colombo

A

Mehran

R

,

Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with vs. without diabetes mellitus

,

Am J Cardiol

,

2011

, vol.

108

7

(pg.

924

-

931

)

741

Mehran

R

Claessen

BE

Godino

C

Dangas

GD

Obunai

K

Kanwal

S

Carlino

M

Henriques

JP

Di Mario

C

Kim

YH

Park

SJ

Stone

GW

Leon

MB

Moses

JW

Colombo

A

,

Long-term outcome of percutaneous coronary intervention for chronic total occlusions

,

JACC Cardiovasc Interv

,

2011

, vol.

4

9

(pg.

952

-

961

)

742

Jones

DA

Weerackody

R

Rathod

K

Behar

J

Gallagher

S

Knight

CJ

Kapur

A

Jain

AK

Rothman

MT

Thompson

CA

Mathur

A

Wragg

A

Smith

EJ

,

Successful recanalization of chronic total occlusions is associated with improved long-term survival

,

JACC Cardiovasc Interv

,

2012

, vol.

5

4

(pg.

380

-

388

)

743

Joyal

D

Afilalo

J

Rinfret

S

,

Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis

,

Am Heart J

,

2010

, vol.

160

1

(pg.

179

-

187

)

744

Hannan

EL

Racz

M

Holmes

DR

King

SB

3rd

Walford

G

Ambrose

JA

Sharma

S

Katz

S

Clark

LT

Jones

RH

,

Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era

,

Circulation

,

2006

, vol.

113

20

(pg.

2406

-

2412

)

745

Grantham

JA

Jones

PG

Cannon

L

Spertus

JA

,

Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the FlowCardia’s Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial

,

Circ Cardiovasc Qual Outcomes

,

2010

, vol.

3

(pg.

284

-

290

)

746

Werner

GS

Hochadel

M

Zeymer

U

Kerber

S

Schumacher

B

Grube

E

Hauptmann

KE

Brueck

M

Zahn

R

Senges

J

,

Contemporary success and complication rates of percutaneous coronary intervention for chronic total coronary occlusions: results from the ALKK quality control registry of 2006

,

EuroIntervention

,

2010

, vol.

6

3

(pg.

361

-

366

)

747

Fefer

P

Knudtson

ML

Cheema

AN

Galbraith

PD

Osherov

AB

Yalonetsky

S

Gannot

S

Samuel

M

Weisbrod

M

Bierstone

D

Sparkes

JD

Wright

GA

Strauss

BH

,

Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry

,

J Am Coll Cardiol

,

2012

, vol.

59

11

(pg.

991

-

997

)

748

Morino

Y

Kimura

T

Hayashi

Y

Muramatsu

T

Ochiai

M

Noguchi

Y

Kato

K

Shibata

Y

Hiasa

Y

Doi

O

Yamashita

T

Morimoto

T

Abe

M

Hinohara

T

Mitsudo

K

,

In-hospital outcomes of contemporary percutaneous coronary intervention in patients with chronic total occlusion insights from the J-CTO Registry (Multicenter CTO Registry in Japan)

,

JACC Cardiovasc Interv

,

2010

, vol.

3

2

(pg.

143

-

151

)

749

Surmely

JF

Tsuchikane

E

Katoh

O

Nishida

Y

Nakayama

M

Nakamura

S

Oida

A

Hattori

E

Suzuki

T

,

New concept for CTO recanalization using controlled antegrade and retrograde subintimal tracking: the CART technique

,

J Invasive Cardiol

,

2006

, vol.

18

7

(pg.

334

-

338

)

750

Sianos

G

Barlis

P

Di Mario

C

Papafaklis

MI

Buttner

J

Galassi

AR

Schofer

J

Werner

G

Lefevre

T

Louvard

Y

Serruys

PW

Reifart

N

,

European experience with the retrograde approach for the recanalisation of coronary artery chronic total occlusions. A report on behalf of the euroCTO club

,

EuroIntervention

,

2008

, vol.

4

1

(pg.

84

-

92

)

751

Colmenarez

HJ

Escaned

J

Fernandez

C

Lobo

L

Cano

S

del Angel

JG

Alfonso

F

Jimenez

P

Banuelos

C

Gonzalo

N

Garcia

E

Hernandez

R

Macaya

C

,

Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis

,

J Am Coll Cardiol

,

2010

, vol.

55

17

(pg.

1854

-

1866

)

752

Saeed

B

Kandzari

DE

Agostoni

P

Lombardi

WL

Rangan

BV

Banerjee

S

Brilakis

ES

,

Use of drug-eluting stents for chronic total occlusions: a systematic review and meta-analysis

,

Catheter Cardiovasc Interv

,

2011

, vol.

77

3

(pg.

315

-

332

)

753

Van den Branden BJ, Rahel BM, Laarman GJ, Slagboom T, Kelder JC, Ten Berg JM, Suttorp MJ

,

Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study)

,

EuroIntervention

,

2012

, vol.

7

10

(pg.

1189

-

1196

)

754

Patel

MR

Marso

SP

Dai

D

Anstrom

KJ

Shunk

KA

Curtus

JP

Brennan

JM

Sedrakyan

A

Messenger

JC

Douglas

PS

,

Comparative effectiveness of drug-eluting vs. bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005–2008

,

JACC Cardiovasc Interv

,

2012

, vol.

5

10

(pg.

1054

-

1061

)

755

Jokhi

P

Curzen

N

,

Percutaneous coronary intervention of ostial lesions

,

EuroIntervention

,

2009

, vol.

5

4

(pg.

511

-

514

)

756

Pritchard

CL

Mudd

JG

Barner

HB

,

Coronary ostial stenosis

,

Circulation

,

1975

, vol.

52

1

(pg.

46

-

48

)

757

Thompson

R

,

Isolated coronary ostial stenosis in women

,

J Am Coll Cardiol

,

1986

, vol.

7

5

(pg.

997

-

1003

)

758

Miller

GA

Honey

M

el-Sayed

H

,

Isolated coronary ostial stenosis

,

Cathet Cardiovasc Diagn

,

1986

, vol.

12

1

(pg.

30

-

34

)

759

Rissanen

V

,

Occurrence of coronary ostial stenosis in a necropsy series of myocardial infarction, sudden death, and violent death

,

Br Heart J

,

1975

, vol.

37

2

(pg.

182

-

191

)

760

Popma

JJ

Dick

RJ

Haudenschild

CC

Topol

EJ

Ellis

SG

,

Atherectomy of right coronary ostial stenoses: initial and long-term results, technical features and histologic findings

,

Am J Cardiol

,

1991

, vol.

67

5

(pg.

431

-

433

)

761

Koh

JS

Koo

BK

Kim

JH

Yang

HM

Park

KW

Kang

HJ

Kim

HS

Oh

BH

Park

YB

,

Relationship between fractional flow reserve and angiographic and intravascular ultrasound parameters in ostial lesions: major epicardial vessel vs. side branch ostial lesions

,

JACC Cardiovasc Interv

,

2012

, vol.

5

4

(pg.

409

-

415

)

762

Muramatsu

T

Tsukahara

R

Ho

M

Ito

S

Inoue

T

Akimoto

T

Hirano

K

,

Efficacy of cutting balloon angioplasty for lesions at the ostium of the coronary arteries

,

J Invasive Cardiol

,

1999

, vol.

11

4

(pg.

201

-

206

)

763

Kurbaan

AS

Kelly

PA

Sigwart

U

,

Cutting balloon angioplasty and stenting for aorto-ostial lesions. Heart

,

1997

, vol.

77

4

(pg.

350

-

352

)

764

Chung

CM

Nakamura

S

Tanaka

K

Tanigawa

J

Kitano

K

Akiyama

T

Matoba

Y

Katoh

O

,

Comparison of cutting balloon vs. stenting alone in small branch ostial lesions of native coronary arteries

,

Circ J

,

2003

, vol.

67

1

(pg.

21

-

25

)

765

Popma

JJ

Brogan

WC

3rd

Pichard

AD

Satler

LF

Kent

KM

Mintz

GS

Leon

MB

,

Rotational coronary atherectomy of ostial stenoses

,

Am J Cardiol

,

1993

, vol.

71

5

(pg.

436

-

438

)

766

Schwartz

L

Morsi

A

,

The draw-back stent deployment technique: a strategy for the treatment of coronary branch ostial lesions

,

J Invasive Cardiol

,

2002

, vol.

14

2

(pg.

66

-

71

)

767

Szabo

S

Abramowitz

B

Vaitkus

P

,

New technique of aorto-ostial stent placement

,

Am J Cardiol

,

2005

, vol.

96

pg.

212H

768

Gutierrez-Chico

JL

Villanueva-Benito

I

Villanueva-Montoto

L

Vazquez-Fernandez

S

Kleinecke

C

Gielen

S

Iniguez-Romo

A

,

Szabo technique vs. conventional angiographic placement in bifurcations 010–001 of Medina and in aorto-ostial stenting: angiographic and procedural results

,

EuroIntervention

,

2010

, vol.

5

7

(pg.

801

-

808

)

769

Park

DW

Hong

MK

Suh

IW

Hwang

ES

Lee

SW

Jeong

YH

Kim

YH

Lee

CW

Kim

JJ

Park

SW

Park

SJ

,

Results and predictors of angiographic restenosis and long-term adverse cardiac events after drug-eluting stent implantation for aorto-ostial coronary artery disease

,

Am J Cardiol

,

2007

, vol.

99

6

(pg.

760

-

765

)

770

Al-Lamee

R

Ielasi

A

Latib

A

Godino

C

Mussardo

M

Arioli

F

Figin

F

Piraino

D

Carlino

M

Montorfano

M

Chieffo

A

Colombo

A

,

Comparison of long-term clinical and angiographic outcomes following implantation of bare metal stents and drug-eluting stents in aorto-ostial lesions

,

Am J Cardiol

,

2011

, vol.

108

8

(pg.

1055

-

1060

)

771

Iakovou

I

Ge

L

Michev

I

Sangiorgi

GM

Montorfano

M

Airoldi

F

Chieffo

A

Stankovic

G

Vitrella

G

Carlino

M

Corvaja

N

Briguori

C

Colombo

A

,

Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions

,

J Am Coll Cardiol

,

2004

, vol.

44

5

(pg.

967

-

971

)

772

Lee

SW

Kim

SH

Kim

SO

Han

S

Kim

YH

Park

DW

Kang

SJ

Lee

CW

Park

SW

Park

SJ

,

Comparative long-term efficacy and safety of drug-eluting stent vs. coronary artery bypass grafting in ostial left main coronary artery disease: analysis of the MAIN-COMPARE registry

,

Catheter Cardiovasc Interv

,

2012

, vol.

80

2

(pg.

206

-

212

)

773

Silber

S

Albertsson

P

Aviles

FF

Camici

PG

Colombo

A

Hamm

C

Jorgensen

E

Marco

J

Nordrehaug

JE

Ruzyllo

W

Urban

P

Stone

GW

Wijns

W

,

Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology

,

Eur Heart J

,

2005

, vol.

26

(pg.

804

-

847

)

774

Patrono

C

Andreotti

F

Arnesen

H

Badimon

L

Baigent

C

Collet

JP

De Caterina

R

Gulba

D

Huber

K

Husted

S

Kristensen

SD

Morais

J

Neumann

FJ

Rasmussen

LH

Siegbahn

A

Steg

PG

Storey

RF

Van de Werf

F

F V

,

Antiplatelet agents for the treatment and prevention of atherothrombosis

,

Eur Heart J

,

2011

, vol.

32

23

(pg.

2922

-

2932

)

775

Patrono

C

Rodriguez

LA

Landolfi

R

Baigent

C

,

Low-Dose Aspirin for the Prevention of Atherothrombosis

,

N Eng J Med

,

2005

, vol.

353

(pg.

2373

-

2383

)

776

Antiplatelet

tc

,

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

,

BMJ

,

2002

, vol.

324

(pg.

71

-

86

)

777

Bellemain-Appaix

A

O'Connor

SA

Silvain

J

Cucherat

M

Beygui

F

Barthélémy

O

Collet

JP

Jacq

L

Bernasconi

F

Montalescot

G

,

Association of Clopidogrel Pretreatment With Mortality, Cardiovascular Events, and Major Bleeding Among Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

,

JAMA

,

2012

, vol.

308

23

(pg.

2507

-

2516

)

778

Price

MJ

Berger

PB

Teirstein

PS

Tanguay

JF

Angiolillo

DJ

Spriggs

D

Puri

S

Robbins

M

Garratt

KN

Bertrand

OF

Stillablower

ME

Aragon

JR

Kandzari

DE

Stinis

CT

Lee

MS

Manoukian

SV

Cannon

CP

Schork

NJ

Topol

EJ

for

GI

,

Standard- vs.high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

,

JAMA

,

2011

, vol.

305

11

(pg.

1097

-

1105

)

779

Grines

CL

Bonow

RO

Casey

DE

Jr.

Gardner

TJ

Lockhart

PB

Moliterno

DJ

O'Gara

P

Whitlow

P

American Heart A, American College of C, Society for Cardiovascular A, Interventions, American College of S, American Dental A, American College of P

,

Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians

,

Circulation

,

2007

, vol.

115

(pg.

813

-

818

)

780

Valgimigli

M

Percoco

G

Barbieri

D

Ferrari

F

Guardigli

G

Parrinello

G

Soukhomovskaia

O

Ferrari

R

,

The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial

,

J Am Coll Cardiol

,

2004

, vol.

44

1

(pg.

14

-

19

)

781

Biondi-Zoccai

G

Valgimigli

M

Margheri

M

Marzocchi

A

Lettieri

C

Stabile

A

Petronio

AS

Binetti

G

Bolognese

L

Bellone

P

Sardella

G

Contarini

M

Sheiban

I

Marra

S

Piscione

F

Romeo

F

Colombo

A

Sangiorgi

G

,

Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial

,

Am Heart J

,

2012

, vol.

163

(5):835.e1–e7

782

Kastrati

A

Mehilli

J

Schuhlen

H

Dirschinger

J

Dotzer

F

ten Berg

JM

Neumann

FJ

Bollwein

H

Volmer

C

Gawaz

M

Berger

PB

Schomig

A

Intracoronary

S

Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study I

,

A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel

,

N Engl J Med

,

2004

, vol.

350

3

(pg.

232

-

238

)

783

Lincoff

AM

Kleiman

NS

Kereiakes

DJ

Feit

F

Bittl

JA

Jackman

JD

Sarembock

IJ

Cohen

DJ

Spriggs

D

Ebrahimi

R

Keren

G

Carr

J

Cohen

EA

Betriu

A

Desmet

W

Rutsch

W

Wilcox

RG

de Feyter

PJ

Vahanian

A

Topol

EJ

,

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs.heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial

,

JAMA

,

2004

, vol.

292

6

(pg.

696

-

703

)

784

Kastrati

A

Neumann

FJ

Mehilli

J

Byrne

RA

Iijima

R

Buttner

HJ

Khattab

AA

Schulz

S

Blankenship

JC

Pache

J

Minners

J

Seyfarth

M

Graf

I

Skelding

KA

Dirschinger

J

Richardt

G

Berger

PB

Schomig

A

Investigators I-RT

,

Bivalirudin vs. unfractionated heparin during percutaneous coronary intervention

,

N Engl J Med

,

2008

, vol.

359

7

(pg.

688

-

696

)

785

Ndrepepa

G

Schulz

S

Keta

D

Mehilli

J

Birkmeier

A

Massberg

S

Laugwitz

K

Neumann

F

Seyfarth

M

Berger

P

Schömig

A

Kastrati

A

,

Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality

,

Am J Cardiol

,

2010

, vol.

105

2

(pg.

163

-

167

)

786

Montalescot

G

White

HD

Gallo

R

Cohen

M

Steg

PG

Aylward

PE

Bode

C

Chiariello

M

King

SB

3rd

Harrington

RA

Desmet

WJ

Macaya

C

Steinhubl

SR

,

Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention

,

N Engl J Med

,

2006

, vol.

355

10

(pg.

1006

-

1017

)

787

Montalescot

G

Gallo

R

White

HD

Cohen

M

Steg

PG

Aylward

PE

Bode

C

Chiariello

M

King

SB

3rd

Harrington

RA

Desmet

WJ

Macaya

C

Steinhubl

SR

,

Enoxaparin vs. unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial

,

JACC Cardiovasc Interv

,

2009

, vol.

2

11

(pg.

1083

-

1091

)

788

Silvain

J

Beygui

F

Barthélémy

O

Pollack

C

Jr.

Cohen

M

Zeymer

U

Huber

K

Goldstein

P

Cayla

G

Collet

J-P

Vicaut

E

Montalescot

G

,

Efficacy and safety of enoxaparin vs. unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

,

BMJ

,

2012

, vol.

344

789

Di Sciascio

G

Patti

G

Pasceri

V

Gatto

L

Colonna

G

Montinaro

A

,

Effectiveness of in-laboratory high-dose clopidogrel loading vs. routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial

,

J Am Coll Cardiol

,

2010

, vol.

56

7

(pg.

550

-

557

)

790

Montalescot

G

Sideris

G

Meuleman

C

Bal-dit-Sollier

C

Lellouche

N

Steg

PG

Slama

M

Milleron

O

Collet

JP

Henry

P

Beygui

F

Drouet

L

,

A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial

,

J Am Coll Cardiol

,

2006

, vol.

48

5

(pg.

931

-

938

)

791

Steinhubl

SR

Berger

S

Mann

JT

Fry

ETA

DeLago

A

Wilmer

C

Topol

EJ

for the Credo

I

,

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention

,

JAMA

,

2002

, vol.

288

(pg.

2411

-

2418

)

792

Widimsky

P

Motovska

Z

Simek

S

Kala

P

Pudil

R

Holm

F

Petr

R

Bilkova

D

Skalicka

H

Kuchynka

P

Poloczek

M

Miklik

R

Maly

M

Aschermann

M

,

Clopidogrel pre-treatment in stable angina: for all patients>6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8

,

Eur Heart J

,

2008

, vol.

29

12

(pg.

1495

-

1503

)

793

Collaborative overview of randomised trials of antiplatelet therapy:I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

,

Antiplatelet Trialists' Collaboration

,

BMJ(Clinical research ed.)

,

1994

, vol.

308

6921

(pg.

81

-

106

)

794

Baigent

C

Blackwell

L

Collins

R

Emberson

J

Godwin

J

Peto

R

Buring

J

Hennekens

C

Kearney

P

Meade

T

Patrono

C

Roncaglioni

MC

Zanchetti

A

,

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

,

Lancet

,

2009

, vol.

373

9678

(pg.

1849

-

1860

)

795

Bertrand

ME

Rupprecht

HJ

Urban

P

Gershlick

AH

,

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS)

,

Circulation

,

2000

, vol.

102

6

(pg.

624

-

629

)

796

Taniuchi

M

Kurz

HI

Lasala

JM

,

Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population

,

Circulation

,

2001

, vol.

104

5

(pg.

539

-

543

)

797

Muller

C

Buttner

HJ

Petersen

J

Roskamm

H

,

A randomized comparison of clopidogrel and aspirin vs. ticlopidine and aspirin after the placement of coronary-artery stents

,

Circulation

,

2000

, vol.

101

6

(pg.

590

-

593

)

798

von Beckerath

N

Taubert

D

Pogatsa-Murray

G

Schomig

E

Kastrati

A

Schomig

A

,

Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900 mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial

,

Circulation

,

2005

, vol.

112

19

(pg.

2946

-

2950

)

799

Valgimigli

M

Campo

G

Monti

M

Vranckx

P

Percoco

G

Tumscitz

C

Castriota

F

Colombo

F

Tebaldi

M

Fucà

G

Kubbajeh

Md

Cangiano

E

Minarelli

M

Scalone

A

Cavazza

C

Frangione

A

Borghesi

M

Marchesini

J

Parrinello

G

Ferrari

R

,

Short- vs. long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

,

Circulation

,

2012

, vol.

125

16

(pg.

2015

-

2026

)

800

Schömig

A

Neumann

FJ

Kastrati

A

Schühlen

H

Blasini

R

Hadamitzky

M

Walter

H

Zitzmann-Roth

EM

Richardt

G

Alt

E

Schmitt

C

Ulm

K

,

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

,

N Engl J Med

,

1996

, vol.

334

17

(pg.

1084

-

1089

)

801

Leon

MB

Baim

DS

Popma

JJ

Gordon

PC

Cutlip

DE

Ho

KK

Giambartolomei

A

Diver

DJ

Lasorda

DM

Williams

DO

Pocock

SJ

Kuntz

RE

,

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators

,

N Engl J Med

,

1998

, vol.

339

23

(pg.

1665

-

1671

)

802

Cassese

S

Byrne

RA

Tada

T

King

LA

Kastrati

A

,

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials

,

Eur Heart J

,

2012

, vol.

33

24

(pg.

3078

-

3087

)

803

Gwon

HC

Hahn

JY

Park

KW

Song

YB

Chae

IH

Lim

DS

Han

KR

Choi

JH

Choi

SH

Kang

HJ

Koo

BK

Ahn

T

Yoon

JH

Jeong

MH

Hong

TJ

Chung

WY

Choi

YJ

Hur

SH

Kwon

HM

Jeon

DW

Kim

BO

Park

SH

Lee

NH

Jeon

HK

Jang

Y

Kim

HS

,

Six-month vs. 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Vs. Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study

,

Circulation

,

2012

, vol.

125

3

(pg.

505

-

513

)

804

Feres

F

Costa

RA

Abizaid

A

Leon

MB

Marin-Neto

JA

Botelho

RV

King

SB

Negoita

M

Liu

M

de Paula

JE

Mangione

JA

Meireles

GX

Castello

HJ

Nicolela

E

Perin

MA

Devito

FS

Labrunie

A

Salvadori

D

Gusmão

M

Staico

R

Costa

JR

de Castro

JP

Abizaid

AS

Bhatt

DL

,

Three vs.Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial

,

JAMA

,

2013

, vol.

310

23

(pg.

2510

-

2522

)

805

Kim

BK

Hong

MK

Shin

DH

Nam

CM

Kim

JS

Ko

YG

Choi

D

Kang

TS

Park

BE

Kang

WC

Lee

SH

Yoon

JH

Hong

BK

Kwon

HM

Jang

Y

,

A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)

,

J Am Coll Cardiol

,

2012

, vol.

60

15

(pg.

1340

-

1348

)

806

Schulz

S

Mehilli

J

Neumann

FJ

Schuster

T

Massberg

S

Valina

C

Seyfarth

M

Pache

J

Laugwitz

KL

Buttner

HJ

Ndrepepa

G

Schomig

A

Kastrati

A

,

ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention

,

Eur Heart J

,

2010

, vol.

31

20

(pg.

2482

-

2491

)

807

Dumaine

R

Borentain

M

Bertel

O

Bode

C

Gallo

R

White

HD

Collet

JP

Steinhubl

SR

Montalescot

G

,

Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials

,

Arch Intern Med

,

2007

, vol.

167

22

(pg.

2423

-

2430

)

808

Mehran

R

Pocock

SJ

Stone

GW

Clayton

TC

Dangas

GD

Feit

F

et al. ,

Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial

,

Eur Heart J

,

2009

, vol.

30

(pg.

1457

-

1466

)

809

Subherwal

S

Bach

RG

Chen

AY

Gage

BF

Rao

SV

Newby

LK

Wang

TY

Gibler

WB

Ohman

EM

Roe

MT

Pollack

CV

Jr.

Peterson

ED

Alexander

KP

,

Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score

,

Circulation

,

2009

, vol.

119

14

(pg.

1873

-

1882

)

810

Pena

A

Collet

JP

Hulot

JS

Silvain

J

Barthélémy

O

Beygui

F

Funck-Brentano

C

Gilles

M

,

Can we override clopidogrel resistance?

,

Circulation

,

2009

, vol.

119

21

(pg.

2854

-

2858

)

811

Roe

MT

Armstrong

PW

Fox

KA

White

HD

Prabhakaran

D

Goodman

SG

Cornel

JH

Bhatt

DL

Clemmensen

P

Martinez

F

Ardissino

D

Nicolau

JC

Boden

WE

Gurbel

PA

Ruzyllo

W

Dalby

AJ

McGuire

DK

Leiva-Pons

JL

Parkhomenko

A

Gottlieb

S

Topacio

GO

Hamm

C

Pavlides

G

Goudev

AR

Oto

A

Tseng

CD

Merkely

B

Gasparovic

V

Corbalan

R

Cinteza

M

McLendon

RC

Winters

KJ

Brown

EB

Lokhnygina

Y

Aylward

PE

Huber

K

Hochman

JS

Ohman

EM

,

Prasugrel vs. clopidogrel for acute coronary syndromes without revascularization

,

N Engl J Med

,

2012

, vol.

367

14

(pg.

1297

-

1309

)

812

Mehta

S

Tanguay

JF

Eikelboom

JW

Jolly

SS

Joyner

CD

Granger

CB

Faxon

DP

Rupprecht

HJ

Budaj

A

Avezum

A

Widimsky

P

Steg

PG

Bassand

JP

Montalescot

G

Macaya

C

Di Pasquale

G

Niemela

K

Ajani

AE

White

HD

Chrolavicius

S

Gao

P

Fox

KAA

Yusuf

S

on behalf of the CI

,

Double-dose vs. standard-dose clopidogrel and high-dose vs. low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

,

Lancet

,

2010

, vol.

376

(pg.

1233

-

1243

)

813

Boersma

E

Harrington

RA

Moliterno

DJ

White

H

Theroux

P

Van de Werf

F

de Torbal

A

Armstrong

PW

Wallentin

LC

Wilcox

RG

Simes

J

Califf

RM

Topol

EJ

Simoons

ML

,

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

,

Lancet

,

2002

, vol.

359

9302

(pg.

189

-

198

)

814

Kastrati

A

Mehilli

J

Neumann

F-J

Dotzer

F

ten Berg

J

Bollwein

H

Graf

I

Ibrahim

M

Pache

J

Seyfarth

M

Schühlen

H

Dirschinger

J

Berger

PB

Schömig

A

,

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

,

JAMA

,

2006

, vol.

295

13

(pg.

1531

-

1538

)

815

Stone

GW

McLaurin

BT

Cox

DA

Bertrand

ME

Lincoff

AM

Moses

JW

White

HD

Pocock

SJ

Ware

JH

Feit

F

Colombo

A

Aylward

PE

Cequier

AR

Darius

H

Desmet

W

Ebrahimi

R

Hamon

M

Rasmussen

LH

Rupprecht

HJ

Hoekstra

J

Mehran

R

Ohman

EM

,

Bivalirudin for patients with acute coronary syndromes

,

N Engl J Med

,

2006

, vol.

355

21

(pg.

2203

-

2216

)

816

Stone

GW

Ware

JH

Bertrand

ME

Lincoff

AM

Moses

JW

Ohman

EM

White

HD

Feit

F

Colombo

A

McLaurin

BT

Cox

DA

Manoukian

SV

Fahy

M

Clayton

TC

Mehran

R

Pocock

SJ

,

Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial

,

JAMA

,

2007

, vol.

298

21

(pg.

2497

-

2506

)

817

Kastrati

A

Neumann

F-J

Schulz

S

Massberg

S

Byrne

RA

Ferenc

M

Laugwitz

K-L

Pache

J

Ott

I

Hausleiter

J

Seyfarth

M

Gick

M

Antoniucci

D

Schömig

A

Berger

PB

Mehilli

J

,

Abciximab and heparin vs. bivalirudin for non-ST-elevation myocardial infarction

,

N Engl J Med

,

2011

, vol.

365

21

(pg.

1980

-

1989

)

818

O'Donoghue

M

Antman

EM

Braunwald

E

Murphy

SA

Steg

PG

Finkelstein

A

Penny

WF

Fridrich

V

McCabe

CH

Sabatine

MS

Wiviott

SD

,

The efficacy safety of prasugrel with without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic utcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis

,

J Am Coll Cardiol

,

2009

, vol.

54

8

(pg.

678

-

685

)

819

Cohen

M

Mahaffey

KW

Pieper

K

Pollack

CV

Jr.

Antman

EM

Hoekstra

J

Goodman

SG

Langer

A

Col

JJ

White

HD

Califf

RM

Ferguson

JJ

,

A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin vs. unfractionated heparin in non-ST-segment elevation acute coronary syndromes

,

J Am Coll Cardiol

,

2006

, vol.

48

7

(pg.

1346

-

1354

)

820

Ferguson

JJ

Califf

RM

Antman

EM

Cohen

M

Grines

CL

Goodman

S

Kereiakes

DJ

Langer

A

Mahaffey

KW

Nessel

CC

Armstrong

PW

Avezum

A

Aylward

P

Becker

RC

Biasucci

L

Borzak

S

Col

J

Frey

MJ

Fry

E

Gulba

DC

Guneri

S

Gurfinkel

E

Harrington

R

Hochman

JS

Kleiman

NS

Leon

MB

Lopez-Sendon

JL

Pepine

CJ

Ruzyllo

W

Steinhubl

SR

Teirstein

PS

Toro-Figueroa

L

White

H

,

Enoxaparin vs.unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial

,

JAMA

,

2004

, vol.

292

1

(pg.

45

-

54

)

821

Kastrati

A

Neumann

F-J

Mehilli

J

Byrne

RA

Iijima

R

Büttner

HJ

Khattab

AA

Schulz

S

Blankenship

JC

Pache

J

Minners

J

Seyfarth

M

Graf

I

Skelding

KA

Dirschinger

J

Richardt

G

Berger

PB

Schömig

A

,

Bivalirudin vs. unfractionated heparin during percutaneous coronary intervention

,

N Engl J Med

,

2008

, vol.

359

7

(pg.

688

-

696

)

822

Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJG, Bassand J-P, Wallentin L, Joyner C, Fox KAA

,

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

,

N Engl J Med

,

2006

, vol.

354

14

(pg.

1464

-

1476

)

10.1016/S0140-6736(14)60924-7

823

Steg

PG

James

S

Harrington

RA

Ardissino

D

Becker

RC

Cannon

CP

Emanuelsson

H

Finkelstein A

HS

Katus

H

Kilhamn

J

Olofsson

S

Storey

RF

Weaver

WD

Wallentin

L

for the

PSG

,

Ticagrelor Vs. Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis

,

Circulation

,

2010

, vol.

122

21

(pg.

2131

-

2141

)

824

Antman

EM

McCabe

CH

Gurfinkel

EP

Turpie

AG

Bernink

PJ

Salein

D

Bayes De Luna

A

Fox

K

Lablanche

JM

Radley

D

Premmereur

J

Braunwald

E

,

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

,

Circulation

,

1999

, vol.

100

15

(pg.

1593

-

1601

)

825

Mehta

SR

Yusuf

S

Peters

RJ

Bertrand

ME

Lewis

BS

Natarajan

MK

Malmberg

K

Rupprecht

H

Zhao

F

Chrolavicius

S

Copland

I

Fox

KA

,

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

,

Lancet

,

2001

, vol.

358

9281

(pg.

527

-

533

)

826

Montalescot

G

Bolognese

L

Dudek

D

Goldstein

P

Hamm

C

Tanguay

J-F

Ten Berg

JM

Miller

DL

Costigan

TM

Goedicke

J

Silvain

J

Angioli

P

Legutko

J

Niethammer

M

Motovska

Z

Jakubowski

JA

Cayla

G

Visconti

LO

Vicaut

E

Widimsky

P

the

AI

,

Pretreatment with Prasugrel in Non-ST-Segment Elevation Acute Coronary Syndromes

,

N Engl J Med

,

2013

, vol.

369

11

(pg.

999

-

1010

)

827

Steg

PG

Jolly

SS

Mehta

SR

Afzal

R

Xavier

D

Rupprecht

HJ

Lopez-Sendon

JL

Budaj

A

Diaz

R

Avezum

A

Widimsky

P

Rao

SV

Chrolavicius

S

Meeks

B

Joyner

C

Pogue

J

Yusuf

S

,

Low-dose vs.standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial

,

JAMA

,

2010

, vol.

304

12

(pg.

1339

-

1349

)

828

Montalescot

G

Wiviott

SD

Braunwald

E

Murphy

SA

Gibson

CM

McCabe

CH

Antman

EM

investigators

T-T

,

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

,

Lancet

,

2009

, vol.

373

9665

(pg.

723

-

731

)

829

Erlinge

D

Ten Berg

J

Foley

D

Angiolillo

DJ

Wagner

H

Brown

PB

Zhou

C

Luo

J

Jakubowski

JA

Moser

B

Small

DS

Bergmeijer

T

James

S

Winters

KJ

,

Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial

,

J Am Coll Cardiol

,

2012

, vol.

60

20

(pg.

2032

-

2040

)

830

Bellemain-Appaix

A

Brieger

D

Beygui

F

Silvain

J

Pena

A

Cayla

G

Barthélémy

O

Collet

JP

Montalescot

G

,

New P2Y12 inhibitors vs. clopidogrel in percutaneous coronary intervention: a meta-analysis

,

J Am Coll Cardiol

,

2010

, vol.

56

19

(pg.

1542

-

1551

)

831

De Luca

G

Navarese

E

Marino

P

,

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials

,

Eur Heart J

,

2009

, vol.

30

(pg.

2705

-

2713

)

832

Montalescot

G

Barragan

P

Wittenberg

O

Ecollan

P

Elhadad

S

Villain

P

Boulenc

JM

Morice

MC

Maillard

L

Pansieri

M

Choussat

R

Pinton

P

,

Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction

,

N Engl J Med

,

2001

, vol.

344

25

(pg.

1895

-

1903

)

833

Neumann

FJ

Kastrati

A

Pogatsa-Murray

G

Mehilli

J

Bollwein

H

Bestehorn

HP

Schmitt

C

Seyfarth

M

Dirschinger

J

Schomig

A

,

Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial

,

JAMA

,

2003

, vol.

290

12

(pg.

1593

-

1599

)

834

Herrmann

HC

Lu

J

Brodie

BR

Armstrong

PW

Montalescot

G

Betriu

A

Neuman

F-J

Effron

MB

Barnathan

ES

Topol

EJ

Ellis

SG

Investigators

F

,

Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals

,

JACC Cardiovascular Interventions

,

2009

, vol.

2

10

(pg.

917

-

924

)

835

Van't Hof

AW

Ten Berg

J

Heestermans

T

Dill

T

Funck

RC

van Werkum

W

Dambrink

JH

Suryapranata

H

van Houwelingen

G

Ottervanger

JP

Stella

P

Giannitsis

E

Hamm

C

,

Ongoing Tirofiban In Myocardial infarction Evaluation 2 study g. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial

,

Lancet

,

2008

, vol.

372

9638

(pg.

537

-

546

)

836

Ten Berg

JM

van 't Hof

AW

Dill

T

Heestermans

T

van Werkum

JW

Mosterd

A

van Houwelingen

G

Koopmans

PC

Stella

PR

Boersma

E

Hamm

C

,

Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome

,

J Am Coll Cardiol

,

2010

, vol.

55

22

(pg.

2446

-

2455

)

837

Montalescot

G

,

Mechanical reperfusion: treat well, treat on time too

,

Lancet

,

2008

, vol.

372

9638

(pg.

509

-

510

)

838

Stone

GW

Maehara

A

Witzenbichler

B

Godlewski

J

Parise

H

Dambrink

JH

Ochala

A

Carlton

TW

Cristea

E

Wolff

SD

Brener

SJ

Chowdhary

S

El-Omar

M

Neunteufl

T

Metzger

DC

Karwoski

T

Dizon

JM

Mehran

R

Gibson

CM

,

Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial

,

JAMA

,

2012

, vol.

307

17

(pg.

1817

-

1826

)

839

Thiele

H

Wöhrle

J

Hambrecht

R

Rittger

H

Birkemeyer

R

Lauer

B

Neuhaus

P

Brosteanu

O

Sick

P

Wiemer

M

Kerber

S

Kleinertz

K

Eitel

I

Desch

S

Schuler

G

,

Intracoronary vs. intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial

,

Lancet

,

2012

, vol.

379

9819

(pg.

923

-

931

)

840

Stone

GW

Witzenbichler

B

Guagliumi

G

Peruga

JZ

Brodie

BR

Dudek

D

Kornowski

R

Hartmann

F

Gersh

BJ

Pocock

SJ

Dangas

G

Wong

SC

Kirtane

AJ

Parise

H

Mehran

R

,

Bivalirudin during primary PCI in acute myocardial infarction

,

N Engl J Med

,

2008

, vol.

358

21

(pg.

2218

-

2230

)

841

Steg

PG

van 't Hof

AW

Hamm

CW

Clemmensen

P

Lapostolle

F

Coste

P

Berg

JT

Van Grunsven

P

Eggink

GJ

Nibbe

L

Zeymer

U

Orto

MC

Nef

H

Steinmetz

J

Soulat

L

Huber

K

Deliargyris

EN

Bernstein

D

Schuette

D

Prats

J

Clayton

TC

Pocock

SJ

Hamon

M

Goldstein

P

,

Bivalirudin Started during Emergency Transport for Primary PCI

,

N Engl J Med

,

2013

, vol.

369

23

(pg.

2207

-

2217

)

842

Shahzad

A

Kemp

I

Mars

C

Wilson

K

Roome

C

Cooper

R

Andron

M

Appleby

C

Fisher

M

Khand

A

Kunadian

B

Mills

JD

Morris

JL

Morrison

WL

Munir

S

Palmer

ND

Perry

RA

Ramsdale

DR

Velavan

P

Stables

RH

for the HEAT-PPCI trial investigators

,

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial

,

Lancet

,

2014

843

Richardt

G

,

Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 Trial

,

Eur Heart J

Published online 9 May 2014;

10.1093/eurheartj/ehu182

844

Collet

J-P

Huber

K

Cohen

M

Zeymer

U

Goldstein

P

Pollack

C

Jr.

Silvain

J

Henry

P

Varenne

O

Carrié

D

Coste

P

Angioi

M

Le Breton

H

Cayla

G

Elhadad

S

Teiger

E

Filippi

E

Aout

M

Vicaut

E

Montalescot

G

Investigators

A

,

A Direct Comparison of Intravenous Enoxaparin With Unfractionated Heparin in Primary Percutaneous Coronary Intervention (from the ATOLL Trial)

,

Am J Cardiol

,

2013

, vol.

112

9

(pg.

1367

-

1372

)

845

Yusuf

S

Mehta

SR

Chrolavicius

S

Afzal

R

Pogue

J

Granger

CB

Budaj

A

Peters

RJ

Bassand

JP

Wallentin

L

Joyner

C

Fox

KA

,

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

,

JAMA

,

2006

, vol.

295

13

(pg.

1519

-

1530

)

846

Zeymer

U

Arntz

HR

Mark

B

Fichtlscherer

S

Werner

G

Scholler

R

Zahn

R

Diller

F

Darius

H

Dill

T

Huber

K

,

Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial

,

Clin Res Cardiol

,

2012

, vol.

101

4

(pg.

305

-

312

)

847

Koul

S

Smith

JG

Schersten

F

James

S

Lagerqvist

B

Erlinge

D

,

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

,

Eur Heart J

,

2011

, vol.

32

23

(pg.

2989

-

2997

)

848

Dorler

J

Edlinger

M

Alber

HF

Altenberger

J

Benzer

W

Grimm

G

Huber

K

Pachinger

O

Schuchlenz

H

Siostrzonek

P

Zenker

G

Weidinger

F

,

Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction

,

Eur Heart J

,

2011

, vol.

32

23

(pg.

2954

-

2961

)

849

De Luca

G

Bellandi

F

Huber

K

Noc

M

Petronio

AS

Arntz

HR

Maioli

M

Gabriel

HM

Zorman

S

De Carlo

M

Rakowski

T

Gyongyosi

M

Dudek

D

,

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis

,

Journal of Thrombosis and Haemostasis: JTH

,

2011

, vol.

9

12

(pg.

2361

-

2370

)

850

Montalescot

G

Zeymer

U

Silvain

J

Boulanger

B

Cohen

M

Goldstein

P

Ecollan

P

Margenet

A

Huber

K

Pollack

C

Bénezet

JF

Stibbe

O

Filippi

E

Teiger

E

Cayla

G

Elhadad

S

Adnet

F

Chouihed

T

Gallula

S

Greffet

A

Aout

M

Collet

JP

Vicaut

E

for the

AI

,

Intravenous Enoxaparin or Unfractionated Heparin in Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

,

Lancet

,

2011

, vol.

378

9792

(pg.

693

-

703

)

851

Chan

AW

Moliterno

DJ

Berger

PB

Stone

GW

DiBattiste

PM

Yakubov

SL

Sapp

SK

Wolski

K

Bhatt

DL

Topol

EJ

,

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)

,

J Am Coll Cardiol

,

2003

, vol.

42

7

(pg.

1188

-

1195

)

852

Bhatt

DL

Stone

GW

Mahaffey

KW

Gibson

CM

Steg

PG

Hamm

CW

Price

MJ

Leonardi

S

Gallup

D

Bramucci

E

Radke

PW

Widimský

P

Tousek

F

Tauth

J

Spriggs

D

McLaurin

BT

Angiolillo

DJ

Généreux

P

Liu

T

Prats

J

Todd

M

Skerjanec

S

White

HD

Harrington

RA

,

Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

,

N Engl J Med

,

2013

, vol.

368

14

(pg.

1303

-

1313

)

853

Steg

PG

Bhatt

DL

Hamm

CW

Stone

GW

Gibson

CM

Mahaffey

KW

Leonardi

S

Liu

T

Skerjanec

S

Day

JR

Iwaoka

RS

Stuckey

TD

Gogia

HS

Gruberg

L

French

WJ

White

HD

Harrington

RA

,

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data

,

Lancet

,

2013

, vol.

382

9919

(pg.

1981

-

1992

)

854

Angiolillo

DJ

Firstenberg

MS

Price

MJ

Tummala

PE

Hutyra

M

Welsby

IJ

Voeltz

MD

Chandna

H

Ramaiah

C

Brtko

M

Cannon

L

Dyke

C

Liu

T

Montalescot

G

Manoukian

SV

Prats

J

Topol

EJ

,

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

,

JAMA

,

2012

, vol.

307

3

(pg.

265

-

274

)

855

Mega

JL

Braunwald

E

Wiviott

SD

Bassand

JP

Bhatt

DL

Bode

C

Burton

P

Cohen

M

Cook-Bruns

N

Fox

KA

Goto

S

Murphy

SA

Plotnikov

AN

Schneider

D

Sun

X

Verheugt

FW

Gibson

CM

the

AACSTI

,

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

,

N Engl J Med

,

2012

, vol.

366

(pg.

9

-

19

)

856

Gibson

CM

Chakrabarti

AK

Mega

J

Bode

C

Bassand

J-P

Verheugt

FWA

Bhatt

DL

Goto

S

Cohen

M

Mohanavelu

S

Burton

P

Stone

G

Braunwald

E

Investigators

A-AT

,

Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51

,

J Am Coll Cardiol

,

2013

, vol.

62

4

(pg.

286

-

290

)

857

Mega

JL

Braunwald

E

Murphy

SA

Plotnikov

AN

Burton

P

Kiss

RG

Parkhomenko

A

Tendera

M

Widimsky

P

Gibson

CM

,

Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51)

,

J Am Coll Cardiol

,

2013

, vol.

61

18

(pg.

1853

-

1859

)

858

Alexander

JH

Lopes

RD

James

S

Kilaru

R

He

Y

Mohan

P

Bhatt

DL

Goodman

S

Verheugt

FW

Flather

M

Huber

K

Liaw

D

Husted

SE

Lopez-Sendon

J

De Caterina

R

Jansky

P

Darius

H

Vinereanu

D

Cornel

JH

Cools

F

Atar

D

Leiva-Pons

JL

Keltai

M

Ogawa

H

Pais

P

Parkhomenko

A

Ruzyllo

W

Diaz

R

White

H

Ruda

M

Geraldes

M

Lawrence

J

Harrington

RA

Wallentin

L

Investigators

A-

,

Apixaban with antiplatelet therapy after acute coronary syndrome

,

N Engl J Med

,

2011

, vol.

365

8

(pg.

699

-

708

)

859

Oldgren

J

Budaj

A

Granger

CB

Khder

Y

Roberts

J

Siegbahn

A

Tijssen

JGP

Van de Werf

F

Wallentin

L

,

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

,

Eur Heart J

,

2011

, vol.

32

22

(pg.

2781

-

2789

)

860

Steg

PG

Mehta

SR

Jukema

JW

Lip

GYH

Gibson

CM

Kovar

F

Kala

P

Garcia-Hernandez

A

Renfurm

RW

Granger

CB

,

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

,

Eur Heart J

,

2011

, vol.

32

20

(pg.

2541

-

2554

)

861

Alexander

JH

Becker

RC

Bhatt

DL

Cools

F

Crea

F

Dellborg

M

Fox

KA

Goodman

SG

Harrington

RA

Huber

K

Husted

S

Lewis

BS

Lopez-Sendon

J

Mohan

P

Montalescot

G

Ruda

M

Ruzyllo

W

Verheugt

F

Wallentin

L

,

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial

,

Circulation

,

2009

, vol.

119

22

(pg.

2877

-

2885

)

862

Mega

JL

Braunwald

E

Mohanavelu

S

Burton

P

Poulter

R

Misselwitz

F

Hricak

V

Barnathan

ES

Bordes

P

Witkowski

A

Markov

V

Oppenheimer

L

Gibson

CM

,

Rivaroxaban vs. placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

,

Lancet

,

2009

, vol.

374

9683

(pg.

29

-

38

)

863

Ruiz-Nodar

JM

Marín

F

Hurtado

JA

Valencia

J

Pinar

E

Pineda

J

Gimeno

JR

Sogorb

F

Valdés

M

Lip

GYH

,

Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis

,

J Am Coll Cardiol

,

2008

, vol.

51

8

(pg.

818

-

825

)

864

Hansen

ML

Sørensen

R

Clausen

MT

Fog-Petersen

ML

Raunsø

J

Gadsbøll

N

Gislason

GH

Folke

F

Andersen

SS

Schramm

TK

Abildstrøm

SZ

Poulsen

HE

Køber

L

Torp-Pedersen

C

,

Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation

,

Archives of Internal Medicine

,

2010

, vol.

170

16

(pg.

1433

-

1441

)

865

Lamberts

M

Olesen

JB

Ruwald

MH

Hansen

CM

Karasoy

D

Kristensen

SL

Køber

L

Torp-Pedersen

C

Gislason

GH

Hansen

ML

,

Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study

,

Circulation

,

2012

, vol.

126

10

(pg.

1185

-

1193

)

866

Faxon

DP

Eikelboom

JW

Berger

PB

Holmes

DR

Jr.

Bhatt

DL

Moliterno

DJ

Becker

RC

Angiolillo

DJ

,

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circulation

,

Cardiovascular Interventions

,

2011

, vol.

4

5

(pg.

522

-

534

)

867

Lip

GYH

Huber

K

Andreotti

F

Arnesen

H

Airaksinen

JK

Cuisset

T

Kirchhof

P

Marín

F

,

Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary:a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

,

Eur Heart J

,

2010

, vol.

31

11

(pg.

1311

-

1318

)

868

Sarafoff

N

Martischnig

A

Wealer

J

Mayer

K

Mehilli

J

Sibbing

D

Kastrati

A

,

Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation

,

J Am Coll Cardiol

,

2013

, vol.

61

20

(pg.

2060

-

2066

)

869

Bangalore

S

Kumar

S

Fusaro

M

Amoroso

N

Attubato

MJ

Feit

F

Bhatt

DL

Slater

J

,

Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials

,

Circulation

,

2012

, vol.

125

23

(pg.

2873

-

2891

)

870

Dewilde

WJ

Oirbans

T

Verheugt

FW

Kelder

JC

De Smet

BJ

Herrman

JP

Adriaenssens

T

Vrolix

M

Heestermans

AA

Vis

MM

Tijsen

JG

van 't Hof

AW

ten Berg

JM

,

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial

,

Lancet

,

2013

, vol.

381

9872

(pg.

1107

-

1115

)

871

Park

S-J

Park

D-W

Kim

Y-H

Kang

S-J

Lee

S-W

Lee

CW

Han

K-H

Park

S-W

Yun

S-C

Lee

S-G

Rha

S-W

Seong

I-W

Jeong

M-H

Hur

S-H

Lee

N-H

Yoon

J

Yang

J-Y

Lee

B-K

Choi

Y-J

Chung

W-S

Lim

D-S

Cheong

S-S

Kim

K-S

Chae

JK

Nah

D-Y

Jeon

D-S

Seung

KB

Jang

J-S

Park

HS

Lee

K

,

Duration of dual antiplatelet therapy after implantation of drug-eluting stents

,

N Engl J Med

,

2010

, vol.

362

15

(pg.

1374

-

1382

)

872

Kedhi

E

Stone

GW

Kereiakes

DJ

Serruys

PW

Parise

H

Fahy

M

Simonton

CA

Sudhir

K

Sood

P

Smits

PC

,

Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials

,

EuroIntervention

,

2012

, vol.

8

5

(pg.

599

-

606

)

873

Silber

S

Kirtane

AJ

Belardi

JA

Liu

M

Brar

S

Rothman

M

Windecker

S

,

Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation

,

Eur Heart J

,

2014

published online February 7

874

Agewall

S

Cattaneo

M

Collet

JP

Andreotti

F

Lip

GY

Verheugt

FW

Huber

K

Grove

EL

Morais

J

Husted

S

Wassmann

S

Rosano

G

Atar

D

Pathak

A

Kjeldsen

K

Storey

RF

Pharmacology

ESCWGoC

Drug

T

Thrombosis

ESCWGo

,

Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy

,

Eur Heart J

,

2013

, vol.

34

(23):1708–1713

1713a–1713b

875

Alexander

KP

Chen

AY

Roe

MT

Newby

LK

Gibson

CM

Allen-LaPointe

NM

Pollack

C

Gibler

WB

Ohman

EM

Peterson

ED

,

Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes

,

JAMA

,

2005

, vol.

294

24

(pg.

3108

-

3116

)

876

Steg

PG

Huber

K

Andreotti

F

Arnesen

H

Atar

D

Badimon

L

Bassand

JP

De Caterina

R

Eikelboom

JA

Gulba

D

Hamon

M

Helft

G

Fox

KA

Kristensen

SD

Rao

SV

Verheugt

FW

Widimsky

P

Zeymer

U

Collet

JP

,

Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology

,

Eur Heart J

,

2011

, vol.

32

15

(pg.

1854

-

1864

)

877

James

S

Budaj

A

Aylward

P

Buck

KK

Cannon

CP

Cornel

JH

Harrington

RA

Horrow

J

Katus

H

Keltai

M

Lewis

BS

Parikh

K

Storey

RF

Szummer

K

Wojdyla

D

Wallentin

L

,

Ticagrelor vs. clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

,

Circulation

,

2010

, vol.

122

11

(pg.

1056

-

1067

)

878

Sousa-Uva

M

Storey

R

Huber

K

Falk

V

Leite-Moreira

A

Amour

J

Attar

NA

Ascione

R

Taggart

D

Collet

JP

,

Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery

,

Eur Heart J

,

2014

, vol.

35

(pg.

1510

-

1514

)

879

Ferraris

VA

Saha

SP

Oestreich

JH

Song

HK

Rosengart

T

Reece

TB

Mazer

CD

Bridges

CR

Despotis

GJ

Jointer

K

Clough

ER

,

2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations

,

The Annals of Thoracic Surgery 2012

, vol.

94

5

(pg.

1761

-

1781

)

880

Smith

PK

Goodnough

LT

Levy

JH

Poston

RS

Short

MA

Weerakkody

GJ

Lenarz

LA

,

Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis

,

J Am Coll Cardiol

,

2012

, vol.

60

5

(pg.

388

-

396

)

881

Varenhorst

C

Alström

U

Scirica

BM

Hogue

CW

Åsenblad

N

Storey

RF

Steg

PG

Horrow

J

Mahaffey

KW

Becker

RC

James

S

Cannon

CP

Brandrup-Wognsen

G

Wallentin

L

Held

C

,

Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery

,

J Am Coll Cardiol

,

2012

, vol.

60

17

(pg.

1623

-

1630

)

882

Kwak

Y-L

Kim

J-C

Choi

Y-S

Yoo

K-J

Song

Y

Shim

J-K

,

Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery

,

J Am Coll Cardiol

,

2010

, vol.

56

24

(pg.

1994

-

2002

)

883

Mahla

E

Suarez

TA

Bliden

KP

Rehak

P

Metzler

H

Sequeira

AJ

Cho

P

Sell

J

Fan

J

Antonino

MJ

Tantry

US

Gurbel

PA

,

Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study

,

Circulation. Cardiovascular interventions

,

2012

, vol.

5

2

(pg.

261

-

269

)

884

Savonitto

S

D'Urbano

M

Caracciolo

M

Barlocco

F

Mariani

G

Nichelatti

M

Klugmann

S

De Servi

S

,

Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel

,

British Journal of Anaesthesia

,

2010

, vol.

104

3

(pg.

285

-

291

)

885

Collet

JP

Himbet

F

Steg

PG

,

Myocardial infarction after aspirin cessation in stable coronary artery disease patients

,

Int J Cardiol

,

2000

, vol.

76

2–3

(pg.

257

-

258

)

886

Deo

SV

Dunlay

SM

Shah

IK

Altarabsheh

SE

Erwin

PJ

Boilson

BA

Park

SJ

Joyce

LD

,

Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis

,

Journal of Cardiac Surgery

,

2013

, vol.

28

2

(pg.

109

-

116

)

887

Stone

GW

Witzenbichler

B

Weisz

G

Rinaldi

MJ

Neumann

FJ

Metzger

DC

Henry

TD

Cox

DA

Duffy

PL

Mazzaferri

E

Gurbel

PA

Xu

K

Parise

H

Kirtane

AJ

Brodie

BR

Mehran

R

Stuckey

TD

,

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

,

Lancet

,

2013

, vol.

382

9892

(pg.

614

-

623

)

888

Parodi

G

Marcucci

R

Valenti

R

Gori

AM

Migliorini

A

Giusti

B

Buonamici

P

Gensini

GF

Abbate

R

Antoniucci

D

,

High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI

,

JAMA

,

2011

, vol.

306

11

(pg.

1215

-

1223

)

889

Breet

NJ

van Werkum

JW

Bouman

HJ

Kelder

JC

Ruven

HJ

Bal

ET

Deneer

VH

Harmsze

AM

van der Heyden

JA

Rensing

BJ

Suttorp

MJ

Hackeng

CM

ten Berg

JM

,

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation (POPular Study)

,

JAMA

,

2010

, vol.

303

8

(pg.

754

-

762

)

890

Aradi

D

Storey

RF

Komocsi

A

Trenk

D

Gulba

D

Kiss

RG

Husted

S

Bonello

L

Sibbing

D

Collet

JP

Huber

K

on behalf of the Working Group on Thrombosis of the European Society of Cardiology

,

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention

,

Eur Heart J

,

2014

, vol.

35

4

(pg.

209

-

215

)

891

Trenk

D

Stone

GW

Gawaz

M

Kastrati

A

Angiolillo

DJ

Müller

U

Richardt

G

Jakubowski

JA

Neumann

F-J

,

A Randomized Trial of Prasugrel Vs. Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study

,

J Am Coll Cardiol

,

2012

, vol.

59

24

(pg.

2159

-

2164

)

892

Collet

J-P

Cuisset

T

Rangé

G

Cayla

G

Elhadad

S

Pouillot

C

Henry

P

Motreff

P

Carrié

D

Boueri

Z

Belle

L

Van Belle

E

Rousseau

H

Aubry

P

Monségu

J

Sabouret

P

O'Connor

SA

Abtan

J

Kerneis

M

Saint-Etienne

C

Barthélémy

O

Beygui

F

Silvain

J

M D

EV

Montalescot

G

,

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

,

N Engl J Med

,

2012

, vol.

367

22

(pg.

2100

-

2109

)

893

Collet

J-P

Hulot

J-S

Pena

A

Villard

E

Esteve

J-B

Silvain

J

Payot

L

Brugier

D

Cayla

G

Beygui

F

Bensimon

G

Funck-Brentano

C

Montalescot

G

,

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

,

Lancet

,

2009

, vol.

373

9660

(pg.

309

-

317

)

894

Mega

JL

Close

SL

Wiviott

SD

Shen

L

Walker

JR

Simon

T

Antman

EM

Braunwald

E

Sabatine

MS

,

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

,

Lancet

,

2010

, vol.

376

9749

(pg.

1312

-

1319

)

895

Mega

JL

Simon

T

Anderson

JL

Bliden

K

Collet

JP

Danchin

N

Giusti

B

Gurbel

P

Horne

BD

Kastrati

A

Montalescot

G

Neumann

FJ

Shen

L

Sibbing

D

Steg

PG

Trenk

D

Wiviott

SD

Sabatine

MS

,

CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis

,

Circulation

,

2009

, vol.

120

S598-b-9

896

Trenk

D

Hochholzer

W

Fromm

MF

Chialda

LE

Pahl

A

Valina

CM

Stratz

C

Schmiebusch

P

Bestehorn

HP

Büttner

HJ

Neumann

FJ

,

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

,

J Am Coll Cardiol

,

2008

, vol.

51

(pg.

1925

-

1934

)

897

Roberts

JD

Wells

GA

Le May

MR

Labinaz

M

Glover

C

Froeschl

M

Dick

A

Marquis

JF

O'Brien

E

Goncalves

S

Druce

I

Stewart

A

Gollob

MH

So

DYF

,

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial: the RAPID GENE trial

,

Lancet

,

2012

, vol.

379

(pg.

1705

-

1711

)

898

Silberman

S

Neukirch-Stoop

C

Steg

PG

,

Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting

,

Am J Cardiol

,

2005

, vol.

95

4

(pg.

509

-

510

)

899

,

A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

,

Lancet

,

1996

, vol.

348

9038

(pg.

1329

-

1339

)

900

Bhatt

DL

Cryer

BL

Contant

CF

Cohen

M

Lanas

A

Schnitzer

TJ

Shook

TL

Lapuerta

P

Goldsmith

MA

Laine

L

Scirica

BM

Murphy

SA

Cannon

CP

Investigators

C

,

Clopidogrel with or without omeprazole in coronary artery disease

,

N Engl J Med

,

2010

, vol.

363

20

(pg.

1909

-

1917

)

901

O'Donoghue

ML

Braunwald

E

Antman

EM

Murphy

SA

Bates

ER

Rozenman

Y

Michelson

AD

Hautvast

RW

Ver Lee

PN

Close

SL

Shen

L

Mega

JL

Sabatine

MS

Wiviott

SD

,

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

,

Lancet

,

2009

, vol.

374

9694

(pg.

989

-

997

)

902

Birkmeyer

JD

Finlayson

EV

Birkmeyer

CM

,

Volume standards for high-risk surgical procedures: potential benefits of the Leapfrog initiative

,

Surgery

,

2001

, vol.

130

3

(pg.

415

-

422

)

903

Post

PN

Kuijpers

M

Ebels

T

Zijlstra

F

,

The relation between volume and outcome of coronary interventions: a systematic review and meta-analysis

,

Eur Heart J

,

2010

, vol.

31

16

(pg.

1985

-

1992

)

904

Jones

DA

Gallagher

S

Rathod

K

Jain

AK

Mathur

A

Uppal

R

Westwood

M

Wong

K

Rothman

MT

Shipolini

A

Smith

EJ

Mills

PG

Timmis

AD

Knight

CJ

Archbold

RA

Wragg

A

,

Clinical outcomes after myocardial revascularization according to operator training status: cohort study of 22 697 patients undergoing percutaneous coronary intervention or coronary artery bypass graft surgery

,

Eur Heart J

,

2013

, vol.

34

37

(pg.

2887

-

2895

)

905

Birkmeyer

JD

Stukel

TA

Siewers

AE

Goodney

PP

Wennberg

DE

Lucas

FL

,

Surgeon volume and operative mortality in the United States

,

N Engl J Med

,

2003

, vol.

349

22

(pg.

2117

-

2127

)

906

Puskas

JD

Mack

MJ

Smith

CR

,

On-pump vs. off-pump CABG

,

N Engl J Med

,

2010

, vol.

362

9

(pg.

853

-

854

)pg.

851

author reply

907

Wijns

W

Kolh

PH

,

Experience with revascularization procedures does matter: low volume means worse outcome

,

Eur Heart J

,

2010

, vol.

31

16

(pg.

1954

-

7

)

908

Zacharias

A

Schwann

TA

Riordan

CJ

Durham

SJ

Shah

A

Papadimos

TJ

Engoren

M

Habib

RH

,

Is hospital procedure volume a reliable marker of quality for coronary artery bypass surgery? A comparison of risk and propensity adjusted operative and midterm outcomes

,

Ann Thorac Surg

,

2005

, vol.

79

6

(pg.

1961

-

1969

)

909

Kurlansky

PA

Argenziano

M

Dunton

R

Lancey

R

Nast

E

Stewart

A

Williams

T

Zapolanski

A

Chang

H

Tingley

J

Smith

CR

,

Quality, not volume, determines outcome of coronary artery bypass surgery in a university-based community hospital network

,

J Thorac Cardiovasc Surg

,

2012

, vol.

143

2

(pg.

287

-

293

)

910

Auerbach

AD

Hilton

JF

Maselli

J

Pekow

PS

Rothberg

MB

Lindenauer

PK

,

Shop for quality or volume? Volume, quality, and outcomes of coronary artery bypass surgery

,

Ann Intern Med

,

2009

, vol.

150

10

(pg.

696

-

704

)

911

Hannan

EL

Wu

C

Walford

G

King

SB

3rd

Holmes

DR

Jr.

Ambrose

JA

Sharma

S

Katz

S

Clark

LT

Jones

RH

,

Volume-outcome relationships for percutaneous coronary interventions in the stent era

,

Circulation

,

2005

, vol.

112

8

(pg.

1171

-

1179

)

912

McGrath

PD

Wennberg

DE

Dickens

JD

Jr.

Siewers

AE

Lucas

FL

Malenka

DJ

Kellett

MA

Jr.

Ryan

TJ

Jr.

,

Relation between operator and hospital volume and outcomes following percutaneous coronary interventions in the era of the coronary stent

,

JAMA

,

2000

, vol.

284

24

(pg.

3139

-

3144

)

913

Nallamothu

BK

Wang

Y

Magid

DJ

McNamara

RL

Herrin

J

Bradley

EH

Bates

ER

Pollack

CV

Jr.

Krumholz

HM

,

Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction-4 analysis

,

Circulation

,

2006

, vol.

113

2

(pg.

222

-

229

)

914

Spaulding

C

Morice

MC

Lancelin

B

El Haddad

S

Lepage

E

Bataille

S

Tresca

JP

Mouranche

X

Fosse

S

Monchi

M

de Vernejoul

N

,

Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry

,

Eur Heart J

,

2006

, vol.

27

9

(pg.

1054

-

1060

)

915

Vakili

BA

Kaplan

R

Brown

DL

,

Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state

,

Circulation

,

2001

, vol.

104

18

(pg.

2171

-

2176

)

916

Ho

V

,

Evolution of the volume-outcome relation for hospitals performing coronary angioplasty

,

Circulation

,

2000

, vol.

101

15

(pg.

1806

-

1811

)

917

Kastrati

A

Neumann

FJ

Schomig

A

,

Operator volume and outcome of patients undergoing coronary stent placement

,

J Am Coll Cardiol

,

1998

, vol.

32

4

(pg.

970

-

976

)

918

Canto

JG

Every

NR

Magid

DJ

Rogers

WJ

Malmgren

JA

Frederick

PD

French

WJ

Tiefenbrunn

AJ

Misra

VK

Kiefe

CI

Barron

HV

,

The volume of primary angioplasty procedures survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators

,

N Engl J Med

,

2000

, vol.

342

21

(pg.

1573

-

1580

)

919

Zahn

R

Gottwik

M

Hochadel

M

Senges

J

Zeymer

U

Vogt

A

Meinertz

T

Dietz

R

Hauptmann

KE

Grube

E

Kerber

S

Sechtem

U

,

Volume-outcome relation for contemporary percutaneous coronary interventions (PCI) in daily clinical practice: is it limited to high-risk patients? Results from the Registry of Percutaneous Coronary Interventions of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK)

,

. Heart

,

2008

, vol.

94

3

(pg.

329

-

335

)

920

Khattab

AA

Hamm

CW

Senges

J

Toelg

R

Geist

V

Bonzel

T

Kelm

M

Levenson

B

Nienaber

CA

Pfannebecker

T

Sabin

G

Schneider

S

Tebbe

U

Neumann

FJ

Richardt

G

,

Sirolimus-eluting stent treatment at high-volume centers confers lower mortality at 6-month follow-up: results from the prospective multicenter German Cypher Registry

,

Circulation

,

2009

, vol.

120

7

(pg.

600

-

606

)

921

Kumbhani

DJ

Cannon

CP

Fonarow

GC

Liang

L

Askari

AT

Peacock

WF

Peterson

ED

Bhatt

DL

,

Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes

,

JAMA

,

2009

, vol.

302

20

(pg.

2207

-

2213

)

922

Levine

GN

Bates

ER

Blankenship

JC

Bailey

SR

Bittl

JA

Cercek

B

Chambers

CE

Ellis

SG

Guyton

RA

Hollenberg

SM

Khot

UN

Lange

RA

Mauri

L

Mehran

R

Moussa

ID

Mukherjee

D

Nallamothu

BK

Ting

HH

,

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

,

J Am Coll Cardiol

,

2011

, vol.

58

24

e44–e122

923

Di Mario

C

Di Sciascio

G

Dubois-Rande

JL

Michels

R

Mills

P

,

Curriculum and syllabus for Interventional Cardiology subspecialty training in Europe

,

EuroIntervention

,

2006

, vol.

2

1

(pg.

31

-

36

)

924

Hlatky

MA

Boothroyd

DB

Reitz

BA

Shilane

DA

Baker

LC

Go

AS

,

Adoption and effectiveness of internal mammary artery grafting in coronary artery bypass surgery among medicare beneficiaries

,

J Am Coll Cardiol

,

2014

, vol.

63

1

(pg.

33

-

39

)

925

Perk

J

De Backer

G

Gohlke

H

Graham

I

Reiner

Z

Verschuren

M

Albus

C

Benlian

P

Boysen

G

Cifkova

R

Deaton

C

Ebrahim

S

Fisher

M

Germano

G

Hobbs

R

Hoes

A

Karadeniz

S

Mezzani

A

Prescott

E

Ryden

L

Scherer

M

Syvanne

M

Scholte op Reimer

WJ

Vrints

C

Wood

D

Zamorano

JL

Zannad

F

,

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

,

Eur Heart J

,

2012

, vol.

33

13

(pg.

1635

-

1701

)

926

Baigent

C

Blackwell

L

Emberson

J

Holland

LE

Reith

C

Bhala

N

Peto

R

Barnes

EH

Keech

A

Simes

J

Collins

R

,

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

,

Lancet

,

2010

, vol.

376

9753

(pg.

1670

-

1681

)

927

Cannon

CP

Braunwald

E

McCabe

CH

Rader

DJ

Rouleau

JL

Belder

R

Joyal

SV

Hill

KA

Pfeffer

MA

Skene

AM

,

Intensive vs. moderate lipid lowering with statins after acute coronary syndromes

,

N Engl J Med

,

2004

, vol.

350

15

(pg.

1495

-

1504

)

928

LaRosa

JC

Grundy

SM

Waters

DD

Shear

C

Barter

P

Fruchart

JC

Gotto

AM

Greten

H

Kastelein

JJ

Shepherd

J

Wenger

NK

,

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

,

N Engl J Med

,

2005

, vol.

352

14

(pg.

1425

-

1435

)

929

Pfeffer

MA

Braunwald

E

Moye

LA

Basta

L

Brown

EJ

Jr.

Cuddy

TE

Davis

BR

Geltman

EM

Goldman

S

Flaker

GC

et al. ,

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

,

N Engl J Med

,

1992

, vol.

327

10

(pg.

669

-

677

)

930

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

,

The SOLVD Investigators

,

N Engl J Med

,

1991

, vol.

325

5

(pg.

293

-

302

)

931

Pfeffer

MA

McMurray

JJ

Velazquez

EJ

Rouleau

JL

Kober

L

Maggioni

AP

Solomon

SD

Swedberg

K

Van de Werf

F

White

H

Leimberger

JD

Henis

M

Edwards

S

Zelenkofske

S

Sellers

MA

Califf

RM

,

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

,

N Engl J Med

,

2003

, vol.

349

20

(pg.

1893

-

1906

)

932

Granger

CB

McMurray

JJ

Yusuf

S

Held

P

Michelson

EL

Olofsson

B

Ostergren

J

Pfeffer

MA

Swedberg

K

,

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

,

Lancet

,

2003

, vol.

362

9386

(pg.

772

-

776

)

933

Yusuf

S

Teo

KK

Pogue

J

Dyal

L

Copland

I

Schumacher

H

Dagenais

G

Sleight

P

Anderson

C

,

Telmisartan, ramipril, or both in patients at high risk for vascular events

,

N Engl J Med

,

2008

, vol.

358

15

(pg.

1547

-

1559

)

934

Yusuf

S

Sleight

P

Pogue

J

Bosch

J

Davies

R

Dagenais

G

,

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators

,

N Engl J Med

,

2000

, vol.

342

3

(pg.

145

-

153

)

935

Fox

KM

,

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

,

Lancet

,

2003

, vol.

362

9386

(pg.

782

-

788

)

936

Critchley

JA

Capewell

S

,

Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review

,

JAMA

,

2003

, vol.

290

1

(pg.

86

-

97

)

937

Iestra

JA

Kromhout

D

van der Schouw

YT

Grobbee

DE

Boshuizen

HC

van Staveren

WA

,

Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review

,

Circulation

,

2005

, vol.

112

6

(pg.

924

-

934

)

938

Taylor

RS

Brown

A

Ebrahim

S

Jolliffe

J

Noorani

H

Rees

K

Skidmore

B

Stone

JA

Thompson

DR

Oldridge

N

,

Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials

,

Am J Med

,

2004

, vol.

116

10

(pg.

682

-

692

)

939

Taylor

RS

Unal

B

Critchley

JA

Capewell

S

,

Mortality reductions in patients receiving exercise-based cardiac rehabilitation: how much can be attributed to cardiovascular risk factor improvements?

,

Eur J Cardiovasc Prev Rehabil

,

2006

, vol.

13

3

(pg.

369

-

374

)

940

Hammill

BG

Curtis

LH

Schulman

KA

Whellan

DJ

,

Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries

,

Circulation

,

2010

, vol.

121

1

(pg.

63

-

70

)

941

Clark

AM

Hartling

L

Vandermeer

B

McAlister

FA

,

Meta-analysis: secondary prevention programs for patients with coronary artery disease

,

Ann Intern Med

,

2005

, vol.

143

9

(pg.

659

-

672

)

942

Heran

BS

Chen

JM

Ebrahim

S

Moxham

T

Oldridge

N

Rees

K

Thompson

DR

Taylor

RS

,

Exercise-based cardiac rehabilitation for coronary heart disease

,

Cochrane Database Syst Rev

,

2011

7

CD001800

943

Janssen

V

De Gucht

V

Dusseldorp

E

Maes

S

,

Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials

,

Eur J Prev Cardiol

,

2013

, vol.

20

4

(pg.

620

-

640

)

944

Zhang

Y

Zhang

X

Liu

L

Zanchetti

A

,

Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial

,

Eur Heart J

,

2011

, vol.

32

12

(pg.

1500

-

1508

)

945

Poole-Wilson

PA

Lubsen

J

Kirwan

BA

van Dalen

FJ

Wagener

G

Danchin

N

Just

H

Fox

KA

Pocock

SJ

Clayton

TC

Motro

M

Parker

JD

Bourassa

MG

Dart

AM

Hildebrandt

P

Hjalmarson

A

Kragten

JA

Molhoek

GP

Otterstad

JE

Seabra-Gomes

R

Soler-Soler

J

Weber

S

,

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial

,

Lancet

,

2004

, vol.

364

9437

(pg.

849

-

857

)

946

Zanchetti

A

Grassi

G

Mancia

G

,

When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal

,

J Hypertens

,

2009

, vol.

27

5

(pg.

923

-

934

)

947

Hansson

L

Zanchetti

A

Carruthers

SG

Dahlof

B

Elmfeldt

D

Julius

S

Menard

J

Rahn

KH

Wedel

H

Westerling

S

,

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

,

Lancet

,

1998

, vol.

351

9118

(pg.

1755

-

1762

)

948

Froelicher

VF

Lehmann

KG

Thomas

R

Goldman

S

Morrison

D

Edson

R

Lavori

P

Myers

J

Dennis

C

Shabetai

R

Do

D

Froning

J

,

The electrocardiographic exercise test in a population with reduced workup bias: diagnostic performance, computerized interpretation, and multivariable prediction. Veterans Affairs Cooperative Study in Health Services #016 (QUEXTA) Study Group. Quantitative Exercise Testing and Angiography

,

Ann Intern Med

,

1998

, vol.

128

12 Pt 1

(pg.

965

-

974

)

949

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus

,

The Diabetes Control and Complications Trial Research Group

,

N Engl J Med

,

1993

, vol.

329

14

(pg.

977

-

986

)

950

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

,

UK Prospective Diabetes Study (UKPDS) Group

,

Lancet

,

1998

, vol.

352

9131

(pg.

837

-

853

)

951

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

,

Lancet

,

1999

, vol.

353

9146

(pg.

9

-

13

)

952

Packer

M

Coats

AJ

Fowler

MB

Katus

HA

Krum

H

Mohacsi

P

Rouleau

JL

Tendera

M

Castaigne

A

Roecker

EB

Schultz

MK

DeMets

DL

,

Effect of carvedilol on survival in severe chronic heart failure

,

N Engl J Med

,

2001

, vol.

344

22

(pg.

1651

-

1658

)

953

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

,

Lancet

,

1999

, vol.

353

9169

(pg.

2001

-

2007

)

954

Flather

MD

Shibata

MC

Coats

AJ

Van Veldhuisen

DJ

Parkhomenko

A

Borbola

J

Cohen-Solal

A

Dumitrascu

D

Ferrari

R

Lechat

P

Soler-Soler

J

Tavazzi

L

Spinarova

L

Toman

J

Bohm

M

Anker

SD

Thompson

SG

Poole-Wilson

PA

,

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)

,

Eur Heart J

,

2005

, vol.

26

3

(pg.

215

-

225

)

955

Pitt

B

Zannad

F

Remme

WJ

Cody

R

Castaigne

A

Perez

A

Palensky

J

Wittes

J

,

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

,

N Engl J Med

,

1999

, vol.

341

10

(pg.

709

-

717

)

956

Zannad

F

McMurray

JJ

Krum

H

van Veldhuisen

DJ

Swedberg

K

Shi

H

Vincent

J

Pocock

SJ

Pitt

B

,

Eplerenone in patients with systolic heart failure and mild symptoms

,

N Engl J Med

,

2011

, vol.

364

1

(pg.

11

-

21

)

957

Pitt

B

Remme

W

Zannad

F

Neaton

J

Martinez

F

Roniker

B

Bittman

R

Hurley

S

Kleiman

J

Gatlin

M

,

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

,

N Engl J Med

,

2003

, vol.

348

14

(pg.

1309

-

1321

)

958

Swedberg

K

Komajda

M

Bohm

M

Borer

JS

Ford

I

Dubost-Brama

A

Lerebours

G

Tavazzi

L

,

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

,

Lancet

,

2010

, vol.

376

9744

(pg.

875

-

885

)

959

Fox

K

Komajda

M

Ford

I

Robertson

M

Bohm

M

Borer

JS

Steg

PG

Tavazzi

L

Tendera

M

Ferrari

R

Swedberg

K

,

Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials

,

Eur Heart J

,

2013

, vol.

34

29

(pg.

2263

-

2270

)

960

Saito

S

Valdes-Chavarri

M

Richardt

G

Moreno

R

Iniguez Romo

A

Barbato

E

Carrie

D

Ando

K

Merkely

B

Kornowski

R

Eltchaninoff

H

James

S

Wijns

W

on behalf of CENTURY II Investigators

,

A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial

,

Eur Heart J

,

2014

, vol.

35

(pg.

2021

-

2031

)

961

Pilgrim

T

Heg

D

Roffi

M

Tüller

D

Muller

O

Vuilliomenet

A

Cook

S

Weilenmann

D

Kaiser

C

Jamshidi

P

Fahrni

T

Moschovitis

A

Noble

S

Eberli

FR

Wenaweser

P

Jüni

P

Windecker

S

,

Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary intervention (BIOSCIENCE): a randomised, single-blind, non-inferiority trial

,

Lancet

,

2014

doi 10.1016/S0140-6736(14)61038-2